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ABSTRACT Next to their primitive role in fat digestion, solubilisation and absorption, nowadays, bile acids (BAs) are considered signaling molecules able to interact with nuclear and membrane endogenous receptors, inducing several cellular networks that regulate lipids, glucose and bile acids homeostasis. Two well-known targets of BAs are the endogenous nuclear receptor FXR (farnesoid-x-receptor) and the membrane receptor GPBAR1 (G-protein coupled receptor 1) and since their activation is linked to the control of different metabolic and enterohepatic functions, they could be considered efficient targets in the treatment of several human diseases. In the last few years, medicinal chemistry modifications on bile acid scaffolds, afforded a large amount of exogenous derivatives with different pharmacological profiles, useful in the treatment of metabolic and enterohepatic disorders, ranging from metabolic syndrome, diabetes, cholestasis and non-alcoholic steatohepatitis. One limit of the therapeutic use of BA derivatives is their promiscuity in binding different receptors and inducing an increase of risk for adverse side effects, due to the activation of several downstream signals controlled by these two receptors. For these reasons, my research work, described in this PhD thesis and developed in this research area, was addressed to the identification of novel selective ligands as potential lead compounds, useful in the treatment of metabolic and enterohepatic disorders, in which the dual modulation is detrimental in terms of side effects. Medicinal chemistry modifications, mainly performed on chenodeoxycholic acid (CDCA) and focused on the length/functionalization of the side chain, as well as on the tetracyclic core, allowed the identification of several lead compounds with promising pharmacological activities in the frame of human FXR-mediated diseases. Another consistent part of my PhD project, in organic synthesis, was spent in the laboratory of the Centro de Investigación Príncipe Felipe of Valencia. During this period, I worked in the asymmetric diversity-oriented synthesis of benzo-fused cyclic amines using homoallylic o-halobenzylamines, as starting material, in which the presence of halogen atoms makes them suitable for the asymmetric synthesis of different compounds, such as heterocycles or benzo-fused compounds. 
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INTRODUCTION: BILE ACIDS AND ENDOGENOUS RECEPTORS BILE ACIDS Bile acids (BAs) are a class of steroid molecules synthesized in the liver from cholesterol. BAs are the main components of bile and can be divided in primary bile acids, such as chenodeoxycholic acid (CDCA) and cholic acid (CA), in highest concentration, and in secondary bile acids such as lithocholic (LCA), deoxycholic (DCA) and ursodeoxycholic acid (UDCA), contained in a small aliquot (Figure 1). From a structural point of view, they are characterized by a steroid core with a truncated side chain at C17, ending with a carboxyl group. BAs are different from natural steroids for the presence of a cis junction between the rings A and B, which confers a “bent form” to the ring A, that is projected out of the plan formed by rings B-C-D. Figure 1. Endogenous bile acids All bile acids possess in their tetracyclic core one or more hydroxyl groups, at C3, C6, C7 or C12, which modulate their physical and chemical properties, as well as their receptor-binding profile. Even though BAs are identified for their ancestral role of lipid digestion and absorption, recently, they are considered key signaling molecules, endowed with both genomic and non genomic effects. These effects are the result of their interaction with several nuclear receptors, such as the farnesoid-X-receptor (FXR), the pregnane-X-receptor (PXR), the constitutive androstane receptor (CAR), the vitamin D receptor (VDR), the liver-X-receptor (LXR), and with G-protein-coupled receptors, such as GPBAR1 (also known as M-BAR, TGR5 or BG37).1-6 Furthermore, primary and secondary bile acids activate voltage and calcium-gated potassium channels (BKCa or KCa1.1) and interact with tyrosine kinase coupled receptors, inducing the transactivation of the epidermal growth factor receptor or EGFR. The above promiscuity supports the H COOHHOUrsodeoxycholic acid            (UDCA) OHH COOHHO Lithocholic acid        (LCA)COOHOHHHOChenodeoxycholic acid            (CDCA) COOHOHHHO OH      Cholic acid            (CA)H HH H H HH H HH H H
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fact that bile acids exert a variety of patho-physiological and pharmacological activities. BILE ACID SYNTHESIS In bile acid synthesis, cholesterol is first converted by liver in primary bile acids, CA and CDCA that in turn are converted by intestinal microbiota in secondary bile acids, DCA, LCA, UDCA as well as in their glycine (human) and taurine (mouse) conjugated forms. The first pathway (or classic) starts from the 7α-hydroxylase cytochrome P-450 (CYP7A1), differently, the alternative pathway (or acidic) is initiated by the sterol 27-hydroxylase (CYP27A1), (Figure 2). Figure 2. Bile acid synthesis Classic pathway furnishes CA and CDCA in substantial equal amounts, whereas the acidic pathway affords mainly CDCA. After their synthesis, primary bile acids and their conjugates are secreted by liver into the small intestine, where are subjected to deamidation and 7α-dehydroxylation reactions, by intestinal microbiota, to lead the formation of secondary bile acids, DCA and LCA. These latters are then absorbed by distal ileum, secreted by enterocytes in the portal 
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and SULT2Α1) and regulates lipoprotein metabolism. In addition, FXR controls lipid metabolism, such as apolipoprotein (apo) C-II, apo C-III, apo A-I, apo E, and phospholipids transfer protein expression. Moreover, FXR induces peroxisome proliferator-activated receptor-α expression, another nuclear receptor controlling triglyceride metabolism. Another important effect is the intestinal activation of FXR that increases the expression and the release of fibroblast growth factor FGF-19.13,16 This factor binds the type 4 of FGF receptor (FGF-R4) and represses CYP7A1 in hepatocytes, with a subsequent reduction of bile acid synthesis. Additionally, FXR activation in the kidney induces the expression of proteins MRP2 (multidrug resistance-associated protein 2) and OSTα/β, on the basolateral surface of renal tubular cells, increasing the potential detoxifying effect of this receptor. For its features, FXR is well known as the physiological sensor of bile acids and protects the liver against the toxic effects due to their accumulation. So the enterohepatic bile acids circulation, as well as the selective intestinal and liver FXR activation, are potential therapeutic targets and could be exploited to modulate bile acids homeostasis and lipid metabolism (Figure 4).10-12 Figure 4. Bile acid homeostasis Of interest, FXR is also involved in the control of glucose homeostasis. The activation of small heterodimer partner (SHP) by FXR decreases the expression of the phosphoenolpyruvate carboxykinase (PEPCK), which plays a key role in 
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gluconeogenesis, and of glucose 6-phosphatase, which regulates the glycogenolysis. FXR: THERAPEUTIC APPLICATIONS FXR ligands have demonstrated beneficial effects in the treatment of several liver disorders, including various types of cholestasis and steatosis.17 Cholestasis is an abnormal flow of BAs resulting from a functional defect of hepatocytes or from obstruction of intra and extra-hepatic bile ducts, caused by infections, drugs, tumor or genetic disorders. In presence of cholestasis, the elevated levels of bile acids lead to the activation of a complex machinery of coordinated mechanisms, which promote bile acids extrusion from the liver. The most common diseases, which induce cholestasis, are the primary biliary cirrhosis (PBC), the primary biliary cirrhosis-autoimmune hepatitis, the primary sclerosing cholangitis (PSC) and the intrahepatic cholestasis of pregnancy (ICP).18-21 In addition, there are other rare autosomal recessive disorders, characterized by cholestasis, due to the mutations of genes encoding for hepatocellular transporters. Until now, FXR ligands have shown beneficial effects in the treatment of PBC. As already mentioned, FXR has also an important role in the regulation of glucose homeostasis, through regulation of gluconeogenesis and glycogenolysis in the liver and also of insulin sensitivity in striated muscle and adipose tissue, suggesting potential beneficial effects of FXR agonists in patients affected with type II diabetes, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).22,23 For all these aspects FXR represents a promising target for drug discovery. FXR: LIGANDS FROM NATURE Several natural FXR ligands have been reported, so far. The first example was guggulsterone (GS), which is a vegetable steroid found in the resin of the guggul plant, Commiphora mukul,24-27 a traditional medicinal herb intensively used in Ayuverdic medicine for the treatment of obesity and lipid disorders. A preliminary pharmacological test suggested that guggulsterone could be a FXR antagonist, but successively a deep characterization demonstrated that it is a 
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partial FXR agonist.27-30 However, its promiscuity in agonizing different NRs reduced the possibility to be considered a lead to treat metabolic disorders. Starting from the identification of guggulsterone, natural steroid molecules, largely distributed in vegetal and marine worlds, have been affirmed as promising candidates in FXR modulation. A great contribution is derived from high-throughput screening, but also from target-oriented discovery of herbal medicines, affording to the identification of several new FXR ligands. Selected examples are sesquiterpenes and triterpenes from Alisma orientalis,31 widely cultivated in Taiwan, China, and Japan and from Schisandra glaucescens Diels (Schisandraceae),32 whose extracts are used in the treatment of several pathologies, as hyperglycemia and hyperlipidemia. Stigmasterol acetate (StigAc), a water-soluble semisynthetic derivative of soy, resulted a dose dependent FXR antagonist, suppressing mediated expression of FXR target genes.33 Also marine ecosystem has been recently demonstrated a promising source of FXR ligands.34 For example, the family of 4-methylene steroids, isolated from the sponges belonging to Theonella species,35-38 represents a novel class of NRs modulators with peculiar pharmacological profiles, ranging from selective FXR antagonists to dual PXR/FXR modulators. Among these compounds, theonellasterol represents the first example of natural full FXR antagonist identified. In proof of concept study, this compound was tested in vivo in a model of obstructive cholestasis,39 providing the first evidence that FXR antagonism has a potential in the treatment of this type of disease. Figure 5. Natural FXR ligands FXR: STEROIDAL AND NON STEROIDAL AGONISTS Steroidal agonists After FXR de-orphanization by BAs, large medicinal chemistry protocols have been performed on their scaffold. Manipulation on CDCA, which represents the HHHO OE,Z-Guggulsterone AcOStigmasterol acetate HO HTheonellasterol
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most potent endogenous FXR agonist, with an EC50 in a range of 4.5-10 µM, with the aim to improve potency, efficacy and metabolic stability, afforded several compounds with promising pharmacological profiles. In detail, the introduction of an ethyl group at C-6 on the CDCA ring B, produced 6-ECDCA/OCA (obeticholic acid or INT-747), a potent FXR agonist.40 OCA has been widely tested in vitro and in vivo.41-45 In a phase III clinical trial in patients with non-alcoholic steatohepatitis (NASH), OCA improved several features of NASH,46 including inflammation and fibrosis. However, in 23% of patients appeared an increase of cholestatic itching with a simultaneous increase of total cholesterol, LDL, and a modest decrease in HDL. Itching was also present in PBC patients and this effect was unsustainable enough to induce drug discontinuation in 40% of patients.47 Indeed OCA is also a GPBAR1 agonist and this receptor has been recently identified as the physiological mediator of itching in mice.48-51 Figure 6. Chemical structure of OCA (or INT-747) Non steroidal FXR agonists The most investigated non-steroidal FXR ligand is GW4064 (Figure 7) endowed with a potency of 70 nM and an efficacy of 140% respect the CDCA. Since 2000, an high number of modifications have been performed around this scaffold, with the aim to improve its limited intestinal absorption (<10%) and to reduce its intrinsic photo-instability due to the presence of the widely delocalized π-electron 
system in the stilbene moiety, that is associated with a potential cell toxicity.  Figure 7. GW4064 and Px-102 
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Thus, several research groups, ranging from academy to industry, have harnessed the chemical space around the stilbene moiety, the position of the carboxyl group on the terminal aryl unit, the nature of classical linker, while the central isoxazole core, the isopropyl group at C-5 and the 2,6-dihalogen substituted phenyl at C-3, 
have been conserved.52,53 As depicted in Figure 7, a potent close derivative of GW4064 is the non steroidal FXR agonist PX20606 (Px-102), which was synthesized by Phenex Pharmaceuticals. Currently Px-102 is in a Phase II study in patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease 
(NAFLD).
 G-PROTEIN COUPLED RECEPTOR 1 (GPBAR1) GPBAR1 (or TGR5, MBAR1) is a member of rhodopsin-like superfamily of G protein coupled receptor (GPCR), mainly expressed in the small intestine,11,12 in plasma membrane of liver, adipose tissue, colon, skeletal muscle cells, macrophages/monocytes and it is activated by secondary bile acids, lithocholic acid (LCA) and its tauro conjugated form (TLCA). This receptor is coupled to a Gs protein and the binding of a ligand leads to the activation of the adenylate cyclase with a subsequent increase of intracellular concentration of cAMP; then the activation of a protein kinase A (PKA) induces a cascade of events with the activation of different cellular pathways. In fact, after its activation by secondary bile acids, GPBAR1 regulates multiple metabolic functions and increases energy expenditure. In intestinal L-cells, GPBAR1 stimulates the secretion of glucagon-like peptide 1 (GLP-1), a hormone that induces insulin secretion, controls the gastrointestinal transit and suppresses appetite. The GLP-1 release from STC-1 cells, is linked to an increase of intracellular ATP levels, the closure of ATP-dependent potassium channels (KATP) and consequent calcium influx.54 In the gastrointestinal tract, GPBAR1 plays a key role also in regulating colonic motility and defecation.55,56 In fact, it is expressed in the inhibitory motor neurons of the myenteric plexus56 of the large intestine, in which is also present the nitric oxide synthase (NOS). Linked to this co-presence, the activation of GPBAR1 by DCA, a secondary bile acid, induces a phasic contraction of isolated segments of longitudinal muscle induced by a neurogenic and nitrergic mechanism. Moreover, 
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the luminal administration of DCA also induces a delay in gastric emptying and small intestinal transit in rodents.56 GPBAR1 is also co-present with 5-hydroxytryptamine (5-HT) in mouse colon entero-chromaffin cells, and calcitonin gene-related peptide (CGRP) in intrinsic primary afferent neurons.56,57 In fact, the results of an in vitro mucosal application of DCA and LCA (<100 µM), to a preparation of mouse colon, showed a response that could be interpreted as the equivalent of in vivo peristalsis. Differently, GPBAR1 suppression inhibits this effect and the antagonism of 5-HT4 and CGRP receptors, blocks GPBAR1-induced peristalsis. These results confirm that GPBAR1 is the mediator of prokinetic actions of bile acids in the colon and that the presence of this receptor is fundamental for the normal defecation process. In fact, genetic defects in GPBAR1, alter intestinal transit in patients with a functional intestine unbalance (for example irritable bowel syndrome).58 In addition, GPBAR1 presents immunity functions59 and is highly expressed in macrophages, where its activation reduces macrophage-effector functions activated by pro-inflammatory events, through the negative regulation of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells). In animal models of liver inflammation, GPBAR1 activation by 23(S)-methyl-CDCA, a selective semi-synthetic bile acid ligand, attenuates the NF-kB activation through the reduction of IkBα phosphorylation, which inhibits NF-kB translocation into nucleus. In rodent models of colitis, GPBAR1 expression is increased in inflamed tissues, and its absence is correlated with an increased susceptibility to develop colitis and a highest intestinal permeability.60 Furthermore, GPBAR1 expression in hepatic macrophages (or Kupffer cells), which stimulates the release of pro-inflammatory cytokine, exerts an important role in the development and progression of NAFLD (Non-Alcholic Fat Liver Disease). For this, GPBAR1 plays an important protective function against steatosis. Therefore, GPBAR1 activation could exert benefic effects in the treatment of atherosclerosis, steatosis, obesity, hyperglycemia, all disorders in partnership to the metabolic syndrome. Moreover, GPBAR1 has been recently demonstrated essential component of the intestinal mucosal barrier and would seem to exert a protective effect against gastrointestinal injury caused by non steroidal anti-inflammatory drugs (FANS).59 Finally, GPBAR1 activation increases the energy expenditure in the adipose tissue, thereby preventing 
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obesity.61 This effect is mediated by the activation of iodothyroninedeiodinase enzyme (D2),62 which stimulates the thermogenesis mediated by thyroid hormones, locally. D2 hormone, in fact, increases the oxidative mitochondrial phosphorylation in brown adipose tissue, as well as in muscles, through the induction of T4 hormone conversion in the corresponding form activated of T3, which interacts with the receptor inducing an increase of energy expenditure (Figure 8). Figure 8. GPBAR1 localization and specific tissue functions In the same way of FXR, GPBAR1 is a negative modulator of bile acids synthesis and re-uptake in biliary tract. In addition, it reduces the accumulation of fats in liver, the blood levels of triglycerides not esterified, and shifts blood cholesterol levels to associations LDL type. Collectively, these findings have prompted the development of dual GPBAR1/FXR agonists as a new frontier in the 
pharmacological treatment of hypercholesterolemia, hypertriglyceridemia, and diabetes mellitus type 2. However, the concomitant activation of both receptors 
endorses with potential side effects, and therefore, the discovery of highly selective FXR or GPBAR1 agonists is therapeutically attractive for a large cluster of human diseases. Consequently, my research activity was mainly focused on the design, synthesis and thorough pharmacological investigation of selective agonists generated on bile acid scaffolds. MODEL OF GPBAR1 Rational drug design represents an efficient approach in developing novel receptor-agonists. However, as the design of new compounds depends on the availability of structural information of molecular targets, there is a strong !
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limitation caused from the absence of the tridimensional structure for GPBAR1. Despite this, the large amount of experimental information available on GPCRs and the high number of structures identified in this class of proteins, allowed to transcend this limitation, using known structures as template to project a tridimensional model for this receptor. In particular, multiple sequences of different GPCRs, such as α and β adrenergic proteins, opioids or adenosine receptor, have been used in order to identify the more conserved regions and the adenosine A2AR-GL31 receptor was identified as possible template for the highest sequence identity values (~19%) with GPBAR1. The alignment between the GPBAR1 model and this template was developed considering the sequence homology of extracellular region, where the ligand is bound. In addition, the formation of disulfide bond between the extracellular loop II and the transmembrane helix III (TM3), due to the presence of well-conserved cysteine residues in GPCRs family, induces rigidity in this region, contributing to the design of the ligand-binding site. In fact, as referred in literature63 this disulfide bond is fundamental to predict the correct GPBAR1 structure. At the end, using Modeler v. 9.11 GPBAR1 tridimensional structure has been built. The receptor was also incorporated in a double phospholipid bilayer (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine or POPC), surrounded from water, in order to simulate the extra-membrane environment and finally molecular dynamic (MD) calculations have been performed. The whole system, especially the transmembrane helices, was very stable during the stimulation (90 ms), with a major flexibility observed for the extracellular and the intracellular loops (Figure 9). Figure 9. Lateral view (A) and superior (B) of GPBAR1 receptor tridimensional model  
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CHAPTER 1 CHENOCHOLANE AND URSOCHOLANE DERIVATIVES The activity of bile acids towards their receptorial counterparts is structure-dependent, with chenodeoxycholic acid (CDCA) and taurolithocholic acid (TLCA), which are the most potent endogenous activators of FXR and GPBAR1 (Figure 10), respectively.9,49,64 Although FXR activation could be an appealing approach to treat enterohepatic diseases,65 in this context, the therapeutic use of endogenous bile acids, with the exception of ursodeoxycholic acid (UDCA), is limited by their toxicity and promiscuity in activating different endogenous receptors, such as the G-protein-coupled receptor 1 or GPBAR1. Administration of 6-ECDCA in PBC patients caused itching in approx. 50-60% that was severe enough to cause drug discontinuation in 40% of patients. Indeed, 6-ECDCA is also a ligand for GPBAR1 and therefore the above side effect might be associated to the activation of the membrane bile acid receptor, which is recently demonstrated bona fide to be the physiological mediator of itching in mice.48,49 Thus, the obtainment of selective FXR ligands, without any GPBAR1 effects, represents a new avenue in the treatment of hepatic disorders such as PBC. Differently, GPBAR1 activation could represent a new opportunity in the treatment of metabolic disorders, such as non-alcoholic steatohepatitis (NASH) or type 2 diabetes. Figure 10. Endogenous bile acids and 6-ECDCA Therefore, selective GPBAR1 ligands could have utility in the treatment of metabolic disorders, in which the increased release of GLP-1 hormone, with a consequent anti-diabetes effect and the regulation of glucose and lipids blood levels, represent an efficacy strategy. In this chapter, the synthesis of a large family of selective FXR and GPBAR1 ligands, starting from the UDCA and CDCA scaffolds, is described. UDCA represents the only endogenous bile acid used in the therapy of cholestasis, with a total safety also when administered in 
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Figure 12. Semisynthetic bile acid derivatives generated starting from CDCA and UDCA scaffolds In particular, we looked for the main chemical modifications, which were the elimination and the inversion of configuration of hydroxyl group in position 3, in the protons spectrum. The occurred elimination was confirmed by the lack of a characteristic signal at δ 3.35 in the proton spectra of chenodeoxycholic acid scaffold and the only appearance of a singlet at δ 3.79  corresponding to the proton in β-configuration on C-7 in compounds 4-8 and of another signal at 
δ 3.46, as multiplet, corresponding to the proton in α-configuration on C-7 in compounds 9-13. The absence of characteristic signals of UDCA scaffold corresponding to protons on C-3 and C-7, in compounds 14-18, confirmed instead the occurred double elimination. The inverted configuration of hydroxyl group at C-3, was established by the value and the shape of the signal corresponding to the carbinol proton at C-3. In fact, in compounds 19-24, H-3 resonated around  4 ppm, down-field shifted respect to the value for the above proton in CDCA and in UDCA (3.35 ppm) as singlet, thus demonstrating its equatorial disposition. Comprehensive pharmacological evaluation allowed the identification of promising lead compounds in several human diseases.   
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1.1 PREPARATION OF CHENOCHOLANE DERIVATIVES  1.1.1 Modification on CDCA: Synthesis of 3-deoxychenocholane derivatives Scheme 1. 3-Deoxychenocholane derivatives. a) NaBr, TBABr, NaClO 10%, MeOH:CH3COOH: H2O:AcOEt 3:1:0.25:6.5; b) p-TsOH, MeOH dry, quantitative yield over two steps; c) p-TsCl, pyridine; d) LiBr, Li2CO3, DMF dry, reflux; e) H2 (1 atm), Pd/C, THF/MeOH 1:1; f) NaBH4, THF/H2O 4:1 v/v, quantitative yield over four steps; g) NaOH 5% in MeOH/H2O 1:1 v/v, quantitative yield; h) DMT-MM, Et3N, taurine, DMF dry, 35%; i) LiBH4, MeOH dry, THF, 0 °C, 79%; j) Et3N.SO3, DMF dry, 80 °C. The synthetic protocol started with CDCA that was subjected to regioselective oxidation with NaClO 10%, NaBr and TBABr, as transfer catalyst of phase, followed by Fischer esterification with p-toluenesulfonic acid in MeOH dry, furnishing methyl ester 32, in quantitative yield.48 Then tosylation with tosyl chloride and pyridine dry, followed by elimination of tosyl group with Li2CO3 and LiBr and double bond hydrogenation with consequent NaBH4 reduction at C-7, gave methyl 3-deoxycholanoate 33, in quantitative chemical yield over four steps (Scheme 1). Alkaline hydrolysis with NaOH 5% in MeOH/H2O 1:1 afforded 3-deoxycholanoic acid (4) in quantitative chemical yield, which was subjected, in a small aliquot, to amidation with taurine.66 Purification on RP-18 column, followed by HPLC, gave compound 5 in pure form as sodium salt. Another aliquot of methyl ester 33 was reduced with LiBH4, in THF/MeOH dry, at the corresponding C-24 alcohol 6, which after HPLC purification on a small aliquot, was in turn subjected to sulfation (Et3N.SO3 1.5 eq. in DMF dry) producing a mixture of compounds 8 and 7, efficiently separated, as pure sodium salts, by HPLC.  
Chapter 1 
	   17	  
1.1.2 Modification on CDCA: Synthesis of 3β-chenodeoxycholane derivatives Scheme 2. 3β-Chenodeoxycholane derivatives. a) p-TsOH, MeOH dry, quantitative yield; b) p-TsCl, pyridine, quantitative yield; c) CH3COOK, DMF: H2O 5:1, reflux, 75%; d) NaOH 5% in MeOH/H2O 1:1 v/v, 89%; e) 2,6-lutidine, t-butyldimethylsilyl trifluoromethanesulfonate, CH2Cl2, 0 °C; f) LiBH4, MeOH dry, THF dry, 0 °C, 84% over two steps; g) HCl 37%, MeOH, 96%; h) Et3N.SO3, DMF dry, 80 °C; i) HCl 37%, MeOH, 76% over two steps. Regioselective tosylation at C-3 (p-tosyl chloride in pyridine dry) on CDCA methyl ester furnished intermediate 39. The preferential tosylation at C-3 results from the major reactivity of equatorial hydroxyl group at C-3 respect to the axial OH at C-7, with the 3α-OH group pointing in a chemical space free from steric interactions. Treatment of compound 39 with potassium acetate in DMF/H2O (Scheme 2), afforded the 3β-hydroxy derivative 40 in 75% yield. Alkaline hydrolysis with NaOH 5% in MeOH/H2O 1:1 at C-24 methyl ester and subsequent HPLC purification, gave pure isoCDCA (19), in 89% yield. Further, an aliquot of 40 was first protected at C-3 and C-7 hydroxyl groups with t-butyldimethylsilyl trifluoromethanesulfonate and 2,6-lutidine in CH2Cl2 dry and then reduced with LiBH4 in THF/MeOH dry furnishing the protected alcohol 41. De-protection on compound 41 with HCl 37% (2-3 drops) in MeOH and HPLC purification, afforded isoCDCOH (20) in quantitative yield. Finally, a small aliquot of 41 was sulphated and after de-protection and HPLC purification, monosulfate derivative 21 was obtained in 76% yield over two steps.    
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1.2 PREPARATION OF URSOCHOLANE DERIVATIVES 1.2.1 Modification on UDCA: Synthesis of 3-deoxyursocholane derivatives Scheme 3. 3-Deoxyursocholane derivatives. a) p-TsOH, MeOH dry, quantitative yield; b) p-TsCl, pyridine, 58%; c) LiBr, Li2CO3, DMF dry, reflux, quantitative yield; d) H2 (1 atm), Pd/C, THF/MeOH dry 1:1, 78%; e) NaOH 5% in MeOH/H2O 1:1 v/v, quantitative yield; g) DMT-MM, Et3N, taurine, DMF dry, 27%; f) LiBH4, MeOH dry, THF dry, 0 °C, 91%; h) Et3N.SO3, DMF dry, 80 °C. For the synthesis of 3-deoxyursocholane derivatives (compounds 9-13, Scheme 3), we performed the same reactions previously described in the Scheme 1 for the preparation of corresponding 3-deoxychenocholane derivatives. 1.2.2 Modification on UDCA: Synthesis of 5β-cholane derivatives UDCA methyl ester was di-tosylated at C-3 and C-6 hydroxyl groups, producing intermediate 36 that was subjected to LiBr/Li2CO3 treatment to obtain the double elimination on ring A and B (Scheme 4). Catalytic hydrogenation (H2, Pd/C in THF/MeOH dry) on the crude product, furnished a mixture of the saturated methyl esters 37 and 38, epimers at C-8. Treatment of methyl ester 37 with LiBH4 and then with Et3N.SO3, furnished alcohol 14 and its corresponding sulfated 15, in 84% and 23% yield, respectively. Alkaline hydrolysis on methyl ester 38 with NaOH 5% in MeOH/H2O 1:1, produced carboxylic acid derivative 16 in 78% yield. At last, an aliquot of methyl ester 38 was treated with LiBH4 and then with Et3N.SO3, affording alcohol 17 in 78% yield and the corresponding sulfate derivative 18, in 43% yield. 
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Scheme 4. 5β-Cholane derivatives. a) p-TsCl, pyridine, quantitative yield; b) LiBr, Li2CO3, DMF dry, reflux, quantitative yield; c) H2 (1 atm), Pd/C, THF/MeOH dry 1:1; d) LiBH4, MeOH dry, THF dry, 0 °C, 84%; e) Et3N.SO3, DMF dry, 80 °C, 23%; f) NaOH 5% in MeOH/H2O 1:1 v/v, 78%; g) LiBH4, MeOH dry, THF dry, 0 °C, 78%; h) Et3N.SO3, DMF dry, 80 °C, 43%. 1.2.3 Modification on UDCA: Synthesis of 3β-ursodeoxycholane derivatives Scheme 5. 3β-Ursodeoxycholane derivatives. a) CH3COOK, DMF: H2O 5:1, reflux, 82%; b) NaOH 5% in MeOH/H2O 1:1 v/v, 87%; c) 2,6-lutidine, t-butyldimethylsilyl trifluoromethanesulfonate, CH2Cl2, 0 °C; d) LiBH4, MeOH dry, THF dry, 0 °C, 94% over two steps; e) HCl 37%, MeOH, 96%; f) Et3N.SO3, DMF dry, 80 °C; g) HCl 37%, MeOH, 67% over two steps. The 3β-ursodeoxycholane derivatives 22-24 (Scheme 5) were obtained following the same synthetic protocol illustrated in Scheme 2 for the corresponding chenodeoxycholane derivatives. 1.3 PHARMACOLOGICAL EVALUATION Pharmacological assays were performed by Prof. Fiorucci’s group at University of Perugia. In vitro transactivation assays have been executed on HepG2 and HEK-293T cells, transfected with the responsive elements for FXR and GPBAR1, respectively (Figures 13 and 14). As illustrated in Figure 13, the elimination of the hydroxyl group at C-3 on CDCA scaffold furnished potent and selective FXR agonists. In detail, with the exception of the 7, 24-disulfate derivative (8), all 3-COOHOHH
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deoxychenocholane derivatives were able to transactivate FXR independently from the functional end-group at C-24 (COOH in 4, CH2OH in 6 and CH2OSO3- in 7). Figure 13. Transactivation assays on FXR. HepG2 cells were transfected with pSG5-FXR, pSG5-RXR, pCMV-βgal, and p(hsp27)TKLUC vectors. Cells were stimulated with compounds 4-24 (10 µM). CDCA (1, 10 µM) was used as a positive control. Results are expressed as mean ± standard error; *p <0.05 versus not treated cells (NT). Differently, the tauro-conjugation of the carboxyl group on the side chain (compound 5) completely abolishes the activity on FXR. Of interest, the substitution of carboxyl end-group with a not conjugable functional group, such as a sulfate, produced derivative 7, with almost the same potency of 4 on FXR and without any GPBAR1 activity (Figure 14). On contrary, the corresponding urso-derivatives 9-13, all sharing the β-configuration of the hydroxyl group at C-7, were inactive towards FXR, demonstrating that the configuration at C-7 is a key structural feature for FXR interaction. Moreover, even though the sulfate 15 showed a potency of action comparable to the CDCA, the most potent endogenous FXR ligand, the results of transactivation for compounds 14-18, demonstrated that the deletion of both hydroxyl groups, in particular at C-7, is detrimental for FXR activation (for examples compound 14 respect 6, and compound 15 respect 7). Modifications on B/C ring junction produced derivatives 16-18, deprived of any activity on FXR, thus confirming the importance of bile acids shape in the interaction with FXR-LBD. Of interest are also the results of inverted configuration in position C-3. As shown in Figure 13, isochenodeoxycholic acid (isoCDCA, 19) was more potent than its precursor CDCA, in activating FXR. Considering the well-known bile acids epimerization 
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at C-3 that occurs in the intestine by bacterial enzymes, the result of isoCDCA transactivation opens the way to other pharmacological investigations of this compound as FXR modulator. Transactivation on CREB-responsive elements in HEK-293T cells, transiently transfected with the membrane bile acid receptor GPBAR1 and with a reporter gene containing a cAMP responsive element (Figure 14), showed that the elimination (at C-3 or both positions) or epimerization (at C-3) of hydroxyl groups on the tetracyclic scaffold is detrimental in term of GPBAR1 activity. Figure 14. Transactivation assays on GPBAR1. HEK-293T cells were co-transfected with GPBAR1 and a reporter gene containing a cAMP responsive element in front of the luciferase gene. Twenty-four hour post transfection cells were stimulated with 4-24 (10 µM). Luciferase activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. TLCA (2, 10 µM) was used as a positive control. Results are expressed as mean ± standard error. *p<0.05 versus not treated cells (NT). 1.3.1 Pharmacological evaluation on 7α-hydroxy-5β-cholan-24-sulfate (7) In the whole series, compound 7α-hydroxy-5β-cholan-24-sulfate (7), a potent and selective FXR agonist, represents a promising building block to produce selective bile acid receptor modulators. HepG2 and HEK-293T cells were stimulated with increasing concentrations of compound 7 (range from 100 nM to 50 µM). As illustrated in Figure 15, panel A, compound 7 was able to transactivate FXR in a dose-dependent manner with an EC50 of 9 µM. Differently, results of GPBAR1 transactivation showed that 7 failed to transactivate GPBAR1 at any concentration tested (Figure 15, panel B). Further, the effect on compound 7 was evaluated on common off-targets, including GR, PPARγ, LXR and PXR. 
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CHAPTER 2 6-ETHYLCHENOCHOLANE DERIVATIVES As pointed before, the introduction of an ethyl group at C-6 on the CDCA ring B afforded to the disclosure of the potent FXR agonist 6-ECDCA/OCA, reported in both peer-reviewed literature40 and in two patent applications of 2002 and 2005.69 In detail, in the main part of my PhD project I focused my attention on the synthetic modifications of 6-ECDCA scaffold. Starting from this building block, my PhD research activity has been mainly focalized on the synthetic modifications of 6-ECDCA scaffold and large libraries of compounds, modified in the side chain and on the tetracyclic moiety, have been generated. Firstly, we decided to harness the carboxyl group at C-24, generating C-24 alcohols 44-47 and, in the above subset, chemical diversity has been also increased with modification at the configurational assessment between C6/C7 substituents (Figure 20). Figure 20. 3α-hydroxy-6-ethylchenocholane derivatives Second, translating the information that the removal or isomerization of the hydroxyl group at C-3 on CDCA scaffold was detrimental in terms of GPBAR1 activation70 generating selective FXR agonists to the 6-ECDCA scaffold, compounds 48-62 (Figures 21 and 22) have been obtained. The first subset includes 3-deoxy-6-ethylcholane derivatives (Figure 21) whereas subset B includes the corresponding 3β-hydroxy-6-ethylcholane derivatives. Also in this case, chemical modifications were expanded at the side chain end-group and at the stereochemical arrangement on C-6 and C-7. Structural characterization on compounds 44-62 was performed by NMR and ESI-MS analysis. These huge medicinal chemistry protocols accompanied by an intense pre-clinical pharmacological evaluation afforded the discovery of promising hit compounds as selective and potent bile acid receptors agonists. In particular, compounds 45 (EUDCOH) and 51 have been patented with the name of BAR501 and BAR704 HHO OH OH HHO OH OH HHO OH OH HHO OH OHECDCOH EUDCOH (or BAR501) isoECDCOH 47464544
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respectively, where the abbreviation BAR is due to the “BAR Pharmaceuticals” company. Figure 21. Subset A: 3-deoxy-6-ethylchenodeoxycholane derivatives Figure 22. Subset B: 3β-hydroxy-6-ethylchenodeoxycholane derivatives 2.1 SYNTHESIS OF 3α-HYDROXY-6-ETHYLCHOLANE DERIVATIVES Alkylation at C-6 on CDCA scaffold represents the key step in the synthetic protocol towards 6-ethylcholane derivatives. As illustrated in the Scheme 6, commercially available chenodeoxycholic acid (CDCA), was regioselectively oxidized at C7 hydroxyl group37 with NaClO 10%, NaBr and TBABr. Scheme 6. Preparation of 6-ethyl intermediate (65). a) NaBr, TBABr, NaClO 10%, MeOH:CH3COOH: H2O:AcOEt 3:1:0.25:6.5; b) p-TsOH, MeOH dry, 65% over two steps; c) DIPA, n-BuLi, TMSCl, TEA dry, THF dry -78 °C; d) acetaldehyde, BF3•OEt2, CH2Cl2, -60 °C, 77% over two steps. HHO OH OHO HHO O OCH3O H(H3C)3SiO OSi(CH3)3 OCH3O HHO O OCH3OCDCA 32 64 65a,b c d 1 2526 7 2117 245
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Esterification on C7 oxidized intermediate with p-TsOH in MeOH dry, gave methyl 7-keto-lithocholanoate (32) in 65% yield over two steps.71 Aldolic addition to a silyl enol-ether intermediate (64) with acetaldehyde and BF3•OET2,72 produced methyl 3α-hydroxy-6-ethylidene-7-keto-5β-cholan-24-oate 65 in 77% chemical yield over two steps. Dipolar couplings H-8/H-25 and Me-26/H-5 in the NOESY spectrum, established the E configuration at the exocyclic double bond as represented in 65. An aliquot of 65 was subjected to NaBH4 reduction at C-7 ketone48 followed by a treatment with LiBH4 in MeOH dry, affording the triol 47 in good chemical yield (Scheme 7). Scheme 7. Modification on ring B of 6-ethylcholane scaffold. a) NaBH4, MeOH dry; b) LiBH4, MeOH dry, THF dry, 0 °C, 85% over two steps; c) H2, Pd/C, THF/MeOH 1:1, quantitative yield; d) LiBH4, MeOH dry, THF dry, 0 °C; e) NaBH4, MeOH dry; f) LiBH4, MeOH dry, THF dry, 0 °C. The reduction with sodium borohydride on 65 occurred in a stereoselective manner, producing the exclusive formation of 7β-hydroxyl derivative (47) as demonstrated by the shape of H-7 (doublet, J = 9.8 Hz) signal in the NMR proton spectrum. The above large value of coupling constant H7/H8 is in full agreement with their trans-diaxial disposition and therefore with the β-orientation of the hydroxyl group at C-7 on ring B. Hydrogenation of the exocyclic double bond (H2 on Pd/C) on compound 65 afforded exclusively the 6β-ethyl group in 66 as demonstrated by dipolar couplings Me-26 (δ 0.83)/Me-19 (δ 1.22) and H-8 (δ 2.56)/H-25 (δ 1.83) in Noesy spectrum. The β-configuration in compound 66 after catalytic hydrogenation, depended on the presence of a cis junction between the rings A and B, which induced the molecule to assume a bent form; in this spatial disposition the methyl group at C-21 position caused a steric hindrance that forced the attack of hydrogen on the α face of double bond and gave the β-configuration 
HHO O OCH3OHHO OHa,b OH65
47
HHO O OCH3O
66
HHO OHOHEUDCOH 45 HHO OHOHisoECDCOH 46c e,fHHO OH OHECDCOH 44d
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of the ethyl group. LiBH4 treatment furnished alcohol 44 whose stereochemical assestement C6α/C7α was substantiated by the almost complete superimposition of proton resonances of all nuclei belonging to the tetracyclic core, with those reported for the 6-ECDCA.37,48 From a mechanistic point of view, LiBH4 treatment first induces the epimerization at C-6 through a keto-enol tautomery where the α epimer at C-6, thermodynamically more stable, is favored. Then, reduction at C-7 proceeds through the approach of the hydride from the upper-face of the steroid nucleus, agreement with the steric influence played by the ethyl group at C-6 and by the ring A, both oriented on the α-face of ring B. For the preparation of the corresponding epimers at C-6 or/and C-7 of compound 44, NaBH4 treatment on methyl ester 66 was performed. Interestingly, sodium borohydride treatment does not induce C-6 epimerization, affording directly the reduction at C-7 keto group. Finally, LiBH4 reduction on the crude reaction furnished a mixture that was then purified in HPLC (88% MeOH:H2O) giving pure 6β-ethyl derivatives 45 and 46, in ratio 7:3. Stereochemical characterization of 6β-ethyl-3α,7α-dihydroxy-5β-cholan-24-ol (isoECDCOH, 46) was based on careful comparison of NMR data with those of compound 44 (Tables 1 and 2). In compound 46, H-7 resonated as singlet (δH 3.60), confirming its equatorial disposition and therefore the α-configuration of C-7 hydroxyl group. The other values in the 1H NMR spectra were almost similar in the shape and in the chemical shift, with the exception of the down-fielded shifted signals for H2-4 (δH 2.30, 1.55 in 46 vs δH 1.88, 1.73 in 44) and for Me-26 (δH 0.95 in 46 vs 0.90 in 44), suggesting the inverted configuration at C-6 in 46. 13C NMR spectrum analysis, supported by the two-dimensional HSQC and HMBC experiments, confirmed this hypothesis revealing deep differences in the chemical shift of several carbons adjacent to C-6 (i.e. C-4 δC 41.4 in 46 respect 34.3 in 44, C-6 δC 51.7 in 46 respect 42.9 in 44, C-8 δC 36.4 in 46 respect 41.3 in 44). In the 1H NMR spectrum of 6β-ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (EUDCOH, 45), H-7 appeared as a doublet doublet (δH 3.74, dd, J = 10.3, 6.0 Hz) with a large coupling constant with H-8, due to their trans di-axial relationship and consequently in agreement with the β-orientation of the hydroxyl group on C-7. ROESY cross-peaks, H-7/H-9, H-7/H-14 and H-7/H-6 confirm the inverted 
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2.2 PHARMACOLOGICAL EVALUATION OF 3α-HYDROXY-6-ETHYLCHOLANE DERIVATIVES Compounds 44-47 were tested in vitro in a luciferase reporter assay on HepG2 and HEK-293T cells, transfected with the responsive elements for FXR and GPBAR1, respectively (Figure 23, panels A and B). Figure 23. Transactivation assays on FXR (Panel A) and GPBAR1 (Panel B): (A) HepG2 cells were transfected with pSG5-FXR, pSG5-RXR, pCMV-βgal, and p(hsp27)TKLUC vectors. Cells were stimulated with compounds 44-47 (10 µM). CDCA (1, 10 µM) was used as positive control. Results are expressed as mean ± standard error; *p <0.05 versus not treated cells (NT). (B) HEK-293T cells were co-transfected with GPBAR1 and a reporter gene containing a cAMP responsive element in front of the luciferase gene. Twenty-four hour post transfection cells were stimulated with 44-47 (10 µM). Luciferase activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. TLCA (2, 10 µM) was used as a positive control. Results are expressed as mean ± standard error. *p<0.05 versus not treated cells (NT). Results illustrated in Figure 23 confirm the fact that the stereochemical arrangement at C-6 and C-7 positions is a key aspect for FXR activation, whereas doesn’t influence GPBAR1 interaction. In fact, alcohols 45-47 resulted potent and selective GPBAR1 agonists whereas derivative 44, with both ethyl and the hydroxyl groups on ring B α-oriented, resulted a dual agonist. 2.2.1 Pharmacological evaluation on EUDCOH (45) Compound 45 (EUDCOH), a potent and selective GPBAR1 agonist, was further evaluated. Concentration-response curves, revealed its inactivity on FXR at any concentration tested, whereas demonstrated its agonistic behavior toward GPBAR1 with an EC50 of 1.03 µM (panels A and B in Figure 24). 
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such as GR, PPARγ, LXR and PXR (Figure 25). As shown in Figure 25 (panels A-D), except a residual activity on PXR (Figure 25 D), compound 45 failed to transactivate the receptors GR, PPARγ and LXR at the concentration of 10 µM. Furthermore, to confirm transactivation assays, compound 45 was evaluated in the regulation of FXR and GPBAR1 canonical functions. As depicted in Figure 26, compound 45 was able in inducing the expression of pro-glucagon mRNA (GLP-1) in GLUTAg cells and cAMP intracellular concentrations in THP-1 cells, while fails in inducing the expression of OSTα, BSEP and SHP, three FXR-targeted genes. 
Figure 25. Specificity of 45 on other nuclear receptors. (A) (B) and (C) HepG2 cells were co-transfected with the Gal4 luciferase reporter vector and with a series of chimeras in which the Gal4 DNA binding domain is fused to the LBD of the indicated nuclear receptors. Cells were treated 18 h with the specific agonists (10 µM) or with 45 (10 µM). (D) HepG2 cells were co-transfected with pSG5-PXR, pSG5-RXR and with the reporter pCYP3A4 promoter-TKLuc and then stimulated with rifaximin (10 µM), a PXR agonist, or with 45 (10 µM). Data are the mean ± S.E. of three experiments.*p<0.05 versus not treated cells (NT). DEXA: Dexamethasone; ROSI: Rosiglitazone; GW: GW3965; RIFAX: Rifaximin. Collectively, these data affirm compound 45 as a potent and selective GPBAR1 agonist. 
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Figure 26. In vitro pharmacological evaluation of FXR/GPBAR1 functions on 45. (A) Real-time PCR analysis of mRNA expression of GPBAR1 target genes: Pro-glucagon in GLUTAg cells primed with 45 (10 µM); effect of 45 (10 µM) on intracellular generation of cAMP in THP-1 cells. The data are the mean ± SE of three experiments: *p < 0.05 versus not treated cells (NT). F: Forskolin 10 µM. TLCA (2) and 6-ECDCA (3) were tested as positive controls (10 µM). Values are normalized relative to GAPDH mRNA and are expressed relative to those of not treated cells (NT), which are arbitrarily set to 1: *p < 0.05 versus not treated cells (NT). (B) Real-time PCR analysis of mRNA expression of FXR target genes: OSTα, BSEP and SHP in HepG2 cells primed with 45 (10 µM). 6-ECDCA (3) was tested as positive control (10 µM). Values are normalized relative to GAPDH mRNA and are expressed relative to those of not treated cells (NT), which are arbitrarily set to 1: *p < 0.05 vs NT. 2.2.1.1 Preclinical in vivo pharmacological evaluation on 45 The interesting in vitro pharmacological results on compound 45 led the attention of our pharmacological partner to a comprehensive investigation on its in vivo effects. Compound 45 (or BAR501) demonstrated beneficial effects on portal hypertension in a rodent model of liver cirrhosis, by exerting genomic and non-genomic effects on cystathione-γ-lyase (CSE), nitric oxide synthase (eNOS) and endothelin (ET)-1, in liver sinusoidal cells.73 Portal hypertension is a common symptom of liver cirrhosis, in which the fibrosis combined with a vasculogenic component contributes to an endothelial dysfunction. This last, in turn, induces contraction of the perisinusoidal hepatic stellate cells (HSC) and increases intrahepatic vascular resistance to portal flow.74-76 Because GPBAR1 expression is limited only to Kupffer and sinusoidal (LSEC) hepatic cells, whose activation regulates the endothelial nitric oxide (NO) synthase (eNOS) activity,77 this suggests the effective role of GPBAR1 in the treatment of endothelial dysfunction in presence of liver cirrhosis. Hepatic cirrhosis was induced in mice by carbon tetrachloride (CCl4) administration for 9 weeks and the dose of BAR501 administered was of 15 mg/kg/day. After 9 weeks treatment, BAR501 effectively protected against occurrence of endothelial dysfunction, by increasing liver CSE 
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Figure 28. Vasodilatory activity of BAR501 in the CCl4 model. (A) Effect on portal pressure, (B) Effect on AST, (C) Effect on alkaline phosphatase (ALP), (D) Effect on albumin, (E) Effect on bilirubin in mice renedered cirrhotic by administration with CCl4. (F-H) Hematoxylin and eosin staining. (I-M) Syrius red staining (Fibrosis). (N) Quantification of Syrius red staining. Data are mean ± SE of 8–10 animals per group. *p<0.05 versus naïve mice. #p<0.05 versus CCl4. Figure 29. Expression of CSE and ET-1 in the CCl4 model of liver cirrhosis. C57BL6 mice were treated for 9 weeks with CCl4 or with the combination of CCl4 plus BAR501 15 mg/kg. The relative hepatic mRNA expression of TGFβ1, COL1α1, αSMA, TNFα, IL1β, GPBAR1 (panel A) and CBS, CSE, eNOS, iNOS, CAV-1 ET-1 (panel B) was assayed by Real-Time PCR. (C) Effect of BAR501 on CSE activity in the CCl4 model. (D) Effect of BAR501 on nitrite/nitrate in CCl4 treated mice. Results are the mean ± SE of 4–8 mice per group. *p<0.05 versus naïve mice. #p<0.05 versus CCl4 alone. Interestingly are the results on CSE expression/activity where BAR501 administration in combination with CCl4, increased the expression of CSE gene, an enzyme involved in the vasodilatation for the release of H2S, whereas had no 
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effect on nitrite/nitrate concentrations (Fig. 29 C and 29 D). Therefore, this result suggests a potential role of this compound in the regulation of endothelial mechanisms in the liver microcirculation. In addition, the ET-1 gene, that is a potent vasoconstrictor factor, was strongly down-regulated by BAR501. Thus, BAR501 effectively reduces vasoconstriction caused by NE and methoxamine in naïve rats and protects against development of portal hypertension in rodent models of cirrhosis and consequent endothelial dysfunction, which was mainly due to insufficient NO production and increased ET-1 generation.74-76,78-95 However, it failed to attenuate liver fibrosis and it is probably due to the absence of GPBAR1-expression in hepatic stellate cells.96 In addition, BAR501 increased the expression of CSE but had no effect on nitrites/nitrates levels. In conclusion, BAR501, a UDCA derivative endowed with robust and selective GPBAR1 agonistic activity, was demonstrated able in attenuating the deleterious consequences of liver cirrhosis. 2.3 PREPARATION OF 3-DEOXY-6-ETHYLCHENOCHOLANE DERIVATIVES For the preparation of 3-deoxy-6-ethylchenocholane derivatives (compounds 48-55, Scheme 8), the key step was the elimination of the hydroxyl group at C-3. This modification, as already discussed, was chosen in order to increase the selectivity of these molecules towards FXR, because the hydroxyl group at C-3 is fundamental for GPBAR1 activation.71 Intermediate 69 (obtained in quantitative yield from 7-KLCA) was prepared as described for 66, with the exception of acetylation at C-3 before the alkylation at C-6, in order to improve the chemical yield. Compound 69 was then treated over night with MeONa in methanol dry, in order to de-acetylate at C-3 and to invert the configuration at C-6 followed by tosylation at C-3, affording 70 in quantitative yield over two steps. 
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Scheme 8. Preparation of 3-deoxy-6-ethylchenocholane derivatives (subset A). a) p-TsOH, MeOH dry; b) acetic anhydride, pyridine, 84% yield over two steps; c) DIPA, n-BuLi, TMSCl, TEA dry, THF dry -78 °C; d) acetaldehyde, BF3(OEt)2, CH2Cl2, -60 °C, 80% over two steps; e) H2, Pd(OH)2, THF/MeOH 1:1, quantitative yield; f) MeONa, MeOH over night; g) p-TsCl, pyridine, quantitative yield over two steps; h) LiBr, Li2CO3, DMF dry, reflux, i) H2, Pd(OH)2, THF/MeOH 1:1, room temperature, 88% over two steps; j) LiBH4, MeOH dry, THF dry, 0 °C, 77%; k) Et3N.SO3, DMF, 95 °C; l) NaOH, MeOH:H2O 1:1 v/v, 98%; m) LiBH4, MeOH dry, THF dry, 0 °C, 83%; n) DMT-MM, Et3N, taurine, DMF dry; o) MeONa, MeOH, 2 h; p) p-TsCl, pyridine, quantitative yield over two steps; q) LiBr, Li2CO3, DMF dry, reflux; r) H2, Pd(OH)2, THF/MeOH 1:1, room temperature, 94% over two steps; s) NaBH4, MeOH dry; t) LiBH4, MeOH dry, THF, 0 °C, 78% over two steps. Elimination by LiBr/Li2CO3 treatment and hydrogenation of the unsaturated ring A transient intermediate, furnished the key derivative 71. LiBH4 reduction produced the concomitant reduction on side chain methyl ester and at C-7 carbonyl group, generating compound 48 in high chemical yield and a small aliquot of the corresponding epimer at C-7 (49), which were efficiently separated in HPLC. In the NMR proton spectra of compounds 48 and 49, the main differences were in the shape and in the chemical shift value for H-7 signal. In 48, H-7 resonated as singlet (δH 3.65), thus determining the equatorial disposition for this proton and the consequent α-configuration of the hydroxyl group on C-7. Differently, in 49, the corresponding proton signal appeared as a triplet (δH 3.07, t, J = 10.0 Hz) with a large coupling constant with H-8 and H-6, respectively, confirming their reciprocal trans di-axial relationship and therefore the β-orientation of the hydroxyl group at C-7. Chemoselective sulfation on a small aliquot of 48 gave the corresponding side chain mono-sulphate 50. Intermediate 
H COOHHO O H COOCH3AcO O7-KLCA 67 H COOCH3OAcO H COOCH3AcO O68a,b e 69H COOCH3 48  R=49  R= OHOHH COOCH3OTsO f,gc,d70 O71 H CH2OR1Rh,i jH COR1Rl,mH COOCH3AcO O o,p H COOCH3OTsO q,r H COOCH3O s,t H CH2OHOH H CH2OHOH69 72 73 50 R1=HR1=HOHR= R1=SO3Na k51  R=52  R= OHOH53 R1=OHR1=OHOHR= R1=NHCH2CH2SO3Na n 54 55
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71 was also used as starting material for the preparation of compounds 51 and 52. Basic hydrolysis with NaOH in MeOH:H2O 1:1 at methyl ester on side chain and then reduction at C-7 by LiBH4 treatment, furnished 51 in high chemical yield, with about 10% of its epimer at C-7 (52), which were separated by HPLC. Amidation with taurine on 51 using the coupling agent DMT-MM in ET3N and RP18/HPLC purification, furnished the corresponding tauro-conjugated 53. As previously demonstrated,71 the stereochemical arrangement at C-6 and C-7 on ring B profoundly influences bile acid receptor selectivity.71 The presence of a 6α-ethyl and a 7α-hydroxyl group produced potent dual agonists, whereas the 6-epimers (6β-ethyl derivatives) were characterized by selective GPBAR1 activity. To produce the 3-deoxy-6β-ethyl-chenodeoxycholane derivatives, the intermediate 69 was subjected to a controlled treatment with MeONa in MeOH (for 2 h) affording de-acetylation at C-3 position without any epimerization at C-6. Tosylation on the crude reaction product gave 72, that was subjected to the same protocol described for compound 70, producing 73 in 94% yield over two steps. NaBH4 treatment on 73 followed by LiBH4 reduction on the crude product, gave a mixture that was purified in HPLC, giving pure 54 in a 54% yield respect its C-7 epimer, compound 55. The good match between 1H and 13C NMR resonances of all nuclei belong to rings B-D of the tetracyclic core in 55 with those referred for 6β-ethyl-3α,7α-dihydroxy-5β-cholan-24-ol (46),71 allowed the definition of 6β/7α orientation in 55. The inverted configuration at C-7 in 54 was first suggested from H-7 signal shape, a dd (δH 3.67, J = 8.7, 4.7 Hz) in 1H NMR with a large coupling constant with H-8, confirming their trans diaxial relationship and the β-orientation of the hydroxyl group at C-7. Definitive confirmation derived from C-14 chemical shift at δC 57.6, invariably down-fielded shifted respect to the corresponding 7α-hydroxycholane derivatives.71 Of interest, the above protocol was unsuccessful in preparing 6β-ethyl C-24 carboxylic acid derivatives. In fact, the basic conditions for the hydrolysis at C-24 methyl ester invariably produced complete epimerization at C-6 forming the more stable thermodynamically 6α-ethyl isomer of 73, thus producing the formation of 6α-ethyl-cholanoic acid derivatives. 
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2.4 PREPARATION OF 3β-HYDROXY-6-ETHYLCHENOCHOLANE DERIVATIVES Scheme 9. Preparation of 3β-hydroxy-6-ethylchenocholane derivatives (subset B). a) CH3COOK, DMF:H2O 5:1 v/v; b) NaOMe, MeOH, 74% over two steps; c) LiBH4, MeOH dry, THF dry, 0 °C, 58%; d) NaOH, MeOH:H2O 1:1 v/v; e) LiBH4, MeOH dry, THF dry, 0 °C, 74% over two steps; f) DMT-MM, Et3N, taurine, DMF dry; g) NaBH4, MeOH dry; h) LiBH4, MeOH dry, THF dry, 0 °C, 74% over three steps. As previously demonstrated, modification at C-3 exerts a great impact on BAs selectivity towards FXR and GPBAR1. In particular, as proved for the removal of 3α-hydroxyl group, also the isomerization of the same function on LCA scaffold robustly attenuated the agonistic activity on GPBAR1. In fact, isoLCA resulted less potent compound than LCA in transactivating GPBAR1,71 whereas isochenodeoxycholic acid (iso-CDCA) resulted more potent than CDCA in transactivating FXR and was devoid of any activity towards GPBAR1.71 With this background in mind, we expanded our library producing the corresponding 3β-hydroxyl derivatives 56-60 (Scheme 9). Treatment with potassium acetate in DMF/H2O on intermediate 72 produced inversion at C-3 position on ring A. At this point two divergent protocols have been performed. First, treatment over night with MeONa/MeOH gave intermediate 74 (74% over two steps), with the α-configuration of the ethyl group at C-6 that was used as starting material in the synthesis of derivatives 56-60. In detail, alkaline hydrolysis followed by LiBH4 treatment gave a mixture of 58 and the corresponding 7β-hydroxyl derivative 59, in a small amount, efficiently separated by HPLC. A small amount of 58 was tauro-conjugated with the formation of derivative 60 in good chemical yield. In parallel, LiBH4 reduction on 74 furnished 
H COOCH3TsO O72 H COOCH3O74 H CH2OHR56  R=57  R=H COR1Ra,b OHOHc58 R=59 R= OHOH60 R= OHHO HOd,e R1=OHR1=OHR1= NHCH2CH2SO3Na fHOH CH2OHRHO a,g,h61 R=62 R= OHOH
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alcohol 56 and a small amount of the corresponding epimer 6α-ethyl-3β,7β-dihydroxy-5β-cholan-24-ol (57). In the second protocol, NaBH4 and then LiBH4 treatment on 72, as starting material, were used for the preparation of 61 and 62 as a mixture, efficiently purified in HPLC. Finally methyl ester 69 was also used for the preparation of 6-ECDCA (3), the reference compound used in the pharmacological evaluation of our library of 6-ethylcholane derivatives (Scheme 10). Prolonged basic treatment (NaOH, MeOH:H2O 1:1) on 69 furnishing the concomitant side chain methyl ester hydrolysis, de-acetylation at C-3 and inversion at C-6 ethyl group. Finally, LiBH4 treatment on intermediate 75 furnished 6-ECDCA (3), in 69% yields over two steps. Scheme 10. a) NaOH, MeOH:H2O 1:1 v/v; b) LiBH4, MeOH dry, THF dry, 0 °C, 69% over two steps.   H COOCH3AcO O H COOHHO O69 75 H COOHOHHO 6-ECDCAa b
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presence of both substituents on ring B in α-configuration produced potent FXR agonists (such as compounds 50, 51, 56 and 58).100 Compound 45 (EUDCOH or BAR501) represented the first example of UDCA derivative with a β-ethyl group at C-6. Results of its transactivation demonstrated that it was devoid of any FXR agonistic activity as its precursor UDCA. However, when compared with UDCA, EUDCOH (45) resulted more potent on GPBAR1 and able to stimulate the expression of pro-glucagon mRNA in GLUTAg cells and consequently to produce GLP-1. The increased production of this hormone (GLP-1) by 45 could be an important effect in the regulation of glucose levels in the diabetes.101 Moreover EUDCOH (45) has been subjected to a thorough pharmacological investigation showing a protective effect against liver cirrhosis. Differently, compound 44, which belonged to the same series, with both ethyl and the hydroxyl groups on ring B in α-configuration, resulted a dual agonist. Among the second library, 3-deoxycholanoic compounds 50 and 51 (subset A), differing in the nature of side chain end-group (sulfate in 50 and carboxylic acid in 51), presented potency on FXR comparable with the 6-ECDCA (3), with EC50 values of 1.1 µM and 950 nM, respectively. The same potency was shared by the corresponding 3β-hydroxyl carboxylic acid 58 (EC50 value of 1.3 µM, subset B). Their in vitro and in vivo pharmacological characterization has led to the discovery of compound 51 as first example of selective FXR agonist. Its therapeutic use could have a potential utility in the treatment of cholestasis and other FXR-mediated disorders, avoiding side effects due to the unwanted activation of GPBAR1.  
Chapter 3 
	   49	  
CHAPTER 3 6-ETHYLNORCHOLANE AND BIS-HOMO-6-ETHYLCHOLANE DERIVATIVES In this section, the preparation and the pharmacological characterization of a large family of 6-ethylcholane derivatives modified in the length of the side chain will be discussed. Firstly, we started with the synthesis of derivatives 76-78, sharing the typical 6-ECDCA scaffold, with the two hydroxyl groups in α-configuration at C-3 and C-7, but characterized to one carbon less on side chain (Figure 36). Figure 36. 3α,7α-dihydroxy-6-ethylnorcholane derivatives In addition, we also decided to manipulate the stereochemical arrangement at C-6/C-7 positions as well as the substituent/configuration at C-3 and the nature of the side chain (OH, COOH or CH2OSO3-), producing another small library of C23 6-ethylcholane derivatives (79-87), which have been explored in term of potency/selectivity towards FXR and GPBAR1 (Figure 37). Figure 37. 6-Ethylnorcholane derivatives generated in this study. Finally, the chemodiversity of availabile bile acid receptor modulators was further expanded, preparing bis-homo-6-ethylcholane derivatives 88-91 (Figure 38).   
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Figure 38. Bis-homo-6-ethylcholane derivatives generated in this study. Thorough pharmacological investigation resulted in the identification of several interesting molecules with differentiated activity profiles ranging from dual modulation to selective agonism towards FXR and /or GPBAR1. Among all compounds prepared in this study, the best hit, compound 77, a dual modulator, has been patented with the name of BAR502. 3.1 PREPARATION OF 3α ,7α-DIHYDROXY-6-ETHYLNORCHOLANE DERIVATIVES	  	  Scheme 11. Modification on the side chain of 6α-ethylcholane scaffold. a) H2, Pd/C, THF/MeOH 1:1, quantitative yield; b) NaOH 5% in MeOH/H2O 1:1 v/v, quantitative yield; c) HCOOH, HClO4, 81%; d) TFA, trifluoroacetic anhydride, NaNO2; e) KOH 30% in MeOH/H2O 1:1 v/v, 86% over two steps; f) LiBH4, MeOH dry, THF dry, 0 °C, 89%; g) LiBH4, MeOH dry, THF dry, 0 °C, 79%; h) p-TsOH, MeOH dry; i) LiBH4, MeOH dry, THF, 0 °C, 98% over two steps. CDCA was alkylated as previously described to obtain the key intermediate 65.71 Exocyclic double bond hydrogenation (H2 on Pd/C) followed by alkaline hydrolysis of methyl ester group on side chain, afforded the 3α-hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid 92 in quantitative yield. The prolonged alkaline hydrolysis with NaOH 5% in H2O:MeOH induced the epimerization at C-6 with COOHOHHHO COOCH3OHHO COOCH3OHHO COOHOHHOCOOHOHOHCO CNOHOHCO COOHOHHO COOHOHHHOa b cd e fCDCA (1) 65 66 9293 94 95 76H H H CNOHHHO 78 CH2OHOHHHO 77ref.77 g h,i
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the exclusive formation of the α-isomer at C-6. In compound 92, H-6 proton signal at δH 2.83 presented a large coupling constant (dd, J = 13.0, 5.5 Hz) and this demonstrated its axial disposition and as consequence the α-orientation of the ethyl group on C-6. Then, Fischer’s esterification on derivative 92 with formic acid and acetic anhydride102,103 formed the derivative protected at C-3 (93) in 81% yield, which was subjected to “Beckmann rearrangement” using sodium nitrite in trifluoroacetic anhydride and trifluoroacetic acid (Scheme 11).104 This mechanism of reaction is concerted, and provided an initial reaction between the carboxyl function at C-24 and the trifluoroacetic acid (TFA) to form a mixed anhydride, essential for the activation of the carbon in α position at the carboxyl group, and the subsequent nitrosation, realized by a carrier of NO. This last compound is the trifluoro acetyl nitrite, generated started from TFA and NaNO2, which in strong acidic condition (HClO4) produced nitrous acid (HNO2). The product of nitrosation reaction is α-nitroso anhydride, which gives tautomerism forming an oxime, that after the interaction with trifluoracetic anhydride (TFAA), results acetylated. Finally, heating results in the formation of nitrile through a concerted mechanism as shown in Scheme 12. To prevent the hydrolysis of the formyl group, the temperature of reaction was set at 38-40°C (Scheme 12). Scheme 12. Mechanism of Beckmann rearrangement The resulting nor-nitrile 94 was subjected to LiBH4 reduction at C-7 carbonyl group, affording 6α-ethyl-3α,7α-dihydroxy-24-nor-5β-cholan-23-nitrile or NorECDCN (78) in 79% yield as single diasteroisomer (HPLC purity >95%). Nor-nitrile 94 was also used in the preparation of compound 76 and the R COOH(CF3CO)2O O O O CF3ROF3C O NOHNO2(CF3CO)2O O O O CF3R NO O O O CF3R N OH (CF3CO)2O O O O CF3R N O OCF3R CN CO2 (CF3CO)2OR= Steroid nucleus ∆
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(10 µM). Luciferase activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. TLCA (2, 10 µM) was used as a positive control. Results are expressed as mean ± standard error. *p<0.05 versus not treated cells (NT). As shown in the Figure 39 (panels A and B), the analysis of the biological results of these compounds confirmed, as observed in the previous work for the C24 6-ethyl derivatives,99 that the α-configuration at C-6 and C-7 positions represented a key structural feature for FXR activity. In particular, of interest, were the pharmacological results on compound (77), the corresponding nor-derivative of 44,71 that resulted the most potent FXR agonist generated in this study, even if it showed a residual GPBAR1 activity. The activity of compound 77 was completely modified replacing the C-23 alcoholic function with a carboxyl or a nitrile group in 76 and 78, respectively, demonstrating a clear shift of their selectivity towards GPBAR1. 3.1.2 Pharmacological evaluation on NorECDCOH (77) In vitro Among the C23 6-ethyl compounds tested, NorECDCOH (77) represents a promising template to consider for further pharmacological experimentations. In Alphascreen assay, compound 77 was demonstrated very potent in the recruitment of SRC-1 co-activator with an efficacy comparable to that of 6-ECDCA (3). Differently, compounds 76 and 78 showed a moderate recruitment of SRC-1. Successively, the specific potency of derivative 77 was investigated by a careful measurement of its concentration-response curve on FXR and GPBAR1 transactivation. As illustrated in Figure 40 panel B, 77 was able in transactivating FXR with an EC50 of 2 µM, while transactivates GPBAR1 with an EC50 of 0.4 
µM (panel C), demonstrating its dual activity. Also, the selectivity was evaluated, testing its activity on other nuclear receptors, such as GR, PPARγ, LXR and PXR (Figure 41). As illustrated in Figure 41, panels A-C, compound 77 at the concentration of 10 µM failed to transactivate GR, PPARγ and LXR. Differently, the results of panel D confirmed its activity on nuclear receptor PXR. In order to elucidate the effective activity of this compound, we have analyzed its ability to regulate FXR and GPBAR1 canonical functions. 
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Figure 43. Effects of BAR502 on scratching behavior in GPBAR1+/+ and GPBAR1-/- mice. (A) GPBAR1+/+ and GPBAR1-/- mice were subjected to intradermal injection of DCA, TLCA, betulinic acid, oleanolic acid, PAR-2 agonist and BAR502. Each agent was tested at the dose of 25 µg. Results are expressed as the number of scratching events during 60 minutes of observation. Results are the mean ± SE of 4–8 mice per group. °p<0.05 versus control group (CTRL); *p<0.05 versus GPBAR1+/+ mice. (B-D) Desensitization of the itching pathway by a second administration of a GPBAR1 ligand. Animals were administered DCA, TLCA or betulinic acid at the dose of 50 µg. After counting scratching for 60 minutes animals were rechallenged with a second dose of the given agonist and the scratching response was recorded for a further 60 minutes of observation. Data are mean ± SE of 6–7 animals per group. p>0.01 versus first dose. Exposure to ANIT caused 100% of lethality at day 10 in GPBAR1-/- mice, while BAR502 administration saved mice from death. The scratching test was performed at day 5 and as shown in Figure 44, BAR502 failed to trigger itching. Moreover, ANIT treatment significantly increased total bilirubin and alkaline phosphatase levels in GPBAR1-/- respect GPBAR1+/+ mice, but not plasma levels of AST. BAR502 attenuated the modifications of alkaline phosphatase and AST level, but had no effect on bilirubin level (Figure 45, panels A-B). At last, a histopathology examination shown that while ANIT caused a severe liver necrosis in GPBAR1 -/-mice, this effect was reduced treating GPBAR1-/- and GPBAR1 +/+ mice with BAR502 (Figure 45, panel D).      
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 Figure 44. Effects of BAR502 on scratching behavior in GPBAR1+/+ and -/- mice administered with ANIT. GPBAR1+/+ and-/- mice were treated for 10 days with ANIT or with the combination of ANIT plus BAR502. At the end of the treatments mice were subjected to intradermal injection of DCA. (A-B) Survival of GPBAR1+/+ and GPBAR1-/- mice in response to ANIT administration. (C) Effect of ANIT on spontaneous scratching and scratching induced by DCA. Scratching tests were performed at day 5. Results are expressed as the number of scratching events during 60 minutes of observation. Results are the mean ± SE of 4–8 mice per group. *p<0.05 versus GPBAR1+/+ mice subjected to intradermal injection of DCA. #p<0.05 versus GPBAR1-/- mice subjected to intradermal injection of DCA. Figure 45. Dual FXR/TGR5 agonist BAR502 improves liver injury in both GPBAR1+/+ and GPBAR1-/- mice. GPBAR1+/+ and GPBAR1-/- mice were treated for 10 days with ANIT or with the combination of ANIT plus BAR502. Serum levels of (A) bilirubin, (B) alkaline phosphatase and (C) AST. Results are the mean ± SE of 4–8 mice per group. *p<0.05 versus GPBAR+/+ mice. °p<0.05 versus GPBAR1+/+ mice treated with ANIT. **p<0.05 versus GPBAR1-/- mice. #p<0.05 versus GP-BAR-/- mice administered with ANIT. (D) Representative histological pictures of H&E-stained livers. (E) Analysis of the number of lesions per field. Results are the mean ± SE of 4–8 mice per group. *p<0.05 versus GPBAR1+/+ mice. °p<0.05 versus GPBAR1+/+ mice treated with 
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ANIT. **p<0.05 versus GPBAR1-/- mice. #p<0.05 versus GPBAR1-/- mice administered with ANIT. 3.1.2.1 Preliminary advanced pharmacological results of 77 In a recent study BAR502 was evaluated in NASH. Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are two prevalent human disorders, which don’t present a specific treatment.106 In fact, NASH is correlated with other complications such as obesity, insulin resistance, dyslipidemia, cardiovascular disorders, cirrhosis and hepatic carcinoma.107-109 In the rodent model of NASH, HFD and fructose were administered to C57BL6 mice for 18 weeks. After four weeks of treatment, the food was reduced and the trend was maintained for all the period of study (Figures 46 A and B). After nine weeks, the mice administered with HFD were more heavy (Figure 46 A) than naïve mice (≈30% increase of body weight compared to 10%), presented high glucose levels and were insulin resistant. HFD insulin-resistant mice were then divided into two groups: HFD administered alone or in combination with BAR502 (15!mg/kg/day). At the end of the study, HFD mice developed the typical features of NASH, which includes elevated AST, cholesterol and HDL plasma levels, while plasma triacylglycerol levels were comparable to naïve mice. As illustrated in Figure 46 E, the liver weight and its percent respect to the body weight were unmodified in this model, in comparison with naïve mice of the same age, whereas the histopathology analysis showed HFD with a severe steatohepatitis and extensive fat deposition (Figure 46 D). Moreover, HFD mice had a significant increased in liver content of triacylglycerol and cholesterol than the control (Figures 46 F and 46 G). In addition, HFD mice developed a moderate liver fibrosis (Figures 46 H and 46 I) and caused the recruitment of inflammatory factor such as IL-1β, IL-6, MCP-1, RANTES and TNFα mRNA (Figure 46 L). These NASH-features were reverted with the administration of BAR502. This treatment was initiated after nine weeks of HFD; from week 9 to week 18 mice were administered only with HFD showing an increase of 3% in body weight, while the treatment with BAR502 resulted in 
≈10% decrease of body weight. BAR502 treatment increased HDL levels (Figure 46 C), reversed the lipid accumulation in liver, inducing a robust reduction of liver steatosis and content of lipids (Figures 46 D–G). In addition, it was able to reduce liver fibrosis by 70% and expression of pro-fibrogenetic genes (αSMA and 
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liver.14 In fact, BAR502 significantly reduced the expression of CD36,110 while up-regulated the expression of ABCG5, a transporter involved in cholesterol extrusion from hepatocytes (Figure 47 B).111 Figure 47. BAR502 represses fatty acid synthesis, activates export of lipids from hepatocytes and activates FXR target genes in the liver. Relative hepatic mRNA expression of genes involved in (A) Triacylglycerols and fatty acid metabolism, (B) Cholesterol metabolism, and (C) Nuclear receptors. Results are the mean ±SE of 5 mice per group. *p<0.05 versus naïve mice, #p<0.05 versus HFD mice. Values are normalized to B2M and ACTβ, the relative mRNA expression is expressed as 2(−Ct). In conclusion, 9 weeks of treatment with BAR502 were able to reverse the steatohepatitis and fibrosis in mice subjected to HFD. BAR502 was able to reduce liver cholesterol and to slightly increase HDL levels, indicating a benefic effect in the control of hepatic cholesterol homeostasis. Because BAR502 was able to attenuate fibrosis in HFD model, this compound was evaluated in reverting liver fibrosis in a rodent model of CCl4 administration. As illustrated in Figure 48, CCl4 administration caused a severe liver disorder measured from AST and bilirubin levels, reduction of albumin plasma levels and increased portal pressure (Figures 48 A and B). These biochemical modifications were associated to a severe fibrosis, as demonstrated by a morphological analysis. BAR502 administration reversed these features and exerted a protective effect against liver fibrosis development. In addition, it reduced AST and bilirubin plasma levels, increased level of albumin and reduced extracellular matrix deposition (Figure 48). 
Chapter 3 
	   61	  
Figure 48. BAR502 protects against liver fibrosis induced by CCl4. Liver fibrosis was induced by carbon tetrachloride (CCl4) administration (i.p. 500 µL/Kg body weight, twice a week for 8 weeks). CCl4 mice were randomized to receive BAR502 (15 mg/kg daily by gavage) or vehicle (distilled water). Data shown are (A) Portal pressure, (B) plasmatic levels of AST, bilirubin and albumin. (C) Hematoxylin and eosin (H&E) staining and (D) Sirius red staining on mice liver tissues; (E) Image J quantification of Sirius red staining. Total RNA extracted from liver was used to evaluate by RT-PCR the relative mRNA expression of (F) marker genes of fibrosis, (G) genes involved in endothelial function and (H) Nuclear receptor genes. Results are the mean ±SE of 6–12 mice per group. *p<0.05 versus naïve mice. #p<0.05 versus CCl4 alone. In addition, mice treatment with BAR502 protected against portal hypertension caused by CCl4 administration. This was the result of induction of both eNOS and CSE genes, which induced vasodilatation by producing nitric oxide (NO) and hydrogen sulfide (H2S), respectively. Because these two genes are expressed in liver sinusoidal cells, which in turn express GPBAR1, this effect could be considered a signal of hepatic GPBAR1 activation.73,112 In summary, in this recent discovery, BAR502 resulted able to exert protective effects against NASH-features, induced in a mice model of HFD. Collectively these data suggest that the dual FXR/GPBAR1 modulation could be a useful tool in treating NASH.   
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3.2 PREPARATION OF 3α-HYDROXY-6-ETHYLNORCHOLANE DERIVATIVES Scheme 13. Preparation of intermediate 98. a) HCOOH, HClO4; b) TFA, trifluoroacetic anhydride, NaNO2; c) KOH 30% in MeOH/H2O 1:1 v/v, 66% over three steps; d) p-TsOH, MeOH dry, quantitative yield. For the preparation of 3α-hydroxy-6-ethylnorcholane derivatives 79-83, the first step was the preparation of the key intermediate methyl ester of 7-keto-norLCA (98) starting from the 7-KLCA as previously reported (Scheme 13).48 Fischer’s esterification with formic acid and perchloric acid on 7-KLCA intermediate, generated the formiate derivative 96, that was successively subjected to a Beckmann rearrangement by treatment with sodium nitrite in a mixture of trifluoroacetic anhydride/trifluoroacetic acid, obtaining the nor-nitrile derivative 97.104 Prolonged alkaline hydrolysis using KOH 30%, furnished the corresponding carboxylic acid that was in turn transformed with methanol and p-toluenesulfonic acid, in the corresponding derivative methylated 98 (66% yield starting from 7-KLCA). Acetylation at C-3 and a consequent Knoevenagel condensation to a silyl enol ether intermediate produced the intermediate 99 (60% over three steps, Scheme 14) that was hydrogenated on the exocyclic double bond with H2 and Pd(OH)2 giving the exclusive formation of the 6β-epimer 100 (quantitative yield). Compound 100 was then treated with an excess of NaBH4 in methanol dry and subjected to LiBH4 reduction directly on the crude product, to give the contemporary deacetylation at C-3 and reduction on C-7 and C-23 positions. HPLC purification afforded the derivative 79 as main product and a small aliquot of its epimer at C-7, compound 81. 
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Scheme 14. Synthesis of 3α-hydroxy-6-ethylnorcholane derivatives. a) acetic anhydride, pyridine; b) DIPA, n-BuLi, TMSCl, TEA dry, THF dry -78 °C; c) acetaldehyde, BF3•OEt2, CH2Cl2, -60 °C, 60% over three steps; d) H2, Pd(OH)2, THF/MeOH dry 1:1, quantitative yield; e) NaBH4, MeOH dry, 0 °C; f) LiBH4, MeOH dry, THF dry, 0 °C, 77% over two steps; g) NaBH4, MeOH dry; h) LiBH4, MeOH dry, THF dry, 0 °C, 85% over two steps; i) H2, Pd(OH)2, THF:MeOH dry 1:1 v/v, quantitative yield; j) NaBH4, MeOH dry, 0 °C; k) NaOH, MeOH:H2O 1:1 v/v, 82% over two steps. In parallel, intermediate 100 was subjected to a controlled NaBH4 reaction, in order to reduce the C-7 ketone group, and maintaining the methyl ester function on compound 101, which was subjected to basic hydrolysis affording the carboxylic acid 80 in 82% over two steps. Intermediate 99 was also used as starting material to prepare derivatives 82 and 83. NaBH4 reaction followed by LiBH4 treatment on 99 produced the 7β-hydroxyl derivatives, as confirmed by the shape of H-7 as a doublet (J = 9.8 Hz), which justified the axial disposition of this proton, and as consequence the β-orientation of the hydroxyl group in the same position. The analysis of NOESY spectrum revealed dipolar couplings H-7/H-24 and Me-25/H-5 defining the E configuration of the exocyclic double bond as illustrated in 82. At the end, catalytic hydrogenation with Pd(OH)2 gave derivative 83, with the presence of a 6α-ethyl group.   
COOMeOHHO COOMeOHAcO COOMeOHAcOa,b,c d98 99 100e,f CH2OHOHHHO CH2OHOHHHO79 81g,h82i83 OHHHOOHHHO CH2OHCH2OH
COROHHHO 101 R=OMe80   R=OHjk
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3.3 PREPARATION OF 3-DEOXY- AND 3β-HYDROXY-6α-ETHYLNORCHOLANE DERIVATIVES Scheme 15. Synthesis of 3-deoxy- and 3β-hydroxy-6α-ethylnorcholane derivatives. a) MeONa, MeOH dry; b) p-TsCl, pyridine, 73% over two steps; c) LiBr, Li2CO3, DMF dry, reflux; d) H2, Pd(OH)2, THF/MeOH dry 1:1, room temperature, quantitative yield over two steps; e) LiBH4, MeOH dry, THF dry, 0 °C, 70%; f) NaOH, MeOH:H2O 1:1 v/v; g) LiBH4, MeOH dry, THF dry, 0 °C, 92% over two steps; h) CH3COOK, DMF:H2O 5:1 v/v; i) NaOH, MeOH:H2O 1:1 v/v; j) LiBH4, MeOH dry, THF dry, 0 °C, 58% over two steps; k) LiBH4, MeOH dry, THF dry, 0 °C, 57%. To prepare 3-deoxy- and 3β-hydroxy-6-ethylnorcholane derivatives 84–87, the key intermediate 100 was subjected to a treatment with MeONa in methanol, in order to de-acetylate the C-3 position and to invert the C-6 position and then to tosylation reaction, using p-tosyl chloride, in order to produce compound 102, in 73% yield over two steps (Scheme 15). Basic treatment with LiBr/Li2CO3 and then hydrogenation on the unsaturated ring A gave 103, which was used as starting material for the preparation of compounds 84 and 85. LiBH4 reduction at C-7 keto and C-23 methyl ester groups gave 84 in 70% chemical yield after purification, whereas alkaline hydrolysis of the methyl ester group followed by LiBH4 treatment and HPLC, gave the carboxyl acid 85 in 92% yield. Finally, the tosyl derivative 102 was also used for the preparation of compounds 86 and 87. Potassium acetate in DMF/H2O treatment furnished the key intermediate 104, with the 3β-hydroxyl group. Reduction at C-7 and C-23 positions using LiBH4 gave, after HPLC purification, compound 86 in 57% yield, while basic hydrolysis 
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The aldehyde was then used as substrate for the following Horner-homologation reaction with methyl (triphenylphosphoranylidene)acetate, giving the protected 
∆
24,25 bis-homo-ECDCA methyl ester 107, in 79% chemical yield (Scheme 16). Hydrogenation on side chain double bond, followed by de-protection with HCl 37% on 107, gave the methyl ester 88 that was used as starting material for the preparation of the carboxylic acid (89) through treatment with NaOH and of the corresponding alcohol 90, using LiBH4 reduction. Further, a small amount of alcohol 90 was subjected to a chemoselective sulfation on C-26 hydroxyl group, giving after RP18 column and HPLC purification, the corresponding sulfate derivative 91 in 25% yield.113 Scheme 16. Preparation of bis-homo-6-ethylcholane derivatives. a) 2,6-lutidine, t-butyldimethylsilyl trifluoromethanesulfonate, CH2Cl2, 0 °C; b) LiBH4, MeOH dry, THF dry, 0 °C, 68% over two steps; c) DMSO, oxalyl chloride, TEA dry, CH2Cl2, −78 °C then methyl (triphenylphosphoranylidene)acetate, 79%; d) H2, Pd(OH)2/C Degussa type, THF/MeOH 1:1, quantitative yield; e) HCl 37%, MeOH, 88%; f) NaOH 5% in MeOH/H2O 1:1 v/v, 89%; g) LiBH4, MeOH dry, THF dry, 0 °C, 78%; h) Et3N.SO3, DMF dry, 95 °C, 25%. 3.5 PHARMACOLOGICAL EVALUATION OF 3α-HYDROXY-, 3-DEOXY-, 3-β-HYDROXY-6-ETHYLNORCHOLANE AND BIS-HOMO-6-ETHYLCHOLANE DERIVATIVES Compounds 79-91 were tested on FXR and GPBAR1 in a luciferase reporter assay on HepG2 and HEK-293T cells, previously transfected with responsive elements for the two receptors. Data shown in Figure 49, panel A, reported the results of FXR transactivations. Once again, the 6α/7α-configuration on ring B represents a peculiar feature for FXR activation. In fact derivatives 79-83, with one or two substituents in β-configuration on ring B, were devoid of any activity on FXR when administered at fixed concentration of 10 µM. Of interest are the 
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transactivation result. Interestingly, the presence of the not conjugable functional group such as the sulfate group on the side chain, points the attention on the positive pharmacokinetic properties of compound 91 and therefore on its therapeutical potential in FXR-mediated diseases. Results on Figure 52, panel A, confirm the inactivity of compounds 79, 81, and 82 towards FXR and indirectly affirm compound 79 as a selective GPBAR1 agonist. RT-PCR in Figure 52, panels B-D, confirmed 91 as dual FXR/GPBAR1 agonist, able to induce the expression of BSEP and OSTα, two canonical FXR targeted genes,114 and of GLP-1, a GPBAR1-regulated effect. Figure 52. (A) Coactivator recruitment assay measuring a direct interaction of FXR with SRC-1; ligands at   2 µM. Results are expressed as percentage of the effect of 3 arbitrarily settled as 100%. NT is referred to the experiment in absence of ligand. Results are expressed as mean ± standard error. (B, C) Real-time PCR analysis of mRNA expression on FXR target genes BSEP (C), and OSTα (B) in HepG2 cells primed with 10 µM of compound 91. CDCA (1) was used as a positive control at 10 µM. (D) Real-time PCR analysis of mRNA expression of GPBAR1 target gene Pro-glucagon (GLP-1) in GLUTAg cells stimulated with 10 µM of compounds 79 and 91, and TLCA (2) used as a positive control at 10 µM. Values are normalized to GAPDH and are expressed relative to those of not treated cells (NT), which are arbitrarily settled to 1. The relative mRNA expression is expressed as 2(−∆∆Ct). In summary, in this chapter I have presented additional chemical modifications on 6-ECDCA scaffold that include the length/nature of the side chain end-group and the stereochemical arrangement of the tetracyclic core. Looking to the pharmacological results on nor-derivatives 76-78, with all substituents on rings A and B in α-configuration, it is possible to establish that the side chain exerts an important influence on the receptor selectivity. Shortened side chain with a hydroxyl terminal group produces a potent FXR agonist (NorECDCOH or 77, EC50 of 2 µM) while the introduction of a negative charge, NorECDCA (76), or a neutral end-group, NorECDCN (78), improves GPBAR1 activity. Indeed, 77 was also endowed with GPBAR1 activity and was able to increase pro-glucagon gene 
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expression in GLUTAg cells. However, because it was most potent to induce FXR canonical functions, it could be considered a preferential FXR ligand. Supporting this view, 77 does not induce itching when administered in in vivo rodent model of cholestasis and presents benefic effects in rodent model of NASH. Furthermore, derivatives 79-91 add important information in term of SAR. As expected, also in this series, the α-orientation of both substituents at C-6 and C-7 positions plays a significant role in FXR and GPBAR1 activities, with all derivatives showing this feature invariably dual agonists (84–91), independently from the length or functional group on side chain as well as the substitution at C-3. On the contrary, modifications on the configuration of one or both substituents on ring B is clearly detrimental in terms of FXR activation, but result an appealing strategy in the identification of selective GPBAR1 agonists, such as compound 79, which was the most potent GPBAR1 activator identified in this study, devoid of any FXR activity.115 	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CHAPTER 4 ASYMMETRIC DIVERSITY-ORIENTED SYNTHESIS OF BENZO-FUSED CYCLIC AMINES Another consistent part of my Ph.D. project was spent in the Centro de Investigación Príncipe Felipe of Valencia, under the supervision of Prof. Santos Fustero. In this period I have participated in the asymmetric diversity-oriented synthesis of benzo-fused cyclic amines. Diversity-oriented synthesis (DOS) is an emerging field consisting in the synthesis of different libraries of molecules for biological screening, which can be used to identify novel ligands for a variety of targets. Modern drug discovery often is based on the screening of small molecules able to bind specific protein target and this target-oriented synthesis, towards individual molecules or focused libraries, can be obtained by retrosynthetic analysis. Also, drug discovery involves screening of small molecules able to modulate biological pathways in the organisms, without any particular activities for specific target. So in the context of this need to reach an efficient and versatile synthetic approach capable to generate complex and different molecular libraries, the diversity-oriented synthesis (DOS) of small molecules is the access key towards new chemotypes with high chemical diversity. One desired goal of DOS is to synthesize a collection of small molecules able to perturb a particular biological pathway, giving eventually the identification of therapeutic proteins that are target of small molecules. DOS provides to obtain different chemical libraries using the minimum number of synthetic steps, starting from a common precursor.116-121 The key for a successful result of this strategy is the use of a suitable substrate with appropriate functional groups in strategic positions. These substituents also must be able to participate in as many different transformations as possible, increasing the complexity of molecules achieved. In the last years, Fustero’s group worked hard in the asymmetric synthesis of benzo-fused carbo-122-128 and heterocycles,127-130 using the 2-halobenzaldehyde as building block (Figure 53).131 
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Figure 53. 2-halobenzaldehyde in Diversity-oriented synthesis Starting from this strategy, they have synthesized interesting building blocks, such as fluorinated128,129 and non-fluorinated isoindolines,129 indanones,126 fluorinated isoindolinones127 and aminosteroid derivatives.123 In literature there are many examples of using of 2-halobenzaldehyde in different synthetic processes for its versatility and ability to produce diverse chemical scaffolds. One example of the involvement of 2-halobenzaldehyde is the synthesis of the antidepressant sertraline by Fustero’s group. In fact, through DOS the 2-halobenzaldehyde was recognized as the starting material of different benzo-fused carbo- and heterocycles such as isoquinolines, indanones and in particular the tetrahydronaphthalene nucleus, which respect the others is more commonly found in natural products or drugs. The more important examples of drugs, which present the tetrahydronaphtalene core are the analgesic morphine and the antidepressant sertraline.124 Figure 54. The analgesic morphine and the antidepressant sertraline So with this aim the synthesis of sertraline was performed and consisted in the three-step one-pot protocol starting from the corresponding aldehyde (Figure 55).124 
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Figure 61. Hypothesized retrosynthesis for 1-amino-1,2-dihydronaphthalene-derived vinyl fluorides The interest to produce fluorine derivatives depends on the great impact that organofluorine compounds have exerted in key industrial fields such as pharmaceutical, agrochemical, or materials industries. For examples many fluorolefins were found in antidiabetes and anti-HIV drugs. The most interesting characteristic is their bioisoterism with an amide group, which confers to fluorolefins the possibility to be incorporated in peptidomimetics, conferring a resistance from proteolytic degradation. Figure 62. Fluorolefin-containing drugs and bioisosterism with amides For their synthesis the reaction conditions were explored, producing a small library of fluorine derivatives (12a-g) where the brome atom adjacent to the fluorine was removed through an optimized treatment with 4 equivalents of NaH in DMF dry. Finally, to reduce the number of steps necessary to afford benzo-fused fluorolefin derivatives, was discovered that the o-(1-fluorovinyl)-benzaldehyde derivative (OFVBA) was a suitable starting material for the condensation/asymmetric allylation/RCM reaction sequence (Figure 64). 
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Scheme 18. Preparation of 3-methylene-1-aminoindane derivatives In order to reach a sustainable methodology, we decided to apply on the 2-iodobenzaldehyde 1a the same optimal reaction conditions showed for compound 2a, to produce the Heck product 5a in one-pot reaction. As illustrated in the Scheme 19, the Ellman amine was firstly added to 2-iodobenzaldehyde 1a in order to produce the imine intermediate. Then it was subjected to an asymmetric allylation with allylzinc bromide and finally to intramolecular Heck reaction. In this way we obtained the derivative 5a in 70% yield over three steps as single diasteroisomer. Scheme 19. Preparation of derivative 5a in one-pot condensation/asymmetric allylation/Heck reaction sequence Moreover, to expand the series of achievable molecules, 5a was submitted to two different processes: first, this compound was subjected to a catalytic hydrogenation with Pd/C in MeOH at room temperature giving cis compound 18a in high chemical yield, whereas an oxidative cleavage of the methylene group, afforded the 3-aminoindanone derivative 19a in 90% yield. At the end, this last intermediate 19a was subjected to a stereoselective reduction on ketone group affording the cis-1,3-aminoalcohol derivative 20a, in 70% yield (Scheme 20). 
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4.3 STUDY OF THE ONE-POT CONDENSATION/ASYMMETRIC ALLYLATION/INTRAMOLECULAR PAUSON-KHAND REACTION (PKR) SEQUENCE Starting from the notable experience in terms of one-pot Ellman’s sulfinimides transformations,124 we decided to apply another one-pot protocol for the asymmetric synthesis of tricyclic enones, using the intramolecular PKR.123 We started our study applying the four-step one-pot transformation: condensation/allylation/Sonogashira/ PKR. However, after the reaction, the desired product 23a was obtained in low concentration (<10%), while compound 2a was obtained in 30% chemical yield, suggesting that the Sonogashira reaction conditions were not fully compatible with the previous protocol of condensation/allylation reactions (Scheme 23). Scheme 23. One-pot condensation/asymmetric allylation/Sonogashira coupling/PKR As Sonogashira coupling seemed to be the obstacle for this one-pot procedure, we decided to perform this step independently and then to apply the one-pot procedure for the corresponding o-alkynylbenzaldehyde derivatives 24a and 24b (Scheme 24). As we can observe, the chemical yield of the one-pot procedure is significantly lower than the corresponding stepwise protocol (Scheme 24), even though the one-pot methodology presents a considerable operational simplicity. Moreover, the diastereoselectivity of compound 24a was affected, as expected, in the one-pot procedure (Scheme 24). This is linked to the dependence of the diastereoselectivity with the substitution at the triple bond, as described in a previous report.123 Differently, the isolation of a single diastereoisomer for compound 24b might be due to a loss of small quantities of minor diastereoisomers during the purification, in accord to the low comprehensive chemical yield obtained (20%, Scheme 24).  
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Scheme 24. One-pot condensation/asymmetric allylation/PKR sequence Concluding, in this report we have described the diversity-oriented synthesis of different substrates starting from available starting material. In particular the 2-iodobenzaldehyde has demonstrated its superior performance as a substrate for diversity-oriented synthesis. Specifically, we have explored the optimization of intramolecular Heck reaction conditions after the obtainment of an undesired product during the Sonogashira cross-couplin reaction. After this, an asymmetric allylation on Ellman’s imines followed by intramolecular Heck reaction afforded 3-methylene-1-aminoindane derivatives, which were subjected to other chemical modifications. On the other hand, also the RCEYM reaction was explored and was observed that the introduction of an alkynyl group in ortho-position to the tert-butylsulfonyl amines, formed substrates suitable to achieve conjugated dienes. Also, we applied the one-pot procedures of asymmetric allylation/intramolecular Heck reaction and of condensation/asymmetric allylation/Pauson–Khand reaction sequence, observing that even though it was a good strategy in an operative point of view, however, it is at expense of chemical yields, which were notable more high in stepwise reaction than in the one-pot procedures.  
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CONCLUSIONS In my PhD research activity, different libraries of promising molecules have been prepared and pharmacologically evaluated in their interaction with bile acid receptors, FXR and GPBAR1. Medicinal chemistry modifications have been performed on endogenous bile acids CDCA and UDCA and on the most potent dual and semisynthetic derivative 6-ECDCA, in order to obtain selective bile acid receptor modulators. In a first phase, compound 7 has been identified as a FXR ligand with an EC50 of ~9 µM. Even though compound 7 resulted less potent than the 6-ECDCA, it induced the expression of FXR targeted genes, mainly OSTα, with a comparable potency with that of the reference molecule. Moreover, compound 7 has been demonstrated a selective FXR agonist without activity towards GPBAR1 in transactivation assay and without inducing the expression of GPBAR1-regulated genes, such as pro-glucagon (or GLP-1), in RT-PCR. The above profile affirms this compound an ideal candidate in the treatment of hepatic FXR-mediated disorders17 where the concomitant GPBAR1 activation induces exacerbation of cholestatic itching. Further, starting from compound 7, we decided to harness the 6-ECDCA scaffold applying these peculiar chemical modifications:  1 Modifications at C-3 hydroxyl group (deletion/inversion) 2 Modifications of the nature of the side chain end-group 3 Modifications on stereochemical arrangement at C6/C7. Except compound 45, which preserves the 3α-OH group, all 6-ethylcholane derivatives prepared in this study were weak GPBAR1 agonists, thus confirming the key role of this functional group in GPBAR1 activation. In addition, the presence of both substituents on ring B in α-configuration produced potent FXR agonists (such as compounds 50, 51, 56 and 58).100 In this part of my project, further pharmacological investigations have been focalized on compounds 45 and 51. Compound 45 is a selective GPBAR1 ligand, which maintains the tetracyclic core of UDCA. In transactivation assay, compound 45 resulted a potent GPBAR1 ligand with an EC50 of 1 µM and devoid of any FXR agonistic activity. Of interest, in vivo pharmacological evaluation affirmed this molecule as a promising candidate in liver cirrhosis. Compound 51 has been demonstrated a selective FXR 
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agonist with a potency (EC50 value of 950 nM) comparable with that of 6-ECDCA (3). Further, compound 51 induces the expression of FXR regulated genes in an ex-vivo RT-PCR assay, also reducing in vivo blood concentration of 7α-hydroxy-4-cholesten-3-one, a key intermediate in the primary bile acid synthesis. Finally, in the third year of Ph.D. activity, I have turned my attention on 6-ECDCA side chain, modifying the length and the nature of the end-group. In this way, the chemical diversity was expanded producing a large library of molecules with truncate or elongated side chains and differentiated in the stereochemical arrangements at C-6/C-7 positions and in the substitution at C-3. In the context of nor-derivatives, the side chain end-group exerts an important influence on receptor selectivity, with the alcohol 77, a potent FXR agonist, while a negative charged end-group, such as in compound 76, or a neutral end-group (78), improved GPBAR1 activity. The most interesting was compound 77, which resulted a potent FXR ligand with an EC50 of 2 µM. Also, it presents a residual activity on GPBAR1 resulting a dual modulator. In addition, further in vivo pharmacological investigations on this compound have been performed. When administered in rodent model of cholestasis, compound 77 did not induce exacerbation of cholestatic itching and in contemporary, it was able to exert protective effects against NASH-features in a mice model of HFD. Moreover, all derivatives with both C-6 and C-7 groups α-orientated, showed a dual activity (84–91), independently by the length of the side chain and by the nature of the end-group, with the bis-homo derivative 91, a potent and selective FXR agonist. Finally, in Valencia, I worked in the diversity-oriented synthesis of different substrates starting from available starting material. Specifically, the optimization of intramolecular Heck reaction conditions have been performed, and after this, an asymmetric allylation on Ellman’s imines followed by intramolecular Heck reaction was applied, affording a class of 3-methylene-1-aminoindane derivatives, which were subjected to further chemical modifications. In contemporary, the RCEYM reaction has been explored demonstrating that the presence of an alkynyl group in ortho to the tert-butyl sulfonyl amines, is instrumental in the preparation of conjugated dienes.  
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EXPERIMENTAL SECTION I. General experimental procedures Chemistry. Specific rotations were measured on a Jasco P-2000 polarimeter. High-resolution ESI-MS spectra were performed with a Micromass Q-TOF mass spectrometer. NMR spectra were obtained on Varian Inova 400, 500 and 700 NMR spectrometers (1H at 400, 500 and 700 MHz, 13C at 100, 125 and 175 MHz, respectively) equipped with a SUN microsystem ultra5 hardware and recorded in CD3OD (δH = 3.31 and, δC = 49.0 ppm) and CDCl3 (δH =7.26 and, δC =77.0 ppm). All of the detected signals were in accordance with the proposed structures. Coupling constants (J values) are given in Hertz (Hz), and chemical shifts (δ) are reported in ppm and referred to CHD2OD and CHCl3 as internal standards. Spin multiplicities are given as s (singlet), br s (broad singlet), d (doublet), or m (multiplet). Through-space 1H connectivities were evidenced using a ROESY experiment with mixing times of 200 and 250 ms, respectively. HPLC was performed with a Waters Model 510 pump equipped with Waters Rheodine injector and a differential refractometer, model 401. Reaction progress was monitored via thin-layer chromatography (TLC) on Alugram silica gel G/UV254 plates. Silica gel MN Kieselgel60 (70-230 mesh) from Macherey-Nagel Company was used for column chromatography. All chemicals were obtained from Sigma-Aldrich, Inc. Silica gel (200-400 mesh) from Macherey-Nagel Company was used for flash chromatography. All chemicals were obtained from Sigma-Aldrich, Inc. Solvents and reagents were used as supplied from commercial sources with the following exceptions. Hexane, ethyl acetate, chloroform, dichloromethane, tetrahydrofuran and triethylamine were distilled from calcium hydride immediately prior to use. Methanol was dried from magnesium methoxide as follow. Magnesium turnings (5 g) and iodine (0.5 g) were refluxed in a small (50-100 mL) quantity of methanol until all of the magnesium has reacted. The mixture was diluted (up to 1 L) with reagent grade methanol, refluxed for 2-3 h then distilled under nitrogen. All reactions were carried out under argon atmosphere using flame-dried glassware. The purities of compounds were determined to be greater than 95% by HPLC. 
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Cell cultures. HepG2 cells were cultured in E-MEM supplemented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin. GLUTAg cells were originally donated by Dr. Drucker D.J., Banting and Best Diabetes Centre, University of Toronto, Toronto General Hospital, 200 Elizabeth Street MBRW-4R402, Toronto, Canada M5G 2C4. GLUTAg cells were cultured in D-MEM, supplemented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin. THP-1 cells were cultured in RPM-I supplemented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin.  Transactivation assay. For FXR mediated transactivation, HepG2 cells were plated at 5x104 cells/well in a 24-well plate. Cells were transfected with 200 ng of the reporter vector p(hsp27)-TK-LUC containing the FXR response element IR1 cloned from the promoter of heat shock protein 27 (hsp27), 100 ng of pSG5-FXR, 100 ng of pSG5-RXR, and 100 of pGL4.70 (Promega), a vector encoding the human Renillagene. The reporter plasmid p(hsp27)-TKLUC has been developed and validated for FXR reporter activity as previously reported.136 At 24 h post-transfection, cells were stimulated 18 h with 10 µM CDCA (1), and compounds tested. For GP-BAR1 mediated transactivation, HEK-293T cells were plated at 1 x 104 cells/well in a 24 well-plate and transfected with 200 ng of pGL4.29 (Promega), a reporter vector containing a cAMP response element (CRE) that drives the transcription of the luciferase reporter gene luc2P, with 100 ng of pCMVSPORT6-human GP-BAR1, and with 100 ng of pGL4.70. At 24 h post-transfection, cells were stimulated 18 h with 10 µM TLCA (2) and compounds tested. After treatments, 10 µL of cellular lysates were read using Dual Luciferase Reporter Assay System (Promega Italia s.r.l., Milan, Italy) according manufacturer specifications using the Glomax 20/20 luminometer (Promega Italia s.r.l., Milan, Italy). For dose-response curves, cells were transfected as described above and then treated with increasing concentrations of compounds tested (0.1, 0.5, 1 and 10 and 50 µM); luciferase activities were assayed and normalized with Renilla activities. To investigate the specificity of some compounds HepG2 cells were transiently transfected with 200 ng reporter vector p(UAS)5XTKLuc, 100 ngpGL4.70 and with a series of vectors containing the ligand binding domain of various nuclear receptors (PPARγ, LXR and GR) cloned upstream of the GAL4-DNA binding domain (i.e. pSG5-PPARγLBD-GAL4DBD, pSG5-LXRLBD-
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GAL4DBD and pSG5-GRLBD-GAL4DBD). At 48 h post-transfection, cells were stimulated 18 h with the appropriate nuclear receptor agonist or with compounds of interest. To investigate the PXR mediated transactivation, HepG2 cells were transfected with 100 ng pSG5-PXR, 100 ng pSG5-RXR, 100 ngpGL4.70 and with 200 ng of the reporter vector containing the PXR target gene promoter (CYP3A4 gene promoter) cloned upstream of the luciferase gene (pCYP3A4promoter-TKLuc). At 48 h post-transfection, cells were stimulated 18 h with 10 µM rifaximin or with compounds tested. Real-Time PCR. Total RNA was isolated using the TRIzol reagent according to the manufacturer’s specifications (Invitrogen). One microgram of purified RNA was treated with DNaseI for 15 min at room temperature, followed by incubation at 95 °C for 3 min in the presence of 2.5 mmol/L EDTA. The RNA was reverse transcribed with Superscript III (Invitrogen) in 20 µL reaction volume using random primers. For Real Time PCR, 10 ng template was dissolved in a 25 µL containing 200 nmol/L of each primer and 12.5 µL of 2X SYBR FAST Universal ready mix (Invitrogen). All reactions were performed in triplicate, and the thermal cycling conditions were as follows: 2 min at 95 °C, followed by 40 cycles of 95 °C for 20 s, 60 °C for 30 s in iCycleriQ instrument (Biorad). The relative mRNA expression was calculated and expressed as 2-(ΔΔCt). Forward and reverse primer sequences were the following:  human GAPDH: gaaggtgaaggtcggagt and catgggtggaatcatattggaa;  human OSTα: tgttgggccctttccaatac and ggctcccatgttctgctcac; human BSEP: gggccattgtacgagatcctaaandtgcaccgtcttttcactttctg;  human SHP: gctgtctggagtccttctgg and ccaatgatagggcgaaagaagag; mouse GAPDH: ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mouse Pro-glucagon: tgaagacaaacgccactcac and caatgttgttccggttcctc. cAMP measurement. cAMP generation in THP-1 cells was assayed using the Direct Cyclic AMP enzyme Immunoassay Kit (Arbor Assay cat. Number K019-H1). THP-1 cells were serum starved over night and then stimulated for 30 min with 10 µM Forskolin or compounds of interest. Direct interaction on FXR by Alphascreen technology in a coactivator recruitment assay. Anti-GST-coated acceptor beads were used to capture the GST-fusion FXR-LBD whereas the biotinylated-SRC-1 peptide was captured by 
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the streptavidin donor beads. Upon illumination at 680 nm, chemical energy is transferred from donor to acceptor beads across the complex streptavidin-Donor/Src-1-Biotin/GSTFXR-LBD/Anti-GST-Acceptor and a signal is produced. The assay was performed in white, low-volume, 384-well Opti plates (PerkinElmer) using a final volume of 25 µL containing final concentrations of 10 nM of purified GST-tagged FXR-LBD protein, 30 nM biotinylated Src-1 peptide, 20 µg/mL anti-GST acceptor beads acceptor beads and 10 µg/mL of streptavidin donor bead (PerkinElmer). The assay buffer contained 50 mM Tris (pH 7.4), 50 mM KCl, 0.1% BSA, and 1 mM DTT. The stimulation times with 1 µL of tested compound (dissolved in 50% DMSO/H2O) were fixed to 30 min at room temperature. The concentration of DMSO in each well was maintained at a final concentration of 4%. After the addition of the detection mix (acceptor and donor beads) the plates were incubated in the dark for 4 h at room temperature and then were read in Envision microplate analyzer (PerkinElmer).  
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II. Experimental procedures for chenocholane and ursocholane derivatives Synthesis of 3-deoxychenocholane derivatives Methyl 3α-hydroxy-7-keto-5β-cholan-24-oate (32). An oven-dried 250 mL flask was charged with chenodeoxycholic acid (2.0 g, 5.1 mmol), sodium bromide (30.0 mg, 0.250 mmol), tetrabutylammonium bromide (5.40 g, 16.8 mmol), and 43 mL of a solution of MeOH/CH3COOH/H2O/AcOEt, 3:1:0.25:6.5 v/v. The mixture was stirred at room temperature until a homogeneous solution formed and then cooled at 0 °C. Sodium hypochlorite solution (10%, 5.0 mL, 5.6 mmol) was added, until the test for hypochlorite (peroxide test paper) was positive, and the yellow suspension was stirred. The mixture was stirred at room temperature for 6 h. Aqueous sodium bisulfite (3.3%) was added to afford a white suspension (negative test for peroxide). Water (50 mL) was added and the mixture stirred at 15 °C for 5 min. Aqueous solution was extracted with AcOEt (3 × 50 mL). The combined organic layer was washed with aqueous sodium bisulfite (50 mL) and water (50 mL) and then dried over anhydrous MgSO4 and evaporated in vacuo to give 2.0 g of 3α-hydroxy-7-keto-5β-cholan-24-oic acid, which was subjected to the next step without any purification. To a solution of this latter intermediate (2.0 g, 5.1 mmol) in MeOH dry (30 mL), p-toluenesulfonic acid (4.40 g, 25.5 mmol) was added. The solution was left to stand at room temperature for 2 h. The mixture was quenched by addition of NaHCO3 saturated solution. After the evaporation of the methanol, the residue was extracted with EtOAc (3 x 150 mL). The combined extract was washed with brine, dried with Na2SO4, and evaporated to give the methyl esters as amorphous solid 32 (1.5 g, 72.7% over two steps). [α]D25= -7.0, c= 0.4. Selected 1H NMR (400 MHz, CDCl3): δ 3.65 (3H, s), 3.55 (1H, m), 2.81 (1H, dd, J =5.9 e 12.3 Hz), 2.33 (1H, m), 2.17 (1H, m), 1.19 (3H, s), 0.88 (3H, d, J = 6.4 Hz), 0.60 (3H, s). 13C NMR (100 MHz, CDCl3): δ 212, 178.3, 71.3, 55.1, 49.9, 49.3, 46.3, 45.6, 43.0, 39.2, 39.0, 37.7, 35.5, 34.5, 31.1, 30.9, 30.2, 29.3, 28.6, 23.3, 22.0, 18.7, 14.4, 12.7. Methyl 7α-hydroxy-5β-cholan-24-oate (33). To a solution of methyl ester of 7-keto-lithocholic acid (32) (130 mg, 0.32 mmol) in dry pyridine (10 mL), tosyl chloride (613 mg, 3.22 mmol) was added, and the mixture was stirred at room temperature for 4 h. It was poured into cold water (10 mL) and extracted with CH2Cl2 (3 × 10 mL). The combined organic layer was washed with saturated 
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NaHCO3 solution (10 mL), and water (10 mL), and then dried over anhydrous MgSO4 and evaporated in vacuo to give 180 mg of methyl 3α-tosyloxy-7-keto-5β-cholan-24-oate (quantitative yield) in the form of colorless needles, that was subjected to next step without any purification. Lithium bromide (55 mg, 0.64 mmol) and lithium carbonate (47 mg, 0.64 mmol) were added to a solution of methyl 3α-tosyloxy-7-keto-5β-cholan-24-oate (180 mg, 0.32 mmol) in dry DMF (10 mL), and the mixture was refluxed for 3 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution (50 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic layer was washed successively with water, saturated NaHCO3 solution and water, and then dried over anhydrous MgSO4 and evaporated to dryness to give 124 mg of oily residue (quantitative yield), that was subjected to next step without any purification. An oven-dried 10 mL flask was charged with 10% palladium on carbon (30 mg) and the previously obtained crude intermediate (124 mg, 0.320 mmol) and the flask was evacuated and flushed with argon. Absolute methanol (5 mL) and dry THF (5 mL) were added, and the flask was flushed with hydrogen. The reaction was stirred at room temperature under H2 (1 atm) over night. The mixture was filtered through Celite, and the recovered filtrate was concentrated to give 125 mg of methyl 7-keto-5β-cholan-24-oate (quantitative yield), that was subjected to next step without any purification. Methyl 7-keto-5β-cholan-24-oate (125 mg, 0.320 mmol) was dissolved in a solution of tetrahydrofuran/water (10 mL, 4/1 v/v) and treated at 0 °C with NaBH4 (720 mg, 1.9 mmol). After 2 h, water and MeOH were added dropwise during a period of 15 min at 0 °C with effervescence being observed. Then after evaporation of the solvents, the residue was diluted with water, acidified with HCl 1 M and extracted with AcOEt (3 x 10 mL). The combined organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to obtain 125 mg of 33 (quantitative yield). [α]D25= +3.5 (c= 2.82, CH3OH); selected 1H NMR (500 MHz, CDCl3): δ 3.84 (1H, s), 3.66 (3H, s), 2.34 (1H, m), 2.22 (1H, m), 0.92 (3H, d, J = 6.5 Hz), 0.90 (3H, s), 0.66 (3H, s); HRMS-ESI m/z 391.3216 [M + H]+, C25H43O3 requires 391.3212. 7α-hydroxy-5β-cholan-24-oic acid (4). Compound 33 (56 mg, 0.15 mmol) was hydrolyzed with a methanol solution of sodium hydroxide (5%, 10 mL) in H2O 
Experimental Section II 
	   92	  
(2 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to give compound 4 in quantitative yield (58 mg). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (95:5) as eluent (flow rate 1 mL/min, tR=8.2 min); [α]D25= -5.3 (c= 0.03, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.79 (1H, s), 2.33 (1H, m), 2.23 (1H, m), 0.96 (3H, d, J = 6.4 Hz), 0.93 (3H, s), 0.70 (3H, s); 13C NMR (100 MHz, CD3OD): δ 178.3,69.4, 57.3, 51.5, 44.9, 43.7, 41.1, 40.8, 38.8, 37.0, 36.2, 34.1, 32.4, 31.6, 30.8, 29.2, 29.0, 24.6, 24.2, 23.4, 22.6, 21.8, 18.8, 12.2; HRMS-ESI m/z 375.2903 [M-H]−, C24H39O3 requires 375.2899. 7α-hydroxy-5β-cholan-24-oyl taurine sodium salt (5). Compound 4 (15.0 mg, 39.9 x 10-3 mmol) in DMF dry (3 mL) was treated with DMT-MM (33 mg, 0.12 mmol) and triethylamine (140 µL, 1.00 mmol) and the mixture was stirred at room temperature for 10 min. Then to the mixture was added taurine (30.0 mg, 0.240 mmol). After 24 h, the reaction mixture was concentrated in vacuo and dissolved in water (5 mL). The solution was poured over a C18 silica gel column. Fraction eluted with H2O/MeOH 99:1 gave a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (83:17) as eluent (flow rate 1 mL/min), to give 7 mg (35%) of compound 5 (tR=7.6 min); [α]D25= -58.2 (c= 0.02, CH3OH); selected 1H NMR (500 MHz CD3OD): δ 3.79 (1H, s), 3.59 (2H, t, J = 7.3 Hz), 2.96 (2H, t, J = 7.3 Hz), 0.97 (3H, d, J = 7.1 Hz), 0.93 (3H, s), 0.69 (3H, s); HRESIMS m/z 482.2951 [M-Na]-, C26H44NO5S requires 482.2940. 7α-hydroxy-5β-cholan-24-ol (6). Dry methanol (50.0 µL, 1.26 mmol) and LiBH4 (630 µL, 2 M in THF, 1.26 mmol) were added to a solution of the compound 33 (70 mg, 0.3 mmol) in dry THF (10 mL) at 0 °C under argon and the resulting mixture was stirred for 3 h at 0 °C. The mixture was quenched by addition of NaOH (1 M, 4 mL) and then allowed to warm to room temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 × 15 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated. Purification by silica gel eluting with 
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ethyl acetate- hexane (85:15) gave the alcohol 6 as a white solid (52 mg, 79%). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (95:5) as eluent (flow rate 1 mL/min, tR=8 min); [α]D25= +5.2 (c= 0.53, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 3.79 (1H, br s), 3.51 (2H, t, J = 6.6 Hz), 0.97 (3H, d, J = 6.6 Hz), 0.93 (3H, s), 0.70 (3H, s); 13C NMR (100 MHz, CD3OD): δ 69.4, 63.6, 57.6, 51.6, 45.6, 43.6, 42.8, 41.1, 40.9, 38.9, 37.0, 36.2, 34.1, 33.3, 31.6, 30.3, 29.3, 29.0, 24.7, 24.5, 22.6, 21.8, 19.2, 12.2; HRMS-ESI m/z 363.3271 [M+H]+, C24H42O2 requires 363.3263. 7α-hydroxy-5β-cholan-24-yl-24-sodium sulfate (7) and 5β-cholan-7α,24-dyl-7,24-disodium disulfate (8). At a solution of diol 6 (40 mg, 0.1 mmol) in DMF dry (3 mL) was added triethylamine-sulfur trioxide complex (88 mg, 0.55 mmol) under an argon atmosphere, and the mixture was stirred at 80 °C for 24 h. Most of the solvent was evaporated and the residue was poured over a RP18 column to remove excess SO3·NEt3. Fraction eluted with MeOH:H2O 45:55 gave a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (50:50) as eluent (flow rate 1 mL/min), to give 24 mg (39%) of compound 8 (tR=20.4 min). [α]D25= -9.3 (c= 0.14, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 4.42 (1H, s), 3.95 (2H, br t, J = 6.5 Hz), 0.96 (3H, d, J = 6.5 Hz), 0.94 (3H, s), 0.69 (3H, s); HR ESIMS m/z 543.2070 [M-Na]-, C24H40O8S2Na requires 543.2062. Fraction eluted with MeOH gave a mixture that was further purified by on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (90:10) as eluent (flow rate 1 mL/min), to give 28 mg (55%) of compound 7 (tR=6.6 min). [α]D25= -7.0 (c= 0.28, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 3.96 (2H, t, J = 6.6 Hz), 3.78 (1H, br s), 3.30 (1H, ovl), 0.96 (3H, d, J = 6.5), 0.92 (3H, s), 0.69 (3H, s); 13C NMR (100 MHz, CD3OD): δ 69.7, 69.4, 57.7, 51.6, 45.0, 43.8, 41.2, 41.0, 39.0, 37.1, 36.3, 34.2, 33.3, 34.2, 33.3, 31.7, 29.5, 29.0, 27.3, 24.3, 22.7, 21.9, 19.2, 12.3; HR ESIMS m/z 441.2679 [M-Na]-, C24H41O5S requires 441.2675. Synthesis of 3β-chenodeoxycholane derivatives 3α-tosyloxy-7α-hydroxy-5β-cholan-24-oate (39). To a solution of CDCA methyl ester (400 mg, 1 mmol) in dry pyridine (10 mL), tosyl chloride (382 mg, 2 x 10-3 
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mol) was added, and the mixture was stirred at room temperature for 4 h. It was poured into cold water (20 mL) and extracted with CH2Cl2 (3 × 50 mL). The combined organic layer was washed with saturated NaHCO3 solution (30 mL), and water (30 mL), and then dried over anhydrous MgSO4 and evaporated in vacuo to give 555 mg of 39 (quantitative yield) in the form of colourless oil. [α]D25= +22.6 (c= 0.93, CH3OH); selected 1H NMR (500 MHz, CDCl3): δ 7.80 (2H, d, J = 8.7 Hz), 7.34 (2H, d, J = 8.5), 4.38 (1H, m), 3.83 (1H, s), 3.62 (3H, s), 2.40 (3H, s), 2.35 (1H, m), 2.23 (1H, m), 0.93 (3H, d, J = 6.4 Hz), 0.89 (3H, s), 0.65 (3H, s); HR ESIMS m/z 561.3288 [M+H]+, C32H49O6S requires 561.3283. Methyl 3β,7α-dihydroxy-5β-cholan-24-oate (40). A solution of 39 (555 mg, 0.990 mmol) and CH3COOK (97 mg, 0.99 mmol) dissolved in water (2 mL) and N,N-dimethylformamide (DMF, 10 mL) was refluxed for 2 h. The solution was cooled at room temperature and then ethyl acetate and water were added. The separated aqueous phase was extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with water, dried (Na2SO4) and evaporated to dryness to give 600 mg of mixture. Purification by silica gel (hexane-ethyl acetate 7:3 and 0.5% TEA) gave 40 as oily oil (300 mg, 75%). [α]D25= +2.6 (c= 1.5, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.96 (1H, s), 3.79 (1H, s), 3.63 (3H, s), 2.47 (dt, J = 2.3, 13.7 Hz), 2.36 (1H, m), 2.26 (1H, m), 0.95 (3H, s), 0.94 (3H, ovl), 0.68 (3H, s); 13C NMR (100 MHz, CD3OD): δ 171.7, 69.3, 67.7, 57.3, 52.0, 51.6, 43.7, 41.1, 40.7, 37.5 (2C), 36.7 (2C), 35.5, 33.4, 32.3, 31.9, 31.0, 29.3, 28.6, 24.6, 23.8, 22.1, 18.8, 12.2; HR ESIMS m/z 407.3173 [M+H]+, C25H43O4 requires 407.3161. 3β,7α-dihydroxy-5β-cholan-24-oic acid (19). Compound 40 (70.0 mg, 0.172 mmol) was hydrolyzed with a methanol solution of sodium hydroxide (5%, 5 mL) in H2O (1 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 5 mm i.d. x 250 mm) with MeOH/H2O (75:25) as eluent (flow rate 1 mL/min), gave 60 mg of 19 as a white solid (89%, tR=22 min). [α]D25= +11 (c= 0.07, CH3OH); selected 1H 
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NMR (400 MHz, CD3OD): δ 3.97 (1H, s), 3.79 (1H, s), 2.47 (1H, dt, J = 2.34, 13.8 Hz), 2.28 (1H, m), 2.13 (1H, m), 0.96 (3H, d, ovl), 0.95 (3H, s), 0.69 (3H, s); HR ESIMS m/z 391.2856 [M-H]-, C24H39O4 requires 391.2848. 3β,7α-dihydroxy-5β-cholan-24-ol (20). 2,6-lutidine (570 µL, 4.90 mmol) and tert-butyldimethylsilyl trifluoromethanesulfonate (336 µL, 1.50 mmol) were added at 0 °C to a solution of 40 (200 mg, 0.5 mmol) in 10 mL of CH2Cl2. After 2 h stirring at 0 °C, the reaction was quenched by addition of aqueous NaHSO4 (1 M, 30 mL). The layers were separated and the aqueous phase was extracted with CH2Cl2 (3 × 100 mL). The combined organic layers were washed with NaHSO4, water, saturated aqueous NaHCO3, and brine and evaporated in vacuo to give 310 mg of methyl 3β, 7α-di(tert-butyldimethylsilyloxy)-5β-cholan-24-oate (quantitative yield) in the form of colorless needles, that was subjected to next step without any purification. To a solution of methyl ester (310 mg, 0.49 mmol) in dry THF (10 mL) at 0 °C, dry methanol (140 µL, 3.4 mmol) and LiBH4 (1.7 mL, 2M in THF, 3.4 mmol) were added. The resulting mixture was stirred for 1 h at 0 °C. The mixture was quenched by addition of 1 M NaOH (1 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated to give 250 mg of 41 as a white solid (84%).	  Methyl ester 41 (200 mg, 0.3 mmol) was dissolved in methanol (5 mL) and 500 µL of HCl 37% v/v were added. After 2 h, silver carbonate was added at the solution to precipitate chloride. Then the reaction mixture was centrifuged and the supernatant was concentrated in vacuo. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 5 mm i.d. x 250 mm) with MeOH/H2O (9:1) as eluent (flow rate 1 mL/min), gave 120 mg of compound 20 as a white solid (96%, tR=7 min). [α]D25= +22.8 (c= 0.06, CH3OH); selected 1H NMR (500 MHz, CD3OD): δ 3.98 (1H, s), 3.80 (1H, s), 3.50 (2H, m), 0.97 (3H, d, J = 6.7 Hz), 0.96 (3H, s), 0.70 (3H, s). 13C NMR (125 MHz, CD3OD): δ 69.3, 67.7, 63.6, 57.6, 51.6, 43.7, 41.1, 40.7, 37.5, 37.4, 37.1, 36.7, 35.5, 33.4, 33.2, 31.0, 30.3, 29.3, 28.5, 24.6, 23.8, 22.1, 19.2, 12.2; HR ESIMS m/z 379.3219 [M+H]+, C24H43O3 requires 379.3212. 3β,7α-dihydroxy-5β-cholan-24-yl-24-sodium sulphate (21). The triethylamine-sulfur trioxide complex (65.6 mg, 0.410 mmol) was added to a solution of 41 
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(50.0 mg, 82.5 x 10-3 mmol) in DMF dry (5 mL) under an argon atmosphere, and the mixture was stirred at 80◦C over night. The solution was then concentrated under vacuum to give 100 mg of crude mixture. The solid was dissolved in methanol (5 mL) and at the solution was added 300 µL of HCl 37% v/v. After 1h, silver carbonate was added at the solution to precipitate chloride. Then the reaction mixture was centrifuged and the supernatant was concentrated in vacuo. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 5 mm i.d. x 250 mm) with MeOH/H2O (55:45) as eluent (flow rate 1 mL/min), gave 30 mg of 21 as colorless amorphous solid (76% over two steps, tR=11.4 min). [α]D25= +18.4 (c= 0.04, CH3OH); selected 1H NMR (500 MHz, CD3OD): δ 3.97 (3H, m), 3.80 (1H, s), 2.49 (1H, t, J = 14.3 Hz), 0.97 (3H, d, ovl), 0.96 (3H, s), 0.70 (3H, s); HR ESIMS m/z 457.2632 [M-Na]-, C24H41O6S requires 457.2624. Synthesis of 3-deoxyursocholane derivatives Methyl 3α-tosyloxy-7β-hydroxy-5β-cholan-24-oate (34). To a solution of UDCA methyl ester (400 mg, 1 mmol) in dry pyridine (10 mL), tosyl chloride (280 mg, 1.5 mmol) was added, and the mixture was stirred at room temperature for 2 h. It was poured into cold water (10 mL) and extracted with CH2Cl2 (3 × 10 mL). Purification by silica gel eluting with ethyl acetate-hexane (8:2) gave compound 34 (320 mg, 58%) as a white solid. [α]D25= +37.6 (c= 0.70, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 7.79 (2H, d, J = 8.5 Hz), 7.33 (2H, d, J = 8.5), 4.40 (1H, m), 3.52 (1H, m), 2.46 (3H, s), 2.35 (1H, m), 2.23 (1H, m), 0.92 (3H, ovl), 0.91 (3H, s), 0.66 (3H, s); HR ESIMS m/z 561.3259 [M+H]+, C32H49O6S requires 561.3250. 7β-hydroxy-5β-cholan-24-oic acid (9). Lithium bromide (73 mg, 0.84 mmol) and lithium carbonate (62 mg, 0.84 mmol) were added to a solution of methyl ester 34 (220 mg, 0.42 mmol) in dry DMF (10 mL), and the mixture was refluxed for 2 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution (10 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic layer was washed successively with water, saturated NaHCO3 solution and water, and then dried over anhydrous MgSO4 and evaporated to dryness to give 162 mg of oily residue (quantitative yield), that was subjected to next step without any purification. 
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An oven-dried 10 mL flask was charged with 10% palladium on carbon (5 mg) and the product obtained (162 mg, 0.420 mmol) and the flask was evacuated and flushed with argon. Absolute methanol (5 mL) and dry THF (5 mL) were added, and the flask was flushed with hydrogen. The reaction was stirred at room temperature under H2 (1 atm) over night. The mixture was filtered through celite, and the recovered filtrate was concentrated to give 128 mg of compound 35 (78%). An amount of compound 35 (40 mg, 1.02 x 10-1 mmol) was hydrolyzed with a methanol solution of sodium hydroxide (5%, 5 mL) in H2O (1 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 20 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to give 9 in a quantitative yield (39.5 mg). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (78:22) as eluent (flow rate 1 mL/min, tR=13.2 min). [α]D25= -95.0 (c= 0.08, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.45 (1H, m), 2.32 (1H, m), 2.21 (1H, m), 0.96 (3H, s), 0.95 (3H, ovl), 0.71 (3H, s); HR ESIMS m/z 375.2901 [M-H]-, C24H39O3 requires 375.2899. 7β-hydroxy-5β-cholan-24-oyl taurine sodium salt (10). Compound 9 (9.0 mg, 2.4 x 10-2 mmol) in DMF dry (3 mL) was treated with DMT-MM (20.0 mg, 71.7 x 10-3 mmol) and triethylamine (85 µL, 0.60 mmol) and the mixture was stirred at room temperature for 10 min. Then to the mixture was added taurine (18 mg, 0.14 mmol). After 24 h, the reaction mixture was concentrated in vacuo and dissolved in water (5 mL). The solution was poured over a C18 silica gel column. Fraction eluted with H2O/MeOH 99:1 gave a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (73:27) as eluent (flow rate 1 mL/min), to give 3.3 mg of 10 (27%, tR=18 min). [α]D25= +4.8 (c= 0.08, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.57 (2H, t, J = 7.2), 3.46 (1H, m), 2.95 (2H, t, J = 7.2), 0.96 (6H, ovl), 0.70 (3H, s); HR ESIMS m/z 482.2945 [M-Na]-, C24H39O3 requires 482.2940. 7β-hydroxy-5β-cholan-24-ol (11). Dry methanol (22 µL, 0.55 mmol) and LiBH4 (276 µL, 2 M in THF, 0.550 mmol) were added to a solution of the compound 
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35 (72 mg, 18.4 x 10-2 mmol) in dry THF (10 mL) at 0 °C under argon and the resulting mixture was stirred for 3 h at 0 °C. The mixture was quenched by addition of NaOH (1.0 M, 0.36 mL) and then allowed to warm to room temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 × 15 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated to give 61 mg of 11 as a white solid (91% yield). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (95:5) as eluent (flow rate 1 mL/min, tR=16 min). [α]D25= +114.6 (c= 0.04, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.51 (2H, t, J = 6.5 Hz), 3.46 (H, m), 0.96 (3H, s), 0.95 (3H, d, ovl), 0.71 (3H, s); HRMS-ESI m/z 363.3268 [M+H]+, C24H42O2 requires 363.3263. 5β-cholan-7β,24-diyl-7,24-disodium disulfate (13) and 7β-hydroxy-5β-cholan-24-yl-24-sodium sulfate (12). At a solution of diol 11 (50.0 mg, 0.138 mmol) in DMF dry (5 mL) was added triethylamine-sulfur trioxide complex (125 mg, 0.690 mmol) under an argon atmosphere, and the mixture was stirred at 80°C for 24 h. Most of the solvent was evaporated and the residue was poured over a RP18 column to remove excess SO3·NEt3. Fraction eluted over a RP18 column with H2O:MeOH 1:1 gave a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (65:35) as eluent (flow rate 1 mL/min), to give 32 mg of 13 (41%, tR=12.4 min); [α]D25= -15.4 (c= 0.03, CH3OH); selected1H NMR (400 MHz CD3OD): δ 3.96 (2H, m), 3.49 (1H, m), 0.97 (6H, ovl), 0.71 (3H, s); HR ESIMS m/z 543.2069 [M-Na]-, C24H40O8S2Na requires 543.2062. Fraction eluted over a RP18 column with MeOH gave a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (83:17) as eluent (flow rate 1 mL/min), to give 26 mg of compound 12 (41%, tR=5.4 min); [α]D25= +21.4 (c= 1.46, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 4.28 (1H, m), 3.96 (2H, m), 0.99 (3H, s), 0.98 (3H, ovl), 0.72 (3H, s); 13C NMR (100 MHz, CD3OD): δ 81.0, 70.9, 56.6 (2C), 45.4, 44.8, 42.6, 41.3, 40.5, 38.3, 36.8, 35.6, 35.2, 33.1, 29.5, 28.8, 28.2, 27.0, 26.9, 
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24.6, 22.1, 21.8, 19.1, 12.5; HR ESIMS m/z 441.2681 [M-Na]-, C24H41O5S requires 441.2675. Synthesis of 5β-cholane derivatives Methyl 3α,7β-ditosyloxy-5β-cholan-24-oate (36). To a solution of UDCA methyl ester (300 mg, 0.7 mmol) in dry pyridine (20 mL), tosyl chloride (1.39 g, 7.30 mmol) was added, and the mixture was stirred at room temperature for 6 h. It was poured into cold water (30 mL) and extracted with CH2Cl2 (3 × 30 mL). Purification by silica gel eluting with ethyl acetate-hexane (8:2) gave 36 (521 mg, quantitative yield) as a white solid. [α]D25= -11 (c= 0.48, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 7.79 (2H, d, J = 8.3 Hz), 7.75 (2H, d, J = 8.3 Hz), 7.36 (2H, d, J = 8.3 Hz), 7.32 (2H, d, J = 8.3 Hz), 4.58 (1H, m), 4.38 (1H, m), 3.67 (3H, s), 2.47 (3H, s), 2.45 (3H, s), 2.33 (1H, m), 2.22 (1H, m), 0.91 (3H, d, J = 6.5 Hz), 0.88 (3H, s), 0.61 (3H, s); HR ESIMS m/z 715.3333 [M+H]+, C39H55O8S2 requires 715.3338. Methyl 5β-cholan-24-oate (37) and 8α epimer 38. Lithium bromide (45 mg, 0.52 mmol) and lithium carbonate (38 mg, 0.52 mmol) were added to a solution of 36 (190 mg, 0.26 mmol) in dry DMF (20 mL), and the mixture was refluxed for 3 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution (50 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined organic layer was washed successively with water, saturated NaHCO3 solution and water, and then dried over anhydrous MgSO4 and evaporated to dryness to give 124 mg of oily residue (quantitative yield), that was subjected to next step without any purification. An oven-dried 10 mL flask was charged with 10% palladium on carbon (10 mg) and the crude product (124 mg, 0.230 mmol) and the flask was evacuated and flushed with argon. Absolute methanol (5 mL) and dry THF (5 mL) were added, and the flask was flushed with hydrogen. The reaction was stirred at room temperature under H2 (1 atm) over night. The mixture was filtered through celite, and the recovered filtrate was concentrated to give 95 mg of crude product, that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH:H2O (995:5) as eluent (flow rate 3 mL/min), to give 25 mg of compound 38 (26%, tR= 25.5 min) and 32 mg of compound 37 (33%; tR= 33 min).  
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Methyl 5β-cholan-24-oate (37). [α]D25= -3.0 (c= 0.03, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 3.66 (3H, s), 2.33 (1H, m), 2.20 (1H, m), 0.91 (6H, ovl), 0.65 (3H, s); 13C NMR (100 MHz, CDCl3): δ 171.9, 56.6, 56.0, 51.5, 43.8, 40.5 (2C), 40.3, 37.7, 35.9, 35.4 (2C), 31.0 (2C), 28.2, 27.5, 27.3, 27.1, 26.5, 24.2 (2C), 21.3, 20.8, 18.2, 12.0; HR ESIMS m/z 375.3267 [M+H]+, C25H43O2 requires 375.3263. Compound 38. [α]D25= +19.7 (c= 0.02, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 3.68 (3H, s), 2.46 (1H, m), 2.35 (1H, dd, J = 10.1, 5.3), 0.95 (3H, d, J = 6.5 Hz), 0.84 (3H, s), 0.81 (3H, s); 13C NMR (100 MHz, CDCl3): δ 172.2, 56.6, 51.5, 43.9 (2C), 37.3, 37.1, 36.7, 35.9, 35.3 (2C), 34.1, 31.0, 30.8, 27.7, 27.1 (2C), 26.6, 25.7, 24.9, 24.6, 21.7, 19.4, 18.7, 18.3; HR ESIMS m/z 375.3265 [M+H]+, C25H43O2 requires 375.3263. 5β-cholan-24-ol (14). Dry methanol (8.0 µL, 0.19 mmol) and LiBH4 (95 µL, 2 M in THF, 0.19 mmol) were added to a solution of 37 (10.0 mg, 26.7 x 10-3 mmol) in dry THF (5 mL) at 0 °C under argon and the resulting mixture was stirred for 3 h at 0 °C. The mixture was quenched by addition of NaOH (1.0 M, 55 µL) and then allowed to warm to room temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 × 15 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated to give 7.8 mg of 14 (84%). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (999.5:0.5) as eluent (flow rate 1 mL/min, tR=18 min); [α]D25= +20.5 (c= 0.20, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 3.62 (2H, m), 0.94 (3H, d, ovl), 0.92 (3H, s), 0.65 (3H, s); 13C NMR (100 MHz, CDCl3): 
δ 63.7, 56.7, 56.3, 43.9, 42.8, 40.6 (2C), 40.3, 37.8, 36.0, 35.6, 31.9, 29.5, 28.3, 27.6, 27.3 (2C), 27.0, 26.8, 24.4, 21.4, 20.9, 18.7, 12.2; HR ESIMS m/z 347.3321 [M+H]+, C24H43O requires 347.3314. 5β-cholan-24-yl-24-sodium sulfate (15). At a solution of 14 (5.0 mg, 1.45 x 10-2 mmol) in DMF dry (3 mL) was added triethylamine-sulfur trioxide complex (12 mg, 7.25 x 10-2 mmol) under an argon atmosphere, and the mixture was stirred at 80°C for 24 h. Most of the solvent was evaporated and the residue was poured over a RP18 column to remove excess SO3·NEt3. Fraction eluted with MeOH 
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give 1.5 mg of compound 15 (23%). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (98:2) as eluent (flow rate 1 mL/min, tR=9.9 min); [α]D25= +9.0 (c= 0.88, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.64 (2H, m), 0.96 (3H, d, ovl), 0.95 (3H, s), 0.69 (3H, s); 13C NMR (100 MHz, CD3OD): δ 69.7, 57.6, 47.9, 45.2, 43.8, 41.9, 41.6, 38.7, 37.3, 36.8, 36.5, 33.2, 29.3, 28.6, 28.4, 28.2, 27.7, 27.1, 25.3, 24.8, 22.4, 22.0, 19.2, 12.5; HR ESIMS m/z 425.2732 [M-H]-, C24H41O4S requires 425.2726. Compound 16. Compound 38 (12.0 mg, 32.0 x 10-3 mmol) was hydrolyzed with a methanol solution of sodium hydroxide (5%, 5 mL) in H2O (1 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to give 9 mg of carboxylic acid 16 (78%). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (99:1) as eluent (flow rate 1 mL/min, tR=21 min); [α]D25= +12.7 (c= 0.28, CHCl3); selected 1H NMR (400 MHz, CD3OD): δ 2.42 (1H, m), 2.28 (1H, m), 0.97 (3H, d, J = 6.8 Hz), 0.85 (3H, s), 0.81 (3H, s); HR ESIMS m/z 359.2958 [M-H]-, C24H39O2 requires 359.2950. Compound 17. Compound 17 (18 mg, 97%) was synthesized, starting from compound 38 (20.0 mg, 53.5 x 10-3 mmol), by analogous procedures to those detailed above for compound 14. An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (999.5:0.5) as eluent (flow rate 1 mL/min, tR=15.8 min); [α]D25= +2.9 (c= 0.18, CHCl3); selected 1H NMR (400 MHz, CDCl3): δ 3.64 (2H, m), 0.97 (3H, d, J = 6.3), 0.85 (3H, s), 0.81 (3H, s); 13C NMR (100 MHz, CDCl3): δ 63.6, 56.9, 44.1 (2C), 42.6, 37.4 (2C), 36.7, 36.1, 35.3, 34.2, 31.7, 29.3, 27.7, 27.2, 27.1, 26.6, 25.8, 24.9, 24.6, 21.7, 19.5, 19.1, 18.1; HR ESIMS m/z 347.3318 [M+H]+, C24H43O requires 347.3314. Compound 18. Compound 18 (8.8 mg, 43%) was synthesized, starting from compound 17 (16.0 mg, 46.2 x 10-3 mmol), by an analogous procedure to that detailed above for compound 15. An analytical sample was obtained by HPLC 
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on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (98:2) as eluent (flow rate 1 mL/min, tR=9 min); [α]D25= +9.7 (c= 0.15, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.96 (2H, m), 0.98 (3H, d, J = 6.3 Hz), 0.87 (3H, s), 0.81 (3H, s); HR ESIMS m/z 425.2733[M-Na]-, C24H41O4S requires 425.2726. Synthesis of 3β-ursodeoxycholane derivatives Methyl 3β,7β-dihydroxy-5β-cholan-24-oate (42). A solution ofcompound 34 (0.10 g, 0.18 mmol) and CH3COOK (18 mg, 0.18 mmol) dissolved in water (1 mL) and N,N-dimethylformamide (DMF, 4 mL) was refluxed for 3 h. The solution was cooled at room temperature and then ethyl acetate and water were added. The separated aqueous phase was extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with water, dried (Na2SO4) and evaporated to dryness. Purification by silica gel (hexane-ethyl acetate 7:3 and 0.5% TEA) gave 42 as an oil (60 mg, 82%). [α]D25= +27.4 (c= 0.10, CH3OH); selected 1H NMR (500 MHz, CDCl3): δ 4.06 (1H, s), 3.65 (3H, s), 3.54 (1H, m), 2.34 (1H, m), 2.21 (1H, m), 0.98 (3H, s), 0.92 (3H, d, J = 6.8 Hz), 0.67 (3H, s); HR ESIMS m/z 407.3169 [M+H]+, C25H43O4 requires 407.3161. 3β,7β-dihydroxy-5β-cholan-24-oic acid (22). Compound 42 (30.0 mg, 73.9 x 10-3 mmol) was hydrolyzed with a methanol solution of sodium hydroxide (5%, 5 mL) in H2O (1 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 5 mm i.d. x 250 mm) with MeOH/H2O (75:25) as eluent (flow rate 1 mL/min), gave 25 mg of 22 as white solid (87%, tR= 10.5 min). [α]D25= +38.1 (c= 0.14, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 4.00 (1H, s), 3.44 (1H, m), 0.99 (3H, s), 0.96 (3H, d, J = 6.3 Hz), 0.69 (3H, s); HR ESIMS m/z 391.2853 [M-H]-, C25H39O4 requires 391.2848. 3β,7β-dihydroxy-5β-cholan-24-ol (23). 2,6-lutidine (86 µL, 0.74 mmol) and tert-butyldimethylsilyl trifluoromethanesulfonate (51 µL, 9.0 mmol) were added at 0 °C to a solution of 42 (30.0 mg, 73.9 x 10-3 mmol) in 5 mL of CH2Cl2. After 
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2 h stirring at 0 °C, the reaction was quenched by addition of aqueous NaHSO4 (1.0 M, 10 mL). The layers were separated and the aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were washed with NaHSO4, water, saturated aqueous NaHCO3, and brine and evaporated in vacuo to give 45 mg of methyl 3β,7β-di(tert-butyldimethylsilyloxy)-5β-cholan-24-oate (96%) in the form of colorless needles, that was subjected to next step without any purification. To a solution of methyl ester (45.0 mg, 71 x 10-3 mmol) in dry THF (5 mL), at 0 °C dry methanol (20 µL, 0.50 mmol) and LiBH4 (250 µL, 2M in THF, 0.50 mmol) was added. The resulting mixture was stirred for 1 h at 0 °C. The mixture was quenched by addition of 1.0 M NaOH (35 µL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated to give 40 mg of 43 as a white solid (94%), that was dissolved in methanol (3 mL) and treated with 100 µL of HCl 37% v/v. After 2 h, silver carbonate was added at the solution to precipitate chloride. Then the reaction mixture was centrifuged and the supernatant was concentrated in vacuo. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (9:1) as eluent (flow rate 1 mL/min), gave 18 mg of compound 23 as a white solid (96%, tR= 6.5 min). [α]D25= +32.5 (c= 0.31, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 4.00 (1H, s), 3.52 (2H, m), 3.43 (1H, m), 1.00 (3H, s), 0.96 (3H, d, J = 6.5 Hz), 0.72 (3H, s); 13C NMR (100 MHz, CD3OD): 
δ 72.0, 67.4, 63.6, 57.6, 56.7, 44.8, 44.4, 41.6, 40.1, 38.6, 38.3, 37.0, 35.6, 35.2, 33.3, 30.8, 30.3, 29.7, 28.4, 27.9, 24.5, 22.7, 19.4, 12.7; HR ESIMS m/z 379.3219 [M+H]+, C24H43O3 requires 379.3212. 3β,7β-dihydroxy-5β-cholan-24-yl-24-sodium sulfate (24). The triethylamine-sulfur trioxide complex (20.0 mg, 0.120 mmol) was added to a solution of 43 (15.0 mg, 24.7 x 10-3 mmol) in DMF dry (5 mL) under an argon atmosphere, and the mixture was stirred at 80◦C for 24h. The solution was then concentrated under vacuum. The solid was dissolved in methanol (3 mL) and at the solution was added 50 µL of HCl 37% v/v. After 1h, silver carbonate was added at the solution to precipitate chloride. Then the reaction mixture was centrifuged and the supernatant was concentrated in vacuo. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 5 mm i.d. x 250 mm) with MeOH/H2O (55:45) as eluent (flow 
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rate 1 mL/min), gave 8 mg of 24 as colourless amorphous solid (67% over two steps, tR= 13.5 min). [α]D25= +30 (c= 0.26, CH3OH); selected 1H NMR (500 MHz, CD3OD): δ 4.00 (1H, s), 3.96 (2H, m), 3.44 (1H, m), 0.99 (3H, s), 0.97 (3H, d, J = 6.6 Hz), 0.72 (3H, s); HR ESIMS m/z 457.2631 [M-Na]-, C24H41O6S requires 457.2624.   
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Spectroscopic Data 1H NMR (400 MHz, CD3OD) of compound 4   	  	  13C NMR (100 MHz, CD3OD) of compound 4 	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1H NMR (500 MHz, CD3OD) of compound 5 	   	  	  	  1H NMR (400 MHz, CD3OD) of compound 6 	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13C NMR (100 MHz, CD3OD) of compound 6 	  	  	   	    1H NMR (400 MHz, CD3OD) of compound 7   	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13C NMR (100 MHz, CD3OD) of compound 7 	  	   	  	  	  1H NMR (400 MHz, CD3OD) of compound 8 	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1H NMR (400 MHz, CD3OD) of compound 9 	  	  	  1H NMR (400 MHz, CD3OD) of compound 10 	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1H NMR (400 MHz, CD3OD) of compound 11 	  	  	  	   	   1H NMR (400 MHz, CD3OD) of compound 12 	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1H NMR (400 MHz, CD3OD) of compound 13 	  	   	    1H NMR (400 MHz, CDCl3) of compound 14 	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13C NMR (100 MHz, CDCl3) of compound 14 	  	  	  	  	   	  	   1H NMR (400 MHz, CD3OD) of compound 15 	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1H NMR (400 MHz, CDCl3) of compound 16  	   1H NMR (400 MHz, CDCl3) of compound 17 	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13C NMR (100 MHz, CDCl3) of compound 17 	  	   	   1H NMR (400 MHz, CD3OD) of compound 18  	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1H NMR (400 MHz, CD3OD) of compound 19  	   1H NMR (500 MHz, CD3OD) of compound 20  
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13C NMR (150 MHz, CD3OD) of compound 20  	  	  1H NMR (400 MHz, CD3OD) of compound 21 	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1H NMR (400 MHz, CD3OD) of compound 22 	  	   	    1H NMR (400 MHz, CD3OD) of compound 23  	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13C NMR (100 MHz, CD3OD) of compound 23 	  	   	  	   1H NMR (500 MHz, CD3OD) of compound 24  
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III. Experimental procedures for 6-ethylchenodeoxycholane derivatives Methyl 3α,7α-trimethylsilyloxy-5β-cholan-6-en-24-oate (64). To a solution of diisopropylamine (6.80 mL, 48.1 mmol) in dry THF (10 mL) was added dropwise a solution of n-butyllithium (18 mL, 2.5 M in hexane, 45 mmol) at −78 °C under nitrogen atmosphere. After 30 min, trimethylchlorosilane (8.10 mL, 64.2 mmol) was added, and the resulting mixture was reacted for an additional 20 min. A solution of methyl 3α-hydroxy-7-keto-5β-cholan-24-oate (32) (1.30 g, 3.21 mmol), previously prepared, in dry THF (10 mL) was added dropwise in 10 min. The mixture was stirred at −78 °C for an additional 45 min, and then triethylamine (16.3 mL, 115.6 x 10-3 mol) was added. After 1 h, the reaction mixture was allowed to warm to −20 °C, treated with aqueous saturated solution of NaHCO3 (10 mL), and brought up to room temperature in 2 h. The organic phase was separated, and the aqueous phase was extracted with ethyl acetate (3 
× 50 mL). The combined organic phases were washed several times with a saturated solution of NaHCO3, water, and brine. After the mixture was dried over anhydrous Na2SO4, the residue was evaporated under vacuum to give 3 g of 64 as a yellow residue, which was subjected to next step without any purification. [α]D25= +2.6, c= 0.16; selected 1H NMR (400 MHz, CDCl3 ): δ 3.67 (3H, s), 3.61 (1H, m), 2.86 (1H, dd, J = 6.8 e 13.4 Hz), 2.36 (1H, m), 2.22 (1H, m), 1.20 (3H, s), 0.92 (3H, d, J = 6.3 Hz), 0.65 (3H, s), 0.0- 0.20 (sʹ  s, 18H); 13C NMR (100 MHz, CDCl3): δ 174.7, 142.8, 109.0, 71.6, 54.8, 51.5, 44.3, 42.6, 40.9, 40.8, 40.3, 40.0, 35.3, 34.6, 32.9, 30.6, 28.6, 27.0, 22.5, 20.9,  18.6, 12.3, 1.3 (2C), 0.3 (2C), 0.2 (2C). Methyl 3α-hydroxy-6-ethyliden-7-keto-5β-cholan-24-oate (65). To a cooled (−60 °C) and stirred solution of acetaldehyde (1.50 mL, 27.5 mmol) and methyl 3α,7α-trimethylsilyloxy-5β-cholan-6-en-24-oate (64) (3.0 g, 5.5 mmol) in dry CH2Cl2 (30 mL) was added dropwise BF3•OEt2 (7.0 ml, 55 mmol). The reaction mixture was stirred for 2 h at −60 °C and allowed to warm to room temperature. The mixture was quenched with saturated aqueous solution of NaHCO3 and extracted with CH2Cl2. The combined organic phases were washed with brine, dried over anhydrous MgSO4, and concentrated under vacuum. Purification on silica gel column, eluting with hexane/AcOEt (9:1) and 0.5% Et3N, afforded pure 65 (1.3 g, 
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85% over two steps). [α]D25= +88.0 c= 0.17; selected 1H NMR (400 MHz, CDCl3): δ 6.15 (1H, q, J = 7.12 Hz), 3.65 (3H, s), 3.55 (1H, m), 1.62 (3H, d), 0.95 (3H, s), 0.85 (3H, d), 0.60 (3H, s); 13C NMR (100 MHz, CDCl3): δ 205.0, 174.6, 143.3, 129.8, 70.4, 54.4, 50.6, 48.6, 45.4, 43.4, 39.0, 38.8, 37.4, 35.1, 34.4, 31.0, 30.9, 29.6 (2C), 28.3, 22.8, 21.2, 18.3, 14.1, 11.3. Compound 47. To a methanol solution of compound 65 (0.40 g, 0.93 mmol), a large excess of NaBH4 was added at 0 °C. The mixture was left at room temperature for 10 h and then water and MeOH was added dropwise during a period of 15 min at 0 °C with effervescence being observed. Then after evaporation of the solvents, the residue was diluted with water and extracted with AcOEt (3 x 50 mL). The combined extract was washed with brine, dried with Na2SO4, and evaporated to give 400 mg of a crude residue that was subjected to the next step without further purification. To a solution of crude residue (0.40 g, 0.93 mmol) in dry THF (30 mL), at 0 °C dry methanol (260 µL, 6.5 mmol) and LiBH4 (3.20 mL, 2M in THF, 6.51 mmol) were added. The resulting mixture was stirred for 2 h at 0 °C. The mixture was quenched by addition of 1 M NaOH (2 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 320 mg of 47 (85% over two steps, tR= 9.2 min). [α]D25=+18.1 (c= 0.36, CH3OH); 1H and 13C NMR spectroscopic data in CD3OD given in Tables 1 and 2; HR ESIMS m/z 405.3373 [M+H]+, C26H45O3 requires 405.3369. Methyl 3α-hydroxy-6β-ethyl-7-keto-5β-cholan-24-oate (66). A solution of 65 (800 x 10-3 g, 1.92 mmol) in THF dry/MeOH dry (20 mL, 1:1 v/v) was hydrogenated in presence of Pd(OH)2 20% wt on activated carbon (25 mg) Degussa type. The mixture was transferred to a standard Parr apparatus and flushed with nitrogen and then with hydrogen several times. The apparatus was shacked under 50 psi of H2. The reaction was stirred at room temperature for 8 h. The catalyst was filtered through Celite, and the recovered filtrate was concentrated under vacuum to give 66 (800 mg, quantitative yield). The β-configuration of ethyl group at C-6 was determined by dipolar couplings H3-26 (δ 0.83)/ H3-19 (δ 1.22) and H-8 (δ 2.56)/H-25 (δ 1.83) in Noesy spectrum (400 
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MHz, mixing time 400 ms). [α]D25= -3.7, c= 0.5; selected1H NMR (400 MHz, CDCl3): δ 3.67 (3H, s), 3.57 (1H, m), 2.57 (1H, t, J = 11.5 Hz), 2.37 (1H, m), 2.24 (1H, dd, J = 6.6, 9.6 Hz), 2.20 (1H, m), 1.22 (3H, s), 0.93 (3H, d, J = 6.2 Hz), 0.85 (3H, t, J = 7.3 Hz), 0.67 (3H, s); 13C NMR (100 MHz, CDCl3): δ 215.1, 178.4, 71.6, 56.3, 50.6, 50.4, 47.5, 46.4, 44.4, 43.8, 40.4, 38.2, 36.6, 36.3, 35.2, 32.4, 32.0, 30.6, 29.3, 25.8, 23.5 (2C), 22.8, 18.8, 12.5; HRMS-ESI m/z 433.3323 [M+H]+, C27H45O4 requires 433.3318. 6β-ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (45) and 6β-ethyl-3α,7α-dihydroxy-5β-cholan-24-ol (46). To a methanol solution of 66 (0.50 g, 1.2 mmol) a large excess of NaBH4 was added at 0 °C. The mixture was left at room temperature for 10 h and then water and MeOH was added dropwise during a period of 15 min at 0 °C with effervescence being observed. Then after evaporation of the solvents, the residue was diluted with water and extracted with AcOEt (3 x 50 mL). The combined extract was washed with brine, dried with Na2SO4, and evaporated to give 900 mg of a crude residue that was subjected to the next step without further purification. To a solution of crude residue (900 x 10-3 g, 2.20 mmol) in dry THF (25 mL), at 0 °C dry methanol (623 µL, 15.4 mmol) and LiBH4 (7.70 mL, 2M in THF, 15.4 mmol) were added. The resulting mixture was stirred for 2 h at 0 °C. The mixture was quenched by addition of 1.0 M NaOH (4.4 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 338 mg of 45 (69% over two steps, tR= 11 min) and 154 mg of 46 (31.4% over two steps, tR= 20.4 min). 6β-ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (EUDCOH, 45). [α]D25= +15.2 (c= 1.21, CH3OH); 1H and 13C NMR spectroscopic data in CD3OD given in Tables 1 and 2. HR ESIMS m/z 407.3529 [M+H]+, C26H47O3 requires 407.3525. 6β-ethyl-3α,7α-dihydroxy-5β-cholan-24-ol (IsoECDCOH, 46). [α]D25= +5.1 (c= 5.74, CH3OH); 1H and 13C NMR spectroscopic data in CD3OD given in Tables 1 and 2. HR ESIMS m/z 407.3532 [M+H]+, C26H47O3 requires 407.3525. 6α-ethyl-3α,7α, 24-5β-cholantriol (44). Methyl ester 66 (300 mg, 0.7 mmol) was dissolved in dry THF (5 mL) at 0 °C in presence of dry methanol (195 µL, 4.83 mmol) and LiBH4 (2.40 mL, 2M in THF, 4.83 mmol). After 8 h, a solution 1.0 M 
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NaOH (1.4 mL) was added and then allowed to warm to room temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated. Purification by silica gel (CH2Cl2/MeOH 95:5) gave triol derivative 44 as a colorless oil (250 mg, 89%); 1H and 13C NMR spectroscopic data in CD3OD given in Tables 1 and 2; HR ESIMS m/z 407.3531 [M+H]+, C26H47O3 requires 407.3525. Methyl 3α-acetoxy-7-keto-5β-cholan-24-oate (67). To a solution of 7-ketolithocholic acid (5.0 g, 13 mmol), dissolved in 100 mL of dry methanol was added p-toluenesulfonic acid (11.0 g, 64.1 mmol). The solution was left to stand at room temperature for 2 h. The mixture was quenched by addition of NaHCO3 saturated solution. After the evaporation of the methanol, the residue was extracted with EtOAc (3 x 150 mL). The combined extract was washed with brine, dried with Na2SO4, and evaporated to give the methyl esters as amorphous solid (5.13 g, quantitative yield). At the solution of the methyl ester (5.13 g, 12.7 mmol) in dry pyridine (100 mL), an excess of acetic anhydride was added. When the reaction was complete, the pyridine was concentrated under vacuum. The residue was poured into cold water (100 mL) and extracted with ethyl acetate (3 × 150 mL). The combined organic phases were dried (Na2SO4) and concentrated to give a residue that was further purified by flash chromatography on silica gel using hexane/ethyl acetate 8:2 and 0.5% of triethylamine as eluent (4.8 g of 67 as a white solid, 84% yield over two steps). Methyl 3α-acetoxy-6-ethylidene-7-keto-5β-cholan-24-oate (68). To a solution of diisopropylamine (23 mL, 0.16 mol) in dry THF (50 mL) was added dropwise a solution of n-butyllithium (60.0 mL, 2.5 M in hexane, 0.150 mol) at -78 °C. After 30 min, trimethylchlorosilane (27.1 mL, 0.210 mol) was added. After additional 30 min, a solution of compound 67 (4.80 g, 10.7 mmol) in dry THF (70 mL) was added. The reaction was stirred at -78 °C for an additional 45 min and then triethylamine (54 mL, 0.38 mol) was added. After 1 h, the reaction mixture was allowed to warm to -20 °C, treated with aqueous saturated solution of NaHCO3 (100 mL) and brought up to room temperature in 2 h. The aqueous phase was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed then with saturated solution of NaHCO3, water and brine. After drying 
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over anhydrous Na2SO4, the residue was evaporated under vacuum to give 6 g of yellow residue, that was diluted in dry CH2Cl2 (50 mL) and cooled at -78 °C. At this stirred solution acetaldehyde (3.0 mL, 53 mmol) and BF3•OEt2 (13.5 mL, 0.107 mol) were added dropwise. The reaction mixture was stirred for 2 h at -60 °C and allowed to warm to room temperature. The mixture was quenched with saturated aqueous solution of NaHCO3 and extracted with CH2Cl2. The combined organic phases were washed with brine, dried over anhydrous Na2SO4 and concentrated under vacuum. Purification by silica gel (hexane-ethyl acetate 9:1 and 0.5% TEA) gave compound 68 (4.1 g, 80% over two steps). NMR analysis demonstrated a diasteromeric ratio E/Z >95%. The E configuration at the exocyclic double bond was established by dipolar coupling H3-26 (δ 1.67)/H-5 (δ 2.62) in Noesy spectrum (400 MHz, mixing time 400 ms); selected 1H NMR (400 MHz, CDCl3): δ 6.16 (1H, q, J = 7.0 Hz, H-25), 4.74 (1H, m, H-3), 3.64 (3H, s, COOCH3), 2.62 (1H, dd, J = 13.0, 3.6 Hz, H-5), 1.98 (3H, s, COCH3), 1.67 (3H, d, J = 7.0 Hz, H3-26), 1.00 (3H, s, H3-19), 0.92 (3H, d, J = 6.0 Hz, H3-21), 0.67 (3H, s, H3-18); 13C NMR (100 MHz, CDCl3): δ  204.5, 174.6, 170.7, 143.1, 130.2, 72.5, 54.5, 51.4, 50.7, 48.6, 45.2, 43.5, 39.1, 38.9, 35.1, 34.9, 34.1, 33.4, 31.0, 30.9, 28.4, 25.9 (2C), 22.8, 21.4, 21.2, 18.4, 12.7, 12.2; HR ESIMS m/z 473.3271 [M+H]+, C29H45O5 requires 473.3267. Methyl 3α-acetoxy-6β-ethyl-7-keto-5β-cholan-24-oate (69). A solution of 68 (4.0 g, 8.5 mmol) in THF dry/MeOH dry (100 mL, 1:1 v/v) was hydrogenated in presence of Pd(OH)2 20% wt on activated carbon (100 mg) Degussa type. The mixture was transferred to a standard Parr apparatus and flushed with nitrogen and then with hydrogen several times. The apparatus was shacked under 50 psi of H2. The reaction was stirred at room temperature for 8 h. The catalyst was filtered through Celite, and the recovered filtrate was concentrated under vacuum to give 69 (4.0 g, quantitative yield). The β-configuration of ethyl group at C-6 was determined by dipolar couplings H3-26 (δ 0.83)/ H3-19 (δ 1.22) and H-8 (δ 2.56)/H-25 (δ 1.83) in Noesy spectrum (400 MHz, mixing time 400 ms); selected 1H NMR (400 MHz, CD3OD): δ 4.65 (1H, m, H-3), 3.66 (3H, s, COOCH3), 2.56 (1H, t, J= 11.5 Hz, H-8), 2.35 (1H, m, H-23a), 2.22 (1H, m, H-23b), 1.99 (3H, s, COCH3), 1.22 (3H, s, H3-19), 0.92 (3H, d, J = 6.3 Hz, H3-21), 0.83 (3H, t, J = 7.2 
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Hz, H3-26), 0.67 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 214.7, 174.3, 170.2, 72.6, 61.7, 54.8, 51.3, 49.0, 48.5, 45.3, 42.7, 42.3 (2C), 38.6, 35.4, 35.1, 35.0, 31.0, 30.8, 28.0 (2C), 26.4, 25.7, 24.7, 21.3, 21.1, 18.2, 12.9, 11.9; HR ESIMS m/z 475.3430 [M+H]+, C29H47O5 requires 475.3423. Methyl 6α-ethyl-7-keto-5β-cholan-24-oate (71). Compound 69 (500 x 10-3 g, 1.05 mmol) was treated with MeONa in methanol to obtain deacetylation at C-3 and inversion at C-6. Tosylation, in the same operative condition previously described,71 furnished 620 mg of 70 (quantitative yield over two steps) that was subjected to the next step without further purification. Lithium bromide (148 mg, 1.70 mmol) and lithium carbonate (125 mg, 1.70 mmol) were added to a solution of 6α-ethyl-3α-tosyloxy-7-keto-5β-cholan-24-oate (500 x 10-3 g, 0.850 mmol) in dry DMF (30 mL), and the mixture was refluxed for 2 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution (20 mL) and extracted with CH2Cl2 (3 × 50 mL). The combined organic layer was washed successively with water, saturated NaHCO3 solution and water, and then dried over anhydrous MgSO4 and evaporated to dryness to give 400 mg of oleous residue (quantitative yield), that was subjected to next step without any purification. Hydrogenation on Pd(OH)2 in the same operative condition previously described furnished 312 mg of 71 (88% over two steps). 6α-ethyl-7α-hydroxy-5β-cholan-24-ol (48) and 6α-ethyl-7β-hydroxy-5β-cholan-24-ol (49). Dry methanol (70.0 µL, 1.70 mmol) and LiBH4 (850 µL, 2 M in THF, 1.7 mmol) were added to a solution of the compound 71 (100 mg, 0.2 mmol) in dry THF (5 mL) at 0 °C under argon and the resulting mixture was stirred for 5 h at 0 °C. The mixture was quenched by addition of NaOH (1.0 M, 480 µL) and then allowed to warm to room temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 ×15 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated to give a mixture of alcohols 48 and 49. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (92:8) as eluent (flow rate 3 mL/min), gave 64 mg of 6α-ethyl-7α-hydroxy-5β-cholan-24-ol 48 (69%, tR= 31 min) and a small amount of 6α-ethyl-7β-hydroxy-5β-cholan-24-ol 49 (8 mg, tR= 24.8 min). 
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6α-ethyl-7α-hydroxy-5β-cholan-24-ol (48). Selected 1H NMR (400 MHz, CD3OD): δ 3.65 (1H, br s, H-7), 3.51 (2H, m, H2-24), 0.97 (3H, d, J = 6.3 Hz, H3-21), 0.92 (3H, s, H3-19), 0.89 (3H, t, J = 7.3 Hz, H3-26), 0.71 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 71.6, 63.6, 57.6, 51.8, 48.7, 43.7, 43.3, 41.5, 41.1, 39.3, 37.5, 37.0, 34.6, 33.2, 30.3, 29.4, 28.8, 25.1, 24.6 (2C), 23.5, 22.5, 22.0, 19.2, 12.3, 12.1; HR ESIMS m/z 391.3579 [M+H]+, C26H47O2 requires 391.3576. 6α-ethyl-7β-hydroxy-5β-cholan-24-ol (49). Selected 1H NMR (500 MHz, CD3OD): δ 3.51 (2H, m, H2-24), 3.07 (1H, t, J = 10.0 Hz, H-7), 0.96 (3H, d, J = 6.6 Hz, H3-21), 0.96 (3H, t, J = 7.3 Hz, H3-26), 0.95 (3H, s, H3-19), 0.71 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 76.3, 63.6, 57.9, 56.8, 46.3, 45.3, 45.0, 44.7, 41.7, 41.1, 38.8, 37.0, 36.3, 33.3, 30.3, 28.1, 27.9 (2C), 25.0 (2C), 22.0, 21.9 (2C), 19.4, 12.7, 11.6; HR ESIMS m/z 391.3581 [M+H]+, C26H47O2 requires 391.3576. 6α-ethyl-7α-hydroxy-5β-cholan-24-yl 24-sodium sulfate (50). Sulfation on C-24 on a small aliquot of diol 48 (20 mg, 0.05 mmol) was performed in the same operative conditions previously described.71,138 RP18/HPLC on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (82:18) as eluent (flow rate 3 mL/min) afforded compound 50 (tR= 14.2 min) as sodium salt. Selected 1H NMR (400 MHz, CD3OD): δ 3.96 (2H, t, J = 6.3 Hz, H2-24), 3.64 (1H, br s, H-7), 0.96 (3H, d, J = 6.6 Hz, H3-21), 0.91 (3H, s, H3-19), 0.88 (3H, t, J = 7.4 Hz, H3-26), 0.69 (3H, s, H3-18); HR ESIMS m/z 469.2991 [M-H]-, C26H45O5S requires 469.2988. 6α-ethyl-7α-hydroxy-5β-cholan-24-oic acid (51) and 6α-ethyl-7β-hydroxy-5β-cholan-24-oic acid (52). Compound 71 (200 mg, 0.5 mmol) was hydrolyzed with NaOH (96 mg, 2.4 mmol) in a solution of MeOH:H2O 1:1 v/v (10 mL). The mixture was stirred for 4 h at reflux. The resulting solution was then acidified with HCl 6 M and extracted with ethyl acetate (3 × 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to give the carboxylic acid intermediate. Crude carboxylic acid intermediate (190 mg, 0.47 mmol) was treated with LiBH4 (1.65 mL, 2M in THF, 3.30 mmol) and MeOH (133 µL, 3.30 mmol) in THF dry (5 mL). Purification by silica gel (CH2Cl2-MeOH 99:1) furnished 157 mg of 6α-ethyl-7α-
Experimental Section III 
	   126	  
hydroxy-5β-cholan-24-oic acid (51, 83%). In same embodiments LiBH4 treatment after alkaline hydrolysis produced small amounts (about 10%) of 6α-ethyl-7β-hydroxy-5β-cholan-24-oic acid (52) that was isolated by HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min, tR= 16 min). 6α-ethyl-7α-hydroxy-5β-cholan-24-oic acid (51). Selected 1H NMR (400 MHz, CD3OD): δ 3.65 (1H, brs, H-7), 2.34 (1H, m, H-23a), 2.20 (1H, m, H-23b), 0.96 (3H, d, J = 6.3 Hz, H3-21), 0.92 (3H, s, H3-19), 0.89 (3H, t, J = 7.4 Hz, H3-26), 0.70 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 178.0, 71.6, 57.4, 51.7, 48.7, 43.8, 43.3, 41.5, 41.1, 39.3, 37.4, 36.8, 34.6, 32.5 (2C), 29.3, 28.8, 25.1, 24.6 (2C), 23.5, 22.5, 22.0, 18.8, 12.2, 12.1; HR ESIMS m/z 403.3214 [M-H]-, C26H43O3 requires 403.3212. 6α-ethyl-7β-hydroxy-5β-cholan-24-oic acid (52). Selected 1H NMR (500 MHz, CD3OD): δ 3.08 (1H, t, J = 9.6 Hz, H-7), 2.32 (1H, m, H-23a), 2.20 (1H, m, H-23b), 0.96 (3H, d, J = 6.2 Hz, H3-21), 0.95 (3H, s, H3-19), 0.85 (3H, t, J = 7.0 Hz, H3-26), 0.70 (3H, s, H3-18); HR ESIMS m/z 403.3217 [M-H]-, C26H43O3 requires 403.3212. 6α-ethyl-7α-hydroxy-5β-cholan-24-oyl taurine sodium sulfate (53). An aliquot of 51 (10.0 mg, 0.0240 mmol) in DMF dry (5 mL) was treated with DMT-MM (20.5 mg, 70 x 10-3 mmol) and triethylamine (83 µL, 0.60 mmol) and the mixture was stirred at room temperature for 10 min. Then to the mixture was added taurine (18 mg, 0.14 mmol). After 3 h, the reaction mixture was concentrated in vacuo and dissolved in water (5 mL). Purification on C18 silica gel column and then HPLC on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (83:17) as eluent (flow rate 3 mL/min), gave 4.5 mg of 6α-ethyl-7α-hydroxy-5β-cholan-24-oyl taurine sodium sulfate (53) (tR=10 min); selected 1H NMR (400 MHz, CD3OD): δ 3.65 (1H, br s, H-7), 3.58 (2H, t, J = 7.0 Hz, CH2-N), 2.96 (2H, t, J = 9.6 Hz, CH2-S), 2.25 (1H, m, H-23a), 2.10 (1H, m, H-23b), 0.97 (3H, d, J = 6.4 Hz, H3-21), 0.92 (3H, s, H3-19), 0.89 (3H, t, J = 7.1 Hz, H3-26), 0.70 (3H, s, H3-18); HR ESIMS m/z 510.3257 [M-H]-, C28H48NO5S requires 510.3253. Methyl 6β-ethyl-7-keto-5β-cholan-24-oate (73). Compound 73 (400 mg, 94% over two steps) was synthesized, starting from compound 72 (600 x 10-3 g, 1.02 
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mmol), by an analogous procedure to that detailed above for compound 71. Compound 72 (620 mg, quantitative yield over two steps) was obtained from 69 (500 x 10-3 g, 1.05 mmol) by an analogous procedure to that detailed above for compound 70, except for reaction time (2 h) of the deacetylation step; selected 1H NMR (400 MHz, CD3OD): δ 3.63 (3H, s, COOCH3), 2.53 (1H, t, J = 11.4 Hz, H-8), 2.33 (1H, m, H-23a), 2.19 (1H, m, H-23b), 1.18 (3H, s, H3-19), 0.89 (3H, d, J = 6.2 Hz, H3-21), 0.81 (3H, t, J = 7.4 Hz, H3-26), 0.64 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD), δ 217.0, 174.9, 62.4, 54.7, 51.5, 50.7,  48.7, 45.7, 43.2, 42.5, 38.8, 37.5, 36.3, 35.2, 31.0, 30.9, 30.3, 28.2, 26.7 (2C), 26.3, 24.9, 21.4, 20.4, 18.3, 13.0, 12.0; HR ESIMS m/z 417.3373 [M+H]+, C27H43O3 requires 417.3369. 6β-ethyl-7β-hydroxy-5β-cholan-24-ol (54) and 6β-ethyl-7α-hydroxy-5β-cholan-24-ol (55). To a methanol solution of 73 (350 mg, 0.84 mmol), a large excess of NaBH4 was added at 0 °C. The mixture was left at room temperature for 2 h and then water and MeOH were added dropwise during a period of 15 min at 0 °C with effervescence being observed. After evaporation of the solvents, the residue was diluted with water and extracted with ethyl acetate (3 x 50 mL). The combined extract was washed with brine, dried with Na2SO4, and evaporated to give 1.3 g of a crude residue that was subjected to the next step without further purification. The crude residue was treated with LiBH4 (2 M in THF) in the same operative condition described for the synthesis of compounds 48 and 49. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (92:8) as eluent (flow rate 3 mL/min), furnished 180 mg of 6β-ethyl-7β-hydroxy-5β-cholan-24-ol (54, 54%, tR= 25 min) and 75.4 mg of 6β-ethyl-7α-hydroxy-5β-cholan-24-ol (55, 23%, tR= 13 min). 6β-ethyl-7β-hydroxy-5β-cholan-24-ol (54). Selected 1H NMR (700 MHz, CD3OD): δ 3.67 (1H, dd, J = 8.7, 4.7 Hz, H-7), 3.51 (2H, m, H2-24), 0.98 (3H, s, H3-19), 0.97 (3H, d, J = 6.6 Hz, H3-21), 0.96 (3H, t, J = 7.4 Hz, H3-26), 0.71 (3H, s, H3-18); 13C NMR (175 MHz, CD3OD): δ  75.5, 63.8, 57.6, 56.5, 44.2, 43.7, 42.8, 41.0, 40.9, 40.8, 38.2 (2C), 36.9, 34.4, 32.8, 29.7, 28.9, 27.0, 26.1, 24.7, 22.2, 22.0 (2C), 19.2, 13.9, 12.3; HR ESIMS m/z 391.3580 [M+H]+, C26H47O2 requires 391.3576. 
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6β-ethyl-7α-hydroxy-5β-cholan-24-ol (55). Selected 1H NMR (700 MHz, CD3OD): δ 3.59 (1H, s, H-7), 3.51 (2H, m, H2-24), 2.23 (1H, dq, J = 13.9, 4.0 Hz, H-4a), 0.97 (3H, d, J = 6.6, H3-21), 0.95 (3H, t, J = 7.1 Hz, H3-26), 0.94 (3H, s, H3-19), 0.70 (3H, s, H3-18); 13C NMR (175 MHz, CD3OD): δ 73.1, 63.2, 57.3, 52.8, 51.4, 49.4, 43.8, 41.3, 39.7, 37.4 (2C), 37.2, 34.2, 32.6 (2C), 29.9, 29.5, 28.9, 28.3, 27.3, 24.5, 21.7, 21.2, 18.8, 14.3, 12.3; HR ESIMS m/z 391.3578 [M+H]+, C26H47O2 requires 391.3576. Methyl 6α-ethyl-3β-hydroxy-7-keto-5β-cholan-24-oate (74). A solution of 72 (900 x 10-3 g, 1.50 mmol) and CH3COOK (147 mg, 1.53 mmol) dissolved in water (2 mL) and N,N-dimethylformamide (DMF, 10 mL) was refluxed for 2 h. The solution was cooled at room temperature and then ethyl acetate and water were added. The separated aqueous phase was extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with water, dried (Na2SO4) and evaporated to dryness to give 1.0 g of mixture. Purification by silica gel (hexane-ethyl acetate 7:3 and 0.5% TEA) gave 500 mg of intermediates oily oil. C-6 inversion in the same operative condition as described for the synthesis of compound 70, furnished compound 74 (500 mg, 74% over two steps); selected 1H NMR (400 MHz, CD3OD): δ 3.96 (1H, m, H-3), 3.64 (3H, s, COOCH3), 2.85 (1H, dd, J = 5.6, 12.3 Hz, H-6), 2.50 (1H, t, J = 11.2 Hz, H-8), 2.33 (1H, m, H-23a), 2.20 (1H, m, H-23b), 1.27 (3H, s, H3-19), 0.95 (3H, d, J = 6.4 Hz, H3-21), 0.81 (3H, t, J = 7.2 Hz, H3-26), 0.71 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 213.4, 174.8, 65.9, 54.8, 51.8, 51.2, 50.0, 49.0, 45.7, 43.2, 42.7, 39.0, 36.2, 35.2, 31.0 (2C), 29.2, 29.0, 28.3, 27.2, 24.6, 24.0, 22.1, 18.7, 18.4, 12.0 (2C); HR ESIMS m/z 433.3322 [M + H]+, C27H45O4 requires 433.3318. 6α-ethyl-3β,7α-dihydroxy-5β-cholan-24-ol (56) and 6α-ethyl-3β,7β-dihydroxy-5β-cholan-24-ol (57). Intermediate 74 (500 x 10-3 g, 1.16 mmol) was treated with LiBH4 as previously described. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 250 mg of compound 56 as a white solid (53%, tR= 12.6 min) and a small amount of compound 57 (23 mg, 5%, tR=8.2 min). 6α-ethyl-3β,7α-dihydroxy-5β-cholan-24-ol (56). Selected 1H NMR (500 MHz CD3OD): δ 3.97 (1H, brs, H-3), 3.66 (1H, brs, H-7), 3.51 (2H, m, H2-24), 0.96 
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(3H, d, J = 6.6 Hz, H3-21), 0.94 (3H, s, H3-19), 0.91 (3H, t, J = 7.5 Hz, H3-26), 0.70 (3H, s, H3-18); 13C NMR (125 MHz, CD3OD): δ  71.4, 67.4, 63.6, 57.6, 51.7, 43.7, 42.8, 41.5, 41.2, 41.1, 37.1 (2C), 33.8, 33.2, 31.3 (2C), 30.3, 29.4, 28.3, 24.6, 24.2, 23.3, 22.3, 19.2, 12.7, 12.1; HR ESIMS m/z 407.3531 [M+H]+, C26H47O3 requires 407.3525. 6α-ethyl-3β,7β-dihydroxy-5β-cholan-24-ol (57). Selected 1H NMR (500 MHz CD3OD): δ 4.01 (1H, brs, H-3), 3.51 (2H, m, H2-24), 3.05 (1H, t, J = 9.7 Hz, H-7), 0.97 (3H, s, H3-19), 0.96 (3H, d, J = 6.4 Hz, H3-21), 0.88 (3H, t, J = 7.6 Hz, H3-26), 0.72 (3H, s, H3-18); 13C NMR (100 MHz CD3OD): δ 76.3, 67.1, 63.6, 57.8, 56.8, 45.0, 44.8, 44.5, 41.7, 40.3, 39.1, 37.0, 35.9, 33.0, 31.2, 30.2, 29.8, 28.4, 28.0, 27.9, 24.8, 22.9, 21.8, 19.3, 12.8, 11.6; HR ESIMS m/z 407.3529 [M+H]+, C26H47O3 requires 407.3525. 6α-ethyl-3β,7α-dihydroxy-5β-cholan-24-oic acid (58) and 6α-ethyl-3β,7β-dihydroxy-5β-cholan-24-oic acid (59). Compounds 58 and 59 (215 mg, 74% over two steps) were synthesized, starting from compound 74 (320 mg, 0.74 mmol), by an analogous procedure to that detailed above for compounds 51 and 52. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 208 mg of 58 as a white solid (65%, tR= 11 min). In same embodiments LiBH4 treatment after alkaline hydrolysis produced small amounts (about 10%) of 59 that was isolated by HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min, 28 mg of 18, 9%, tR= 8 min). 6α-ethyl-3β,7α-dihydroxy-5β-cholan-24-oic acid (58). Selected 1H NMR (400 MHz, CD3OD): δ 3.97 (1H, brs, H-3), 3.67 (1H, br s, H-7), 2.33 (1H, m, H-23a), 2.21 (1H, m, H-23b), 0.96 (3H, d, J = 6.5 Hz, H3-21), 0.94 (3H, s, H3-19), 0.91 (3H, t, J = 7.6 Hz, H3-26), 0.70 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): 
δ 178.3, 71.3, 67.5, 57.4, 51.7, 43.8, 42.8, 41.5, 41.2, 41.0, 37.0, 36.7, 33.8, 32.4, 32.0, 31.1 (2C), 29.3, 28.3, 24.6, 24.2, 23.3, 22.2, 18.8, 12.3, 12.2; HR ESIMS m/z 419.3169 [M-H]- C26H43O4 requires 419.3167. 6α-ethyl-3β,7β-dihydroxy-5β-cholan-24-oic acid (59). Selected 1H NMR (500 MHz, CD3OD): δ 4.01 (1H, brs, H-3), 3.06 (1H, t, J = 9.7 Hz, H-7), 2.32 (1H, m, H-23a), 2.19 (1H, m, H-23b), 0.97 (3H, s, H3-19), 0.96 (3H, d, ovl, H3-21), 0.87 
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(3H, t, J = 7.7 Hz, H3-26), 0.71 (3H, s, H3-18); HR ESIMS m/z 419.3169 [M-H-]- C26H43O4 requires 419.3167. 6α-ethyl-3β,7α-dihydroxy-5β-cholan-24-oyl taurine sodium sulfate (60). Compound 60 was synthesized, starting from compound 58 (10.0 mg, 0.0230 mmol), by an analogous procedure to that detailed above for compound 53; selected 1H NMR (500 MHz, CD3OD): δ 3.97 (1H, brs, H-3), 3.67 (1H, br s, H-7), 3.59 (2H, t, J = 6.8 Hz, CH2-N), 2,96 (2H, t, J = 6.8 Hz, CH2-S), 0.97 (3H, d, J = 6.4 Hz, H3-21), 0.95 (3H, s, H3-19), 0.91 (3H, t, J = 7.1 Hz, H3-26), 0.70 (3H, s, H3-18); HR ESIMS m/z 526.3206 [M-H]-, C28H48NO6S requires 526.3202. 6β-ethyl-3β,7β-dihydroxy-5β-cholan-24-ol (61) and 6β-ethyl-3β,7α-dihydroxy-5β-cholan-24-ol (62). Compound 72 was treated with CH3COOK as previously described for compound 74. NaBH4/LiBH4 reduction on the corresponding 7-keto intermediate (100 x 10-3 g, 0.230 mmol) in the same operative conditions described for the synthesis of compounds 54 and 55 afforded a mixture whose HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 48.3 mg of 61 (52 % over two steps, tR= 11 min) and 20.7 mg of 62 (22 % over two steps, tR= 13 min). 6β-ethyl-3β,7β-dihydroxy-5β-cholan-24-ol (61). Selected 1H NMR (700 MHz, CD3OD): δ 3.59 (1H, brs, H-3), 3.57 (1H, dd, J = 12.6, 2.3Hz, H-7), 3.51 (2H, m, H2-24), 0.98 (3H, s, H3-19), 0.96 (3H, ovl, H3-21), 0.96 (3H, t, ovl, H3-26), 0.70 (3H, s, H3-18); 13C NMR (175 MHz, CD3OD): δ 75.2, 68.3, 63.6, 58.3, 57.1, 45.7 (2C), 44.2, 41.8 (2C), 41.2, 40.0, 37.0, 35.9, 33.3, 31.1, 30.3, 29.4 (2C), 26.6 (2C), 23.2 (2C), 19.3, 13.0, 12.3; HR ESIMS m/z 407.3530 [M+H]+, C26H47O3 requires 407.3525. 6β-ethyl-3β,7α-dihydroxy-5β-cholan-24-ol (62). Selected 1H NMR (700 MHz, CD3OD): δ 3.91 (1H, brs, H-3), 3.60 (1H, br s, H-7), 3.51 (2H, m, H2-24), 2.45 (1H, t, J = 13.3 Hz, H-4a), 0.97 (3H, s, H3-19), 0.97 (3H, ovl, H3-21), 0.95 (3H, t, J = 7.4 Hz, H3-26), 0.71 (3H, s, H3-18); 13C NMR (175 MHz, CD3OD): δ 72.8, 67.4, 63.4, 57.2, 51.3, 51.2, 43.2, 41.6, 40.5, 37.3, 37.1 (2C), 36.9, 34.0, 33.3, 32.1, 30.3, 29.3, 28.9, 28.6, 26.3, 24.9, 22.0, 19.3, 13.8, 12.1; HR ESIMS m/z 407.3528 [M+H]+, C26H47O3 requires 407.3525. 
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6α-ethyl-chenodeoxycholic acid (3). Compound 69 (500 x 10-3 g, 1.05 mmol) was hydrolyzed with NaOH (208 mg, 5.20 mmol) in a solution of MeOH:H2O 1:1 v/v (10 mL), as previously described. The mixture was stirred for 5 h at reflux. The resulting solution was then acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to give the carboxylic acid intermediate 75. This compound was subjected to the LiBH4 reduction of the C7-carbonyl group. Purification gave 305 mg of 6-ECDCA (3) as a white solid (69% over two steps). Specific biological assays Bile acids determination Sample preparation. The stock solutions of the individual tauro-conjugated and un-conjugated bile acids were prepared separately in methanol at a concentration of 1 mg/mL. All stock solutions were stored at −20 ◦C. Calibration standards were prepared by combining appropriate volumes of each bile acid stock solution and methanol. The calibration range was from 10 nM to 100 µM of each bile acid in the final solution. Mice serum sample aliquots of 100 µL were deproteinized with 1 mL of cold acetonitrile with 5% of NH4OH vortexing for 1 min. After centrifugation at 16000 g for 10 min, the clear supernatant was transferred to a new vial, snap frozen and lyophilized.  The sample was then re-dissolved in methanol–water (2:1, v/v) for tauro-conjugated bile acids determination and in methanol-ammonium acetate 10 mM with 0.005% formic acid (3:2, v/v) for un-conjugated bile acids determination. A bile acids extraction yield of 95% has been estimated. Liquid chromatography and mass spectrometry. For LC–MS/MS analysis, chromatographic separation was carried out on the HPLC–MS system LTQ XL ThermoScientific equipped with Accelera 600 Pump and Accelera AutoSampler system. The mixture was separated on a Jupiter 5μC18 column from Phenomenex (150 x 2.00 mm). Tauro-conjugated bile acids were separated at a flow rate of 200 µL/min using a methanol–aqueous ammonium acetate (NH4OAc) gradient. Mobile phase A was 5% methanol in water containing 2 mM ammonium 
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acetate at pH 7, mobile phase B was methanol, containing ammonium acetate at 2 mM. The gradient started at 30 % B and increased to 100% B in 20 min, kept at 100% B for 5 min then decreased to 30% B in 1 min and kept at 30% B for 10 min. ESI was performed in negative ion mode, the ion source temperature was set at 280 ◦C. The tune page parameters were automatically optimized injecting taurocholic acid at 1 µM as standard. The MS/MS detection was operated in MRM mode using a collision energy of 20 (arbitrary units), the observed transitions were: tauromuricholic acid (t-MCA) at 13.5 min MRM of 514.28 Th→514.28 Th, taurohyocholic acid (t-HCA) at 15.6 min MRM of 498.29 Th→498.29 Th, taurocholic acid (t-CA) at 16.6 min MRM of 514.28 Th→514.28 Th, taurochenodeoxycholic acid (t-CDCA) at 18.5 min MRM of 498.29 Th→498.29 Th, taurodeoxycholic acid (t-DCA) at 18.9 min MRM of 498.29 Th→498.29 Th, taurolithocholic acid (t-LCA) at 22.3 min MRM of 482.29 Th→482.29 Th and tauro-10 (t-10) at 25.3 min MRM of 510.29 Th→510.63 Th. Un-conjugated bile acids were separated at a flow rate of 200 µL/min using 10 mM ammonium acetate in water at 0.005% formic acid as the mobile phase A 10 mM ammonium acetate in methanol at 0.005% formic acid as mobile phase B. The gradient program started at 60% B and increased to 95% B in 25 min, kept at 95% B for 9 min then decreased to 60% B in 1 min and kept at 60% B for 10 min. ESI was performed in negative ion mode, the ion source temperature was set at 280 ◦C. The tune page parameters were automatically optimized injecting CA at 1 µM as standard. The MS/MS detection was operated in MRM mode using a collision energy of 15 (arbitrary units). The observed transitions were: hyocholic acid (HCA) at 8.9 min MRM of 391.29 Th→391.29 Th, cholic acid (CA) at 10.2 min MRM of 407.28 Th→407.28 Th, chenodeoxycholic acid (CDCA) at 13.8 min MRM of 391.29 Th→391.29 Th, deoxycholic acid (DCA) at 14.4 min MRM of 391.29 Th→391.29 Th, lithocholic acid (LCA) at 17.5 min MRM of 375.28 Th→375.28 Th and 10 at 20.5 min MRM of 403.63 Th→403.63Th.   
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Determination of 7α-hydroxy-4-cholesten-3-one Sample preparation. Stock solutions of 7 alpha-hydroxy-4-cholesten-3-one were separately prepared at 5 mg/mL using MeOH as solvent. Five dilutions were obtained mixing 1 ng, 10 ng, 100 ng, 1 µg and 10 µg of 7α-hydroxy-4-cholesten-3-one in 50 µL of MeOH. Later on, 10 µL of glacial acetic acid and 10 mg of Girard T reagent (diluted in 40 µL of water) were added and kept in the dark at r.t. overnight (final volume of 100 µL).137 Mice serum sample aliquots of 50 µL were deproteinized with 500 µL of cold acetonitrile with 5% of NH4OH vortexing for 60 min. After centrifugation at 16000 g for 10 min, the clear supernatant was transferred to a new vial, snap frozen and lyophilized. The sample was then re-dissolved in 50 µL of MeOH. Later on, 10 µL of glacial acetic acid and 10 mg of Girard T reagent (diluted in 40 µL of water) were added and kept in the dark at r.t. overnight (final volume of 100 µL). Liquid chromatography and mass spectrometry analysis. For LC-MS/MS analysis, chromatographic separation was carried out on the HPLC–MS system LTQ XL ThermoScientific equipped with Accelera 600 Pump and Accelera AutoSampler system. The mixture was separated on a Jupiter C18 column from Phenomenex (150 x 2.00 mm) and the column flow rate was set at 150 µL/min. Samples were separated using a acetonitrile-metanol-aqueous gradient. Mobile phase A was water/MeOH/ACN at 50/33.3/16.7% in 0.1% TFA, mobile phase B was MeOH/ACN at 66.6/33.4% in 0.1% TFA. The gradient started at 35% B and increased to 95% B in 15 min, kept at 95% B for 10 min then decreased to 35% B in 1 min and kept at 35% B for 10 min. ESI was performed in positive ion mode, the ion source temperature was set at 280 ◦C. The MS/MS detection was operated using a collision energy of 40 (arbitrary units). 7α-hydroxy-4-cholesten-3-one modified by GT reagent gave a positive ion at m/z of 514.5 at 12.0 min and MS/MS analysis gave fragments at m/z of 455.4, 437.4, 427.4, 163.1, 151.1, 135.1, 123.1. Specific biological assay used for compound 45 Chemicals. Compound 45 or BAR501 was synthesized as described. Norepinephrine (NE), L-methionine, methoxamine, TLCA, oleanolic acid, betulinic acid, UDCA and LY294002 were from Sigma Aldrich (Milan, Italy). 
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Animals. C57BL6 and male Wistar rats were from Harlan Nossan (Udine, Italy). GPBAR1 null mice (generated directly into C57BL/6NCrl background), and congenic littermates on C57BL/6NCrl mice were originally donated by Dr. Galya Vassileva (Schering-Plough Research Institute, Kenilworth).73 The colonies were maintained in the animal facility of University of Perugia. Mice were housed under controlled temperatures (22 °C) and photoperiods (12:12-hour light/ dark cycle), allowed unrestricted access to standard mouse chow and tap water and allowed to acclimate to these conditions for at least 5 days before inclusion in an experiment. A total number of 96 mice and 21 rats were used in this study. The study was conducted in agreement with the Italian law and the protocol was approved by a ethical committee of University of Perugia and by a National committee of Ministry of Health (permission n. 245/2013-B). The health and body conditions of the animals were monitored daily by the veterinarian in the animal facility. The study protocol caused minor suffering, however, animals that lost more than 25% of the initial body weight were euthanized. At the day of sacrifice (prior to measure the portal pressure the animals (mice) were deeply anesthetized with a mixture of tiletamine hypochoride and zolazepam hypocloride/xylazine at a dose of 50/5 mg/kg. Similarly rats, at the day of sacrifice rats were deeply anesthetized with a lethal dose tiletamine hypochoride and zolazepam hypocloride/xylazine and liver were isolated and perfused. Animal models. Liver cirrhosis was induced by carbon tetrachloride (CCl4) administration. For this purpose, C57BL6 mice (40 animals) were administered i.p. 500 µL/Kg body weight of CCl4 in an equal volume of paraffin oil twice a week for 9 weeks. CCl4 mice were randomized to receive BAR501 (15 mg/kg daily by gavage) or vehicle (distilled water). In another experimental set-ting, wild type C57BL6 mice were administered 500 µL/Kg body weight of CCl4 in an equal vol-ume of paraffin oil twice a week for 3 weeks. CCl4 mice were then randomized to receive BAR501 (30 and 45 mg/kg daily by gavage) or vehicle (distilled water). Serum bilirubin, albumin, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) were measured by routine biochemical clinical chemistry. For histological examination, portions of the right and left liver lobes were fixed in 10% formalin, embedded in paraffin, sectioned and stained with Sirius red and hematoxylin/ eosin (H&E). In a further 
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model, moderate hyperhomocysteinemia77 was induced in Gpbar1+/+ and Gpbar1-/- mice (56 animals) by administration of L-methionine (1 g/kg daily by gavage) for a period of 4 weeks (n = 20). Mice administered L-methionine were randomized to receive BAR501 (20 mg/kg daily by gavage) or vehicle (distilled water). Isolated and perfused rat liver preparation. To investigate the effect of BAR501 on intrahepatic microcirculation, naïve rats were administered BAR501 (15 mg/kg daily by gavage) or water for 6 days. At the end of this period, analysis of hepatic vascular responses to NE (from 0.01 to 100 µmol/L) or methoxamine (100 µM) was performed using the isolated and perfused rat liver preparation, as described previously.77,84,140-141 The vasomotor responses to changes of liver flow (shear stress) was measured as described previously77,84-87,140-141 During these studies, the global viability of livers was assessed by standard criteria: i.e. inspection of gross appearance, stable pH of the perfusate, stable perfu-sion pressure for 20 min and bile flow >1 µL/min per g liver. The flow rate during each individual perfusion was maintained at a constant rate of 20 mL/min (S1 Table). Cell cultures. Human liver sinusoidal cells (LSEC) were from Innoprot (cat. N° P10652, Barcelona, Spain). LSEC were cultured in endothelial cell medium (Innoprot) additioned with 5% fetal bovine serum, endothelial cell growth supplement (ECGS) (Innoprot) and antibiotics. HepG2 (HB-8065), THP1 (TIB-202) and HEK293T (CRL-1573) cell lines were from ATCC (Manassas, VA; USA). HepG2 cells were cultured in E-MEM supplemented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin. HEK293T cells were cultured in DMEM supplemented with 10% FBS, 1% glutamine, and 1% penicillin/streptomycin. GLUTAg cells, a murine intestinal endocrine cell line, were kindly donated by Dr. D. J. Drucker, Banting and Best Diabetes Centre, Univer-sity of Toronto, Toronto, Canada, and cultured in D-MEM, supplemented with 10% FBS, 1% glutamine, and 1% penicillin/streptomycin. RNA extraction and Real-Time PCR. Total RNA was isolated from LSEC or tissues using the TRIzol reagent according to the manufacturer’s specifications (Life Technologies). One microgram of RNA was purified from genomic DNA by DNase-I treatment (Life Technologies) and reverse-transcribed using random hexamer primers with Superscript-II (Life Technologies) in a 20-µL reaction 
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volume. Ten ng cDNA were amplified in a 20 µl solution containing 200 nM of each primer and 10 µl of KAPA SYBR FAST Universal qPCR Kit (KAPA BIOSYSTEMS). All reactions were performed in triplicate, and the thermal cycling conditions were as follows: 3 min at 95 °C, followed by 40 cycles of 95 °C for 15 s, 56 °C for 20 s and 72 °C for 30 s. The relative mRNA expression was calculated accordingly to the Ct method. PCR primers were designed using the software PRIMER3 (http://frodo.wi.mit.edu/ primer3/) using published data obtained from the NCBI database. Forward and reverse primer sequences were as follows: hGAPDH: gaaggtgaaggtcggagt and catgggtggaatca tattggaa; hCSE: cactgtccaccacgttcaag and gtggctgctaaacctgaagc; hCBS: tcgtgatgccagagaagatg and ttggggatttcgttcttcag; hTGR5: cactgttgt ccctcctctcc and acactgctttggctgcttg; heNOS: agtgaaggcgacaatcctgtat and agggacaccacgtcatactcat; hET1: agggctgaagacattatggaga and cctggtttgtcttaggtgttcc; mGAPDH: ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mpro-glucagon: tgaagacaaacgccactcac and caatgttgttccggttcctc; mTGFb1: ttgcttcagctccacagaga and tggttgta gagggcaaggac; mCOL1A1: acgtcctggtgaagttggtc and cagggaagcctcttt ctcct; maSMA: tgtgctggactctggagatg and gaaggaatagccacgctcag; mTNFa: acggcatggatctcaaagac and gtgggtgaggagcacgtagt; mTGR5: ggcctggaactctgttatcg and gtccctcttggctcttcctc; mIL1b: tcacagcagca catcaacaa and tgtcctcatcctcgaaggtc; mCBS: agaagtgccctggctgtaaa and caggactgtcgggatgaagt; mCSE: tgctgccaccattacgatta and gatgccaccctcc tgaagta; meNOS: agaagagtccagcgaacagc and tgggtgctgaactgacagag; miNOS: acgagacggataggcagaga and cacatgcaaggaagggaact; mET1: tgccaagcagg aaaagaact and acgaaaagatgccttgatgc; mCAV1: ttgaagatgtgattgcagaacc and tcgtagacaacaagcggtaaaa. CSE activity. CSE activity was measured in liver tissues or in serum starved LSEC administered with 10 µM TLCA or BAR501 for 24 and 48 hr according to a previously published method.84 
Experimental Section III 
	   137	  
Nitrite/Nitrate. Hepatic nitrate/nitrite concentrations were measured by a colorimetric assay (Cayman Chemical, Ann Arbor, Michigan; USA). Spectroscopic Data 1H NMR (400 MHz, DMSO) of compound 44    1H NMR (700 MHz, CD3OD) of compound 45     
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13C NMR (175 MHz, CD3OD) of compound 45 	        1H NMR (700 MHz, CD3OD) of compound 46  	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1H NMR (500 MHz, CD3OD) of compound 47 	   	  	  	  	  	  13C NMR (100 MHz, CD3OD) of compound 47    	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1H NMR (400 MHz, CD3OD) of compound 48 	   	      1H NMR (500 MHz, CD3OD) of compound 49   	  	   	  
Experimental Section III 
	   141	  
1H NMR (400 MHz, CD3OD) of compound 50  	    1H NMR (400 MHz, CD3OD) of compound 51 	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1H NMR (700 MHz, CD3OD) of compound 54 	   	     1H NMR (700 MHz, CD3OD) of compound 55 	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1H NMR (500 MHz, CD3OD) of compound 56 	   	  	     1H NMR (500 MHz, CD3OD) of compound 57 	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1H NMR (500 MHz, CD3OD) of compound 58  	   	  	  	   1H NMR (500 MHz, CD3OD) of compound 59 	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1H NMR (500 MHz, CD3OD) of compound 60 	   	  	  	  1H NMR (500 MHz, CD3OD) of compound 61 	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1H NMR (700 MHz, CD3OD) of compound 62 	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IV. Experimental procedures for 6-ethylnorcholane and bis-homo-6-ethylcholane derivatives Synthesis of 3α ,7α-dihydroxy-6-ethylnorcholane derivatives 6α-ethyl-3α-hydroxy-7-keto-5β-cholan-24-oic acid (92). Compound 66 prepared as previously illustrated in Experimental section II (1.1 g, 2.5 mmol) was hydrolyzed with a methanol solution of sodium hydroxide (5%, 30 mL) in H2O (6 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure to give 92 in a quantitative yield (1.1 g). An analytical sample was obtained by silica gel chromatography eluting with CH2Cl2/MeOH 95:5. [α]D25= -21.5 (c= 0.35, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.46 (1H, m), 2.83 (1H, dd, J = 13.0, 5.5 Hz), 2.50 (1H, t, J = 11.2 Hz), 2.34 (1H, m), 2.20 (1H, m), 1.22 (3H, s), 0.96 (3H, d, J = 6.6 Hz), 0.81 (3H, t, J = 7.3 Hz), 0.71 (3H, s); 13C NMR (100 MHz, CD3OD): δ 215.5, 187.0, 71.7, 56.4, 53.3, 52.2, 51.2, 50.5, 45.4, 43.8, 40.4, 36.8, 36.6, 35.3, 32.6, 32.3, 32.0, 30.6, 29.3, 25.6, 23.9, 23.0, 20.8, 18.8, 12.5, 12.3; HRMS-ESI m/z 419.3164 [M+H]+, C26H43O4 requires 419.3161. 6α-ethyl-3α-formyloxy-7-keto-5β-cholan-24-oic acid (93). A solution of 92 (1.0 g, 2.6 mmol) in 30 mL of 90% formic acid containing 90 µL of 70% perchloric acid was stirred at 47-50 °C for 6 h. The temperature of the heating bath was lowered to 40 °C, then 24 mL of acetic anhydride was added over 10 min and the mixture was stirred for 10 min more. The solution was cooled to room temperature, poured into 50 mL of water and extracted with diethyl ether. The organic layers were washed with water to neutrality, dried over Na2SO4, and evaporated to give 940 mg of 93 (81%). An analytical sample was obtained by silica gel chromatography eluting with CH2Cl2/MeOH 95:5. [α]D25= -25.9 (c= 0.56, CH3OH); selected 1H NMR (400 MHz CDCl3): δ 7.99 (1H, s), 4.79 (1H, m), 2.71 (1H, dd, J = 5.9,12.8 Hz), 1.29 (3H, s), 0.93 (3H, d, J = 6.3 Hz), 0.80 (3H, t, J = 7.2 Hz), 0.66 (3H, s); 13C NMR (100 MHz CDCl3): δ 212.5, 180.0, 160.6, 73.2, 54.8, 51.9, 50.6, 49.9, 48.9, 43.6, 42.6, 38.9, 35.7, 35.1, 33.8, 30.9, 30.7, 30.3,28.2, 27.6, 25.9, 24.5, 23.4, 21.8, 18.8, 12.0, 11.9; HRMS-ESI m/z 447.3116 [M+H]+, C27H43O5 requires 447.3110. 
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6α-ethyl-3α-formyloxy-7-keto-24-nor-5β-cholan-23-nitrile (94). Crude 93 (930 mg, 2.1 mmol), 6.7 mL of cold trifluoroacetic acid, and 1.80 mL (15.6 mmol) of trifluoroacetic anhydride were stirred at 0-5 °C until dissolution. Sodium nitrite (435 mg, 6.30 mmol) was added in small portions. After the addition was complete, the reaction mixture was stirred first at 0-5 °C for 1 h, then at 38-40 °C for 2 h. On completion, the reaction was neutralized with NaOH 2 M, then the product was extracted with 50 mL of diethyl ether (3 x 50 mL), followed by washing with brine and dried over anhydrous Na2SO4. The ether was removed under reduced pressure to afford 860 mg of 94 in quantitative yield, that was subjected to next step without any purification. 6α-ethyl-3α-hydroxy-7-keto-24-nor-5β-cholan-23-oic acid (95). Crude compound 94 (860 mg, 2.1 mmol) was refluxed with 30% KOH in ca. 50 mL of methanol/water 1:l. After 48 h stirring, the basic aqueous solution was neutralized with HCl 6 M. Then methanol was evaporated and the residue was extracted with AcOEt (3 x 50 mL). The combined organic layers were washed with brine, dried and evaporated to dryness to give white solid residue 95 (723 mg, 86%). An analytical sample was obtained by silica gel chromatography eluting with CH2Cl2/MeOH 95:5. [α]D25= -25.2 (c= 0.22, CH3OH); selected 1H NMR (400 MHz CD3OD): δ 3.46 (1H, m), 2.82 (1H, dd, J = 6.4, 12.6 Hz), 1.25 (3H, s), 1.25 (3H, d ovl), 0.81 (3H, t, J = 7.3 Hz), 0.74 (3H, s); 13C NMR (100 MHz CD3OD): 
δ 215.7, 177.6, 71.7, 56.3, 53.3, 51.2, 50.6, 50.5, 45.3, 43.8, 42.5, 40.4, 36.8, 35.3, 35.0, 32.6, 30.5, 29.4, 25.6, 23.9, 22.9, 20.9, 19.6, 12.5, 12.3; HRMS-ESI m/z 405.3008 [M+H]+, C25H41O4 requires 405.3005. 6α-ethyl-3α,7α-dihydroxy-24-nor-5β-cholan-23-oic acid (NorECDCA, 76). To a solution of 95 (500 x 10-3 g, 1.20 mmol) in dry THF (30 mL), at 0 °C dry methanol (360 µL, 8.4 mmol) and LiBH4 (4.2 mL, 2M in THF, 8.4 mmol) was added. The resulting mixture was stirred for 1 h at 0 °C. The mixture was quenched by addition of 1.0 M NaOH (2.4 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated. Purification by silica gel (CH2Cl2:MeOH 9:1) gave 76 as a white solid (400 mg, 82%). An analytical sample was obtained by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 1 mL/min, tR =9.6 min); [α]D25= +3.3 (c= 1.04, CH3OH); selected 1H NMR (500 
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MHz, CD3OD): δ 3.66 (1H, s), 3.32 (1H, ovl), 2.35 (1H, dd, J = 13.4, 3.3 Hz), 1.00 (3H, d, J = 6.4 Hz), 0.92 (3H, s), 0.90 (3H, t, J = 7.1 Hz), 0.74 (3H, s); 13C NMR (125 MHz, CD3OD): δ 178.0, 72.9, 70.9, 57.6, 51.4, 46.7, 43.7, 43.6, 42.8, 41.2, 40.8, 36.8, 36.0, 34.8, 34.4, 34.0, 31.0, 29.1, 24.3, 23.4, 23.3, 21.8, 19.3, 12.0, 11.8; HR ESIMS m/z 405.3011 [M-H]-, C25H41O4 requires 405.3005. 6α-ethyl-3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol (NorECDCOH, 77). Compound 95 (200 mg, 0.5 mmol) was dissolved in 50 mL of dry methanol and treated with p-toluenesulfonic acid in catalytic amount. The solution was left to stand at room temperature for 2 h. The mixture was quenched by addition until the neutrality of NaHCO3 saturated solution. Most of the solvent was evaporated, and the residue was extracted with EtOAc. To a solution of crude solid (220 mg, quantitative yield) in dry THF (10 mL), at 0 °C dry methanol (158 µL, 3.90 mmol) and LiBH4 (1.90 mL, 2M in THF, 3.90 mmol) was added. The resulting mixture was stirred for 1 h at 0 °C. The mixture was quenched by addition of 1.0 M NaOH (1.1 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated. Silica gel chromatography eluting with hexane/EtOAc 6:4 afforded compound 77 (191 mg, 98% over two steps). An analytical sample was obtained by on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 1 mL/min, tR=10.8 min); [α]D25= +4.4 (c= 1.42, CH3OH); 1H and 13C NMR spectroscopic data in CD3OD given in Tables 1 and 2; HR ESIMS m/z 393.3374 [M+H]+, C25H45O3 requires 393.3369. 6α-ethyl-3α,7α-dihydroxy-24-nor-5β-cholan-23-nitrile (NorECDCN, 78). To a solution of 94 (200 mg, 0.5 mmol) in dry THF (10 mL), at 0 °C dry methanol (142 µL, 3.50 mmol) and LiBH4 (1.80 mL, 2M in THF, 3.50 mmol) was added. The resulting mixture was stirred for 2 h at 0 °C. The mixture was quenched by addition of 1 M NaOH (1 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 805 mg of 78 (79%, tR=15.2 min). [α]D25= -13.4 (c= 0.47, CH3OH); selected 1H NMR (700 MHz, CD3OD): δ 3.66 (1H, br s), 3.31 (1H, ovl), 2.46 (1H, dd, J =3.8, 16.9 Hz), 2.34 (1H, dd, J = 7.4,16.9 Hz) 1.16 (3H, d, J = 6.5 Hz), 0.91 (3H, t, J = 7.5 Hz), 0.92 (3H, s), 0.73 (3H, s); 13C NMR (175 
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MHz, CD3OD): δ 120.3, 72.9, 70.9, 56.1, 51.5, 46.7, 43.4, 42.9, 41.4, 40.2, 36.5, 36.2, 34.3 (2C), 34.2, 30.7, 29.2, 24.9, 24.4, 23.4, 23.3, 21.9, 18.5, 12.1, 11.6; HR ESIMS m/z 388.3221 [M+H]+, C25H42NO2 requires 388.3216. Synthesis of 3α-hydroxy-, 3-deoxy-, 3β-hydroxy-6-ethylnorcholane and bis-homo-6-ethylcholane derivatives. Methyl 3α-hydroxy-7-keto-24-nor-5β-cholan-23-oate (98). 7-KLCA (2.0 g, 5.1 mmol) was subjected to Beckmann degradation at C24 and methylation at C-23 furnishing 98 in 66% yield. The Beckmann degradation was previously described for the synthesis of 3α,7α-dihydroxy-6-ethylnorcholane derivatives. Methyl (E)-3α-acetoxy-6-ethylidene-7-keto-24-nor-5β-cholan-23-oate (99). At the solution of the methyl ester 98 (1.32 g, 3.38 mmol) in dry pyridine (10 mL), an excess of acetic anhydride (3.2 mL, 34 mmol) was added. After 2 h, the pyridine was concentrated under vacuum. The residue was poured into cold water (100 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic phases were dried (Na2SO4) and concentrated to give a residue that was further purified by flash chromatography on silica gel using hexane/ethyl acetate 95:5 and 0.5% of triethylamine as eluent. To a solution of diisopropylamine (7.2 mL, 51 mmol) in dry THF (50 mL) was added dropwise a solution of n-butyllithium (19.0 mL, 2.5 M in hexane, 47.6 mmol) at -78 °C. After 30 min, trimethylchlorosilane (8.20 mL, 64.6 mmol) was added. After additional 30 min, a solution of residue (1.46 g, 3.40 mmol) in dry THF (10 mL) was added. The reaction was stirred at -78 °C for 45 min and then triethylamine (16.6 mL, 119 mmol) was added. After 1 h, the reaction mixture was allowed to warm to -20 °C, treated with aqueous saturated solution of NaHCO3 (100 mL) and brought up to room temperature in 2 h. The aqueous phase was extracted with ethyl acetate (3 x 50 mL). The combined organic phases were washed then with saturated solution of NaHCO3, water and brine. After drying, the residue was evaporated under vacuum to give 2 g of residue, that was dilutedin dry CH2Cl2 (20 mL) and cooled at -78 °C. At this stirred solution acetaldehyde (960 µL, 17.0 mmol) and BF3·OEt2 (4.2 mL, 34 mmol) were added dropwise. The reaction mixture was stirred for1 h at -60 °C and allowed to warm to room temperature. The mixture was quenched with saturated aqueous solution of NaHCO3 and extracted with CH2Cl2. The combined organic phases were washed with brine, dried over anhydrous Na2SO4 and 
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concentrated under vacuum. Purification by silica gel (hexane-ethyl acetate 99:1 and 0.5% TEA) gave compound 99 (940 mg, 60% over three steps). NMR analysis demonstrated a diasteromeric ratio E/Z >95%. The E configuration at the exocyclic double bond was established by dipolar coupling H3-25 (δ 1.67)/H-5 (δ 2.61) in NOESY spectrum (400 MHz, mixing time 400 ms). [α]D25= -3.31 (c= 3.25, CH3OH); selected1H NMR (400 MHz, CDCl3): δ 6.17 (1H, q, J = 7.2 Hz, H-24), 4.75 (1H, m, H-3), 3.64 (3H, s, COOCH3), 2.61 (1H, dd, J = 13.1, 4.0 Hz, H-5), 1.98 (3H, s, COCH3), 1.67 (3H, d, J = 7.2 Hz, H3-25), 1.00 (3H, s, H3-19), 0.97 (3H, d, J = 6.8 Hz, H3-21), 0.67 (3H, s, H3-18); 13C NMR (100 MHz, CDCl3): δ 204.5, 174.2, 170.5, 143.0, 130.6, 72.5, 54.7, 51.4, 50.7, 48.6, 45.3, 43.7, 41.5, 39.1, 38.8, 34.6, 34.2, 33.6, 33.4, 28.5, 25.9 (2C), 22.8, 21.3 (2C), 19.7, 12.7, 12.1;  HR ESIMS m/z 459.3107 [M+H]+, C28H43O5 requires 459.3110. Methyl 3α-acetoxy-6β-ethyl-7-keto-24-nor-5β-cholan-23-oate (100). A solution of 99 (600 x 10-3 g, 1.30 mmol) in THF dry/MeOH dry (100 mL, 1:1 v/v) was hydrogenated in presence of Pd(OH)2 20% wt on activated carbon (100 mg) Degussa type. The mixture was transferred to a standard Parr apparatus and flushed with nitrogen and hydrogen several times. The apparatus was shacked under 50 psi of H2. The reaction was stirred at room temperature for 12 h. The catalyst was filtered through Celite, and the recovered filtrate was concentrated under vacuum to give 100 (600 mg, quantitative yield). The β-configuration of ethyl group at C-6 was determined by dipolar couplings H3-25 (δ 0.83)/ H3-19 (δ 1.22) in NOESY spectrum (400 MHz, mixing time 400 ms). [α]D25= +10.4 (c= 0.39, CH3OH); selected 1H NMR (400 MHz, CDCl3): δ 4.65 (1H, m, H-3), 3.67 (3H, s, COOCH3), 2.60 (1H, t, J = 11.2 Hz, H-8), 2.43 (1H, dd, J = 14.2, 2.6 Hz, H-22a), 1.98 (3H, s, COCH3), 1.88 (1H, m ovl, H-6), 1.22 (3H, s, H3-19), 0.98 (3H, d, J = 6.4 Hz, H3-21), 0.83 (3H, t, J = 7.0 Hz, H3-25), 0.70 (3H, s, H3-18); 13C NMR (100 MHz, CDCl3): δ 215.3, 174.0, 170.5, 72.8, 61.9, 55.0, 51.4, 49.2, 48.7, 45.5, 42.9, 42.6, 41.4, 38.7 (2C), 35.6, 35.3, 34.9, 28.3 (2C), 26.5, 25.9, 24.8, 21.4, 21.3, 19.6, 13.0, 12.1; HR ESIMS m/z 461.3265 [M+H]+, C28H45O5 requires 461.3267.  6β-ethyl-3α,7β-hydroxy-24-nor-5β-cholan-23-ol (79) and 6β-ethyl-3α,7α-hydroxy-24-nor-5β-cholan-23-ol (81). A methanol solution of compound 100 
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(100 mg, 0.2 mmol), a large excess of NaBH4 was added at 0 °C. The mixture was left at room temperature for 10 h and then water and MeOH was added dropwise during a period of 15 min at 0 °C with effervescence being observed. Then after evaporation of the solvents, the residue was diluted with water and extracted with ethyl acetate (3 x 50 mL). The combined extract was washed with brine, dried with Na2SO4, and evaporated to give 90 mg of a crude residue that was subjected to the next step without further purification. To a solution of crude residue (90.0 mg, 0.214 mmol) in dry THF (15 mL), at 0 °C dry methanol (60.0 µL, 1.49 mmol) and LiBH4 (749 µL, 2 M in THF, 1.49 mmol) were added. The resulting mixture was stirred for 2 h at 0 °C. The mixture was quenched by addition of 1.0 M NaOH (0.43 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (86:14) as eluent (flow rate 3 mL/min), gave 47 mg of 79 (54%, tR= 11 min) and 20 mg of 81 (23%, tR= 15 min). 6β-ethyl-3α,7β-hydroxy-24-nor-5β-cholan-23-ol (79). [α]D25= +11.57 (c= 0.14, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.73 (1H, dd, J = 10.5, 5.5 Hz, H-7), 3.61 (1H, m, H-23a), 3.51 (1H, m, ovl, H-23b), 3.51 (1H, m, ovl, H-3), 0.98 (3H, d, ovl, H3-21), 0.97 (3H, s, H3-19), 0.96 (3H, t, ovl, H3-25), 0.70 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 75.2, 71.8, 60.8, 57.5, 56.6, 51.5, 45.5, 44.8, 42.0, 41.4, 40.7, 40.3, 39.9, 36.9, 36.0, 34.2, 30.5, 29.6, 28.3, 26.2, 23.4, 22.0, 19.4, 14.7, 12.9; HR ESIMS m/z 393.3365 [M+H]+, C25H45O3 requires 393.3369. 6β-ethyl-3α,7α-hydroxy-24-nor-5β-cholan-23-ol (81). [α]D25= +9.16 (c= 0.62, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.63 (1H, m, H-23a), 3.60 (1H, m, H-7), 3.55 (1H, m, H-23b), 3.37 (1H, m, H-3), 2.30 (1H, q, J = 12.5 Hz, H-4a), 0.97 (3H, d, J = 6.6 Hz, H3-21), 0.95 (3H, s, H3-19), 0.95 (3H, t, J = 7.0 Hz, H3-25), 0.72 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 72.8, 72.7, 60.8, 57.9, 52.7, 51.4, 47.5, 43.7, 42.3, 41.0, 39.9, 37.5, 37.3, 36.7, 34.2, 33.3, 31.0, 29.6, 29.4, 26.2, 24.8, 21.6, 19.3, 14.5, 12.1; HR ESIMS m/z 393.3367 [M+H]+, C25H45O3 requires 393.3369. 6β-ethyl-3α,7β-hydroxy-24-nor-5β-cholan-23-oic acid (80). To a methanol solution of compound 100 (200 x 10-3 g, 0.440 mmol), a large excess of NaBH4 
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was added at 0 °C. The mixture was left at room temperature for 2 h and then water and MeOH were added dropwise during a period of 15 min at 0 °C with effervescence being observed. After evaporation of the solvents, the residue was diluted with water and extracted with ethyl acetate (3 x 50 mL). The combined extract was washed with brine, dried with Na2SO4 and evaporated to give 216 mg of 101 that was subjected to the next step without further purification. Compound 101 (216 mg, 0.520 mmol) was hydrolyzed with NaOH (207 mg, 5.17 mmol) in a solution of MeOH:H2O 1:1 v/v (20 mL). The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 10 mm i.d. x 250 mm) with MeOH/H2O (86:14) as eluent (flow rate 3 mL/min), gave compound 80 (147 mg, 0.360 mmol) as a white solid (82%, tR= 9 min). [α]D25= +23.7 (c= 0.14, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.74 (1H, dd, J = 10.1, 5.7 Hz, H-7), 3.50 (1H, m, ovl, H-3), 2.42 (1H, d, J = 11.0 Hz, H-22a), 1.02 (3H, d, ovl, H3-21), 1.00 (3H, s, H3-19), 0.96 (3H, t, J = 7.0 Hz, H3-25), 0.76 (3H, s, H3-18); HR ESIMS m/z 405.3001 [M-H]-, C25H41O4 requires 405.3005. 6-ethylidene-3α,7β-dihydroxy-24-nor-5β-cholan-23-ol (82). Compound 99 (100 mg, 0.2 mmol) was subjected to the same operative condition previously described for compounds 79 and 81. HPLC purification on a Nucleodur 100-5 C18 (5µm; 10 mm i.d. x 250 mm) with MeOH/H2O (86:14) as eluent (flow rate 3 mL/min), gave 73 mg of compound 82 (tR= 8 min, 85% over two steps). [α]D25= +20.6 (c= 2.43, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 5.66 (1H, q, J = 6.8 Hz, H-24), 3.92 (1H, d, J = 9.8 Hz, H-7), 3.60 (1H, m, H-23a), 3.56 (1H, m, H-3), 3.55 (1H, m, H-23b), 2.52 (1H, dd, J = 3.7, 13.2 Hz, H-5), 1.63 (3H, d, J = 6.8 Hz, H3-25), 0.98 (3H, d, J = 6.5 Hz, H3-21), 0.95 (3H, s, H3-19), 0.71 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 143.7, 115.4, 74.1, 71.8, 60.8, 58.0, 57.1, 46.1, 45.9, 45.1, 41.6, 41.1, 39.9, 37.0, 36.4, 35.8, 34.1, 30.9, 29.8, 28.1, 23.5, 22.5, 19.5, 12.7, 12.6; HR ESIMS m/z 391.3208 [M+H]+, C25H43O3 requires 391.3212. 
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6α-ethyl-3α,7β-dihydroxy-24-nor-5β-cholan-23-ol (83). A solution of 82 (30.0 mg, 0.0760 mmol) in THF dry/MeOH dry (5 mL, 1:1 v/v) was hydrogenated in presence of Pd(OH)2 20% wt on activated carbon (10 mg) Degussa type. The reaction was stirred at room temperature for 12 h. The catalyst was filtered through Celite, and the recovered filtrate was concentrated under vacuum to give 83 (30 mg, quantitative yield). [α]D25= -3.3 (c= 0.10, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.62 (1H, m, H-23a), 3.54 (1H, m, H-23b), 3.45 (1H, m, H-3), 3.08 (1H, t, J = 9.8 Hz, H-7), 0.97 (3H, d, J = 6.5 Hz, H3-21), 0.95 (3H, s, H3-19), 0.86 (3H, t, J = 7.4 Hz, H3-25), 0.73 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 76.4, 72.5, 60.8, 57.9, 57.2, 46.2, 45.1, 44.7, 41.8, 41.2, 40.0, 39.8, 36.5, 35.6, 34.2, 31.2, 30.9, 29.9, 27.9, 24.1, 22.7, 22.0, 19.5, 12.7, 11.7; HR ESIMS m/z 393.3365 [M+H]+, C25H45O3 requires 393.3369. Methyl 3α-toxyloxy-6α-ethyl-7-keto-24-nor-5β-cholan-23-oate (102). Compound 100 (300 x 10-3 g, 0.650 mmol) was treated with 0.5 M MeONa (13 mL) in dry methanol and stirred at room temperature over night, in order to obtain the de-acetylation at C-3 and inversion at C-6. Then after addition of water and evaporation of the solvents, the residue was diluted with water and extracted with ethyl acetate (3 x 50 mL). The combined extract was washed with brine, dried with Na2SO4 and evaporated to give 240 mg of a crude residue that was subjected to the next step without further purification. To a solution of a crude residue (240 mg, 0.520 mmol) in dry pyridine (10 mL), tosyl chloride (1.11 g, 12.2 mmol) was added, and the mixture was stirred at room temperature for 6 h. It was poured into cold water (30 mL) and extracted with CH2Cl2 (3 × 30 mL), to give 270 mg of 102 (73% over two steps) that was subjected to the next step without further purification. 6α-ethyl-7α-hydroxy-24-nor-5β-cholan-23-ol (84). Lithium bromide (50.0 mg, 0.580 mmol) and lithium carbonate (42.2 mg, 0.580 mmol) were added to a solution of compound 102 (150 mg, 0.26 mmol) in dry DMF (10 mL), and the mixture was refluxed for 2 h. After cooling to room temperature, the mixture was slowly poured into 10% HCl solution (10 mL) and extracted with CH2Cl2 (3 
× 30 mL). The combined organic layer was washed successively with water, saturated NaHCO3 solution and water, and then dried over anhydrous MgSO4 and evaporated to dryness to give 145 mg of oily residue (quantitative yield), 
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that was subjected to next step without any purification. An oven-dried 10 mL flask was charged with 10% palladium on carbon (5 mg) and the product obtained (145 mg, 0.250 mmol) and the flask was evacuated and flushed with argon. Absolute methanol (5 mL) and dry THF (5 mL) were added, and the flask was flushed with hydrogen. The reaction was stirred at room temperature under H2 (1 atm) over night. The mixture was filtered through celite and the recovered filtrate was concentrated to give 110 mg of 103 (0.026 mmol, quantitative yield over two steps). Dry methanol (35.0 µL, 0.870 mmol) and LiBH4 (435 µL, 2 M in THF, 0.870 mmol) were added to a solution of 103 (50.0 mg, 0.124 mmol) in dry THF (5 mL) at 0 °C under argon and the resulting mixture was stirred for 3 h at 0 °C. The mixture was quenched by addition of NaOH (1.0 M, 0.25 mL) and then allowed to warm to room temperature. Ethyl acetate was added and the separated aqueous phase was extracted with ethyl acetate (3 × 15 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated. HPLC purification on a Nucleodur 100-5 C18 (5µm; 5 mm i.d. x 250 mm) with MeOH/H2O (9:1) as eluent (flow rate 1 mL/min), gave 32.5 mg of 84 (tR= 17.2 min, 70%). [α]D25= +1.0 (c= 2.15, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.66 (1H, br s, H-7), 3.61 (1H, m, H-23a), 3.54 (1H, m, H-23b), 0.96 (3H, d, J = 6.7 Hz, H3-21), 0.91 (3H, s, H3-19), 0.89 (3H, t, J = 7.3 Hz, H3-25), 0.70 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 71.5, 60.8, 57.8, 51.7, 48.6, 43.8, 43.3, 41.5, 41.1, 39.9, 39.2, 37.4, 34.5, 34.2, 29.4, 28.8, 25.0, 24.6 (2C), 23.5, 22.5, 22.0, 19.4, 12.2, 12.1; HR ESIMS m/z 377.3423 [M+H]+, C25H45O2 requires 377.3420. 6α-ethyl-7α-hydroxy-24-nor-5β-cholan-23-oic acid (85). Compound 103 (60.0 mg, 0.150 mmol) was hydrolyzed with NaOH (57.6 mg, 1.44 mmol) in a solution of MeOH:H2O 1:1 v/v (6 mL) on reflux for 4 h. Crude carboxylic acid intermediate (65 mg, 0.17 mmol) was treated with LiBH4 by analogous procedures to those detailed above for compound 84. Purification by silica gel (CH2Cl2-MeOH 99:1) furnished 53.5 mg of compound 85 (0.140 mmol, 92%). [α]D25= +1.5 (c= 0.27, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.64 (1H, br s, H-7), 2.41 (1H, dd, J = 11.0, 2.6 Hz, H-22a), 1.00 (3H, d, J = 6.0 Hz, H3-21), 0.90 (3H, s, H3-19), 0.87 (3H, t, J = 7.4 Hz, H3-25), 0.71 (3H, s, H3-18); 
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13C NMR (100 MHz, CD3OD): δ 178.9, 71.6, 57.5, 51.7, 48.6, 43.8, 43.4, 43.3, 41.5, 40.9, 39.1, 37.4, 35.2, 34.6, 29.4, 28.8, 25.0, 24.6 (2C), 23.5, 22.4, 22.0, 20.1, 12.2, 12.1; HR ESIMS m/z 389.3052 [M-H]-, C25H41O3 requires 389.3056. Methyl 3β-hydroxy-6α-ethyl-7-keto-24-nor-5β-cholan-23-oate (104). A solution of intermediate 102 (100 x 10-3 g, 0.170 mmol) and CH3COOK (18 mg, 0.18 mmol) dissolved in water (1 mL) and N,N-dimethylformamide (DMF, 4 mL), was refluxed for 3 h. The solution was cooled at room temperature and then ethyl acetate and water were added. The separated aqueous phase was extracted with ethyl acetate (3 × 30 mL). The combined organic phases were washed with water, dried (Na2SO4) and evaporated to dryness to give intermediate 104 (100 mg) that was used as starting material in the synthesis of compounds 86 and 87 without further purification. 6α-ethyl-3β,7α-dihydroxy-24-nor-5β-cholan-23-ol (86). Compound 104 (60.0 mg, 0.140 mmol) was subjected at LiBH4 reduction with the same procedures previous described for compound 84, to give 55 mg of a crude residue. HPLC purification on a Nucleodur 100-5 C18 (5 µm; 5 mm i.d. x 250 mm) with MeOH/H2O (8:2) as eluent (flow rate 1 mL/min), gave 31 mg of 86 (tR= 14 min, 57%). [α]D25= +7.1 (c= 1.23, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.97 (1H, br s, H-3), 3.67 (1H, br s, H-7), 3.61 (1H, m, H-23a), 3.55 (1H, m, H-23b), 0.97 (3H, d, J = 6.6 Hz, H3-21), 0.95 (3H, s, H3-19), 0.91 (3H, t, J = 7.4 Hz, H3-25), 0.71 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 71.4, 67.4, 60.8, 57.9, 51.8, 43.8, 42.8, 41.5, 41.2, 41.1, 39.9, 37.0, 34.2, 33.8, 31.3, 31.2, 29.4, 28.3, 24.6, 24.2, 23.3, 22.3, 19.4, 12.2, 12.1; HR ESIMS m/z 393.3365 [M+H]+, C25H45O3 requires 393.3369. 6α-ethyl-3β,7α-dihydroxy-24-nor-5β-cholan-23-oic acid (87). Compound 104 (40.0 mg, 0.0950 mmol) was hydrolyzed with sodium hydroxide in a solution of MeOH: H2O 1:1 (5 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure, to give a crude residue (35 mg, 0.086 mmol) that was subjected at LiBH4 reduction, with the same procedures previous described for compound 85. HPLC 
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purification on a Nucleodur 100-5 C18 (5 µm; 5 mm i.d. x 250 mm) with MeOH/H2O (88:12) as eluent (flow rate 3 mL/min), gave 22.5 mg of 87 as a white solid (58% over two steps, tR= 9 min). [α]D25= +2.0 (c= 0.47, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.97 (1H, br s, H-3), 3.66 (1H, br s, H-7), 2.42 (1H, dd, J = 11.3, 3.3 Hz, H-22a), 1.02 (3H, d, J = 6.0 Hz, H3-21), 0.94 (3H, s, H3-19), 0.91 (3H, t, J = 7.3 Hz, H3-25), 0.73 (3H, s, H3-18); 13C NMR (100 MHz, CD3OD): δ 177.7, 71.3, 67.4, 57.4, 51.8, 43.8 (2C), 42.8, 41.5, 41.2, 41.0, 37.0, 35.1, 33.8, 31.3, 31.2, 29.4, 28.3, 24.6, 24.2, 23.3, 22.2, 20.0, 12.2, 12.1; HR ESIMS m/z 405.3003 [M-H]-, C25H41O4 requires 405.3005. 6α-ethyl-3α,7α-di(tert-butyldimethylsilyloxy)-5β-cholan-24-ol (106). 2,6-lutidine (5.35 mL, 46.0 mmol) and tert-butyldimethylsilyl trifluoromethanesulfonate (3.15 mL, 13.7 mmol) were added at 0 °C to a solution of compound 105, prepared as previously reported, (1.0 g, 2.3 mmol) in 30 mL of CH2Cl2. After 2 h stirring at 0 °C, the reaction was quenched by addition of aqueous NaHSO4 (1 M, 100 mL). The layers were separated and the aqueous phase was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were washed with NaHSO4, water, saturated aqueous NaHCO3, and brine and evaporated in vacuo to give 2.2 g of methyl 6α-ethyl-3α,7α-di(tert- butyldimethylsilyloxy)-5β-cholan-24-oate in the form of colorless needles, that was subjected to next step without any purification. To a solution of methyl ester (2.2 g, 3.4 mmol) in dry THF (30 mL), at 0 °C dry methanol (413 µL, 10.2 mmol) and LiBH4 (5.10 mL, 2M in THF, 10.2 mmol) was added. The resulting mixture was stirred for 2 h at 0 °C. The mixture was quenched by addition of 1.0 M NaOH (6.8 mL) and then ethyl acetate. The organic phase was washed with water, dried (Na2SO4) and concentrated. Purification by silica gel (hexane/ethyl acetate 99:1 and 0.5% TEA) gave 106 as a white solid (1 g, 68% over two steps). Methyl 6α-ethyl-3α,7α-di(tert-butyldimethylsilyloxy)-25,26-bis-homo-5β-chol-24-en-26-oate (107). DMSO (1.56 mL, 22.0 mmol) was added dropwise for 15 min to a solution of oxalyl chloride (5.49 mL, 11.0 mmol) in dry dichloromethane (30 mL) at -78 °C under argon atmosphere. After 30 min a solution of alcohol 106 (1.0 g, 1.6 mmol) in dry CH2Cl2 was added via cannula and the mixture was stirred at -78 °C for 30 min. Et3N (2.18 mL, 15.7 mmol) was added dropwise. After 1 h methyl (triphenylphosphoranylidene)acetate (1.64 g, 4.70 mmol) was 
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added and the mixture was allowed to warm to room temperature. A saturated solution of NaCl was added and the aqueous phase was extracted with diethyl ether (3 × 50 mL). The combined organic phases were washed with water, dried (Na2SO4) and concentrated. Purification by silica gel (hexane-ethyl acetate 995:5 and 0.5% TEA) gave compound 107 as colorless oil (850 mg, 79%). Methyl 6α-ethyl-3α,7α-dihydroxy-25, 26-bis-homo-5β-cholan-26-oate (88). A solution of compound 107 (850 mg, 1.2 mmol) in THF dry/MeOH dry (5 mL/5 mL, v/v) was hydrogenated in presence of Pd(OH)2 5% wt on activated carbon Degussa type (5 mg). The flask was evacuated and flushed first with argon and then with hydrogen. After 12 h, the reaction was complete. The catalyst was filtered through celite, and the recovered filtrate was concentrated under vacuum to give the methyl ester, which was dissolved in methanol (40 mL). At the solution was added 1 mL of HCl 37% v/v. After 1h, silver carbonate was added at the solution to precipitate chloride. Then the reaction mixture was centrifuged and the supernatant was concentrated in vacuo to give compound 88 as colourless amorphous solids (500 mg, 88%). An analytical sample was purified by HPLC on a Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (98:2) as eluent (flow rate 1 mL/min), to give compound 88 (tR= 7min). [α]D25= +6.85 (c= 0.14, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.66 (3H, s, COOCH3), 3.65 (1H, ovl, H-7), 3.31 (1H, ovl, H-3), 2.32 (2H, t, J = 7.71 Hz, H2-25), 0.94 (3H, d, J = 6.4 Hz, H3-21), 0.92 (3H, s, H3-19), 0.91 (3H, t, J = 6.8 Hz, H3-28), 0.69 (3H, s, H3-18); 13C NMR (175 MHz, CD3OD): δ 176.0, 73.2, 71.2, 57.7, 51.9, 51.7, 47.0, 43.7, 43.1, 41.6, 41.1, 37.1, 36.9, 36.8, 36.6, 34.5, 34.4 (2C), 31.3, 29.4, 26.7, 26.4, 24.6, 23.8, 23.5, 22.0, 19.2, 12.3, 12.1; HR ESIMS m/z 463.3783 [M+H]+, C29H51O4 requires 463.3787 6α-ethyl-3α,7α-dihydroxy-25,26-bis-homo5β-cholan-26-oic acid (89). Compound 88 (200 x 10-3 g, 0.430 mmol) was hydrolyzed with sodium hydroxide in a solution of MeOH:H2O 1:1 (10 mL) overnight under reflux. The resulting solution was then concentrated under vacuum, diluted with water, acidified with HCl 6 M and extracted with ethyl acetate (3 x 50 mL). The collected organic phases were washed with brine, dried over Na2SO4 anhydrous and evaporated under reduced pressure. HPLC purification on a Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 
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mm) with MeOH/H2O (92:8) as eluent (flow rate 1 mL/min), gave 172 mg of 89 as a white solid (89%, tR= 7 min). [α]D25= -0.72 (c= 0.08, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.66 (1H, br s, H-7), 3.31 (1H, m ovl, H-3), 2.24 (2H, t, J = 7.3 Hz, H2-25), 0.95 (3H, d, J = 6.4 Hz, H3-21), 0.92 (3H, s, H3-19), 0.91 (3H, t, J = 6.9 Hz, H3-28), 0.70 (3H, s, H3-18); 13C NMR (175 MHz, CD3OD): δ 186.7, 73.3, 71.3, 57.7, 51.7, 47.0, 43.7, 43.1, 41.6, 41.1, 37.1, 36.9, 36.8, 36.6, 34.5, 34.4 (2C), 31.3, 29.4, 27.0 (2C), 24.6, 23.8, 23.5, 22.0, 19.2, 12.2, 12.0; HR ESIMS m/z 447.3469 [M-H]-, C28H47O4 requires 447.3474. 6α-ethyl-3α,7α-dihydroxy-25,26-bis-homo-5β-cholan-26-ol (90). Compound 88 (300 x 10-3 g, 0.650 mmol) was subjected to a LiBH4 reduction with the same procedure previous described for compound 106, to give 280 mg of crude residue. HPLC purification on a Nucleodur 100-5 C18 (5µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (9:1) as eluent (flow rate 1 mL/min), gave 220 mg of 90 (78%, tR= 14 min). [α]D25= +10.6 (c= 0.25, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.64 (1H, br s, H-7), 3.53 (2H, t, J = 6.6 Hz, H2-26), 3.30 (1H, m ovl, H-3), 0.94 (3H, d, J = 6.7 Hz, H3-21), 0.91 (3H, s, H3-19), 0.90 (3H, t, J = 7.0 Hz, H3-28), 0.68 (3H, s, H3-18); 13C NMR (175 MHz, CD3OD): δ 73.3, 71.3, 63.1, 57.7, 51.7, 47.0, 43.7, 43.1, 41.6, 41.1, 37.1, 36.8 (2C), 36.6, 34.5, 34.4, 33.7, 31.3, 29.5, 27.4, 27.0, 24.6, 23.8, 23.5, 22.0, 19.3, 12.3, 12.0; HR ESIMS m/z 435.3835 [M+H]+, C28H51O3 requires 435.3838. 6α-ethyl-3α,7α-dihydroxy-25,26-bis-homo-5β-cholan-26-yl-26-sodium sulfate (91). The triethylamine-sulfur trioxide complex (65.3 mg, 0.360 mmol) was added to a solution of compound 90 (50.0 mg, 0.120 mmol) in DMF dry (3 mL) under an argon atmosphere, and the mixture was stirred at 70◦C for 24 h. The solvent was concentrated in vacuo. The residue was poured over a RP18 column. Fraction eluted with MeOH 100% gave a mixture that was further purified by HPLC on a Nucleodur 100-5 C18 (5 µm; 4.6 mm i.d. x 250 mm) with MeOH/H2O (78:22) as eluent (flow rate 1 mL/min), to give 16 mg (0.030 mmol, 25%) of compound 91 (tR= 16 min). [α]D25= -6.14 (c= 0.07, CH3OH); selected 1H NMR (400 MHz, CD3OD): δ 3.99 (2H, t, J = 6.6 Hz, H2-26), 3.65 (1H, br s, H-7), 3.31 (1H, m ovl, H-3), 0.94 (3H, d, J = 6.2 Hz, H3-21), 0.91 (3H, s, H3-19), 0.90 (3H, t, J = 7.0 Hz, 
Experimental Section IV 
	   161	  
H3-28), 0.69 (3H, s, H3-18); HR ESIMS m/z 513.3247 [M-Na]-, C28H49O6S requires 513.3250. Specific biological assay used for compound 77 Chemicals. Design and synthesis of 77 (6α-ethyl-3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol or BAR502) has been described previously. The agent was dissolved daily in drinking water containing 1% methyl cellulose before its administration by gavage (100 µL). Animal Studies of ANIT. GP-BAR1 null mice (GP-BAR1-B6= GP-BAR12/2 mice, generated directly into C57BL/6NCrl background), and congenic littermates on C57BL/6NCrl mice were kindly gifted by Dr. Galya Vassileva (Schering-Plough Research Institute, Kenilworth). Mice were housed under controlled temperatures (22uC) and photoperiods (12:12-hour light/dark cycle), allowed unrestricted access to standard mouse chow and tap water and allowed to acclimate to these conditions for at least 5 days before inclusion in an experiment. Protocol for ANIT administration was approved by Ministry of Health (decree N°245/2013-B). Mice (6 male for group) were treated 9 days with ANIT (Sigma-Aldrich) dissolved in corn oil (10 mg/kg, os) or corn oil alone (control mice). At the end of the treatment mice were subjected to intradermal injection of 25 µg DCA, 6-ECDCA, UDCA, compound 77 and the scratching response was recorded for 60 min. Serum levels of total bilirubin, aspartate aminotransferase (AST) and alkaline phosphatase were measured by routine clinical chemistry testing performed on a Hitachi 717 automatic analyzer. Animal model of NASH. C57BL6 mice 24 weeks old were fed a high fat diet containing 60% kj fat (ssniff ® EF acc. D12492 (I) mod.) and fructose in drinking water (42 g/l) or normal diet (6 mice) for 18 weeks11–13. After 10 weeks of HFD, mice were randomized to receive HFD alone (9 mice) or HFD plus BAR502 (15 mg/kg/day) body weight by gavage (9 mice) for 8 weeks. HFD mice were administered 100 µL of 1% methyl cellulose in drinking water. Mice were housed under controlled temperatures (22 °C) and photoperiods (12:12-hour light/dark cycle), allowed unrestricted access to standard mouse chow and tap water and allowed to acclimate to these conditions for at least 5 days before inclusion in an experiment. The care and use of the animals were approved by the Institutional Animal Care and Use Committee of the University of Perugia and 
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were in accordance to European guidelines for care of experimental animals. Protocols were approved by the Italian Minister of Health and Istituto Superiore di Sanità (Italy) and were in agreement with the European guideline for use of experimental animals (permission n. 41/2014-B released to AD). The general health of the animals was monitored daily by the Veterinarian in the animal facility. The study protocol caused minor suffering, however, animals that lost more than 25% of the initial body weight were euthanized. At the day of sacrifice mice were deeply anesthetized with a mixture of tiletamine hypochoride and zolazepam hypocloride/xylazine at a dose of 50/5 mg/kg. Food intake was estimated as the difference of weight between the offered and the remnant amount of food at 7-days intervals. The food was provided as pressed pellets and the residual spillage was not considered. Liver fibrosis. Liver fibrosis was induced by carbon tetrachloride (CCl4) administration according to a previously published method.139 For this purpose, C57BL6 mice were administered i.p. 500 µL/kg body weight of CCl4 in an equal volume of paraffin oil twice a week for 8 weeks. CCl4 mice were randomized to receive BAR502 (15 mg/kg daily by gavage) or vehicle (distilled water). Tissue histology. For histological examination, portions of the right and left liver lobes and epididymal white adipose tissue (epWAT) were fixed in 10% formalin, embedded in paraffin, sectioned and stained with Sirius red and hematoxylin/ eosin (H&E), for morphometric analysis. NASH severity was scored in H&E-stained cross sections using an adapted grading system of human NASH. The level of macrove- sicular and microvesicular steatosis was determined at 40 × magnification relative to the total liver area analyzed and expressed as a percentage. Inflammation was scored by counting the number of aggregates of inflammatory cells per field using a 100 × magnification. The average of five random fields was taken. Relative values against the average of the HFC control group were calculated. Hepatic fibrosis was identified using Sirius Red stained slides and evaluated using an adapted grading system of human NASH. The presence of pathological collagen deposition was scored as either absent (0), observed within perisinusoidal/perivenular or periportal area (1), within both perisinusoidal and periportal areas (2), bridging fibrosis (3) or cirrhosis (4). The sum of the scores (degree of steatosis, hepatocyte ballooning, lobular 
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inflammation, and portal inflammation) was considered as the total pathology score. Biochemical analyses. AST, triglyceride, total- and HDL- cholesterol, albumin and fasting glucose concentrations were quantified using an automated clinical chemistry analyzer (Cobas, Roche) with enzymatic methods. Plasma insulin levels were measured by ELISA assays according to the manufacturer’s instructions. The homeostatic model assessment (HOMA) of IR and insulin sensitivity index was calculated by the concentrations of plasma glucose and insulin.   
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Spectroscopic data 1H NMR (500 MHz, CD3OD) of compound 76 	  	  	  1H NMR (400 MHz, CD3OD) of compound 77 	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 13C NMR (100 MHz, CD3OD) of compound 77   	  	  	  	  1H NMR (700 MHz, CD3OD) of compound 78 	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1H NMR (400 MHz, CD3OD) of compound 79 	    1H NMR (400 MHz, CD3OD) of compound 80   	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1H NMR (400 MHz, CD3OD) of compound 81 	   	    1H NMR (400 MHz, CD3OD) of compound 82   	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1H NMR (400 MHz, CD3OD) of compound 83  	    1H NMR (400 MHz, CD3OD) of compound 84  	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1H NMR (400 MHz, CD3OD) of compound 85  	   1H NMR (400 MHz, CD3OD) of compound 86  	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1H NMR (400 MHz, CD3OD) of compound 87  	    1H NMR (400 MHz, CD3OD) of compound 88   	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1H NMR (400 MHz, CD3OD) of compound 89   	  	  	  1H NMR (400 MHz, CD3OD) of compound 90 	  	  1H	  NMR	  (400	  MHz,	  CD3OD)	  of	  compound18	  	  	  	  	  	  	  	  
Experimental Section V 
	   172	  
V. Experimental procedures for benzo-fused cyclic amines General procedure for the intramolecular Heck reaction A solution of the corresponding substituted 2-iodobenzyl sulfinyl amide 1 (1.0 equiv), Pd(OAc)2 (0.1 equiv), PPh3 (0.2 equiv), Et3N (2.0 equiv) and Ag2CO3 (2.0 equiv) in toluene (0.1 M) was heated to 70 LC for 12 h. The solvent was removed under reduced pressure, and the crude product was purified by flash chromatography to give compounds 5. Compounds 5a–d have previously been described, and their spectroscopic data are in fully agreement with the literature.142 General procedure for the ring-closing enyne metathesis A solution of 21 (1.0 equiv), 1,7-octadiene (8.0 equiv) and Grubbs II catalyst (0.05 equiv) in CH2Cl2 (0.1 M) was heated to 90 LC for 24 h. The solvent was removed under reduced pressure, and the crude product was purified by flash chromatography to give compounds 22. (RS)-2-Methyl-N-[(S)-4-(1-phenilvinyl)-1,2-dihydronaphthalen-1-yl]propane-2-sulfinamide (22a). The title compound was obtained following the general procedure described above. Flash chromatography [n-hexane/EtOAc (1:1)] afforded compound 22a as a brown solid (99 %). [α]D25= +24.3 (c= 1.0; CHCl3); selected 1H NMR (300 MHz, CDCl3): δ 1.23 (s, 9H), 2.68 (ddd, J = 17.2, 7.1, 4.9 Hz, 1H), 2.89 (ddd, J = 17.2, 5.7, 4.3 Hz, 1H), 3.51 (d, J = 8.1 Hz, 1H), 4.59 (dd, J = 13.7, 7.2 Hz, 1H), 5.35 (d, J =1.6Hz, 1H), 5.67 (d, J = 1.6Hz, 1H), 6.10 (t, J = 4.5 Hz, 1H), 7.00 (dd, J = 7.6, 1.2 Hz, 1H), 7.10 (td, J = 7.5, 1.5 Hz, 1H), 7.17 (td, J = 7.4, 1.5 Hz, 1H), 7.23 (d, J = 1.9 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 7.26 (s, 1H), 7.36–7.43 (m, 3H); 13C NMR (75 MHz, CDCl3): δ 22.7 (3xCH3), 32.6 (CH2), 54.3 (CH), 56.1 (C), 115.4 (CH2), 125.1 (CH), 126.3 (CH), 126.6 (2xCH), 126.8 (CH), 127.3 (CH), 127.7 (CH), 128.0 (CH), 128.3 (2xCH), 133.5 (C), 135.6 (C), 139.6 (C), 139.7 (C), 147.9 (C); HRMS (EI) calculated for C22H25NOS [M+H]+: 352.1730, found: 352.1737. (RS)-N-[(S)-7-Methoxy-4-(1-phenylvinyl)-1,2-dihydronaphthalen-1-yl]-2-methylpropane-2-sulfinamide (22b). The title compound was obtained following the general procedure described above. Flash chromatography [n-hexane/EtOAc 
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(1:1)] afforded compound 22b as a brown solid (82 %). [α]D25 = +21.0 (c= 1.0; CHCl3); selected 1H NMR (300 MHz, CDCl3): δ 1.25 (s, 9H), 2.62 (ddd, J = 16.9, 8.0, 4.6 Hz, 1H), 2.87 (ddd, J = 16.9, 5.7, 4.5 Hz, 1H), 3.49 (d, J = 7.5 Hz, 1H), 3.76 (s, 3H), 4.49–4.60 (m, 1H), 5.34 (d, J = 1.7 Hz, 1H), 5.64 (d, J = 1.7 Hz, 1H), 5.97 (t, J = 4.5 Hz, 1H), 6.61 (dd, J = 8.5, 2.7 Hz, 1H), 6.91 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 2.7 Hz, 1H), 7.21–7.26 (m, 3H), 7.37–7.42 (m, 2H); 13C NMR (75 MHz, CDCl3): δ 22.7, 32.7, 54.9, 55.2, 56.2, 112.3, 112.8, 115.2, 122.7, 126.6, 127.7, 128.3, 137.7, 139.3, 139.8, 148.1, 158.8; HRMS (EI) calculated for C23H27NO2S [M+H]+: 382.1762, found: 382.1760. (RS)-N-[(S)-4-(1-(3-Methoxyphenyl)vinyl)-1,2-dihydronaphthalen-1-yl]-2-methylpropane-2-sulfinamide (22c). The title compound was obtained following the general procedure described above. Flash chromatography [n-hexane/EtOAc (1:1)] nafforded compound 22c as a brown solid (95 %). [α]D25= + 5.0 (c= 1.0; CHCl3); selected 1H NMR (300 MHz, CDCl3): δ 1.23 (s, 9H), 2.67 (ddd, J = 17.2, 7.3, 4.8 Hz, 1H), 2.88 (ddd, J = 17.2, 5.8, 4.3 Hz, 1H), 3.51 (d, J = 8.5 Hz, 1H), 3.76 (s, 3H), 4.57 (dd, J = 13.9, 7.6 Hz, 1 H) 5.34 (d, J = 1.6 Hz, 1H), 5.66 (d, J = 1.6 Hz, 1H), 6.08 (t, J = 4.5 Hz, 1H), 6.78 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 6.95–6.99 (m, 2H), 7.01 (dd, J = 7.5, 1.4 Hz, 1H), 7.08–7.20 (m, 3H), 7.35–7.41 (m, 1H); 13C NMR (75 MHz, CDCl3): δ 22.7 (3xCH3), 32.7 (CH2), 54.5 (CH), 55.2 (CH3), 56.1 (C), 112.7 (CH), 112.7 (CH), 115.7 (CH2), 119.3 (CH), 125.2 (CH), 126.3 (CH), 126.6 (2xCH), 127.4 (CH), 127.9 (2xCH), 129.3 (CH), 133.5 (C), 135.7 (C), 139.6 (C), 141.3 (C), 147.8 (C), 159.6 (C); HRMS (EI) calculated for C23H27NO2S [M+H]+: 382.1835, found: 382.1819. (RS)-N-[(S)-4-(1-(3,5-Bis(trifluoromethyl)phenyl)vinyl)-1,2-dihydronaphthalen-1-yl]-2-methylpropane-2-sulfi-namide (22d). The title compound was obtained following the general procedure described above. Flash chromatography [n-hexane/EtOAc (1:1)] afforded compound 22d as a brown solid (73%). [α]D25= +15.0 (c= 1.0; CHCl3); selected 1H NMR (300 MHz, CDCl3): δ 1.22 (s, 9H), 2.74 (ddd, J = 17.4, 7.1, 4.8 Hz, 1H), 2.92 (ddd, J = 17.3, 6.0, 4.3 Hz, 1H), 3.48 (d, J = 8.8 Hz, 1H), 4.58 (dd, J = 15.2, 6.7 Hz, 1H), 5.56 (d, J = 0.7 Hz, 1H), 5.78 (d, J = 0.9 Hz, 1H), 6.15 (t, J = 4.5 Hz, 1H), 6.90 (dd, J = 7.6, 1.1 Hz, 1H), 7.13 (td, J = 7.5, 1.4 Hz, 1H), 7.22 (td, J = 7.5, 1.4 Hz, 1H), 7.41 (d, J = 7.4 Hz, 1H), 7.75 (s, 
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1H), 7.80 (s, 2H); 19F NMR (282 MHz, CDCl3): δ -62.84 (2xCF3); 13C NMR (75 MHz, CDCl3): δ 22.6 (3xCH3), 32.7 (CH2), 54.4 (CH), 56.2 (C), 119.1 (CH2), 121.5 (d, 3JCF = 5.5 Hz, 2xCH), 125.9 (CH), 126.6(CH), 126.8 (q, 1JCF = 272.9 Hz, 2xCF3), 126.9 (CH), 127.1 (CH), 127.9 (CH), 128.1 (CH), 131.8 (d, 2JCF = 33.2 Hz, 2xC), 132.4 (C), 135.9 (C), 138.2 (C), 142.2 (C), 145.7 (C); HRMS (EI) calculated for C24H23NOF6S [M+H]+: 488.1477, found: 488.1464. (RS)-N-[(S)-4-(1-(4-Methoxyphenyl)vinyl)-1,2-dihydronaphthalen-1-yl]-2-methylpropane-2-sulfinamide (22e). The title compound was obtained following the general procedure described above. Flash chromatography [n-hexane/EtOAc (1:1)] afforded compound 22e as a brown solid (98 %). [α]D25= + 6.0 (c= 1.0; CHCl3); selected 1H NMR (300 MHz, CDCl3): δ 1.23 (s, 9H), 2.66 (ddd, J = 17.2, 7.2, 4.8 Hz, 1H), 2.88 (ddd, J = 17.1, 5.7, 4.3 Hz, 1H), 3.52 (d, J = 8.1 Hz, 1H), 3.76 (s, 3H), 4.58 (dd, J = 13.7, 7.4 Hz, 1H), 5.24 (d, J = 1.6 Hz, 1H), 5.57 (d, J = 1.7 Hz, 1H), 6.08 (t, J = 4.5 Hz, 1H), 6.74–6.80 (m, 2H), 7.00 (dd, J = 7.5, 1.3 Hz, 1H), 7.10 (td, J = 7.5, 1.5 Hz, 1H), 7.17 (td, J = 7.4, 1.5 Hz, 1H), 7.30–7.36 (m, 2H), 7.39 (d, J = 6.9 Hz, 1H); 13C NMR (75 MHz, CDCl3): δ 22.7 (3xCH3), 32.6 (CH2), 54.4 (CH), 55.2 (CH3), 56.1 (C), 113.6 (CH2), 113.7 (CH), 124.9 (CH), 126.4 (2xCH), 126.7 (CH), 127.3 (CH), 127.8 (2xCH), 128.0 (CH), 132.3(C), 133.6 (C), 135.6 (C), 139.8 (C), 147.3 (C), 159.3 (C); HRMS (EI) calculated for C23H27NO2S [M+H]+: 382.1835, found: 382.1833. (RS)-N-[(S)-4-(Hex-1-en-2-yl)-1,2-dihydronaphthalen-1-yl]-2-methylpropane-2-sulfinamide (22f). The title compound was obtained following the general procedure described above. Flash chromatography [n- hexane/EtOAc (1:1)] afforded compound 22f as a brown solid (50 %). [α]D25= +7.9 (c= 1.0; CHCl3); selected 1H NMR (300 MHz, CDCl3): δ 0.86 (t, J = 7.1 Hz, 3H), 1.18 (s, 9H), 1.28–1.35 (m, 2H), 1.47 (d, J = 4.8 Hz, 2H), 2.24 (t, J = 7.0 Hz, 2H), 2.58 (ddd, J = 17.0, 6.9, 5.0 Hz, 1H), 2.73 (ddd, J = 17.0, 5.6, 4.3 Hz, 1H), 3.47 (d, J = 8.7 Hz, 1H), 4.45 (dd, J = 14.8, 6.5 Hz, 1H), 5.00 (d, J = 2.3 Hz, 1H), 5.08 (ddd, J = 2.3, 1.2 Hz, 1.2 Hz, 1H), 5.86 (t, J = 4.5 Hz, 1H), 7.19–7.28 (m, 3H), 7.35–7.40 (m, 1H); 13C NMR (75 MHz, CDCl3): δ 13.9 (CH3), 22.2 (CH2), 22.6 (3xCH3), 30.5 (CH2), 32.4 (CH2), 35.5 (CH2), 54.7 (CH), 56.1 (C), 114.2 (CH2), 122.0 (CH), 
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125.7 (CH), 126.7 (CH), 127.3 (CH), 127.9 (CH), 133.3 (C), 136.3 (C), 140.8 (C), 148.7 (C); HRMS (EI) calculated for C20H29NOS [M+H]+: 332.2043, found: 332.2040.  
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ABSTRACT: Nuclear and G-protein coupled receptors are considered major targets for drug discovery. FXR and GP-BAR1,
two bile acid-activated receptors, have gained increasing consideration as druggable receptors. Because endogenous bile acids
often target both receptor families, the development of selective ligands has been proven diﬃcult, exposing patients to side eﬀects
linked to an unwanted activation of one of the two receptors. In the present study, we describe a novel library of semisynthetic
bile acid derivatives obtained by modiﬁcations on the cholane scaﬀold. The pharmacological characterization of this library led to
the discovery of 7α-hydroxy-5β-cholan-24-sulfate (7), 6β-ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (EUDCOH, 26), and 6α-ethyl-
3α, 7α-dihydroxy-24-nor-5β-cholan-23-ol (NorECDCOH, 30) as novel ligands for FXR and GP-BAR1 that might hold utility in
the treatment of FXR and GP-BAR1 mediated disorders.
■ INTRODUCTION
Bile acids (BAs), the end-products of cholesterol catabolism,
are signaling molecules activating several cellular networks1,2
through the recognition of nuclear and membrane receptors. At
least four members of the nuclear receptors (NRs) superfamily,
the farnesoid-X-receptor (FXR), the constitutive androstane
receptor (CAR), the pregnane-X- receptor (PXR), the vitamin
D receptor (VDR),3−7 and G-protein-coupled receptor, GP-
BAR1 (also known as M-BAR, TGR5, or BG37), are activated
at physiological concentrations by primary and secondary bile
acids.8,9
BAs are generated in the liver as primary bile acids, cholic
acid (CA) and chenodeoxycholic acid (CDCA) conjugated
with glycine and taurine and then secreted in the small intestine
and transformed by the intestinal microbiota into secondary
bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA).
CDCA (1 in Figure 1) and its conjugated forms are
endogenous ligands for FXR, while LCA and its corresponding
tauro- and glyco-conjugates (TLCA 2 in Figure 1) are the most
potent natural agonists for GP-BAR1. The main physiological
role for FXR is to function as a bile acids sensor. FXR regulates
bile acids absorption, synthesis, and secretion in the intestine,
liver, and kidney and is considered a promising target in
cholestasis, a liver disorder that occurs primarily in the context
of genetic mutation of basolateral or apical membrane
transporters in hepatocytes.10 Cholestasis represents the main
biochemical feature of primary biliary cirrhosis11,12 (PBC) and
sclerosing cholangitis (PSC), two immune-mediated disorders
characterized by progressive bile duct destruction for which
medical therapy is still poorly eﬀective.11,12 In this context, the
use of endogenous bile acids, with the exception of
ursodeoxycholic acid (UDCA), is poorly eﬀective due to their
toxicity and for their promiscuity in activating G-protein-
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coupled receptors, including GP-BAR1. Although GP-BAR1
agonists represent a novel opportunity in the treatment of
enterohepatic and metabolic disorders such as nonalcoholic
steatohepatitis (NASH) and type 2 diabetes,2,13,14 a recent
study has provided evidence that this receptor is the
physiological mediator of pruritus,15 a common symptom
observed in cholestasis and a highly frequent side eﬀect
occurring in clinical trials16 in PBC patients administered with
6α-ethyl-chenodeoxycholic acid (6-ECDCA, obeticholic acid, 3
in Figure 1), a dual FXR and GP-BAR1 ligand.17,18 Thus, it can
be predicted that highly selective FXR agonists, devoid of GP-
BAR1 agonism, will avoid this side eﬀect and might have utility
in the treatment of PBC.
On the other hand, selective GP-BAR1 ligands hold utility in
the treatment of metabolic disorders through their ability to
trigger the release of glucagon-like peptide (GLP)-1, an insulin-
tropic and antidiabetic hormone.
In this frame, bile acid scaﬀold has been subjected to intense
medicinal chemistry modiﬁcations, producing several deriva-
tives with diﬀerent pharmacological proﬁle, ranging from dual
modulators to selective agonists toward FXR and GP-BAR1. In
detail, the introduction of an ethyl at C-6 on the CDCA ring B
has produced potent dual agonists. Structure−activity analysis
has demonstrated that this change retains its potent eﬀect and
is not modulated by changes in the side chain. Indeed,
harnessing the carboxyl group of 6-ECDCA by the introducing
a sulfate group at position 24 or at position 23 on a shortened
side chain increases the potency toward both FXR and GP-
BAR1.18,19 In contrast, a marked selectivity toward GP-BAR1
over FXR has been achieved with the methylation at C-23
position.20 Interestingly, the removal of the hydroxyl group at
C-3 on CDCA scaﬀold impacts on bile acid receptor selectivity
generating a derivative, 3-deoxy-CDCA, that still transactivates
FXR but is devoid of any activity toward GP-BAR1.21 The same
pattern was observed by modifying the hydroxyl group at C-3
on LCA or its tauro-conjugated 2. Indeed, removal or
isomerization (iso-LCA) of the 3R-hydroxyl group as well as
its substitution with a sulfate moiety robustly attenuates the
agonistic activity on GP-BAR1.21
In the present report, we describe the generation of a novel
family of selective FXR and GP-BAR1 ligands based on the
UDCA and CDCA scaﬀolds. Speciﬁcally, we have harnessed
around the functionality of tetracyclic core, including a
speculation on the stereochemistry of ring junctions, and on
the functional groups on the side chain, to obtain a novel library
of steroidal derivatives (Figure 2).
Our investigation was also expanded on the 6-ethylcholane
scaﬀold, providing evidence that the stereochemical arrange-
ment of ring B substituents as well as the length and the nature
of the end group on the side chain (Figure 3) allow modulation
Figure 1. CDCA and TLCA, the most potent endogenous activators of FXR and GP-BAR1, respectively. 6-ECDCA, a potent semisynthetic dual
agonist.
Figure 2. Natural bile acid derivatives generated in this study.
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Figure 3. 6-Ethylcholane scaﬀold derivatives generated in this study.
Scheme 1. 3-Deoxy-chenocholane Derivativesa
aReagents and conditions: (a) p-TsCl, pyridine; (b) LiBr, Li2CO3, DMF, reﬂux; (c) H2 (1 atm), Pd/C, THF/MeOH 1:1; (d) NaBH4, THF/H2O
4:1 v/v, quantitative yield over four steps; (e) NaOH 5% in MeOH/H2O 1:1 v/v, quantitative yield; (f) DMT-MM, Et3N, taurine, DMF dry, 35%;
(g) LiBH4, MeOH dry, THF, 0 °C, 79%; (h) Et3N·SO3, DMF, 80 °C.
Scheme 2. 3-Deoxy-ursocholane Derivativesa
aReagents and conditions: (a) p-TsCl, pyridine, 58%; (b) LiBr, Li2CO3, DMF, reﬂux, quantitative yield; (c) H2 (1 atm), Pd/C, THF/MeOH 1:1,
78%; (d) NaOH 5% in MeOH/H2O 1:1 v/v, quantitative yield; (e) DMT-MM, Et3N, taurine, DMF dry, 27%; (f) LiBH4, MeOH dry, THF, 0 °C,
91%; (g) Et3N·SO3, DMF, 80 °C.
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of the speciﬁcity toward FXR and GP-BAR1. Deep
pharmacological investigations resulted in the identiﬁcation of
several compounds as potent and selective bile acid receptor
agonists.
■ RESULTS
Modiﬁcation on CDCA: Preparation of 3-Deoxy-
chenocholane Derivatives. As previously described, regio-
selective CDCA oxidation followed by methylation furnished
methyl ester 32 in quantitative yield.18 Tosylation and
elimination at C-3 hydroxyl group followed by double bond
reduction and subsequent sodium borohydride treatment gave
methyl 3-deoxy-cholanoate 33 in quantitative chemical yield
over four steps (Scheme 1). Alkaline hydrolysis furnished 3-
deoxy-cholanoic acid (4) in quantitative chemical yield, that in
a small aliquot was subjected to the reaction of amidation with
taurine.22 Puriﬁcation on RP-18 column followed by HPLC
furnished 5 in pure form and as sodium salt. An aliquot of
methyl ester 33 was transformed in the corresponding C-24
alcohol 6 (LiBH4, MeOH/THF) that in turn was subjected to
sulfation (Et3N·SO3 1.5 equiv), aﬀording a mixture of disulfate
derivative 8 and side chain monosulfate derivative 7 that was
eﬃciently separated by HPLC.
Modiﬁcation on UDCA: Preparation of 3-Deoxy-
ursocholane Derivatives. UDCA methyl ester treatment
with 1.5 equiv of tosyl chloride resulted in a mixture of 3- and
7-monotosyl derivatives that was eﬃciently separated by silica
gel column, aﬀording pure 34 in 58% yield. Following the same
synthetic protocol described before for the corresponding
cheno-derivative, derivatives 9−13 (Scheme 2) were obtained
in high chemical yield.
5β-Cholane Derivatives. UDCA methyl ester was
ditosylated at C-3 and C-7 hydroxyl groups, furnishing
intermediate 36 that was subjected to LiBr/Li2CO3 treatment
to achieve the double elimination on ring A and ring B
(Scheme 3). Hydrogenation (H2, Pd/C, THF/MeOH) on the
crude reaction product furnished a mixture of the saturated
methyl esters 37 and 38, epimers at C-8 and generated through
the attack of hydrogen on the up and down face of Δ7 double
bond, respectively. Treatment of 5β-cholane methyl ester 37
with LiBH4 and then with Et3N·SO3 furnished alcohol 14 and
its sulfate derivative 15. C-8 epimer 38 was subjected to the
same synthetic protocol, including also basic hydrolysis of
methyl ester function, obtaining acid carboxylic derivative 16,
alcohol 17, and the corresponding sulfate derivative 18.
Scheme 3. 5β-Cholane Derivativesa
aReagents and conditions: (a) p-TsCl, pyridine, quantitative yield; (b) LiBr, Li2CO3, DMF, reﬂux, quantitative yield; (c) H2 (1 atm), Pd/C, THF/
MeOH 1:1; (d) NaOH 5% in MeOH/H2O 1:1 v/v, 84%; (e) DMT-MM, Et3N, taurine, DMF dry, 23%; (f) NaOH 5% in MeOH/H2O 1:1 v/v,
78%; (g) LiBH4, MeOH dry, THF, 0 °C, 78%; (g) Et3N·SO3, DMF, 80 °C, 43%.
Scheme 4. 3β-Chenodeoxycholane Derivativesa
aReagents and conditions: (a) p-TsCl, pyridine, quantitative yield; (b) CH3COOK, DMF; H2O 5:1, reﬂux, 75%; (c) NaOH 5% in MeOH/H2O 1:1
v/v, 89%; (d) 2,6-lutidine, t-butyldimethylsilyltriﬂuoromethanesulfonate, CH2Cl2, 0 °C; (e) LiBH4, MeOH dry, THF, 0 °C, 84% over two steps; (f)
HCl 37%, MeOH, 96%; (g) Et3N·SO3, DMF, 80 °C; (h) HCl 37%, MeOH, 76% over two steps.
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Preparation of 3β-Chenodeoxycholane and 3β-Urso-
deoxycholane Derivatives. Regioselective tosylation at C-3
hydroxyl group on CDCA methyl ester followed by inversion of
conﬁguration with potassium acetate in DMF/H2O (Scheme 4)
aﬀorded the 3β-hydroxy derivative 40 in 74% over two steps.
Hydrolysis at C-24 methyl ester gave isoCDCA (19), whereas
protection at C-3 and C-7 carbinols and then reduction at C-24
methyl ester furnished the protected intermediate 41. Sulfation
and then deprotection aﬀorded monosulfate derivative 21
whereas direct deprotection gave isoCDCOH (20).
As depicted in Scheme 5, the corresponding 3β-ursodeoxy-
cholane derivatives 22−24 were prepared starting from methyl
ester 34 and following the same synthetic protocol reported in
Scheme 4.
Modiﬁcation on 6-Ethylcholane Scaﬀold. As previously
demonstrated, the introduction of an α-ethyl group at C-6 on
CDCA ring B profoundly improves the activity of the
endogenus bile acid, producing 6-ECDCA (3, in Figure 1), a
potent dual FXR/GP-BAR1 agonist. Even if also the
corresponding 7β-isomer, 6α-ethylUDCA, was proved to be
eﬀective in ﬁbrosis, to data analysis on the eﬀect produced in
term of biological activity and selectivity by the modiﬁcation in
the conﬁguration of ring B substituents has not be faced.
Moreover starting from the well demonstrated ability of bile
alcohols to activate FXR, also the modiﬁcation on carboxyl
group of 6-ECDCA could be instrumental in generating
selective modulators. Thus, an intense medicinal chemistry
protocol was also performed on 6-ethylcholane scaﬀold.
Scheme 5. 3β-Ursodeoxycholane Derivativesa
aReagents and conditions: (a) CH3COOK, DMF; H2O 5:1, reﬂux, 82%; (b) NaOH 5% in MeOH/H2O 1:1 v/v, 87%; (c) 2,6-lutidine, t-
butyldimethylsilyltriﬂuoromethanesulfonate, CH2Cl2, 0 °C, 96%; (d) LiBH4, MeOH dry, THF, 0 °C, 94% over two steps; (e) HCl 37%, MeOH,
96%; (f) Et3N·SO3, DMF, 80 °C; (g) HCl 37%, MeOH, 67% over two steps.
Scheme 6. Modiﬁcation on Ring B of 6-Ethylcholane Scaﬀolda
aReagents and conditions: (a) NaBH4, MeOH; (b) LiBH4, MeOH dry, THF, 0 °C, 85% over two steps; (c) H2 (1 atm), Pd/C, THF/MeOH 1:1;
(d) NaBH4, MeOH; (e) LiBH4, MeOH dry, THF, 0 °C.
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An aliquot of 44, prepared in a 77% yield starting from
CDCA,18 was subjected to NaBH4 reduction at C-7 ketone
followed by treatment with LiBH4 to aﬀord triol 28 in good
chemical yield (Scheme 6). Interestingly, sodium borohydride
treatment on 44 proceeded in a stereoselective manner,
aﬀording the exclusive formation of 7β-hydroxyl derivative as
judged by the shape of H-7 as a doublet (J = 9.8 Hz) which is
consistent with an axial disposition for this proton, and
therefore with the β-orientation of the hydroxyl group on ring
B. Dipolar couplings H-7/H-25 and Me-26/H-5 in the NOESY
spectrum allowed deﬁnition the E conﬁguration for the
exocyclic double bond as depicted in 28.
Exocyclic double bond hydrogenation (H2 on Pd/C) on 44
aﬀorded 45 in quantitative yield that was transformed in the
compound 25 following the synthetic procedure previously
described.18 In agreement with the steric inﬂuence played by
the ethyl group at C-6 and by the ring A, both oriented on the
α-face of ring B, and as demonstrated by the shape of H-7
signal as a singlet, NaBH4 treatment on free carboxyl acid
proceeded in a stereoselective manner, aﬀording the exclusive
formation of 6α-ethyl-3α,7α-dihydroxy-5β-cholan-24-ol (ECD-
COH, 25) through the approach of the hydride from the
upper-face of the steroid nucleus. The stereochemical assign-
ment reported for 25 was substantiated by the almost complete
superimposition of proton resonances of all nuclei belonging to
the tetracyclic nucleus with those reported for 3.18,23
To access C-6 and/or C-7 epimers of compound 25, we
devised an alternative synthetic procedure encompassing
NaBH4 treatment on methyl ester 45 and then LiBH4. As
depicted in Scheme 6, prolonged NaBH4 treatment in
methanol produced extensive C-6 epimerization and partial
reduction at C-7 carbonyl group. LiBH4 reduction on the crude
reaction product aﬀorded a mixture whose HPLC puriﬁcation
(88% MeOH:H2O) gave pure 6β-ethyl derivatives 26 and 27,
epimeric at C-7 in a 69/31 ratio. Structural and stereochemical
characterization on 6β-ethyl-3α,7α-dihydroxy-5β-cholan-24-ol
(isoECDCOH, 27) was based on careful comparison of NMR
data with those of 25 (Supporting Information, Tables S1 and
S2).
As in 25, H-7 proton in 27 resonated as a singlet (δH 3.60),
thus establishing the equatorial disposition for this proton and
therefore the α-conﬁguration of the hydroxyl group at C-7. The
remaining resonances in the 1H NMR spectra of 25 and 27
were almost similar in the shape and in the chemical shift
values, with the exception of the down-ﬁelded shifted signals for
H2-4 (δH 2.30, 1.55 in 27 vs δH 1.88, 1.73 in 25) and for Me-26
(δH 0.95 in 27 vs 0.90 in 25), which suggested the inverted
conﬁguration at C-6 in 27.
The 13C NMR spectrum of 27 (Supporting Information,
Table S2), interpreted with the help of HSQC and HMBC
experiments, conﬁrmed this hypothesis, revealing a profound
modiﬁcation in the chemical shift of several carbon centers
around C-6 (i.e., C-4 δC 41.4 in 27 vs 34.3 in 25; C-6 δC 51.7 in
27 vs 42.9 in 25; C-8 δC 36.4 in 27 vs 41.3 in 25).
In the 1H NMR spectrum of 6β-ethyl-3α,7β-dihydroxy-5β-
cholan-24-ol (EUDCOH, 26), H-7 was observed as a doublet
doublet (δH 3.74, dd, J = 10.3, 6.0 Hz) with a large coupling
constant with H-8, thus pointing toward their trans diaxial
relationship and therefore to the β-orientation of the hydroxyl
group at C-7. ROESY cross-peaks H-7/H-9, H-7/H-14, and H-
7/H-6 conﬁrmed the inversion of conﬁguration at C-7 and also
suggested the cis stereochemical arrangement of the sub-
stituents at C-6 and C-7. Deﬁnitive conﬁrmation of the β-
orientation of the ethyl group at C-6 derived from the observed
good match in the carbon resonances of all ring A nuclei with
those of compound 27 (Supporting Information, Table S2).
Next, we turned our attention to 6-ECDCA side chain,
investigating also the eﬀect of the length and the functional
group on bile acid receptor selectivity (Scheme 7).
3α-Hydroxy-6α-ethyl-7-keto-5β-cholan-24-oic acid (46) was
subjected to Beckmann degradation at C-24 as previously
described,18 and the resulting nor-nitrile 47 was subjected to
LiBH4 reduction at C-7 carbonyl group, aﬀording 6α-ethyl-
3α,7α-dihydroxy-24-nor-5β-cholan-23-nitrile (NorECDCN,
31) in high yield and as a single diasteroisomer (HPLC purity
>95%).
Nor-nitrile 47 was used also as starting material in the
preparation of NorECDCA (29) and the corresponding
alcohol, NorECDCOH (30). Prolonged alkaline hydrolysis
aﬀorded carboxylic acid 48 that was in turn subjected to LiBH4
reduction at C-7. Puriﬁcation by silica gel (CH2Cl2:MeOH 9:1)
gave NorECDCA (29) as a white solid in 89% chemical yield.
Methyl ester formation on intermediate 48, followed by
simultaneous reduction at C-23 methyl ester function and at
C-7 carbonyl group, furnished 30 in 98% yield. In this case, no
epimerization at C-6 was observed and all attempts to obtain
Scheme 7. Modiﬁcation on the Side Chain of 6α-Ethylcholane Scaﬀolda
aReagents and conditions: (a) LiBH4, MeOH dry, THF, 0 °C, 79%; (b) KOH 30% in MeOH/H2O 1:1 v/v, 2 h; (c) LiBH4, MeOH dry, THF, 0 °C,
89%; (d) p-TsOH, MeOH dry; (e) LiBH4, MeOH dry, THF, 0 °C, 98% over two steps.
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alternative stereochemical arrangements of the substituents at
C-6 and C-7 on nor 6-ethylcholane scaﬀold failed, producing
invariably the 6α-ethyl-7α-hydroxy relationship.
Pharmacological Evaluation. Derivatives 4−31 were
tested for their activity on FXR and GP-BAR1. For this
purpose, we used a luciferase reporter assay with HepG2 and
HEK-293T cells transfected with FXR and GP-BAR1,
respectively (Figures 4 and 5).
Results shown in Figures 4 and 5 demonstrated that several
compounds generated in this study were potent agonists for
FXR or GP-BAR1. As reported in Figure 4, we found that the
deletion of the hydroxyl group at C-3 in the CDCA scaﬀold
produces potent and selective FXR agonists.
In detail, with the exception of the 7,24-disulfate derivative 8,
all the 3-deoxy-chenocholane derivatives maintain the ability to
transactivate FXR independently from the functional group at
C-24 on the side chain (COOH in 4, CH2OH in 6, and
CH2OSO3
− in 7). Tauro conjugation of the carboxyl group on
the side chain completely abolishes the agonism on FXR
(compare 5 versus 4 in Figure 4) and thus eradicates the
therapeutical potential of derivative 4 in FXR mediated
diseases. Interestingly, the substitution of carboxyl end group
with a nonconjugable functional group such as the sulfate group
produces the equipotent derivative 7, devoid of any GP-BAR1
activity (Figure 5), as a promising selective FXR agonist.
As expected, the corresponding urso-derivatives 9−13, all
sharing the β-conﬁguration at the C-7 hydroxyl group, were
inactive toward FXR, thus demonstrating, once again, that the
conﬁguration at C-7 is a key structural feature in FXR
recognition. Even if the sulfate derivative 15 showed a potency
comparable to that of CDCA, the endogenus ligand of FXR, the
general trend observed for 5β-cholane derivatives 14−18
demonstrates that the elimination of the hydroxyl group at
C-7 is detrimental for FXR (compare 14 versus 6, and 15
versus 7) activity.
The modiﬁcation in B/C ring junction produces derivatives
16−18, devoid of any activity toward FXR, thus conﬁrming the
Figure 4. Transactivation assays on FXR. HepG2 cells were transfected with pSG5-FXR, pSG5-RXR, pCMV-βgal, and p(hsp27)TKLUC vectors.
Cells were stimulated with compounds 4−31 (10 μM). CDCA (1, 10 μM) was used as a positive control. Results are expressed as mean ± standard
error; *p < 0.05 versus not treated cells (NT).
Figure 5. Transactivation assays on GP-BAR1. HEK-293T cells were cotransfected with GP-BAR1 and a reporter gene containing a cAMP
responsive element in front of the luciferase gene. Twenty-four h post transfection, cells were stimulated with 4−31 (10 μM). Luciferase activity
served as a measure of the rise in intracellular cAMP following activation of GP-BAR1. TLCA (2, 10 μM) was used as a positive control. Results are
expressed as mean ± standard error. *p < 0.05 versus not treated cells (NT).
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profound impact engaged by bile acid molecular shape in ﬁtting
in FXR-LBD.
Of interest are also the results of epimerization at position C-
3. As shown in Figure 4, isochenodeoxycholic acid (isoCDCA,
19) is more potent than the cognate CDCA in transactivating
FXR. This result, along with the well-known bile acids
epimerization at C-3 occurring in the intestine by bacterial
enzymes, open the way to further pharmacological speculation
on isoCDCA as FXR modulator.
Results of transactivations of CREB-responsive elements in
HEK-293T transiently transfected with the membrane bile acid
receptor GP-BAR1 (Figure 5) revealed that, independently by
the functional group on the side chain, the elimination/
epimerization of the hydroxyl groups on the tetracyclic core of
5β-cholane scaﬀold is detrimental in terms of activation of GP-
BAR1 (compounds 4−24 in Figure 5).
Profoundly diﬀerent were the results on 6-ethylcholane
derivatives 25−31. As shown in Figures 4 and 5, the analysis of
the biological results for the compounds in this subset indicates
that the C-6 and C-7 conﬁguration represents a key structural
feature for FXR activity, whereas it is in-inﬂuent in terms of GP-
BAR1 activity. Indeed, C-24 side chain alcohols 26−28 resulted
potent and selective membrane bile acid receptor agonists,
whereas derivative 25, with both ethyl and the hydroxyl groups
on ring B α-oriented, is a dual agonist. Of interest,
NorECDCOH (30), the corresponding nor-derivative of 25,
shows a residual GP-BAR1 activity but represents the most
potent FXR agonist generated in this study. The speciﬁcity of
30 is completely reverted by the replacement of the C-23
Figure 6. Concentration−response curve of 7, 26, and 30 on FXR (A,C,E) and GP-BAR1 (B,D,F). FXR transactivation was measured in a luciferase
reporter assay using HepG2 cells transfected with FXR. GP-BAR1 activity was measured in HEK-293T cells cotransfected with GP-BAR1 and a
reporter gene containing a cAMP responsive element in front of the luciferase gene (CRE). Twenty-four h post transfection, cells were stimulated
with increasing concentrations of each agent: range from 100 nM to 50 μM. Results are expressed as mean ± standard error. *p < 0.05 versus not
treated cells (NT).
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alcoholic moiety with a carboxyl or a nitrile group as in 29 and
31, respectively, showing a clear shift of their selectivity toward
GP-BAR1.
Pharmacological Evaluation on 7α-Hydroxy-5β-chol-
an-24-sulfate (7), EUDCOH (26), and NorECDCOH (30).
Among all tested compounds, 7α-hydroxy-5β-cholan-24-sulfate
(7), NorECDCOH (30), and EUDCOH (26) represent
promising templates for generating selective bile acid receptor
modulators.
The relative potency of selected members of this novel family
of semisynthetic cholane derivatives was ﬁrst investigated by a
detailed measurement of concentration−response curve of
compounds 7, 26, and 30 on FXR and GP-BAR1 trans-
activation. As illustrated in Figure 6A,C,E, 7 and 30
transactivate FXR with an EC50 of 9 and 2 μM, respectively,
while 26 failed to transactivate FXR at any concentration tested.
In addition, 26 and 30 transactivate GP-BAR1 with EC50s of
1.03 and 0.4 μM (Figure 6D,F), respectively, while 7 failed to
transactivate GP-BAR1 at any concentration tested (Figure
7B).
To further investigate the speciﬁcity of the above selected
compounds, we have tested whether 7, 26, and 30 interact with
other nuclear receptors including GR, PPARγ, LXR, and PXR.
As shown in Figure 7A−C, these compounds at the
concentration of 10 μM failed to transactivate GR, PPARγ,
and LXR, respectively. It is noteworthy that 7, 26, and 30
transactivate the nuclear receptor PXR (Figure 7D).
We have subsequently analyzed whether 7, 26, and 30
regulate canonical functions exerted by FXR and GP-BAR1. As
shown in Figure 8A,B, both 26 and 30 were able to induce the
Figure 7. Speciﬁcity of 7, 26, and 30 on other nuclear receptors. (A−C) HepG2 cells were cotransfected with the Gal4 luciferase reporter vector and
with a series of chimeras in which the Gal4 DNA binding domain is fused to the LBD of the indicated nuclear receptors. Cells were treated 18 h with
the speciﬁc agonists (10 μM) or with 7, 26, and 30 (10 μM). (D) HepG2 cells were cotransfected with pSG5-PXR, pSG5-RXR, and with the
reporter pCYP3A4 promoter-TKLuc and then stimulated with rifaximin (10 μM), a PXR agonist, or with 7, 26, and 30 (10 μM). Data are the mean
± SE of three experiments. *p < 0.05 versus not treated cells (NT). DEXA, dexamethasone; ROSI, rosiglitazone; GW, GW3965; RIFAX, rifaximin.
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expression of pro-glucagon mRNA in GLUTAg cells, an
intestinal endocrine cell line, as well as to increase cAMP
concentrations in THP-1 cells, while 7 failed to regulate these
canonical GP-BAR1 functions.
In vitro characterization of FXR target genes (i.e., OSTα,
BSEP, and SHP) was carried out by assessing the response of
HepG2 cells primed with 7, 26, and 30. As illustrated in Figure
9, both 7 and 30 induce the expression of OSTα, BSEP, and
SHP, while 26 failed to regulate these canonical FXR target
genes.
To measure the ability of the more active compounds to
straightly recruit SRC-1, a coactivator recruitment assay using
Alphascreen technology was applied. In this assay, the ligand
induces the recruitment of a coactivator to the LBD of hFXR.
Data shown in Figure 10 clearly conﬁrm the transactivation
results and also substantiate the delineated structure−activity
relationship.
CDCA (1) and 6-ECDCA (3) were tested as positive
controls and reference molecules (the eﬀect of CDCA was
arbitrarily settled as 100%), 7, 15, and 25−31 were tested at
ﬁxed concentration of 4 μM, and the results were compared to
the assay carried out in absence of ligand (response at 10%).
Compound 30 showed a very potent activity in the recruitment
of SRC-1 coactivator and high aﬃnity to FXR, almost
comparable to that measured for 3. Compounds 7, 15, 25,
29, and 31 showed a moderate recruitment of SRC-1, and 26−
28 resulted completely unable to recruit the coactivator.
In Vivo Eﬀects. Since it has previously demonstrated that
bile acids cause itch through the activation of GP-BAR1,15 we
have next investigated whether compound 30, a potent FXR
Figure 8. In vitro pharmacological evaluation of GP-BAR1 functions on 7, 26, and 30. (A) Real-time PCR analysis of mRNA expression of GP-BAR1
target gene Pro-glucagon in GLUTAg cells primed with 7, 26, and 30 (10 μM). TLCA (2) and 6-ECDCA (3) were tested as positive controls (10
μM). Values are normalized relative to GAPDH mRNA and are expressed relative to those of not treated cells (NT), which are arbitrarily set to 1: *p
< 0.05 versus not treated cells (NT). (B) Eﬀect of 7, 26, and 30 (10 μM) on intracellular generation of cAMP in THP-1 cells. The data are the mean
± SE of three experiments: *p < 0.05 versus not treated cells (NT). F: forskolin 10 μM.
Figure 9. In vitro pharmacological evaluation of FXR target genes on 7, 26, and 30. Real-time PCR analysis of mRNA expression of FXR target
genes OSTα (A), BSEP (B), and SHP (C) in HepG2 cells primed with 7, 26, and 30, respectively (10 μM). 6-ECDCA (3) was tested as positive
control (10 μM). Values are normalized relative to GAPDH mRNA and are expressed relative to those of not treated cells (NT), which are
arbitrarily set to 1: *p < 0.05 vs NT.
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agonist endowed with a residual GP-BAR1 activity, triggers
itching behavior in a mouse model of pruritus linked to the
activation of GP-BAR1.
For this purpose, GP-BAR1+/+ and GP-BAR1−/− mice were
treated with ANIT for 9 days and then subjected to intradermal
injection of bile acids (i.e., 3, DCA, UDCA) and compound 30.
As shown in Figure 11, ANIT treatment signiﬁcantly
increased AST levels in GP-BAR1−/− animals in comparison
with GP-BAR1+/+ mice (Figure 11D, *p < 0.05), while no
signiﬁcant changes in total bilirubin and alkaline phosphatase
were observed among these groups (Figure 11B,C). It is
noteworthy that mice were rendered cholestatic by treatment
with ANIT developed a GP-BAR1 dependent itching when
challenged with bile acids DCA or 6-ECDCA (3) (Figure 11,
panel E, *p < 0.05), while UDCA and compound 30 failed to
induce itching, thus demonstrating that 30 is an FXR agonist
despite its residual activity on GP-BAR1.
■ DISCUSSION AND CONCLUSION
Bile acid activated receptors are a family of nuclear and G
protein activated receptors that are currently investigated for
their potential in the treatment of a variety of gastrointestinal
and metabolic disorders.2 Receptors activated by bile acids are
largely concentrated in the liver and gastrointestinal tract and
are promiscuous in term of ligand speciﬁcity. FXR is the main
bile acid sensor in the gastrointestinal tract and liver, and its
activation reduces bile acid synthesis while increasing
detoxiﬁcation. For these reason, FXR has been deemed a
target for treating cholestasis.1,2 However, preclinical studies
have shown that FXR activation worsens liver damage in rodent
model of cholestasis, while FXR ablation attenuates liver injury
in bile duct ligated mice. In mild nonobstructive cholestasis,
FXR activation ameliorates bile ﬂow impairment. These
observations have led to the concept that FXR activation
could be beneﬁcial in treating cholestasis in PBC patients.
Clinical trials carried out with 6-ECDCA (3, INT747, or
obeticholic acid), a compound we ﬁrst developed in 2002,17 has
led however to exacerbation of itching, a side eﬀect that greatly
limits the beneﬁt of this approach.12,16 It has to be noted,
however, that 6-ECDCA is a dual FXR and GP-BAR1 ligand,
and GP-BAR1 has recently been demonstrated to be the main
receptor involved in mediating itching caused by bile acids.15
Thus, it appears that dual FXR/GP-BAR1 ligands hold the
potential for detrimental side eﬀects in cholestasis.
In the present study, we have harnessed on the CDCA and
UDCA scaﬀolds to generate semisynthetic derivatives that are
selective for FXR or GP-BAR1. The results of this investigation
has led to the discovery of compound 7, a selective FXR ligand,
compound 26, a selective GP-BAR1 ligand, and compound 30,
a highly preferential FXR ligand endowed with a minimal GP-
BAR1 agonistic activity.
7α-Hydroxy-5β-cholan-24-sulfate (7) transactivates FXR in
transactivation assay with an EC50 of ∼9 μM that is
approximately 10−15 fold less potent than 6-ECDCA (3) in
this assay (Supporting Information, Figure S1). However, its
potency in inducing the expression of OSTα, a FXR target gene
in the liver, is comparable to that of 6-ECDCA (Figure 9). In
comparison to 6-ECDCA, compound 7 has no eﬀect on GP-
BAR1, nor does it induces a GP-BAR1 target gene such as pro-
glucagon in GLUTAg cells. GLUTAg cells are a line of murine
L cells, an enteroendocrine cell population highly concentrated
in the terminal ileum that releases GLP-1, a hormone involved
in insulin secretion and a well validated target in the treatment
of diabetes.24 The fact that 7 has no eﬀect on GP-BAR1 should
make this agent an ideal candidate in the treatment of
cholestasis. This compound should avoid the risk of itching, a
common side eﬀect of 6-ECDCA,12 likely due to GP-BAR1
activation.
EUDCOH (26) is an alcohol generated on the ursodeoxy-
cholane scaﬀold and represents the ﬁrst example of UDCA
derivative substituted at C-6 with a β-oriented ethyl group.
Results from detailed analysis of its activity demonstrate that
this derivative is devoid of FXR agonistic activity as is the
parent compound UDCA. However, in comparison to UDCA,
EUDCOH (26) is a rather potent ligand for GP-BAR1 and
stimulates pro-glucagon mRNA accumulation in GLUTAg cells.
Because GLP-1, a peptide that represents the product of pro-
glucagon, is a major pharmacological target in the treatment of
type 2 diabetes,25 one might speculate that compound 26 could
be an important tool for targeting the GLP-1/insulin axis in
diabetes. Its pharmacological characterization is ongoing.
Figure 10. Coactivator recruitment assay measuring a direct interaction of FXR with Src-1. Anti-GST-coated acceptor beads captured GST-fusion
FXR-LBD and the biotinylated-SRC-1 peptide was captured by the streptavidin donor beads. FXR-LBD recruited SRC-1 in the presence of ligand at
4 μM and, upon illumination at 680 nm, chemical energy is transferred from donor to acceptor beads across the complex streptavidin-donor/Src-1-
biotin/ligand/GSTFXR-LBD/anti-GST-acceptor and a signal is produced. Results are expressed as percentage of the eﬀect of CDCA (1) arbitrarily
settled as 100%. NT is referred to the experiment carried out in absence of ligand. Results are expressed as mean ± standard error.
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NorECDCOH (30), a truncated side chain alcohol with both
substituents on ring B in α-conﬁguration, is a potent FXR
ligand with an EC50 of 2 μM, very close to that of 6-ECDCA
(3). The two agents induce the expression of OSTα with the
same potency. In addition to the ability to transactivate FXR,
NorECDCOH (30) retains a certain capacity of inducing GP-
BAR1 and, indeed, it increases pro-glucagon gene expression in
GLUTAg cells. Because its potency in inducing FXR target
genes largely overwhelms that on GP-BAR1, NorECDCOH
(30) should be considered a highly preferential FXR ligand.
Supporting this view it does not induce itching when
administered in vivo.
Pruritus is a common ﬁnding in cholestasis and remains an
unmet clinical need.26 Despite autotaxin having been shown to
be a candidate mediator for itching in cholestasis,27,28
administration of PBC patients with 6-ECDCA/obeticholic
acid causes/worsens pruritus that is severe enough to cause
drug discontinuation in 40% of patients. The high incidence of
pruritus was unexpected and not predicted on the basis of FXR
agonism. Nevertheless, the fact that 6-ECDCA/obeticholic acid
activates GP-BAR1 provides a rational molecular explanation
for this side eﬀect. This view is further strengthened by the
consideration that UDCA, which is a weak ligand for GP-BAR1,
does not cause itching. Whether or not itching caused by 6-
ECDCA/obeticholic acid in PBC patients is mediated by GP-
BAR1 needs additional investigations and other molecular
mechanisms could be involved. In the present study, we have
developed a model to investigate whether pruritus in cholestasis
is linked to GP-BAR1 activation. The results presented in
Figure 11 demonstrate that itching in animals administered
with ANIT, a common model for drug induced liver injury and
cholestasis, is GP-BAR1 dependent. Indeed, while 6-ECDCA
induced itching and this eﬀect was lost in GP-BAR1−/− mice,
compound 30 failed to trigger an itching behavior. These data
establish that compound 30 might have utility in cholestatic
conditions.
By using a chenodeoxycholane scaﬀold, we have demon-
strated that modiﬁcation at C-3 hydroxyl group could be
instrumental in generating selective FXR agonists (e.g.,
compounds 4, 6, 7, 19). Indeed, 7 represents the most potent
Figure 11. Eﬀects of 30 on scratching in GP-BAR1+/+ and GP-BAR1−/− mice. GP-BAR1+/+ and GP-BAR1−/− mice were administered with ANIT for
9 days. At the end of the treatments, mice were subjected to intradermal injection of deoxycholic acid (DCA), 6-ECDCA (3), UDCA, and 30.
Scratching tests were performed at day 11 as summarized in (A). Serum levels of (B) alkaline phosphatase, (C) total bilirubin, and (D) AST in GP-
BAR1+/+ and GP-BAR1−/− animals not treated or administered with ANIT. (E) DCA and 3 robustly stimulated scratching in GP-BAR1-WT mice
but not in GP-BAR1−/− mice, while spontaneous scratching was the same in GP-BAR1+/+ and GP-BAR1−/− mice subjected to intradermal injection
of UDCA and 30. Results are the mean ± standard error of six animals for group and were expressed as the number of scratching events during 60
min of observation.
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agonist so far generated with a simpliﬁed cholane scaﬀold
whose total synthesis is therefore amenable of scale up.
Moreover, from a metabolic point of view, the presence of the
stable and nonconjugable sulfate group on its side chain
highlights the therapeutic potential of derivative 7 in human
FXR mediated diseases.
Of interest are also the results on 6-ethylcholane derivatives
25−31. Data shown in the Figures 4 and 5 indicate that the C-6
and C-7 α-conﬁguration represents a key structural feature for
FXR activity with epimerized alcohols 26−28 resulting in
potent and selective GP-BAR1 agonists, whereas derivative 25,
with both ethyl and the hydroxyl groups on ring B α-oriented,
is a dual agonist. Looking to nor derivatives 29−31,
pharmacological results emphasize the side chain as the pointer
in determining FXR/GP-BAR1 selectivity on semisynthetic
6α,7α-substituted cholane derivatives. In fact, the introduction
of an hydroxyl group on a C-24 side chain improves GP-BAR1
selectivity (25) with respect to the corresponding C-24
carboxyl acid (6-ECDCA) and also C-24 sulfate derivative,
both potent dual agonists.18 On the contrary, the shortening of
the side chain generates a potent FXR agonist when an
hydroxyl group is present as side chain end terminus as in
NorECDCOH (30), whereas the introduction of a negative
charge, NorECDCA (29), or a neutral end group, NorECDCN
(31), improve GP-BAR1 selectivity (compare 30 vs 29 and 31
in Figures 4 and 5).
In summary, in the present report, we describe a novel series
of FXR and GP-BAR1 selective agonists using known bile acid
scaﬀold. The pharmacological characterization of several
members of this series has led to the discovery of novel
potential leads that might hold utility in the treatment of FXR
and GP-BAR1 mediated disorders.
■ EXPERIMENTAL SECTION
Chemistry. Speciﬁc rotations were measured on a Jasco P-2000
polarimeter. High-resolution ESI-MS spectra were performed with a
Micromass Q-TOF mass spectrometer. NMR spectra were obtained
on Varian Inova 400, 500, and 700 NMR spectrometers (1H at 400,
500, and 700 MHz, 13C at 100, 125, and 175 MHz, respectively)
equipped with a SUN microsystem ultra5 hardware and recorded in
CD3OD (δH = 3.31 and δC = 49.0 ppm) and CDCl3 (δH = 7.26 and δC
= 77.0 ppm). All of the detected signals were in accordance with the
proposed structures. Coupling constants (J values) are given in hertz
(Hz), and chemical shifts (δ) are reported in ppm and referred to
CHD2OD and CHCl3 as internal standards. Spin multiplicities are
given as s (singlet), br s (broad singlet), d (doublet), t (triplet), or m
(multiplet). Through-space 1H connectivities were evidenced using a
ROESY experiment with mixing times of 200 and 250 ms, respectively.
HPLC was performed with a Waters model 510 pump equipped
with Waters Rheodine injector and a diﬀerential refractometer, model
401. Reaction progress was monitored via thin-layer chromatography
(TLC) on Alugram silica gel G/UV254 plates. Silica gel MN Kieselgel
60 (70−230 mesh) from Macherey-Nagel Company was used for
column chromatography. All chemicals were obtained from Sigma-
Aldrich, Inc.
Silica gel (200−400 mesh) from Macherey-Nagel Company was
used for ﬂash chromatography. All chemicals were obtained from
Sigma-Aldrich, Inc. Solvents and reagents were used as supplied from
commercial sources with the following exceptions. Hexane, ethyl
acetate, chloroform, dichloromethane, tetrahydrofuran, and triethyl-
amine were distilled from calcium hydride immediately prior to use.
Methanol was dried from magnesium methoxide as follows.
Magnesium turnings (5 g) and iodine (0.5 g) were reﬂuxed in a
small (50−100 mL) quantity of methanol until all of the magnesium
has reacted. The mixture was diluted (up to 1 L) with reagent grade
methanol, reﬂuxed for 2−3 h, and then distilled under nitrogen. All
reactions were carried out under argon atmosphere using ﬂame-dried
glassware.
The purities of compounds were determined to be greater than 95%
by HPLC. Compounds 25, 32, 44, 45, 47, and 48 were prepared as
previously reported.18,23
Synthetic Procedures. Methyl 7α-Hydroxy-5β-cholan-24-oate
(33). To a solution of 32 (130 mg, 0.32 mmol) in dry pyridine (10
mL), tosyl chloride (613 mg, 3.22 mmol) was added, and the mixture
was stirred at room temperature for 4 h. It was poured into cold water
(10 mL) and extracted with CH2Cl2 (3 × 10 mL). The combined
organic layer was washed with saturated NaHCO3 solution (10 mL)
and water (10 mL) and then dried over anhydrous MgSO4 and
evaporated in vacuo to give 180 mg of methyl 3α-tosyloxy-7-keto-5β-
cholan-24-oate (quantitative yield) in the form of colorless needles,
which was subjected to the next step without any puriﬁcation.
Lithium bromide (55 mg, 0.64 mmol) and lithium carbonate (47
mg, 0.64 mmol) were added to a solution of methyl 3α-tosyloxy-7-
keto-5β-cholan-24-oate (180 mg, 0.32 mmol) in dry DMF (10 mL),
and the mixture was reﬂuxed for 3 h. After cooling to room
temperature, the mixture was slowly poured into 10% HCl solution
(50 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined
organic layer was washed successively with water, saturated NaHCO3
solution, and water and then dried over anhydrous MgSO4 and
evaporated to dryness to give 124 mg of oily residue (quantitative
yield) that was subjected to next step without any puriﬁcation.
An oven-dried 25 mL ﬂask was charged with 10% palladium on
carbon (30 mg) and the previously obtained crude intermediate (124
mg, 0.32 mmol), and the ﬂask was evacuated and ﬂushed with argon.
Absolute methanol (5 mL) and dry THF (5 mL) were added, and the
ﬂask was ﬂushed with hydrogen. The reaction was stirred at room
temperature under H2 (1 atm) overnight. The mixture was ﬁltered
through Celite, and the recovered ﬁltrate was concentrated to give 125
mg of methyl 7-keto-5β-cholan-24-oate (quantitative yield), which was
subjected to the next step without any puriﬁcation.
Methyl 7-keto-5β-cholan-24-oate (125 mg, 0.32 mmol) was
dissolved in a solution of tetrahydrofuran/water (10 mL, 4/1 v/v)
and treated at 0 °C with NaBH4 (722 mg, 1.9 mmol). After 2 h, water
and MeOH were added dropwise during a period of 15 min at 0 °C,
with eﬀervescence being observed. Then after evaporation of the
solvents, the residue was diluted with water, acidiﬁed with HCl 1 N,
and extracted with AcOEt (3 × 10 mL). The combined organic phases
were washed with brine, dried over Na2SO4 anhydrous, and evaporated
under reduced pressure to obtain 125 mg of 33 (quantitative yield);
[α]D
25 = +3.5 (c 2.82, CH3OH). Selected
1H NMR (500 MHz
CDCl3): δ 3.84 (1H, s), 3.66 (3H, s), 2.34 (1H, m), 2.22 (1H, m),
0.92 (3H, d, J = 6.5 Hz), 0.90 (3H, s), 0.66 (3H, s). HRMS-ESI m/z
391.3216 [M + H]+, C25H43O3 requires 391.3212.
7α-Hydroxy-5β-cholan-24-oic Acid (4). Compound 33 (56 mg,
0.14 mmol) was hydrolyzed with a methanol solution of sodium
hydroxide (5%, 10 mL) in H2O (2 mL) overnight under reﬂux. The
resulting solution was then concentrated under vacuum, diluted with
water, acidiﬁed with HCl 6 N, and extracted with ethyl acetate (3 × 50
mL). The collected organic phases were washed with brine, dried over
Na2SO4 anhydrous, and evaporated under reduced pressure to give
compound 4 in quantitative yield (54 mg). An analytic sample was
obtained by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. ×
250 mm) with MeOH/H2O (95:5) as eluent (ﬂow rate 1 mL/min, tR
= 8.2 min); [α]D
25 = −5.3 (c 0.03, CH3OH). Selected
1H NMR (400
MHz CD3OD): δ 3.79 (1H, s), 2.33 (1H, m), 2.23 (1H, m), 0.96 (3H,
d, J = 6.4 Hz), 0.93 (3H, s), 0.70 (3H, s). 13C NMR (100 MHz
CD3OD): δ 178.3, 69.4, 57.3, 51.5, 44.9, 43.7, 41.1, 40.8, 38.8, 37.0,
36.2, 34.1, 32.4, 31.6, 30.8, 29.2, 29.0, 24.6, 24.2, 23.4, 22.6, 21.8, 18.8,
12.2. HRMS-ESI m/z 375.2903 [M − H]−, C24H39O3 requires
375.2899.
7α-Hydroxy-5β-cholan-24-oyl Taurine Sodium Salt (5). Com-
pound 4 (15 mg, 0.04 mmol) in DMF dry (3 mL) was treated with
DMT-MM (33 mg, 0.12 mmol) and triethylamine (140 μL, 1 mmol),
and the mixture was stirred at room temperature for 10 min. Then to
the mixture was added taurine (30 mg, 0.24 mmol). After 24 h, the
reaction mixture was concentrated under vacuo and dissolved in water
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(5 mL). The solution was poured over a C18 silica gel column.
Fraction eluted with H2O/MeOH 99:1 gave a mixture that was further
puriﬁed by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. ×
250 mm) with MeOH/H2O (83:17) as eluent (ﬂow rate 1 mL/min)
to give 7 mg (35%) of compound 5 (tR = 7.6 min); [α]D
25 = −58.2 (c
0.02, CH3OH). Selected
1H NMR (500 MHz CD3OD): δ 3.79 (1H,
s), 3.59 (2H, t, J = 7.3 Hz), 2.96 (2H, t, J = 7.3 Hz), 0.97 (3H, d, J =
7.1 Hz), 0.93 (3H, s), 0.69 (3H, s). HRESIMS m/z 482.2951 [M −
Na]−, C26H44NO5S requires 482.2940.
7α-Hydroxy-5β-cholan-24-ol (6). Dry methanol (50 μL, 1.26
mmol) and LiBH4 (630 μL, 2 M in THF, 1.26 mmol) were added to a
solution of the compound 33 (70 mg, 0.18 mmol) in dry THF (10
mL) at 0 °C under argon, and the resulting mixture was stirred for 3 h
at 0 °C. The mixture was quenched by addition of NaOH (1 M, 0.4
mL) and then allowed to warm to room temperature. Ethyl acetate
was added, and the separated aqueous phase was extracted with ethyl
acetate (3 × 15 mL). The combined organic phases were washed with
water, dried (Na2SO4), and concentrated. Puriﬁcation by silica gel
eluting with ethyl acetate−hexane (85:15) gave the alcohol 6 as a
white solid (52 mg, 79%). An analytic sample was obtained by HPLC
on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. × 250 mm) with
MeOH/H2O (95:5) as eluent (ﬂow rate 1 mL/min, tR = 8 min);
[α]D
25 = +5.2 (c 0.53, CH3OH). Selected
1H NMR (400 MHz
CD3OD): δ 3.79 (1H, br s), 3.51 (2H, t, J = 6.6 Hz), 0.97 (3H, d, J =
6.6 Hz), 0.93 (3H, s), 0.70 (3H, s). 13C NMR (100 MHz CD3OD): δ
69.4, 63.6, 57.6, 51.6, 45.6, 43.6, 42.8, 41.1, 40.9, 38.9, 37.0, 36.2, 34.1,
33.3, 31.6, 30.3, 29.3, 29.0, 24.7, 24.5, 22.6, 21.8, 19.2, 12.2. HRMS-
ESI m/z 363.3271 [M + H]+, C24H42O2 requires 363.3263.
7α-Hydroxy-5β-cholan-24-yl-24-sodium Sulfate (7) and 5β-
Cholan-7α,24-dyl-7,24-disodium Disulfate (8). At a solution of diol
6 (40 mg, 0.11 mmol) in DMF dry (3 mL) was added triethylamine−
sulfur trioxide complex (88 mg, 0.55 mmol) under an argon
atmosphere, and the mixture was stirred at 80 °C for 24 h. Most of
the solvent was evaporated, and the residue was poured over a RP18
column to remove excess SO3·NEt3. Fraction eluted with MeOH/H2O
45:55 gave a mixture that was further puriﬁed by HPLC on a
Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. × 250 mm) with MeOH/
H2O (50:50) as eluent (ﬂow rate 1 mL/min), to give 24 mg (39%) of
compound 8 (tR = 20.4 min); [α]D
25= −9.3 (c 0.14, CH3OH).
Selected 1H NMR (400 MHz CD3OD): δ 4.42 (1H, s), 3.95 (2H, br t,
J = 6.5 Hz), 0.96 (3H, d, J = 6.5 Hz), 0.94 (3H, s), 0.69 (3H, s).
HRESIMS m/z 543.2070 [M − Na]−, C24H40O8S2Na requires
543.2062.
Fraction eluted with MeOH gave a mixture that was further puriﬁed
by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. × 250 mm)
with MeOH/H2O (90:10) as eluent (ﬂow rate 1 mL/min), to give 28
mg (55%) of compound 7 (tR = 6.6 min); [α]D
25 = −7.0 (c 0.28,
CH3OH). Selected
1H NMR (400 MHz CD3OD): δ 3.96 (2H, t, J =
6.6 Hz), 3.78 (1H, br s), 3.30 (1H, ovl), 0.96 (3H, d, J = 6.5 Hz), 0.92
(3H, s), 0.69 (3H, s). 13C NMR (100 MHz CD3OD): δ 69.7, 69.4,
57.7, 51.6, 45.0, 43.8, 41.2, 41.0, 39.0, 37.1, 36.3, 34.2, 33.3, 34.2, 33.3,
31.7, 29.5, 29.0, 27.3, 24.3, 22.7, 21.9, 19.2, 12.3. HRESIMS m/z
441.2679 [M − Na]−, C24H41O5S requires 441.2675.
Methyl 3α-Tosyloxy-7β-hydroxy-5β-cholan-24-oate (34). To a
solution of UDCA methyl ester (400 mg, 0.99 mmol) in dry pyridine
(10 mL), tosyl chloride (280 mg, 1.5 mmol) was added, and the
mixture was stirred at room temperature for 2 h. It was poured into
cold water (10 mL) and extracted with CH2Cl2 (3 × 10 mL).
Puriﬁcation by silica gel eluting with ethyl acetate−hexane (8:2) gave
compound 34 (320 mg, 58%) as a white solid; [α]D
25 = +37.6 (c 0.70,
CH3OH). Selected
1H NMR (400 MHz CDCl3): δ 7.79 (2H, d, J =
8.5 Hz), 7.33 (2H, d, J = 8.5 Hz), 4.40 (1H, m), 3.52 (1H, m), 2.46
(3H, s), 2.35 (1H, m), 2.23 (1H, m), 0.92 (3H, d, ovl), 0.91 (3H, s),
0.66 (3H, s). HRESIMS m/z 561.3259 [M + H]+, C32H49O6S requires
561.3250.
7β-Hydroxy-5β-cholan-24-oic Acid (9). Lithium bromide (73 mg,
0.84 mmol) and lithium carbonate (62 mg, 0.84 mmol) were added to
a solution of methyl ester 34 (220 mg, 0.42 mmol) in dry DMF (10
mL), and the mixture was reﬂuxed for 2 h. After cooling to room
temperature, the mixture was slowly poured into 10% HCl solution
(10 mL) and extracted with CH2Cl2 (3 × 30 mL). The combined
organic layer was washed successively with water, saturated NaHCO3
solution, and water and then dried over anhydrous MgSO4 and
evaporated to dryness to give 162 mg of oily residue (quantitative
yield), which was subjected to next step without any puriﬁcation.
An oven-dried 25 mL ﬂask was charged with 10% palladium on
carbon (5 mg) and the product obtained (162 mg, 0.42 mmol), and
the ﬂask was evacuated and ﬂushed with argon. Absolute methanol (5
mL) and dry THF (5 mL) were added, and the ﬂask was ﬂushed with
hydrogen. The reaction was stirred at room temperature under H2 (1
atm) overnight. The mixture was ﬁltered through Celite, and the
recovered ﬁltrate was concentrated to give 128 mg of compound 35
(78%). An amount of compound 35 (40 mg, 10.2 × 10−2 mmol) was
hydrolyzed with a methanol solution of sodium hydroxide (5%, 5 mL)
in H2O (1 mL) overnight under reﬂux. The resulting solution was then
concentrated under vacuum, diluted with water, acidiﬁed with HCl 6
N, and extracted with ethyl acetate (3 × 20 mL). The collected organic
phases were washed with brine, dried over Na2SO4 anhydrous, and
evaporated under reduced pressure to give 9 in a quantitative yield
(39.5 mg). An analytic sample was obtained by HPLC on a Nucleodur
100−5 C18 (5 μm; 4.6 mm i.d. × 250 mm) with MeOH/H2O (78:22)
as eluent (ﬂow rate 1 mL/min, tR = 13.2 min); [α]D
25 = −95.0 (c 0.08,
CH3OH). Selected
1H NMR (400 MHz CD3OD): δ 3.45 (1H, m),
2.32 (1H, m), 2.21 (1H, m), 0.96 (3H, s), 0.95 (3H, d, ovl), 0.71 (3H,
s). HRESIMS m/z 375.2901 [M − H]−, C24H39O3 requires 375.2899.
7β-Hydroxy-5β-cholan-24-oyl Taurine Sodium Salt (10). Com-
pound 9 (9 mg, 23.9 × 10−3 mmol) in DMF dry (3 mL) was treated
with DMT-MM (20 mg, 71.7 × 10−3 mmol) and triethylamine (85 μL,
0.6 mmol), and the mixture was stirred at room temperature for 10
min. Then to the mixture was added taurine (18 mg, 0.14 mmol).
After 24 h, the reaction mixture was concentrated under vacuo and
dissolved in water (5 mL). The solution was poured over a C18 silica
gel column. Fraction eluted with H2O/MeOH 99:1 gave a mixture that
was further puriﬁed by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6
mm i.d. × 250 mm) with MeOH/H2O (73:27) as eluent (ﬂow rate 1
mL/min), to give 3.3 mg of 10 (27%, tR = 18 min); [α]D
25 = +4.8 (c
0.08, CH3OH). Selected
1H NMR (400 MHz CD3OD): δ 3.57 (2H, t,
J = 7.2 Hz), 3.46 (1H, m), 2.95 (2H, t, J = 7.2 Hz), 0.96 (6H, ovl),
0.70 (3H, s). HRESIMS m/z 482.2945 [M − Na]−, C24H39O3 requires
482.2940.
7β-Hydroxy-5β-cholan-24-ol (11). Dry methanol (22 μL, 0.55
mmol) and LiBH4 (276 μL, 2 M in THF, 0.55 mmol) were added to a
solution of the compound 35 (71.9 mg, 18.4 × 10−2 mmol) in dry
THF (10 mL) at 0 °C under argon, and the resulting mixture was
stirred for 3 h at 0 °C. The mixture was quenched by addition of
NaOH (1 M, 364 μL) and then allowed to warm to room temperature.
Ethyl acetate was added, and the separated aqueous phase was
extracted with ethyl acetate (3 × 15 mL). The combined organic
phases were washed with water, dried (Na2SO4), and concentrated to
give 61 mg of 11 as a white solid (91%). An analytic sample was
obtained by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. ×
250 mm) with MeOH/H2O (95:5) as eluent (ﬂow rate 1 mL/min, tR
= 16 min); [α]D
25 = +114.6 (c 0.04 CH3OH). Selected
1H NMR (400
MHz CD3OD): δ 3.51 (2H, t, J = 6.5 Hz), 3.46 (1H, m), 0.96 (3H, s),
0.95 (3H, d, ovl), 0.71 (3H, s). HRMS-ESI m/z 363.3268 [M + H]+,
C24H42O2 requires 363.3263.
5β-Cholan-7β,24-diyl-7,24-disodium Disulfate (13) and 7β-
Hydroxy-5β-cholan-24-yl-24-sodium Sulfate (12). At a solution of
diol 11 (50 mg, 0.138 mmol) in DMF dry (5 mL) was added
triethylamine−sulfur trioxide complex (125 mg, 0.69 mmol) under an
argon atmosphere, and the mixture was stirred at 80 °C for 24 h. Most
of the solvent was evaporated, and the residue was poured over a RP18
column to remove excess SO3·NEt3. Fraction eluted over a RP18
column with H2O:MeOH 1:1 gave a mixture that was further puriﬁed
by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. × 250 mm)
with MeOH/H2O (65:35) as eluent (ﬂow rate 1 mL/min), to give 32
mg of 13 (41%, tR = 12.4 min); [α]D
25 = −15.4 (c 0.03, CH3OH).
Selected 1H NMR (400 MHz CD3OD): δ 3.96 (2H, m), 3.49 (1H,
m), 0.97 (6H, ovl), 0.71(3H, s). HRESIMS m/z 543.2069 [M − Na]−,
C24H40O8S2Na requires 543.2062.
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Fraction eluted over a RP18 column with MeOH gave a mixture
that was further puriﬁed by HPLC on a Nucleodur 100−5 C18 (5 μm;
4.6 mm i.d. × 250 mm) with MeOH/H2O (83:17) as eluent (ﬂow rate
1 mL/min), to give 26 mg of compound 12 (41%, tR = 5.4 min);
[α]D
25 = +21.4 (c 1.46, CH3OH). Selected
1H NMR (400 MHz
CD3OD): δ 4.28 (1H, m), 3.96 (2H, m), 0.99 (3H, s), 0.98 (3H, d,
ovl), 0.72 (3H, s). 13C NMR (100 MHz CD3OD): δ 81.0, 70.9, 56.6
(2C), 45.4, 44.8, 42.6, 41.3, 40.5, 38.3, 36.8, 35.6, 35.2, 33.1, 29.5, 28.8,
28.2, 27.0, 26.9, 24.6, 22.1, 21.8, 19.1, 12.5. HRESIMS m/z 441.2681
[M − Na]−, C24H41O5S requires 441.2675.
Methyl 3α,7β-Ditosyloxy-5β-cholan-24-oate (36). To a solution of
UDCA methyl ester (300 mg, 0.73 mmol) in dry pyridine (20 mL),
tosyl chloride (1.39 g, 7.3 mmol) was added and the mixture was
stirred at room temperature for 6 h. It was poured into cold water (30
mL) and extracted with CH2Cl2 (3 × 30 mL). Puriﬁcation by silica gel
eluting with ethyl acetate−hexane (8:2) gave 36 (521 mg, quantitative
yield) as a white solid; [α]D
25 = −11 (c 0.48, CH3OH). Selected
1H
NMR (400 MHz CDCl3): δ 7.79 (2H, d, J = 8.3 Hz), 7.75 (2H, d, J =
8.3 Hz), 7.36 (2H, d, J = 8.3 Hz), 7.32 (2H, d, J = 8.3 Hz), 4.58 (1H,
m), 4.38 (1H, m), 3.67 (3H, s), 2.47 (3H, s), 2.45 (3H, s), 2.33 (1H,
m), 2.22 (1H, m), 0.91 (3H, d, J = 6.5 Hz), 0.88 (3H, s), 0.61 (3H, s).
HRESIMS m/z 715.3333 [M + H]+, C39H55O8S2 requires 715.3338.
Methyl 5β-Cholan-24-oate (37) and 8α Epimer 38. Lithium
bromide (45 mg, 0.52 mmol) and lithium carbonate (38 mg, 0.52
mmol) were added to a solution of 36 (190 mg, 0.26 mmol) in dry
DMF (20 mL), and the mixture was reﬂuxed for 3 h. After cooling to
room temperature, the mixture was slowly poured into 10% HCl
solution (50 mL) and extracted with CH2Cl2 (3 × 30 mL). The
combined organic layer was washed successively with water, saturated
NaHCO3 solution, and water and then dried over anhydrous MgSO4
and evaporated to dryness to give 124 mg of oily residue (quantitative
yield), which was subjected to next step without any puriﬁcation.
An oven-dried 25 mL ﬂask was charged with 10% palladium on
carbon (10 mg) and the crude product (124 mg, 0.23 mmol), and the
ﬂask was evacuated and ﬂushed with argon. Absolute methanol (5 mL)
and dry THF (5 mL) were added, and the ﬂask was ﬂushed with
hydrogen. The reaction was stirred at room temperature under H2 (1
atm) overnight. The mixture was ﬁltered through Celite, and the
recovered ﬁltrate was concentrated to give 95 mg of crude product,
which was further puriﬁed by HPLC on a Nucleodur 100−5 C18 (5
μm; 10 mm i.d. × 250 mm) with MeOH:H2O (995:5) as eluent (ﬂow
rate 3 mL/min), to give 25 mg of compound 38 (26%, tR = 25.5 min)
and 32 mg of compound 37 (33%; tR= 33 min).
Methyl 5β-Cholan-24-oate (37). [α]D
25 = −3.0 (c 0.03, CH3OH).
Selected 1H NMR (400 MHz CDCl3): δ 3.66 (3H, s), 2.33 (1H, m),
2.20 (1H, m), 0.91 (6H, ovl), 0.65 (3H, s). 13C NMR (100 MHz
CDCl3): δ 171.9, 56.6, 56.0, 51.5, 43.8, 40.5 (2C), 40.3, 37.7, 35.9,
35.4 (2C), 31.0 (2C), 28.2, 27.5, 27.3, 27.1, 26.5, 24.2 (2C), 21.3, 20.8,
18.2, 12.0. HRESIMS m/z 375.3267 [M + H]+, C25H43O2 requires
375.3263.
Compound 38. [α]D
25 = +19.7 (c 0.02, CH3OH). Selected
1H
NMR (400 MHz CDCl3): δ 3.68 (3H, s), 2.46 (1H, m), 2.35 (1H, dd,
J = 10.1, 5.3 Hz), 0.95 (3H, d, J = 6.5 Hz), 0.84 (3H, s), 0.81 (3H, s).
13C NMR (100 MHz CDCl3): δ 172.2, 56.6, 51.5, 43.9 (2C), 37.3,
37.1, 36.7, 35.9, 35.3 (2C), 34.1, 31.0, 30.8, 27.7, 27.1 (2C), 26.6, 25.7,
24.9, 24.6, 21.7, 19.4, 18.7, 18.3. HRESIMS m/z 375.3265 [M + H]+,
C25H43O2 requires 375.3263.
5β-Cholan-24-ol (14). Dry methanol (8 μL, 0.19 mmol) and LiBH4
(95 μL, 2 M in THF, 0.19 mmol) were added to a solution of 37 (10
mg, 26.7 × 10−3 mmol) in dry THF (5 mL) at 0 °C under argon, and
the resulting mixture was stirred for 3 h at 0 °C. The mixture was
quenched by addition of NaOH (1 M, 55 μL) and then allowed to
warm to room temperature. Ethyl acetate was added, and the separated
aqueous phase was extracted with ethyl acetate (3 × 15 mL). The
combined organic phases were washed with water, dried (Na2SO4),
and concentrated to give 7.8 mg of 14 (84%). An analytic sample was
obtained by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. ×
250 mm) with MeOH/H2O (999.5:0.5) as eluent (ﬂow rate 1 mL/
min, tR = 18 min); [α]D
25 = +20.5 (c 0.20, CH3OH). Selected
1H
NMR (400 MHz CDCl3): δ 3.62 (2H, m), 0.94 (3H, d, ovl), 0.92 (3H,
s), 0.65 (3H, s). 13C NMR (100 MHz CDCl3): δ 63.7, 56.7, 56.3, 43.9,
42.8, 40.6 (2C), 40.3, 37.8, 36.0, 35.6, 31.9, 29.5, 28.3, 27.6, 27.3 (2C),
27.0, 26.8, 24.4, 21.4, 20.9, 18.7, 12.2. HRESIMS m/z 347.3321 [M +
H]+, C24H43O requires 347.3314.
5β-Cholan-24-yl-24-sodium sulfate (15). At a solution of 14 (5
mg, 14.5 × 10−3 mmol) in DMF dry (3 mL) was added
triethylamine−sulfur trioxide complex (12 mg, 72.5 × 10−3 mmol)
under an argon atmosphere, and the mixture was stirred at 80 °C for
24 h. Most of the solvent was evaporated, and the residue was poured
over a RP18 column to remove excess SO3·NEt3. Fraction eluted with
MeOH gave 1.5 mg of compound 15 (23%). An analytic sample was
obtained by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6 mm i.d. ×
250 mm) with MeOH/H2O (98:2) as eluent (ﬂow rate 1 mL/min, tR
= 9.9 min); [α]D
25 = +9.0 (c 0.88, CH3OH). Selected
1H NMR (400
MHz CD3OD): δ 3.64 (2H, m), 0.96 (3H, d, ovl), 0.95 (3H, s), 0.69
(3H, s). 13C NMR (100 MHz CD3OD): δ 69.7, 57.6, 47.9, 45.2, 43.8,
41.9, 41.6, 38.7, 37.3, 36.8, 36.5, 33.2, 29.3, 28.6, 28.4, 28.2, 27.7, 27.1,
25.3, 24.8, 22.4, 22.0, 19.2, 12.5. HRESIMS m/z 425.2732 [M − H]−,
C24H41O4S requires 425.2726.
Compound 16. Compound 38 (12 mg, 32.0 × 10−3 mmol) was
hydrolyzed with a methanol solution of sodium hydroxide (5%, 5 mL)
in H2O (1 mL) overnight under reﬂux. The resulting solution was then
concentrated under vacuum, diluted with water, acidiﬁed with HCl 6
N, and extracted with ethyl acetate (3 × 50 mL). The collected organic
phases were washed with brine, dried over Na2SO4 anhydrous, and
evaporated under reduced pressure to give 9 mg of carboxyl acid 16
(78%). An analytic sample was obtained by HPLC on a Nucleodur
100−5 C18 (5 μm; 4.6 mm i.d. × 250 mm) with MeOH/H2O (99:1)
as eluent (ﬂow rate 1 mL/min, tR = 21 min); [α]D
25 = +12.7 (c 0.28,
CHCl3). Selected
1H NMR (400 MHz CDCl3): δ 2.42 (1H, m), 2.28
(1H, m), 0.97 (3H, d, J = 6.8 Hz), 0.85 (3H, s), 0.81 (3H, s).
HRESIMS m/z 359.2958 [M − H]−, C24H39O2 requires 359.2950.
Compound 17. Compound 17 (18 mg, 97%) was synthesized,
starting from compound 38 (20 mg, 53.5 × 10−3 mmol), by analogous
procedures to those detailed above for compound 14. An analytic
sample was obtained by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6
mm i.d. × 250 mm) with MeOH/H2O (999.5:0.5) as eluent (ﬂow rate
1 mL/min, tR = 15.8 min); [α]D
25 = +2.9 (c 0.18, CHCl3). Selected
1H
NMR (400 MHz CDCl3): δ 3.64 (2H, m), 0.97 (3H, d, J = 6.3 Hz),
0.85 (3H, s), 0.81 (3H, s). 13C NMR (100 MHz CDCl3): δ 63.6, 56.9,
44.1 (2C), 42.6, 37.4 (2C), 36.7, 36.1, 35.3, 34.2, 31.7, 29.3, 27.7, 27.2,
27.1, 26.6, 25.8, 24.9, 24.6, 21.7, 19.5, 19.1, 18.1. HR ESIMS m/z
347.3318 [M + H]+, C24H43O requires 347.3314.
Compound 18. Compound 18 (8.8 mg, 43%) was synthesized,
starting from compound 17 (16 mg, 46.2 × 10−3 mmol), by an
analogous procedure to that detailed above for compound 15. An
analytic sample was obtained by HPLC on a Nucleodur 100−5 C18 (5
μm; 4.6 mm i.d. × 250 mm) with MeOH/H2O (98:2) as eluent (ﬂow
rate 1 mL/min, tR = 9 min); [α]D
25 = +9.7 (c 0.15, CH3OH). Selected
1H NMR (400 MHz CD3OD): δ 3.96 (2H, m), 0.98 (3H, d, J = 6.3
Hz), 0.87 (3H, s), 0.81 (3H, s). HRESIMS m/z 425.2733 [M − Na]−,
C24H41O4S requires 425.2726.
Methyl 3α-Tosyloxy-7α-hydroxy-5β-cholan-24-oate (39). To a
solution of CDCA methyl ester (400 mg, 1.0 mmol) in dry pyridine
(10 mL), tosyl chloride (382 mg, 2.0 mmol) was added and the
mixture was stirred at room temperature for 4 h. It was poured into
cold water (20 mL) and extracted with CH2Cl2 (3 × 50 mL). The
combined organic layer was washed with saturated NaHCO3 solution
(30 mL) and water (30 mL) and then dried over anhydrous MgSO4
and evaporated in vacuo to give 555 mg of 39 (quantitative yield) in
the form of colorless oil; [α]D
25 = +22.6 (c 0.93, CH3OH). Selected
1H NMR (500 MHz CDCl3): δ 7.80 (2H, d, J = 8.5 Hz), 7.34 (2H, d, J
= 8.5 Hz), 4.38 (1H, m), 3.83 (1H, s), 3.62 (3H, s), 2.40 (3H, s) 2.35
(1H, m), 2.23 (1H, m), 0.93 (3H, d, J = 6.4 Hz), 0.89 (3H, s), 0.65
(3H, s). HRESIMS m/z 561.3288 [M + H]+, C32H49O6S requires
561.3283.
Methyl 3β,7α-Dihydroxy-5β-cholan-24-oate (40). A solution of 39
(555 mg, 0.99 mmol) and CH3COOK (97 mg, 0.99 mmol) dissolved
in water (2 mL) and N,N!-dimethylformamide (DMF, 10 mL) was
reﬂuxed for 2 h. The solution was cooled at room temperature, and
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then ethyl acetate and water were added. The separated aqueous phase
was extracted with ethyl acetate (3 × 30 mL). The combined organic
phases were washed with water, dried (Na2SO4), and evaporated to
dryness to give 600 mg of mixture. Puriﬁcation by silica gel (hexane−
ethyl acetate 7:3 and 0.5% TEA) gave 40 as oily oil (300 mg, 75%);
[α]D
25 = +2.6 (c 1.5, CH3OH). Selected
1H NMR (400 MHz
CD3OD): δ 3.96 (1H, s), 3.79 (1H, s), 3.63 (3H, s), 2.47 (dt, J = 2.3,
13.7 Hz), 2.36 (1H, m), 2.26 (1H, m), 0.95 (3H, s), 0.94 (3H, d, ovl),
0.68 (3H, s). 13C NMR (100 MHz CD3OD): δ 171.7, 69.3, 67.7, 57.3,
52.0, 51.6, 43.7, 41.1, 40.7, 37.5 (2C), 36.7 (2C), 35.5, 33.4, 32.3, 31.9,
31.0, 29.3, 28.6, 24.6, 23.8, 22.1, 18.8, 12.2. HRESIMS m/z 407.3173
[M + H]+, C25H43O4 requires 407.3161.
3β,7α-Dihydroxy-5β-cholan-24-oic Acid (19). Compound 40 (70
mg, 17.2 × 10−2 mmol) was hydrolyzed with a methanol solution of
sodium hydroxide (5%, 5 mL) in H2O (1 mL) overnight under reﬂux.
The resulting solution was then concentrated under vacuum, diluted
with water, acidiﬁed with HCl 6 N, and extracted with ethyl acetate (3
× 50 mL). The collected organic phases were washed with brine, dried
over Na2SO4 anhydrous, and evaporated under reduced pressure.
HPLC puriﬁcation on a Nucleodur 100−5 C18 (5 μm; 5 mm i.d. ×
250 mm) with MeOH/H2O (75:25) as eluent (ﬂow rate 1 mL/min)
gave 60 mg of 19 as a white solid (89%, tR= 22 min); [α]D
25 = +11 (c
0.07, CH3OH). Selected
1H NMR (400 MHz CD3OD): δ 3.97 (1H,
s), 3.79 (1H, s), 2.47 (1H, dt, J = 2.34, 13.8 Hz), 2.28 (1H, m), 2.13
(1H, m), 0.96 (3H, d, ovl), 0.95 (3H, s), 0.69 (3H, s). HR ESIMS m/z
391.2856 [M − H]−, C24H39O4 requires 391.2848.
3β,7α-Dihydroxy-5β-cholan-24-ol (20). 2,6-lutidine (570 μL, 4.9
mmol) and tert-butyldimethylsilyltriﬂuoromethanesulfonate (336 μL,
1.5 mmol) were added at 0 °C to a solution of 40 (200 mg, 0.49
mmol) in 10 mL of CH2Cl2. After 2 h stirring at 0 °C, the reaction was
quenched by addition of aqueous NaHSO4 (1 M, 30 mL). The layers
were separated, and the aqueous phase was extracted with CH2Cl2 (3
× 100 mL). The combined organic layers were washed with NaHSO4,
water, saturated aqueous NaHCO3, and brine and evaporated in vacuo
to give 310 mg of methyl 3β,7α-di(tert-butyldimethylsilyloxy)-5β-
cholan-24-oate (quantitative yield) in the form of colorless needles,
which was subjected to the next step without any puriﬁcation. To a
solution of methyl ester (310 mg, 0.49 mmol) in dry THF (10 mL) at
0 °C, dry methanol (140 μL, 3.4 mmol) and LiBH4 (1.7 mL, 2 M in
THF, 3.4 mmol) were added. The resulting mixture was stirred for 1 h
at 0 °C. The mixture was quenched by addition NaOH 1 M (1 mL)
and then ethyl acetate. The organic phase was washed with water,
dried (Na2SO4), and concentrated to give 250 mg of 41 as a white
solid (84%). Methyl ester 41 (200 mg, 0.33 mmol) was dissolved in
methanol (5 mL), and 500 μL of HCl 37% v/v were added. After 2 h,
silver carbonate was added at the solution to precipitate chloride. Then
the reaction mixture was centrifuged and the supernatant was
concentrated in vacuo. HPLC puriﬁcation on a Nucleodur 100−5
C18 (5 μm; 5 mm i.d. × 250 mm) with MeOH/H2O (9:1) as eluent
(ﬂow rate 1 mL/min) gave 120 mg of compound 20 as a white solid
(96%, tR = 7 min); [α]D
25 = +22.8 (c 0.06, CH3OH). Selected
1H
NMR (500 MHz CD3OD): δ 3.98 (1H, s), 3.80 (1H, s), 3.50 (2H,
m), 0.97 (3H, d, J = 6.7 Hz), 0.96 (3H, s), 0.70 (3H, s). 13C NMR
(125 MHz CD3OD): δ 69.3, 67.7, 63.6, 57.6, 51.6, 43.7, 41.1, 40.7,
37.5, 37.4, 37.1, 36.7, 35.5, 33.4, 33.2, 31.0, 30.3, 29.3, 28.5, 24.6, 23.8,
22.1, 19.2, 12.2. HRESIMS m/z 379.3219 [M + H]+, C24H43O3
requires 379.3212.
3β,7α-Dihydroxy-5β-cholan-24-yl-24-sodium Sulfate (21). The
triethylamine−sulfur trioxide complex (65.6 mg, 0.41 mmol) was
added to a solution of 41 (50 mg, 82.5 × 10−3 mmol) in DMF dry (5
mL) under an argon atmosphere, and the mixture was stirred at 80 °C
overnight. The solution was then concentrated under vacuum to give
100 mg of crude mixture. The solid was dissolved in methanol (5 mL)
and at the solution was added 300 μL of HCl 37% v/v. After 1 h, silver
carbonate was added at the solution to precipitate chloride. Then the
reaction mixture was centrifuged, and the supernatant was
concentrated in vacuo. HPLC puriﬁcation on a Nucleodur 100−5
C18 (5 μm; 5 mm i.d. × 250 mm) with MeOH/H2O (55:45) as
eluent (ﬂow rate 1 mL/min) gave 30 mg of 21 as colorless amorphous
solid (76% over two steps, tR = 11.4 min); [α]D
25 = +18.4 (c 0.04,
CH3OH). Selected
1H NMR (500 MHz CD3OD): δ 3.97 (3H, m),
3.80 (1H, s), 2.49 (1H, t, J = 14.3 Hz), 0.97 (3H, d, ovl), 0.96 (3H, s),
0.70 (3H, s). HRESIMS m/z 457.2632 [M − Na]−, C24H41O6S
requires 457.2624.
Methyl 3β,7β-Dihydroxy-5β-cholan-24-oate (42). A solution of
compound 34 (100 mg, 0.18 mmol) and CH3COOK (18 mg, 0.18
mmol) dissolved in water (1 mL) and N,N!-dimethylformamide
(DMF, 4 mL) was reﬂuxed for 3 h. The solution was cooled at room
temperature, and then ethyl acetate and water were added. The
separated aqueous phase was extracted with ethyl acetate (3 × 30 mL).
The combined organic phases were washed with water, dried
(Na2SO4), and evaporated to dryness. Puriﬁcation by silica gel
(hexane−ethyl acetate 7:3 and 0.5% TEA) gave 42 as an oil (60 mg,
82%); [α]D
25 = +27.4 (c 0.10, CH3OH). Selected
1H NMR (500 MHz
CDCl3): δ 4.06 (1H, s), 3.65 (3H, s), 3.54 (1H, m), 2.34 (1H, m),
2.21 (1H, m), 0.98 (3H, s), 0.92 (3H, d, J = 6.8 Hz), 0.67 (3H, s).
HRESIMS m/z 407.3169 [M + H]+, C25H43O4 requires 407.3161.
3β,7β-Dihydroxy-5β-cholan-24-oic Acid (22). Compound 42 (30
mg, 73.9 × 10−3 mmol) was hydrolyzed with a methanol solution of
sodium hydroxide (5%, 5 mL) in H2O (1 mL) overnight under reﬂux.
The resulting solution was then concentrated under vacuum, diluted
with water, acidiﬁed with HCl 6 N, and extracted with ethyl acetate (3
× 50 mL). The collected organic phases were washed with brine, dried
over Na2SO4 anhydrous, and evaporated under reduced pressure.
HPLC puriﬁcation on a Nucleodur 100−5 C18 (5 μm; 5 mm i.d. ×
250 mm) with MeOH/H2O (75:25) as eluent (ﬂow rate 1 mL/min)
gave 25 mg of 22 as white solid (87%, tR= 10.5 min); [α]D
25 = +38.1 (c
0.14, CH3OH). Selected
1H NMR (400 MHz CD3OD): δ 4.00 (1H,
s), 3.44 (1H, m), 0.99 (3H, s), 0.96 (3H, d, J = 6.3 Hz), 0.69 (3H, s).
HRESIMS m/z 391.2853 [M − H]−, C25H39O4 requires 391.2848.
3β,7β-Dihydroxy-5β-cholan-24-ol (23). 2,6-Lutidine (86 μL, 0.74
mmol) and tert-butyldimethylsilyltriﬂuoromethanesulfonate (51 μL, 9
mmol) were added at 0 °C to a solution of 42 (30 mg, 73.9 × 10−3
mmol) in 5 mL of CH2Cl2. After 2 h stirring at 0 °C, the reaction was
quenched by addition of aqueous NaHSO4 (1 M, 10 mL). The layers
were separated, and the aqueous phase was extracted with CH2Cl2 (3
× 20 mL). The combined organic layers were washed with NaHSO4,
water, saturated aqueous NaHCO3, and brine and evaporated in vacuo
to give 45 mg of methyl 3β,7β-di(tert-butyldimethylsilyloxy)-5β-
cholan-24-oate (96%) in the form of colorless needles, which was
subjected to next step without any puriﬁcation. To a solution of
methyl ester (45 mg, 71 × 10−3 mmol) in dry THF (5 mL), at 0 °C
dry methanol (20 μL, 0.50 mmol) and LiBH4 (250 μL, 2 M in THF,
0.50 mmol) was added. The resulting mixture was stirred for 1 h at 0
°C. The mixture was quenched by addition NaOH 1 M (35 μL) and
then ethyl acetate. The organic phase was washed with water, dried
(Na2SO4), and concentrated to give 40 mg of 43 as a white solid
(94%), which was dissolved in methanol (3 mL) and treated with 100
μL of HCl 37% v/v. After 2 h, silver carbonate was added at the
solution to precipitate chloride. Then the reaction mixture was
centrifuged and the supernatant was concentrated in vacuo. HPLC
puriﬁcation on a Nucleodur 100−5 C18 (5 μm; 10 mm i.d. × 250
mm) with MeOH/H2O (9:1) as eluent (ﬂow rate 1 mL/min) gave 18
mg of compound 23 as a white solid (96%, tR = 6.5 min); [α]D
25 =
+32.5 (c 0.31, CH3OH). Selected
1H NMR (400 MHz CD3OD): δ
4.00 (1H, s), 3.52 (2H, m), 3.43 (1H, m), 1.00 (3H, s), 0.96 (3H, d, J
= 6.5 Hz), 0.72 (3H, s). 13C NMR (100 MHz CD3OD): δ 72.0, 67.4,
63.6, 57.6, 56.7, 44.8, 44.4, 41.6, 40.1, 38.6, 38.3, 37.0, 35.6, 35.2, 33.3,
30.8, 30.3, 29.7, 28.4, 27.9, 24.5, 22.7, 19.4, 12.7. HRESIMS m/z
379.3219 [M + H]+, C24H43O3 requires 379.3212.
3β,7β-Dihydroxy-5β-cholan-24-yl-24-sodium Sulfate (24). The
triethylamine−sulfur trioxide complex (20 mg, 0.12 mmol) was added
to a solution of 43 (15 mg, 24.7 × 10−3 mmol) in DMF dry (5 mL)
under an argon atmosphere, and the mixture was stirred at 80 °C for
24 h. The solution was then concentrated under vacuum. The solid
was dissolved in methanol (3 mL) and at the solution was added 50
μL of HCl 37% v/v. After 1 h, silver carbonate was added at the
solution to precipitate chloride. Then the reaction mixture was
centrifuged and the supernatant was concentrated in vacuo. HPLC
puriﬁcation on a Nucleodur 100−5 C18 (5 μm; 5 mm i.d. × 250 mm)
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with MeOH/H2O (55:45) as eluent (ﬂow rate 1 mL/min) gave 8 mg
of 24 as colorless amorphous solid (67% over two steps, tR= 13.5
min); [α]D
25 = +30 (c 0.26, CH3OH). Selected
1H NMR (500 MHz
CD3OD): δ 4.00 (1H, s), 3.96 (2H, m), 3.44 (1H, m), 0.99 (3H, s),
0.97 (3H, d, J = 6.6 Hz), 0.72 (3H, s). HRESIMS m/z 457.2631 [M −
Na]−, C24H41O6S requires 457.2624.
Compound 28. To a methanol solution of compound 44 (400 mg,
0.93 mmol), a large excess of NaBH4 was added at 0 °C. The mixture
was left at room temperature for 10 h, and then water and MeOH was
added dropwise during a period of 15 min at 0 °C with eﬀervescence
being observed. Then after evaporation of the solvents, the residue was
diluted with water and extracted with AcOEt (3 × 50 mL). The
combined extract was washed with brine, dried with Na2SO4, and
evaporated to give 400 mg of a crude residue that was subjected to the
next step without further puriﬁcation. To a solution of crude residue
(400 mg, 0.93 mmol) in dry THF (30 mL), at 0 °C dry methanol (260
μL, 6.51 mmol) and LiBH4 (3.2 mL, 2 M in THF, 6.51 mmol) were
added. The resulting mixture was stirred for 2 h at 0 °C. The mixture
was quenched by addition of 1 M NaOH (2 mL) and then ethyl
acetate. The organic phase was washed with water, dried (Na2SO4),
and concentrated. HPLC puriﬁcation on a Nucleodur 100−5 C18 (5
μm; 10 mm i.d. × 250 mm) with MeOH/H2O (88:12) as eluent (ﬂow
rate 3 mL/min) gave 320 mg of 28 (85% over two steps, tR = 9.2 min);
[α]D
25 = +18.1 (c 0.36, CH3OH).
1H and 13C NMR spectroscopic data
in CD3OD are given in Supporting Information, Tables S1 and S2.
HRESIMS m/z 405.3373 [M + H]+, C26H45O3 requires 405.3369.
6β-Ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (26) and 6β-Ethyl-
3α,7α-dihydroxy-5β-cholan-24-ol (27). To a methanol solution of
45 (1.1 g, 2.5 mmol), a large excess of NaBH4 was added at 0 °C. The
mixture was left at room temperature for 10 h, and then water and
MeOH was added dropwise during a period of 15 min at 0 °C with
eﬀervescence being observed. Then after evaporation of the solvents,
the residue was diluted with water and extracted with AcOEt (3 × 50
mL). The combined extract was washed with brine, dried with
Na2SO4, and evaporated to give 1.3 g of a crude residue that was
subjected to the next step without further puriﬁcation. To a solution of
crude residue (1.1 g, 2.5 mmol) in dry THF (30 mL), at 0 °C dry
methanol (708 μL, 17.5 mmol) and LiBH4 (8.7 mL, 2 M in THF, 17.5
mmol) were added. The resulting mixture was stirred for 2 h at 0 °C.
The mixture was quenched by addition of 1 M NaOH (6 mL) and
then ethyl acetate. The organic phase was washed with water, dried
(Na2SO4), and concentrated. HPLC puriﬁcation on a Nucleodur 100−
5 C18 (5 μm; 10 mm i.d. × 250 mm) with MeOH/H2O (88:12) as
eluent (ﬂow rate 3 mL/min) gave 805 mg of 26 (79%, tR = 11 min)
and 361 mg of 27 (35%, tR = 20.4 min).
6β-Ethyl-3α,7β-dihydroxy-5β-cholan-24-ol (26). [α]D
25 = +15.2 (c
1.21, CH3OH).
1H and 13C NMR spectroscopic data in CD3OD given
in Supporting Information, Tables S1 and S2. HRESIMS m/z
407.3529 [M + H]+, C26H47O3 requires 407.3525.
6β-Ethyl-3α,7α-dihydroxy-5β-cholan-24-ol (27). [α]D
25 = +5.1 (c
5.74, CH3OH).
1H and 13C NMR spectroscopic data in CD3OD given
in Supporting Information, Tables S1 and S2. HRESIMS m/z
407.3532 [M + H]+, C26H47O3 requires 407.3525.
6α-Ethyl-3α,7α-dihydroxy-24-nor-5β-cholan-23-nitrile (31). To a
solution of 47 (200 mg, 0.52 mmol) in dry THF (10 mL), at 0 °C dry
methanol (150 μL, 3.6 mmol) and LiBH4 (1.8 mL, 2 M in THF, 3.6
mmol) was added. The resulting mixture was stirred for 2 h at 0 °C.
The mixture was quenched by addition of 1 M NaOH (1 mL) and
then ethyl acetate. The organic phase was washed with water, dried
(Na2SO4), and concentrated. HPLC puriﬁcation on a Nucleodur 100−
5 C18 (5 μm; 10 mm i.d. × 250 mm) with MeOH/H2O (88:12) as
eluent (ﬂow rate 3 mL/min) gave 805 mg of 31 (79%, tR = 15.2 min);
[α]D
25 = −13.4 (c 0.47, CH3OH).
1H NMR (700 MHz CD3OD): δ
3.66 (1H, br s), 3.31 (1H, ovl), 2.46 (1H, dd, J = 3.8, 16.9 Hz), 2.34
(1H, dd, J = 7.4, 16.9 Hz) 1.16 (3H, d, J = 6.5 Hz), 0.91 (3H, t, J = 7.5
Hz), 0.92 (3H, s), 0.73 (3H, s). 13C NMR (175 MHz CD3OD): δ
120.3, 72.9, 70.9, 56.1, 51.5, 46.7, 43.4, 42.9, 41.4, 40.2, 36.5, 36.2, 34.3
(2C), 34.2, 30.7, 29.2, 24.9, 24.4, 23.4, 23.3, 21.9, 18.5, 12.1, 11.6.
HRESIMS m/z 388.3221 [M + H]+, C25H42NO2 requires 388.3216.
6α-Ethyl-3α,7α-dihydroxy-24-nor-5β-cholan-23-oic Acid (29). To
a solution of 48 (500 mg, 1.2 mmol) in dry THF (30 mL), at 0 °C dry
methanol (360 μL, 8.4 mmol) and LiBH4 (4.2 mL, 2 M in THF, 8.4
mmol) was added. The resulting mixture was stirred for 1 h at 0 °C.
The mixture was quenched by addition of 1 M NaOH (2.4 mL) and
then ethyl acetate. The organic phase was washed with water, dried
(Na2SO4), and concentrated. Puriﬁcation by silica gel (CH2Cl2/
MeOH 9:1) gave 29 as a white solid (400 mg, 82%). An analytic
sample was obtained by HPLC on a Nucleodur 100−5 C18 (5 μm; 4.6
mm i.d. × 250 mm) with MeOH/H2O (88:12) as eluent (ﬂow rate 1
mL/min, tR = 9.6 min); [α]D
25 = +3.3 (c 1.04, CH3OH).
1H NMR
(500 MHz CD3OD): δ 3.66 (1H, s), 3.32 (1H, ovl), 2.35 (1H, dd, J =
13.4, 3.3 Hz), 1.00 (3H, d, J = 6.4 Hz), 0.92 (3H, s), 0.90 (3H, t, J =
7.1 Hz), 0.74 (3H, s). 13C NMR (125 MHz CD3OD): δ 178.0, 72.9,
70.9, 57.6, 51.4, 46.7, 43.7, 43.6, 42.8, 41.2, 40.8, 36.8, 36.0, 34.8, 34.4,
34.0, 31.0, 29.1, 24.3, 23.4, 23.3, 21.8, 19.3, 12.0, 11.8; HR ESIMS m/z
405.3011 [M − H]−, C25H41O4 requires 405.3005.
6α-Ethyl-3α,7α-dihydroxy-24-nor-5β-cholan-23-ol (30). Com-
pound 48 (420 mg, 1.0 mmol) was dissolved in 90 mL of dry
methanol and treated with p-toluenesulfonic acid in catalytic amount.
The solution was left to stand at room temperature for 2 h. The
mixture was quenched by addition until the neutrality of NaHCO3
saturated solution. Most of the solvent was evaporated, and the residue
was extracted with EtOAc. To a solution of crude solid (420 mg,
quantitative yield) in dry THF (10 mL), at 0 °C dry methanol (300
μL, 7.0 mmol) and LiBH4 (3.5 mL, 2 M in THF, 7.0 mmol) was
added. The resulting mixture was stirred for 1 h at 0 °C. The mixture
was quenched by addition of 1 M NaOH (2.0 mL) and then ethyl
acetate. The organic phase was washed with water, dried (Na2SO4),
and concentrated. Silica gel chromatography eluting with hexane/
EtOAc 6:4 aﬀorded compound 30 (383 mg, 98% over two steps). An
analytic sample was obtained by HPLC on a Nucleodur 100−5 C18 (5
μm; 4.6 mm i.d. × 250 mm) with MeOH/H2O (88:12) as eluent (ﬂow
rate 1 mL/min, tR = 10.8 min); [α]D
25 = +4.4 (c 1.42, CH3OH).
1H
and 13C NMR spectroscopic data in CD3OD given in Supporting
Information, Tables S1 and S2. HR ESIMS m/z 393.3374 [M + H]+,
C25H45O3 requires 393.3369.
Cell Cultures. HepG2 cells were cultured in E-MEM supple-
mented with 10% FBS, 1% glutamine, 1% penicillin/streptomycin.
GLUTAg cells were originally donated by Dr. D. J. Drucker,
Banting and Best Diabetes Centre, University of Toronto, Toronto
General Hospital, 200 Elizabeth Street MBRW-4R402, Toronto,
Canada M5G 2C4. GLUTAg cells were cultured in D-MEM,
supplemented with 10% FBS, 1% glutamine, and 1% penicillin/
streptomycin.
THP-1 cells were cultured in RPM-I supplemented with 10% FBS,
1% glutamine, and 1% penicillin/streptomycin.
Transactivation Assay. For FXR mediated transactivation,
HepG2 cells were plated at 5 × 104 cells/well in a 24 well plate.
Cells were transfected with 200 ng of the reporter vector p(hsp27)-
TK-LUC containing the FXR response element IR1 cloned from the
promoter of heat shock protein 27 (hsp27), 100 ng of pSG5-FXR, 100
ng of pSG5-RXR, and 100 of pGL4.70 (Promega), a vector encoding
the human Renilla gene. The reporter plasmid p(hsp27)-TKLUC has
been developed and validated for FXR reporter activity as previously
reported.29
At 24 h post-transfection, cells were stimulated 18 h with 10 μM
CDCA (1) and compounds 4−31. For GP-BAR1 mediated trans-
activation, HEK-293T cells were plated at 1 × 104 cells/well in a 24
well-plate and transfected with 200 ng of pGL4.29 (Promega), a
reporter vector containing a cAMP response element (CRE) that
drives the transcription of the luciferase reporter gene luc2P, with 100
ng of pCMVSPORT6-human GP-BAR1, and with 100 ng of pGL4.70.
At 24 h post-transfection, cells were stimulated 18 h with 10 μM
TLCA (2) and compounds 4−31. After treatments, 10 μL of cellular
lysates were read using Dual Luciferase Reporter Assay System
(Promega Italia srl, Milan, Italy) according manufacturer speciﬁcations
using the Glomax20/20 luminometer (Promega Italia srl, Milan, Italy).
For dose−response curves, cells were transfected as described above
and then treated with increasing concentrations of 7, 26, and 30 (0.1,
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0.5, 1, and 10 and 50 μM); luciferase activities were assayed and
normalized with Renilla activities.
To investigate the speciﬁcity of compounds 7, 26, and 30, HepG2
cells were transiently transfected with 200 ng of reporter vector
p(UAS)5XTKLuc, 100 ng of pGL4.70, and with a series of vectors
containing the ligand binding domain of various nuclear receptors
(PPARγ, LXR, and GR) cloned upstream of the GAL4-DNA binding
domain (i.e., pSG5-PPARγLBD-GAL4DBD, pSG5-LXRLBD-
GAL4DBD, and pSG5-GRLBD-GAL4DBD). At 48 h post-trans-
fection, cells were stimulated 18 h with the appropriate nuclear
receptor agonist or with 7, 26, and 30. To investigate the PXR
mediated transactivation, HepG2 cells were transfected with 100 ng of
pSG5-PXR, 100 ng of pSG5-RXR, 100 ng of pGL4.70, and with 200
ng of the reporter vector containing the PXR target gene promoter
(CYP3A4 gene promoter) cloned upstream of the luciferase gene
(pCYP3A4promoter-TKLuc). At 48 h post-transfection, cells were
stimulated 18 h with 10 μM rifaximin or with 7, 26, and 30.
Real-Time PCR. Total RNA was isolated using the TRIzol reagent
according to the manufacturer’s speciﬁcations (Invitrogen). One
microgram of puriﬁed RNA was treated with DNaseI for 15 min at
room temperature, followed by incubation at 95 °C for 3 min in the
presence of 2.5 mmol/L EDTA. The RNA was reverse transcribed
with Superscript III (Invitrogen) in 20 μL reaction volume using
random primers. For Real Time PCR, a 10 ng template was dissolved
in 25 μL containing 200 nmol/L of each primer and 12.5 μL of 2×
SYBR FAST Universal ready mix (Invitrogen). All reactions were
performed in triplicate, and the thermal cycling conditions were as
follows: 2 min at 95 °C, followed by 40 cycles of 95 °C for 20 s and 60
°C for 30 s in iCycler iQ instrument (Biorad). The relative mRNA
expression was calculated and expressed as 2−(ΔΔCt). Forward and
reverse primer sequences were the following: human GAPDH,
gaaggtgaaggtcggagt and catgggtggaatcatattggaa; human OSTα,
tgttgggccctttccaatac and ggctcccatgttctgctcac; human BSEP, gggccattg-
tacgagatcctaa and tgcaccgtc t t t tcact t tc tg ; human SHP,
gctgtctggagtccttctgg and ccaatgatagggcgaaagaagag; mouse GAPDH,
ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mouse Pro-gluca-
gon, tgaagacaaacgccactcac and caatgttgttccggttcctc.
cAMP Measurement. cAMP generation in THP-1 cells was
assayed using the Direct Cyclic AMP enzyme immuno-assay kit (Arbor
Assay cat. no. K019-H1). THP-1 cells were serum starved overnight
and then stimulated for 30 min with 10 μM forskolin or 7, 26, and 30.
Animal Studies. GP-BAR1 null mice (GP-BAR1-B6 = GP-
BAR12/2 mice, generated directly into C57BL/6NCrl background)
and congenic littermates on C57BL/6NCrl mice were kindly gifted by
Dr. Galya Vassileva (Schering-Plough Research Institute, Kenilworth).
Mice were housed under controlled temperatures (22 °C) and
photoperiods (12:12 h light/dark cycle), allowed unrestricted access to
standard mouse chow and tap water, and allowed to acclimate to these
conditions for at least 5 days before inclusion in an experiment.
Protocol for ANIT administration was approved by Ministry of Health
(decree no. 245/2013-B). Mice (six males per group) were treated for
nine days with ANIT (Sigma-Aldrich) dissolved in corn oil (10 mg/kg,
os) or corn oil alone (control mice). At the end of the treatment, mice
were subjected to intradermal injection of 25 μg of DCA, 6-ECDCA,
UDCA, and compound 30 and the scratching response was recorded
for 60 min. Serum levels of total bilirubin, aspartate aminotransferase
(AST), and alkaline phosphatase were measured by routine clinical
chemistry testing performed on a Hitachi 717 automatic analyzer.
Direct Interaction on FXR by Alphascreen Technology in a
Coactivator Recruitment Assay. Anti-GST-coated acceptor beads
were used to capture the GST-fusion FXR-LBD, whereas the
biotinylated-SRC-1 peptide was captured by the streptavidin donor
beads. Upon illumination at 680 nm, chemical energy is transferred
from donor to acceptor beads across the complex streptavidin-donor/
Src-1-biotin/GSTFXR-LBD/anti-GST-acceptor and a signal is pro-
duced. The assay was performed in white, low-volume, 384-well Opti
plates (PerkinElmer) using a ﬁnal volume of 25 μL containing ﬁnal
concentrations of 10 nM of puriﬁed GST-tagged FXR-LBD protein, 30
nM biotinylated Src-1 peptide, 20 μg/mL anti-GST acceptor beads
acceptor beads, and 10 μg/mL of streptavidin donor bead
(PerkinElmer). The assay buﬀer contained 50 mM Tris (pH 7.4),
50 mM KCl, 0.1% BSA, and 1 mM DTT. The stimulation times with 1
μL of tested compound (dissolved in 50% DMSO/H2O) were ﬁxed to
30 min at room temperature. The concentration of DMSO in each
well was maintained at a ﬁnal concentration of 4%. After the addition
of the detection mix (acceptor and donor beads), the plates were
incubated in the dark for 4 h at room temperature and then were read
in an Envision microplate analyzer (PerkinElmer).
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a b s t r a c t
Bile acids, the end products of cholesterol metabolism, activate multiple mechanisms through the inter-
action with membrane G-protein coupled receptors including the bile acid receptor GPBAR1 and nuclear
receptors such as the bile acid sensor, farnesoid X receptor (FXR). Even if dual FXR/GPBAR1 agonists are
largely considered a novel opportunity in the treatment of several liver and metabolic diseases, selective
targeting of one of these receptors represents an attractive therapeutic approach for a wide range of
disorders in which dual modulation is associated to severe side effects. In the present study we have
investigated around the structure of LCA generating a small library of cholane derivatives, endowed with
dual FXR agonism/GPBAR1 antagonism. To the best of our knowledge, this is the first report of bile acid
derivatives able to antagonize GPBAR1.
 2015 Elsevier Inc. All rights reserved.
1. Introduction
Bile acids, the end product of cholesterol metabolism, are
amphipathic molecules essential for lipid and fat-soluble vitamins
solubilization, absorption and metabolism. Bile acids produced in
hepatocytes, as primary bile acids, cholic acid (CA) and chen-
odeoxycholic acid (CDCA), are secreted in the bile ducts, stored
in the gallbladder, and then released into the duodenum upon
ingestion of a meal to facilitate absorption of triglycerides, choles-
terol, and lipid-soluble vitamins [1–5]. In the intestine, primary
bile acids undergo a complex metabolism by the intestinal micro-
biota resulting in generation of secondary bile acids, deoxycholic
acid (DCA) and lithocholic acid (LCA). Bile acids are efficiently reab-
sorbed (>95%) from the intestine, mainly by active transport medi-
ated by the ileal bile acid transporters but also through passive
diffusion in the upper small intestine and colon. Synthesis and
transport of bile salts are undergo extensive feedback and feed-
forward regulation by transcriptional and post-transcriptional
mechanisms.
Basic research in the past 2 decades showed that bile acids are
signaling molecules activating several cellular networks through
the recognition of nuclear and membrane receptors, such as the
http://dx.doi.org/10.1016/j.steroids.2015.11.003
0039-128X/ 2015 Elsevier Inc. All rights reserved.
Abbreviations: BSEP, bile salt export pump; CDCA, chenodeoxycholic acid; CRE,
cAMP response element; CREB, cAMP-response element binding protein; DMT-MM,
4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride; 6-ECDCA/
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farnesoid X receptor (FXR), pregnane X receptor (PXR), vitamin D
receptor (VDR), and the cell surface G protein-coupled receptor
(GPCR), GPBAR1 [1–6].
A key regulator of hepatocellular bile salt homeostasis is the
bile acid receptor farnesoid X receptor (FXR) [1–3]. FXR, is the main
sensor of bile acid levels in hepatocytes and in enterocytes and reg-
ulates the expression/activity of a number of downstream targets
by binding to specific DNA response elements as an heterodimeric
complex with the retinoid X receptor (RXR). One FXR target gene is
SHP, which encodes an atypical nuclear receptor that lacks a
ligand-binding domain and dimerizes with and inactivates both
LRH1 and LXRa, resulting in a decrease in CYP7A1 expression
and inhibition of bile acid synthesis through the neutral pathway
[1–3]. In addition, FXR ligands negatively regulate basolateral bile
acid uptake by hepatocytes via repression of NTCP and OATP-1 and
-4, while stimulate the overall gene expression of both canalicular
MRP3 (multidrug resistance-associated protein 3) and BSEP and
alternative basolateral efflux transporters, MRP4 and OSTa and b
(SLC51 solute carrier family 51, a and b subunit). In hepatocytes,
FXR activation increases the expression of genes encoding for pro-
teins involved in bile acid detoxification: CYP3A4 (cytochrome
P450, family 3, subfamily A, polypeptide 4), UGT1A3, (UDP-
glucuronosyltransferase 1A3) and Sult2A1 (sulfotransferase family,
cytosolic, 2A member 1) [1–3]. Together, these changes lead to a
reduced uptake, reduced de novo synthesis and increased excretion
of bile acids by hepatocytes. In the intestine, FXR activation mod-
ulates the expression of specific transporters by repressing the
human apical sodium bile acids transporter (ASBT) and inducing
the basolateral organic solute transporters (OSTa and OSTb).
Importantly, activation of intestinal FXR increases the expression
and causes the release of FGF-15, (FGF-19 in humans) [1–5] which,
after binding to the type-4 of FGF receptor (FGF-R4) in hepatocytes,
represses Cyp7A1 [1–3].
FXR is validated target in the treatment of liver and metabolic
disorders. Currently, FXR ligands have shown beneficial effects in
treating cholestasis, in patients affected by primary biliary
cirrhosis (PBC) and primary sclerosing cholangitis (PSC), two
immune-mediated disorders characterized by progressive bile duct
destruction [7,8]. FXR also has an important role in regulating
glucose metabolism through regulation of gluconeogenesis and
glycogenolysis in the liver, as well as regulation of peripheral insu-
lin sensitivity in striated muscle and adipose tissue, suggesting
potential beneficial effects of FXR agonists in patients with type
II diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalco-
holic steatohepatitis (NASH) [9–11].
In addition to their role of signal molecules activating the
nuclear receptor FXR, bile acids also activates the G-protein cou-
pled receptor GPBAR1 (or TGR5) [6]. GPBAR1 is highly expressed
along the intestinal tract, with the highest expression found in
the ileum and colon [12]. Despite the liver being a major bile acid
target organ, GPBAR1 expression in the liver is very low. GPBAR1 is
expressed in liver sinusoidal endothelial cells, gallbladder epithe-
lial cells, and Kupffer cells. GPBAR1 is also expressed in nontradi-
tional bile acid target organs including white and brown adipose,
spleen, kidney, pancreas, lung, macrophages, and the central
nervous system [12,13]. It is generally recognized that GPBAR1
signaling plays important roles in energy and glucose metabolism
as well as anti-inflammation in the digestive system.
Both conjugated bile acids and free bile acids are known to bind
and activate FXR and GPBAR1. Indeed the activity toward the two
bile acid receptors is structure dependent, with CDCA (EC50
approximately 10 lM) and its conjugated forms the most potent
endogenous FXR activators and LCA and taurolithocholic acid
(TLCA, EC50 value of 0.53 lM), the strongest natural agonists of
GPBAR1.
In the last years bile acid scaffold has been subjected to intense
medicinal chemistry strategies, affording to the identification of
potent steroidal derivatives with different pharmacological pro-
files, from dual to selective agonists toward FXR and GPBAR1
[14]. Sure dual agonists represent a novel opportunity in the treat-
ment of dyslipidemia and related disorders [9–11]. On the other
hands, cholestasis is the main therapeutic area for potent FXR ago-
nists. 6-ECDCA/OCA (obeticholic acid) (a dual FXR/GPBAR1 agonist)
[15,16] and Px-102 (non steroidal agonist) have been investigated
in clinical trials and the results of the phase II trial with OCA
support the notion that FXR activation could be beneficial in this
setting [17,18]. However, the use of OCA associates with several
side effects the most disturbing of which was itching that was
not observed in Phase II pilot study in patients with NAFLD with
Px102, a non-steroidal ligand [19]. The explanation for this side
effect remains unclear but the recent demonstration that GPBAR1
is the physiological mediator of pruritus [20], suggests that the
development of highly selective FXR agonists, devoid of GPBAR1
agonism, could be a rational strategy to circumvent the side effect
and might have utility in the treatment of PBC.
Intrinsically steroidal ligands are promiscuous covering the
same chemical space of the endogenous activators of FXR and
GPBAR1. Indeed the recent observation that the elimination of
the hydroxyl groups on the tetracyclic core of 5b-cholane scaffold
is detrimental in term of GPBAR1 activation [21,22], could be
instrumental in generating selective FXR ligands devoid of any
activity toward GPBAR1. In this context and in the frame of our
interest in the discovery of nuclear receptor modulators, we have
decided to manipulate LCA chemical scaffold modifying the
functionalities of tetracyclic core, the stereochemistry of A/B rings
junction, the length and the functionalization of the side chain.
Pharmacological investigations on the so generated small library
of cholane derivatives (Fig. 1) resulted in the identification for
the first time of potent FXR agonists/GP-BAR1 antagonists.
2. Material and methods
2.1. General experimental procedures
Specific rotations were measured on a Jasco P-2000 polarimeter.
High-resolution ESI-MS spectra were performed with a Micromass
Q-TOF mass spectrometer. NMR spectra were obtained on Varian
Inova 400, 500 and 700 NMR spectrometers (1H at 400, 500 and
700 MHz, 13C at 100, 125 and 175 MHz, respectively) equipped
with a SUN microsystem ultra5 hardware and recorded in
CD3OD (dH = 3.30 and dC = 49.0 ppm) and CDCl3 (dH = 7.26 and
dC = 77.0 ppm). All of the detected signals were in accordance with
the proposed structures. Coupling constants (J values) are given in
Hertz (Hz), and chemical shifts (d) are reported in ppm and
referred to CHD2OD and CHCl3 as internal standards. Spin multi-
plicities are given as s (singlet), br s (broad singlet), d (doublet),
or m (multiplet). Through-space 1H connectivities were evidenced
using a ROESY experiment with mixing times of 200 and 250 ms,
respectively.
HPLC was performed with a Waters Model 510 pump equipped
with Waters Rheodine injector and a differential refractometer,
model 401. Reaction progress was monitored via thin-layer
chromatography (TLC) on Alugram silica gel G/UV254 plates. Silica
gel MN Kieselgel 60 (70–230 mesh) from Macherey–Nagel
Company was used for column chromatography. All chemicals
were obtained from Sigma–Aldrich, Inc.
All chemicals were obtained from Sigma–Aldrich, Inc. Solvents
and reagents were used as supplied from commercial sources with
the following exceptions. Tetrahydrofuran and triethylamine were
distilled from calcium hydride immediately prior to use. Methanol
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was dried frommagnesiummethoxide as follow. Magnesium turn-
ings (5 g) and iodine (0.5 g) are refluxed in a small (50–100 mL)
quantity of methanol until all of the magnesium has reacted. The
mixture is diluted (up to 1 L) with reagent grade methanol,
refluxed for 2–3 h then distilled under nitrogen. All reactions were
carried out under argon atmosphere using flame-dried glassware.
The purities of compounds were determined to be greater than
95% by HPLC. Compound 20 was prepared as previously reported
[23,24].
2.2. Synthetic methods
2.2.1. Methyl 3a-tosiloxy-5b-cholan-24-oate (12)
To a solution of lithocholic acid (2 g, 5.31 mmol), dissolved in
50 mL of dry methanol was added p-toluenesulfonic acid (4.5 g,
26.5 mmol). The solution was left to stand at room temperature
for 1 h. The mixture was quenched by addition until the neutrality
of NaHCO3 saturated solution. After the evaporation of the metha-
nol, the residue was extracted with ethyl acetate. The combined
extract was washed with brine, dried with Na2SO4, and evaporated
to give the methyl ester as amorphous solid (2.1 g, quantitative
yield).
At the solution of the methyl ester (2 g, 5.13 mmol) in dry pyr-
idine (30 mL), tosyl chloride (4.9 g, 25.6 mmol) was added, and the
mixture was stirred at room temperature for 8 h. It was poured
into cold water (50 mL) and extracted with CH2Cl2 (3  50 mL).
The combined organic phases were washed with saturated NaHCO3
solution (50 mL) and water (50 mL), dried (Na2SO4) and concen-
trated to give 2.57 g of 12 as a white solid (92%). [a]D
25 = +59.5
(c 0.02,CH3OH); selected
1H NMR (500 MHz,CDCl3): dH 7.77 (2H,
d, J = 8.2 Hz), 7.31 (2H,d, J = 8.2 Hz), 4.43 (1H,m), 3.64 (3H,s), 2.32
(1H,m), 2.19 (1H,m), 0.88 (3H,d,J = 6.6 Hz), 0.86 (3H,s), 0.60 (3H,s);
HR ESIMS m/z 545.3309 [M+H]+, C32H49O5S requires 545.3301.
2.2.2. Methyl 5b-cholan-24-oate (13)
Lithium bromide (800 mg, 9.2 mmol) and lithium carbonate
(680 mg, 9.2 mmol) were added to a solution of compound 12
(2.5 g, 4.6 mmol) in dry DMF (30 mL), and the mixture was
refluxed for 2 h. After cooling to room temperature, the mixture
was slowly poured into saturated NaHCO3 solution (50 mL) and
extracted with ethyl acetate (3  50 mL). The combined organic
layer was washed successively with water, and then dried over
anhydrous MgSO4 and evaporated to dryness to give 1.7 g of oily
residue (quantitative yield), that was subjected to next step with-
out any purification.
A solution of compound previously obtained (1.7 g, 4.6 mmol)
in THF dry/MeOH dry (10 mL/10 mL, v/v) was hydrogenated in
presence of Pd(OH)2 20% wt on activated carbon Degussa type
(30 mg) in PARR apparatus. The flask was evacuated and flushed
first with argon and then with hydrogen (about 5 atm). After
12 h, the reaction was complete. The mixture was filtered through
celite, and the recovered filtrate was concentrated to give 1.7 g of
crude product. Purification by silica gel (hexane/ethyl acetate
95:5) gave compound 13 as a colorless oil (1.27 g,74%).
[a]25
D = 3.0 (c 0.03,CH3OH); selected
1H NMR (400 MHz,CDCl3):
d 3.68 (3H,s), 2.37 (1H,m), 2.24 (1H,m), 0.94 (3H,d,ovl), 0.93
(3H,s), 0.66 (3H,s) 13C NMR (100 MHz,CDCl3): d 175.2, 56.9, 56.3,
51.8, 44.0 (2C), 40.8, 40.6, 37.9, 36.2, 35.7, 31.4 (2C), 28.5, 27.8,
27.6, 27.4, 26.9 (2C), 24.6, 21.6, 21.2, 18.6, 12.4. HR ESIMS m/z
375.3267 [M+H]+, C25H43O2 requires 375.3263.
2.2.3. 5b-cholan-24-oic acid (3)
Compound 13 (500 mg, 1.33 mmol) was hydrolyzed with a
methanol solution of sodium hydroxide (5%, 5 mL) in H2O (5 mL)
overnight under reflux. The resulting solution was then concen-
trated under vacuum, diluted with water, acidified with HCl 6 N
and extracted with ethyl acetate (3  50 mL). The collected organic
phases were washed with brine, dried over Na2SO4 anhydrous and
evaporated under reduced pressure to give 480 mg of compound 3
(quantitative yield). An analytic sample was obtained by HPLC on a
Nucleodur 100–5 C18 (5 lm; 10 mm i.d.  250 mm) with MeOH/
H2O (999.5:0.5) as eluent (flow rate 3 mL/min, tR = 21 min);
[a]25
D = +13.3 (c 0.32,CHCl3); selected
1H NMR (400 MHz CDCl3): d
2.39 (1H,m), 2.26 (1H,m), 0.93 (3H,d, J = 6.6 Hz), 0.91 (3H,s), 0.66
(3H,s). 13C NMR (100 MHz CDCl3): d 179.1, 56.8, 56.2, 50.6, 43.9,
43.0, 40.7, 40.5, 37.8, 36.1 (2C), 35.6 (2C), 31.1, 28.4, 27.7, 27.5,
27.3, 26.8, 24.5, 21.6, 21.0, 18.5, 12.3. HR ESIMS m/z 359.2956
[MH], C24H39O2 requires 359.2950.
2.2.4. 5b-cholan-24-oyl taurine sodium salt (4)
Compound 3 (50 mg, 0.14 mmol) in DMF dry (3 mL) was treated
with DMT-MM (77.5 mg, 0.28 mmol) and triethylamine (70 lL,
0.49 mmol) and the mixture was stirred at room temperature for
10 min. Then to themixturewas added taurine (15 mg, 0.16 mmol).
After 24 h, the reaction mixture was concentrated under vacuo and
dissolved in water (5 mL). The mixture was purified by HPLC on a
Nucleodur 100–5 C18 (5 lm; 4.6 mm i.d.  250 mm) with
COR
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Fig. 1. A: CDCA and TLCA, the endogenous activators of FXR and GPBAR1, respectively. B: 5b- and 5a-cholane derivatives generated in this study.
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MeOH/H2O (83:17) as eluent (flow rate 1 mL/min), to give 3.5 mg of
compound 4 (tR = 11 min); [a]25
D = +22.5 (c 0.05,CH3OH); selected
1H NMR (400 MHz,CD3OD): d 3.58 (2H,t, J = 7.0 Hz), 2.95 (2H,t,
J = 7.0 Hz), 2.24 (1H,m), 2.08 (1H,m), 0.95 (3H,d,ovl), 0.94 (3H,s),
0.68 (3H,s). HR ESIMSm/z 480.3150 [MNa], C27H46NO4S requires
480.3153.
2.2.5. 3a-formyloxy-5b-cholan-24-oic acid (14)
A solution of lithocholic acid 11 (500 mg, 1.3 mmol) in 10 mL of
90% formic acid containing 25 lL of 70% perchloric acid was stirred
at 47–50 C for 12 h. The temperature of the heating bath was low-
ered to 40 C, then 5 mL of acetic anhydride was added and the
mixture was stirred for 15 min. The solution was cooled to room
temperature, poured into 50 mL of water and extracted with
diethyl ether. The organic layers were washed with saturated
NaHCO3 solution (50 mL) and water to neutrality, dried over
Na2SO4, and evaporated to give 540 mg of 14 (quantitative yield).
An analytic sample was obtained by silica gel chromatography
eluting with CH2Cl2:MeOH 9:1. Selected
1H NMR (400MHz CD3OD):
d 8.04 (1H,s), 4.85 (1H,m), 2.39 (1H,m), 2.25 (1H,m), 0.93 (3H,s),
0.92 (3H,d, J = 6.7 Hz), 0.65 (3H,s); 13C NMR (100 MHz CD3OD): d
178.1, 160.8, 74.4, 56.5, 55.9, 41.9, 40.5, 40.2, 40.1, 35.8 (3C),
35.4 (2C), 32.3, 30.8, 30.7, 28.2, 27.0, 26.3, 24.2, 23.4, 20.8, 18.2,
12.1; HRMS-ESIm/z 405.2997 [M+H]+, C25H41O4 requires 405.2999.
2.2.6. 3a-formyloxy-24-nor-5b-cholan-23-nitrile (15)
Crude 14 (500 mg, 1.2 mmol), 3.8 mL of cold trifluoroacetic acid,
and 1 mL (7.2 mmol) of trifluoroacetic anhydride were stirred at
0 C until dissolution. Sodium nitrite (248 mg, 3.6 mmol) was
added at the solution. The reaction mixture was stirred first at
0–5 C for 1 h, then at 45–50 C for 3 h. When the reaction was
completed, it was neutralized with NaOH 2 N, then the product
was extracted with 50 mL of diethyl ether (3  50 mL), followed
by washing with brine and dried over anhydrous Na2SO4. The ether
was removed under reduced pressure to afford 380 mg of 15 (85%),
that was subjected to next step without any purification.
2.2.7. 24-nor-lithodeoxycholic acid (16)
Compound 15 (350 mg, 0.94 mmol) was refluxed in ca. 50 mL of
methanol–water 1:1 with 30% KOH. After 2 h, the basic aqueous
solution was neutralized with HCl 6 N. Then methanol was evapo-
rated and the residue was extracted with ethyl acetate (3  50 mL)
and then with CH2Cl2 (3  50 mL). The organic layers were washed
with brine, dried and evaporated to dryness to give white solid
residue, that was purified by silica gel chromatography, eluting
with CH2Cl2:MeOH 9:1 (340 mg, quantitative yield). An analytic
sample was purified by HPLC on a Nucleodur 100–5 C18 (5 lm;
4.6 mm i.d.  250 mm) with MeOH/H2O (95:5) as eluent (flow rate
1 mL/min), to give compound 16 (tR = 10.5 min). [a]25
D = +21.9
(c 0.58,CH3OH); selected
1H NMR (400MHz CD3OD): d 3.54 (1H,m),
2.41 (2H,m), 1.00 (3H,d, J = 7.0 Hz), 0.94 (3H,s), 0.71 (3H,s). 13C
NMR (100 MHz CD3OD): d 178.0, 72.5, 57.9, 57.5, 43.6, 42.5, 41.9,
41.4, 37.2, 37.1, 36.5, 35.7, 34.9, 31.1, 29.3, 28.3, 27.6, 25.2, 23.9,
21.9, 19.9, 12.5; HRMS-ESI m/z 363.2895 [M+H]+, C23H39O3
requires 363.2899.
2.2.8. 24-nor-5b-cholanoic acid (5)
Compound 5 (210 mg, 75% over five steps) was synthesized,
starting from compound 16 (300 mg, 0.82 mmol) as described in
Scheme 2, by an analogous procedure to that detailed above for
compound 3. An analytic sample was obtained by HPLC on a Nucle-
odur 100–5 C18 (5 lm; 10 mm i.d.  250 mm) with MeOH/H2O
(999.5:0.5) as eluent (flow rate 3 mL/min, tR = 20 min); [a]D
25 =
+24.6 (c 0.03,CH3OH); selected
1H NMR (400 MHz CD3OD): d 2.41
(1H,m), 1.00 (3H,d, J = 6.0 Hz), 0.95 (3H,s), 0.72 (3H,s); 13C NMR
(100 MHz CD3OD): d 178.0, 58.0, 57.6, 45.2, 44.0, 42.8, 41.9, 41.5,
38.7, 37.3, 36.5, 35.0, 29.3, 28.6, 28.4, 28.2, 27.7, 25.3, 24.8, 22.4,
21.9, 20.0, 12.5; HR ESIMSm/z 347.2947 [M+H]+, C23H39O2 requires
347.2950.
2.2.9. Methyl cholan-3,5-dien-24-oate (21)
At a solution of the ditosylate 20 (500 mg, 0.7 mmol) in water
(3 ml) and N,N0-dimethylformamide (DMF; 27 ml) was added
CH3COOK (206 mg, 2.1 mmol) and the mixture was refluxed for
36 h. The solution was cooled at room temperature, then water
and ethyl acetate were added and the separated aqueous phase
was extracted with ethyl acetate (3  20 mL). The combined
organic phases were washed with water, dried (Na2SO4) and con-
centrated to give a mixture. Purification by silica gel eluting with
hexane–ethyl acetate (99:1) gave the diene 21 (200 mg, 78%).
selected 1H NMR (400 MHz CD3OD): d 5.92 (1H, d, J = 9.7 Hz),
5.58 (1H,d, J = 11.3 Hz), 5.38 (1H,m), 3.66 (3H,s), 2.34 (1H,m),
2.22 (1H,m), 0.94 (3H,d, J = 5.8 Hz), 0.92 (3H,s), 0.70 (3H,s); 13C
NMR (100 MHz CD3OD): d 174.8, 141.5, 129.1, 125.2, 123.2, 57.0,
55.8, 51.5, 48.4, 43.4, 39.8, 35.4, 33.8, 31.9, 31.8, 31.7, 31.0, 30.9,
28.1, 24.2, 23.9, 23.0, 20.9, 18.8, 12.0. HR ESIMS m/z 371.2947
[M+H]+, C25H39O2 requires 371.2950.
2.2.10. Methyl 5a-cholan-24-oate (6)
A solution of methyl chol-3,5-dien-24-oate 21 (150 mg,
0.40 mmol) in absolute methanol (5 mL) and dry THF (5 mL) was
added in an oven-dried 50 mL flask, that was charged with 10% pal-
ladium on carbon (10 mg). The flask was evacuated and flushed
first with argon and then with hydrogen. The reaction was stirred
at room temperature under H2 (1 atm) for 1 h. The mixture was
filtered through celite, and the recovered filtrate was concentrated
to give 147 mg of compound 6 (quantitative yield). [a]25
D = 2.9 (c
2.54,CH3OH); selected
1H NMR (400 MHz CDCl3): d 3.66 (3H,s),
2.34 (1H,m), 2.21 (1H,m), 0.91 (3H,d, J = 6.4 Hz), 0.77 (3H,s), 0.64
(3H,s); 13C NMR (100 MHz CDCl3): d 176.0, 56.9, 56.2, 55.0, 51.6,
47.3, 40.4, 39.0 (2C), 35.7 (3C), 32.5, 31.4, 31.3, 29.4, 29.3, 28.4,
27.2, 24.5, 22.6, 21.2, 18.6, 12.5, 12.4; HR ESIMS m/z 375.3269
[M+H]+, C25H43O2 requires 375.3263.
2.2.11. 5a-cholan-24-oic acid (7)
Compound 6 (50 mg, 0.13 mmol) was hydrolyzed with a metha-
nol solution of sodium hydroxide (5%, 5 mL) in H2O (1 mL) over-
night under reflux. The resulting solution was then concentrated
under vacuum, diluted with water, acidified with HCl 6 N and
extracted with ethyl acetate (3  30 mL). The collected organic
phases were washed with brine, dried over Na2SO4 anhydrous
and evaporated under reduced pressure to give compound 7
(40 mg, 87%). An analytic sample was obtained by HPLC on a
Nucleodur 100–5 C18 (5 lm; 4.6 mm i.d.  250 mm) with MeOH/
H2O (92:8) as eluent (flow rate 1 mL/min, tR = 12 min); [a]25
D =
+17.7 (c 0.14,CH3OH); selected
1H NMR (400 MHz,CD3OD): d
2.31 (1H,m), 2.20 (1H,m), 0.94 (3H,d, J = 6.2 Hz), 0.81 (3H,s), 0.69
(3H,s). HR ESIMS m/z 359.2953 [MH], C24H39O2 requires
359.2950.
2.2.12. 5a-cholan-24-oyl-taurine sodium salt (8)
Compound 7 (10 mg, 27.8  103 mmol) in DMF dry (3 mL) was
treated with DMT-MM (16 mg, 58.2  103 mmol) and triethy-
lamine (70 lL, 0.49 mmol) and the mixture was stirred at room
temperature for 10 min. Then to the mixture was added taurine
(15 mg, 0.16 mmol). After 24 h, the reaction mixture was concen-
trated under vacuo and dissolved in water (5 mL). The mixture
was purified by HPLC on a Nucleodur 100–5 C18 (5 lm; 4.6 mm
i.d.  250 mm) with MeOH/H2O (83:17) as eluent (flow rate
1 mL/min), to give 3.5 mg (27%) of compound 8 (tR = 10.4 min);
[a]25
D = +37. (c 0.03,CH3OH); selected
1H NMR (400 MHz,CD3OD):
d 3.58 (2H,t, J = 7.0 Hz), 2.96 (2H,t, J = 7.0 Hz), 2.24 (1H,m), 2.09
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(1H,m), 0.95 (3H,d, J = 6.2 Hz), 0.82 (3H,s), 0.69 (3H,s). HR ESIMS
m/z 452.2840 [MNa], C25H42NO4S requires 452.2835.
2.2.13. 5a-cholan-24-ol (9)
Dry methanol (40 lL, 0.94 mmol) and LiBH4 (470 lL, 2 M in
THF, 0.94 mmol) were added to a solution of the compound 8
(50 mg, 0.13 mmol) in dry THF (10 mL) at 0 C under argon and
the resulting mixture was stirred for 2 h at 0 C. The mixture was
quenched by addition of NaOH (1 M, 260 lL) and then allowed to
warm to room temperature. Ethyl acetate was added and the
separated aqueous phase was extracted with ethyl acetate
(3  15 mL). The combined organic phases were washed with
water, dried (Na2SO4) and concentrated. Purification by silica gel
eluting with CH2Cl2–MeOH (85:15) gave the alcohol 9 as a white
solid (45 mg, quantitative yield). An analytic sample was obtained
by HPLC on a Nucleodur 100–5 C18 (5 lm; 4.6 mm i.d.  250 mm)
with MeOH/H2O (92:8) as eluent (flow rate 1 mL/min,
tR = 17.6 min); [a]25
D = +5.5 (c 1.14,CH3OH); selected
1H NMR
(400 MHz CDCl3): d 3.51 (2H, m), 0.87 (3H, d, J = 6.3 Hz), 0.72
(3H,s), 0.60 (3H,s). 13C NMR (100 MHz CDCl3): d 63.6, 56.6, 56.1,
54.7, 47.0, 42.6, 40.1, 38.6, 35.6, 35.5 (2C), 32.2, 31.8, 29.3, 29.0
(2C), 28.2, 26.8, 24.2, 22.2, 20.8, 18.6, 12.2, 12.1; HR ESIMS m/z
347.3318 [M+H]+, C24H43O requires 347.3314.
2.2.14. 5a-cholan-24-yl-24-triethylammonium sulfate (10)
At a solution of compound 9 (10 mg, 0.028 mmol) in DMF dry
(3 mL) was added triethylamine-sulfur trioxide complex (26 mg,
0.144 mmol) under an argon atmosphere, and the mixture was
stirred at 95 C for 12 h. Most of the solvent was evaporated and
the residue was poured over a RP18 column to remove excess
SO3NEt3. Fraction eluted with MeOH:H2O 1:1 contained 10 as
ammonium salt. HPLC on a Nucleodur 100–5 C18 (5 lm; 4.6 mm
i.d.  250 mm) with MeOH/H2O (90:10) as eluent (flow rate
1 mL/min), gave 1.4 mg of compound 10 (18%, tR = 5 min) as
sodium salt. [a]25
D = 26.7 (c 0.02,CH3OH); selected
1H NMR
(400 MHz,CD3OD): d 3.95 (2H,t, J = 6.7 Hz), 0.94 (3H,d, J = 6.5 Hz),
0.81 (3H,s), 0.69 (3H,s). HR ESIMS m/z 425.2730 [MNa],
C24H41O4S requires 425.2726.
2.3. Pharmacological assays
2.3.1. Cell culture
HepG2, an immortalized epatocarcinoma cell line, was cultured
and maintained at 37 C and 5% CO2 in E-MEM additioned with 10%
FBS, 1% glutamine and 1% penicillin/streptomycin.
HEK-293T and Glutag cells were cultured and maintained at
37 C and 5% CO2 in D-MEM additioned with 10% FBS, 1% glutamine
and 1% penicillin/streptomycin.
2.3.2. Luciferase reporter gene assay
To evaluate FXR mediated transactivation, HepG2 cells were
transfected with 100 ng of human pSG5-FXR, 100 ng of human
pSG5-RXR, 200 ng of the reporter vector p(hsp27)-TK-LUC contain-
ing the FXR response element IR1 cloned from the promoter of heat
shock protein 27 (hsp27) and with 100 ng of pGL4.70 (Promega), a
vector encoding the human Renilla gene. To evaluate GPBAR1
mediated transactivation, HEK-293T cells were transfected with
200 ng of human pGL4.29 (Promega), a reporter vector containing
a cAMP response element (CRE) that drives the transcription of the
luciferase reporter gene luc2P, with 100 ng of pCMVSPORT6-
human GPBAR1, and with 100 ng of pGL4.70. At 24 h post-
transfection, cells were stimulated 18 h with 10 lM CDCA (1),
TLCA (2) and compounds 3–10. In another experimental setting,
at 24 h post-transfection, cells were stimulated with 50 lM of
compounds 3–10 in combination with 10 lM CDCA (1) or TLCA
(2). Luciferase activities were assayed and normalized with Renilla
activities.
To calculate the IC50 of 3 and 7 versus GPBAR1, a dose response
curve was performed in HEK-293T transfected as described above
and stimulated 18 h with 1, 5, 25 and 50 lM of compounds 3 and 7.
After treatments, 10 lL of cellular lysates were read using Dual
Luciferase Reporter Assay System (Promega Italia srl, Milan, Italy)
according manufacturer specifications using the Glomax20/20
luminometer (Promega Italia srl, Milan, Italy). Luciferase activities
were assayed and normalized with Renilla activities.
2.3.3. Real-Time PCR
Total RNA was isolated from HepG2 or Glutag cells using the
TRIzol reagent according to the manufacturer’s specifications
(Invitrogen). One microgram of purified RNA was treated with
DNase-I and reverse transcribed with Superscript II (Invitrogen).
For Real Time PCR, 10 ng template was dissolved in 25 lL contain-
ing 200 nmol/L of each primer and 12.5 lL of 2 SYBR FAST
Universal ready mix (Invitrogen). All reactions were performed in
triplicate, and the thermal cycling conditions were as follows:
2 min at 95 C, followed by 40 cycles of 95 C for 20 s and 60 C
for 30 s in iCycler iQ instrument (Biorad). The relative mRNA
expression was calculated and expressed as 2-(DDCt). Forward
and reverse primer sequences were the following: human GAPDH,
gaaggtgaaggtcggagt and catgggtggaatcatattggaa; human OSTa,
tgttgggccctttccaatac and ggctcccatgttctgctcac; human BSEP,
gggccattgtacgagatcctaa and tgcaccgtcttttcactttctg; human SHP,
gctgtctggagtccttctgg and ccaatgatagggcgaaagaagag; mouse GAPDH,
ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mouse
Pro-glucagon, tgaagacaaacgccactcac and caatgttgttccggttcctc.
3. Results
3.1. Chemistry
3.1.1. 5b-cholane derivatives (Schemes 1 and 2)
5b-cholanic acid 3 was prepared from LCA in a five steps reac-
tion protocol (Scheme 1). LCA methyl ester intermediate was tosy-
lated at C-3 hydroxyl group furnishing 12 in a 92% yield over two
steps. Elimination (LiBr/Li2CO3) and subsequent hydrogenation
(H2, Pd(OH)2, THF/MeOH) on the crude reaction product furnished
methyl 5b-cholanoate 13 that in turn was transformed in the cor-
responding C24 acid 3 by alkaline hydrolysis (NaOH, MeOH/H2O)
in quantitative chemical yield. A small aliquot of the so obtained
5b-cholanic acid 3 was then subjected to the reaction of amidation
with taurine in the presence of the versatile coupling agent
DMTMM, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmor-
pholinium chloride [25], giving the amide derivative as ammonium
sulfate salt. Purification on RP-18 column followed by HPLC
furnished 4 in pure form and as sodium salt.
The synthetic protocol towards nor-cholanic acid 5 (Scheme 2)
encompassed Beckmann one carbon degradation [26,27]. LCA
was protected as performate derivative 14 by treatment of LCA
with formic acid in presence of catalytic amounts of perchloric
acid. Treatment with sodium nitrite in a mixture of trifluoroacetic
anhydride and trifluoroacetic acid afforded 23-nitrile intermediate
15 in 85% yield over two steps (Scheme 2) that was in turn trans-
formed in the corresponding norLCA 16 through prolonged alkaline
hydrolysis. Methanol/p-toluenesulfonic acid treatment gave C23
methyl ester that was subjected to the same synthetic protocol
depicted in the Scheme 1. Briefly, tosylation/elimination at C3
and then hydrogenation of the double bond on ring A afforded
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methyl ester 18. Finally basic hydrolysis of methyl ester function
gave the desiderated nor 5b-cholanic acid 5 in 64% overall chemical
yield.
3.1.2. 5a-Cholane derivatives (Scheme 3)
Treatment of methyl hyodeoxycholanoate 19 with tosyl chlo-
ride in pyridine afforded the 3a,6a-ditosyloxy-5b-cholanoate
(20) in satisfactory yield (quantitative yield) (see Scheme 3).
Refluxing in DMF and CH3COOK for 1 h produced elimination at
C-3 and C-6 to give the dyene 21, which in turn was hydrogenated
to afford the required A/B trans ring junction in methyl ester 6.
Hydrolysis at C-23 methyl ester gave nor 5a-cholanic acid 7,
that in a small aliquot was subjected to the reaction of amidation
with taurine and purification (RP-18/HPLC) giving the tauro-
conjugate 8 sodium salt. An aliquot of methyl ester 6 was
transformed in the corresponding C-23 alcohol 9 that in turn was
subjected to sulfation affording the side chain sulfate derivative 10.
3.2. Pharmacological evaluation
Derivatives 3–10 were tested for their activity on FXR and
GPBAR1 in a luciferase reporter assay on HepG2 and HEK-293T
cells transfected with human FXR and GPBAR1, respectively
(Figs. 2 and 3).
As previously demonstrated [21], 5b-cholanic acid 3 transacti-
vated FXR with a potency comparable with the endogenus activa-
tor CDCA (1) and, interestingly this activity was also shared by the
corresponding 5a-cholanoic acid 7, thus demonstrating that, in
absence of the hydroxyl groups at C-3 and at C-7, also a flat cholane
scaffold could activate FXR. Nor-carboxyl acid derivative 5 was
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Scheme 1. 5b-Cholane derivatives: Reagents and Conditions. (a) p-TsOH, MeOH dry; (b) p-TsCl, pyridine, 92% over two steps; (c) LiBr, Li2CO3, DMF, reflux; (d) H2 3 atm, Pd
(OH)2/C degussa type, THF/MeOH 1:1, 74% over two steps; (e) NaOH, MeOH:H2O 1:1 v/v, quantitative; (f) DMT-MM, Et3N, taurine, DMF dry.
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Scheme 2. Preparation of nor-cholanic acid 5 Reagents and Conditions. (a) HCOOH, HClO4, quantitative; (b) TFA, trifluoroacetic anhydride, NaNO2, 85%; (c) KOH 30% in MeOH/
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Scheme 3. 5a-Cholane derivatives Reagents and Conditions. (a) p-TsCl, pyridine; (b) CH3COOK, DMF/H2O 9:1, reflux, 78% over two steps; (c) H2, Pd/C, THF/MeOH 1:1, room
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almost inactive when tested at 10 lM (Fig. 2A). Moreover, when 5
was tested at 50 lM in the presence of CDCA (Fig. 2B), the ratio
RLU/RRU was higher than that of CDCA, indicating that 5 might
be a weak FXR agonist.
Data shown in Fig. 3 revealed that the elimination of the hydro-
xyl group at C-3 on the tetracyclic core of LCA is detrimental in
term of activation of the membrane bile acid receptor (compounds
3–9 in Fig. 3, Panel A). Indeed data in Panel B are quite interesting.
Cell stimulation in presence of TLCA 2 reveals that, among this ser-
ies, derivatives 3, 5, 7 were relatively effective in inhibiting
GPBAR1 activation caused by TLCA, thus behaving as antagonists
and this result represents the first report of cholanic acid deriva-
tives as dual modulators of FXR/GPBAR1 with an agonistic profile
toward the nuclear bile acid sensor and an antagonistic behavior
toward the membrane receptor.
Antagonistic activity of compounds 3 and 7 was further investi-
gated by a detailed measurement of concentration–response curve
on GPBAR1. As illustrated in Fig. 4, compounds 3 and 7 inhibited
the transactivation of GPBAR1 with an IC50 of 28 and 22 lM,
respectively.
Compound 3 was further investigated in vitro and its effects on
FXR and GPBAR1 target genes assessed by RT-PCR. As shown in
Fig. 5, panels A-D, 5b-cholanic acid 3 was able to induce the
expression of BSEP, SHP and OSTa genes in HepG2 cells whereas
antagonized the expression of pro-glucagon mRNA in GLUTAg
cells, thus demonstrating that this molecule is an effective FXR
agonist endowed with antagonistic activity toward GPBAR1.
4. Discussion and conclusion
FXR senses the intracellular presence of bile acids by activating
multiple mechanisms, such as promotion of bile acid export from
liver, down-regulation of bile acid import and also attenuation of
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Fig. 2. Transactivation assays on FXR. A, Luciferase reporter assay performed in HepG2 transiently transfected with human pSG5-FXR, pSG5-RXR, pCMV-bgal, and p(hsp27)
TKLUC vectors and measured as RLU/RRU (Relative Luciferase Unit/Relative Renilla Unit). Twenty-four hours post transfection, cells were stimulated with compounds 3–10
(10 lM). CDCA (1, 10 lM) was used as a positive control. Results are expressed as mean ± standard error; *p < 0.05 versus not treated cells (NT). B, HepG2 cells were
transfected as described in A. Twenty-four hours post transfection cells were stimulated with 10 lM CDCA (1) alone or in combination with compounds 3–10 (50 lM).
*p < 0.05 versus not treated cells (NT). #p < 0.05 versus CDCA (1) stimulated cells.
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Fig. 3. Transactivation assays on GPBAR1. A, Luciferase reporter assay performed in HEK-293T cells transiently transfected with human GPBAR1 and a reporter gene
containing a cAMP responsive element in front of the luciferase gene and measured as RLU/RRU (Relative Luciferase Unit/Relative Renilla Unit). Twenty-four hours post
transfection, cells were stimulated with compounds 3–10 (10 lM). TLCA (2, 10 lM) was used as a positive control. Results are expressed as mean ± standard error. ⁄p < 0.05
versus not treated cells (NT). B, HEK-293T cells were transfected as described in A. Twenty-four hours post transfection cells were stimulated with 10 lM TLCA (2) alone or in
combination with compounds 3–10 (50 lM). ⁄p < 0.05 versus not treated cells (NT). #p < 0.05 versus TLCA stimulated cells.
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de novo bile acid synthesis. As a consequence, FXR has been iden-
tified as an appealing target in the treatment of cholestasis and
liver steatosis, where bile acid levels are impaired. In addition,
FXR plays a crucial beneficial role in hepatic triglyceride homeosta-
sis, and in glucose metabolism. Therefore, FXR agonists are promis-
ing for the treatment of NAFLD, dyslipidemia and type 2 diabetes
[7–10]. After FXR de-orphanization by endogenus bile acids
[1–3], bile acid scaffold has been subjected to intense medicinal
chemistry modifications, producing several steroidal derivatives
with different pharmacological profiles, and, of interest, endowed
with good physicochemical properties and higher drug-like
profiles when compared to non-steroidal ligands.
Since steroidal ligands cover the same chemical space of the
endogenous activators, they are intrinsically promiscuous toward
FXR and GPBAR1 and, with few exception, this kind of speculation
mainly afforded dual modulators [14,22,28].
Besides this promiscuity supports the use of dual FXR/GPBAR1
agonists in the treatment of nonalcoholic steatohepatitis (NASH)
and type 2 diabetes [9], the recent identification of GPBAR1 as
the physiological mediator of pruritus [20], a common symptom
observed in cholestasis, highly limits the pharmacological utility
of dual agonists in the treatment of primary biliary cirrhosis
(PBC) and related cholestatic disorders. In this context, the discov-
ery of highly selective FXR agonists, devoid of GPBAR1 agonism,
represents a good promise in the identification of new pharmaco-
logical protocols for PBC, an orphan disease for which therapeutic
options are limited and poorly effective. In the present study, we
have harnessed on the LCA scaffold modifying the functionalities
of tetracyclic core, the stereochemistry of A/B ring junction, the
length and the functionalization of the side chain. The results of
this investigation has led to the discovery of compounds 3, 5 and
7, 5b-cholanoic acid, 5b-norcholanoic acid, and 5a-cholanoic acid,
respectively, as the first examples of bile acid derivatives endowed
with FXR agonism and GPBAR1 antagonism. Analysis of transacti-
vation data clearly affirms the carboxylic group on the side chain
as a key structural feature in GPBAR1 antagonism. Independently
by the length of the side chain (C24 in 3 and C23 in 5) and by
the shape of the tetracyclic core, all carboxylic acids generated in
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this study were relatively effective in inhibiting GPBAR1 activation
caused by TLCA. In fact, both 5b-cholanoic acid 3 and 5a-cholanoic
acid 7, with a bent and a flat shape (A/B cis junction in 3 and the
A/B trans junction in 5), inhibited TLCA-induced transactivation
of GPBAR1 with comparable IC50 values (28 lM and 22 lM, respec-
tively, Fig. 4). Of interest is the observation that the presence of a
larger negative charged end group such as the sulfate group in
10 and the sulfonate group in the tauro-conjugated derivatives 4
and 8, is detrimental in term of GPBAR1 antagonism for both
5a- and 5b-cholane derivatives.
In conclusion, on the best of our knowledge, this result
represents the first report of cholanoic acid derivatives able to
antagonize GPBAR1. These compounds represent novel chemical
probes, useful component of today’s research arsenal of bile acid
derivatives, in dissecting and in shedding light on the complex
biological pathways under GPBAR1 control.
The analysis of their in vivo effects could result in the identifi-
cation of new therapeutical approach to FXR mediated liver
disorders in which the concomitant activation of GPBAR1 is
associated to severe side-effects.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.steroids.2015.11.
003.
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www.nature.com/scientificreportsInsights on FXR selective modulation. speculation on bile acid chemical space in the discovery of potent and selective agonistsValentina sepe1, Carmen Festa1, Barbara Renga2, Adriana Carino2, sabrina Cipriani2, Claudia Finamore1, Dario Masullo1, Federica del Gaudio3,4, Maria Chiara Monti3, stefano Fiorucci2 & Angela Zampella1Bile acids are the endogenous modulators of the nuclear receptor FXR and the membrane receptor 
GPBAR1. FXR represents a promising pharmacological target for the treatment of cholestatic liver disorders. Currently available semisynthetic bile acid derivatives cover the same chemical space of bile acids and therefore they are poorly selective toward BA receptors, increasing patient risk for adverse 
side effects. In this report, we have investigated around the structure of CDCA describing the synthesis and the in vitro and in vivo pharmacological characterization of a novel family of compounds modified on the steroidal tetracyclic core and on the side chain. pharmacological characterization resulted in the 
identification of several potent and selective FXR agonists. These novel agents might add utility in the 
treatment of cholestatic disorders by potentially mitigating side effects linked to unwanted activation 
of GPBAR1.
Farnesoid X receptor (FXR) is one of the 48 ligand-activated nuclear transcription factor proteins. Mostly 
expressed in hepatocytes, biliary epithelium, small bowel enterocytes, renal tubular cells and adrenal glands, FXR 
senses the intracellular presence of bile acids (BAs) by inducing changes in gene expression1,2. The results of the 
consequent activated multiple mechanisms include promotion of bile acid export from liver, down-regulation of 
bile acid import and also attenuation of de-novo bile acid synthesis3. Thus, FXR has been identified as an appeal-
ing target in the treatment of cholestasis and liver steatosis4–6. In addition to its canonical role in regulating bile 
acid homeostasis, FXR plays a crucial beneficial role in hepatic triglyceride (TG) homeostasis, as well as in glucose 
metabolism. FXR lowers hepatic TG content and serum TG levels and improves insulin resistance and hyperg-
lycemia. Therefore, FXR agonists are promising for the treatment of non-alcoholic fatty liver disease (NAFLD), 
dyslipidemia and type 2 diabetes7–10.
Among endogenous occurring BAs, chenodeoxycholic acid (CDCA, 1 in Fig. 1) is the most potent natural 
FXR ligand (EC50 ~ 10 µ M), whereas deoxycholic acid and lithocholic acid are weaker natural ligands
11.
In addition, secondary BAs activate the membrane G-protein-coupled receptor GPBAR1 (also known as 
M-BAR, TGR5 or BG37)12, and the exogenous dual control over the two receptors represents an attractive strat-
egy for the treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes13–15.
On the other hands, GPBAR1 has been recently identified as the physiological mediator of pruritus16, a com-
mon symptom observed in cholestasis and the severity of this side effect limits the pharmacological utility of dual 
agonists in the treatment of primary biliary cirrhosis (PBC) and related cholestatic disorders. In this context, the 
discovery of highly selective FXR agonists, devoid of GPBAR1 agonism, represents a promising approach in the 
identification of new pharmacological protocols for PBC, an orphan disease for which therapeutic options are 
limited and poorly effective.
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Indeed, in the last ten years bile acid scaffold has been subjected to intense medicinal chemistry modifica-
tions, producing several steroidal derivatives modified on the side chain in the length and in the nature of the 
end-group and on the tetracyclic core. Since steroidal ligands cover the same chemical space of BAs, they are 
intrinsically promiscuous toward FXR and GPBAR1 and, with few exception, this kind of speculation mainly 
afforded dual modulators17,18. Indeed, the removal or isomerization of the hydroxyl group at C-3 on LCA or 
its tauro-conjugated form (TLCA, 2 in Fig. 1), the most potent GPBAR1 agonist among endogenous BAs19, 
is detrimental in term of GPBAR1 agonism, and this observation was recently translated on CDCA scaffold 
demonstrating that 3-deoxy-5β -cholane derivatives are selective FXR ligands17. Independently from the func-
tional group at C-24 on the side chain, derivatives 3–5 (Fig. 1) were demonstrated selective FXR agonists with 
7α -hydroxy-5β -cholan-24-sulfate (5) transactivating FXR with an EC50 of ~ 9 µ M. Even if less potent in trans-
activation assay than 6-ethylchenodeoxycholic acid, 6-ECDCA/OCA (6), the most potent steroidal FXR agonist 
generated so far, the potency of compound 5 in inducing the expression of OSTα , a FXR target gene in the liver, is 
comparable to that of 6-ECDCA. However 6-ECDCA is also a GPBAR1 activator20,21, and administration of PBC 
patients has led to exacerbation of itching causing drug discontinuation in 40% of patients22.
With this background in mind, we decided to proceed in the modification of the hydroxyl group at C-3 on 
6-ethylcholane scaffold generating a library of 6-ethylcholane derivatives that are divided in two subsets (Fig. 2): 
subset A includes the 3-deoxy-6-ethyl derivatives, and subset B includes the 3β -hydroxyl derivatives.
As shown in the Fig. 2, in each subset, our investigation was also expanded on the side chain-end group and 
on the stereochemical arrangement of 6-ethyl and 7-hydroxyl substituents on ring B affording to the discovery of 
several derivatives as potent and selective FXR agonists.Results
Modification on 6-ethylchenodeoxycholane scaffold in the preparation of subset A derivatives 
(Fig. 3). Methyl ester formation and acetylation at C-3 hydroxyl group on 7-KLCA furnished intermediate 22 
in 84% yield over two steps. Aldolic addition to a silyl enol ether intermediate generated 23. Hydrogenation at 
the exocyclic double bond (H2 on Pd(OH)2) afforded exclusively the 6β -ethyl group in 24 (80% yield over three 
steps) as demonstrated by dipolar couplings Me-26 (δ 0.83)/Me-19 (δ 1.22) and H-8 (δ 2.56)/H-25 (δ 1.83) in 
Noesy spectrum. First, compound 24 was treated with MeONa in methanol to effect de-acetylation at C-3 and 
inversion at C-6 and then with tosyl chloride to afford 25 in quantitative yield over two steps. Elimination by 
LiBr/Li2CO3 treatment and hydrogenation of the unsaturated-ring A transient intermediate furnished the key 
derivative 26. LiBH4 treatment produced the concomitant reduction at C-24 methyl ester and at C-7 carbonyl 
group furnishing 7 in high chemical yield and a small aliquot of the corresponding epimer at C-7 (8), efficiently 
separated by HPLC.
Chemoselective sulfation at C-24 hydroxyl group on a small aliquot of 7 gave the corresponding sulfate deriv-
ative 9. Intermediate 26 was also used as starting material for the preparation of compounds 10 and 11. Alkaline 
hydrolysis of the methyl ester followed by LiBH4 treatment furnished 10 in high chemical yield with about 10% 
of 6α -ethyl-7β -hydroxy-5β -cholan-24-oic acid (11) that was isolated by HPLC. Amidation with taurine on the 
major 6α -ethyl-7α -hydroxy-5β -cholan-24-oic acid (10) and C18 silica gel column/HPLC purification provided 
the corresponding tauro-conjugated 12.
As previously demonstrated, stereochemical arrangement of the substituents at C-6 and C-7 on ring B pro-
foundly affects bile acid receptor selectivity17. Invariably the presence of the 6α -ethyl and the 7α -hydroxyl groups 
produces potent agonists with dual FXR/GPBAR1 activity whereas the 6-epimers (6β -ethyl derivatives) are 
selective GPBAR1 agonists. To access to 3-deoxy-6β -ethylchenodeoxycholane derivatives, compound 24 was 
treated with MeONa in MeOH for 2 h reaction time affording de-acetylation at C-3 without epimerization at 
C-6. Tosylation on the crude reaction product furnished 27 that was subjected to the same operative condition 
described for compound 26, to obtain 28 in 94% yield over two steps. Treatment of 28 with NaBH4 in methanol 
followed by LiBH4 reduction on the crude reaction product to secure the complete reduction of the methyl ester 
Figure 1. CDCA and TLCA, the most potent endogenous activators of FXR and GPBAR1, respectively. 
3-Deoxy-5β -cholane derivatives 3–5 as selective FXR ligands and 6-ECDCA, a potent semi-synthetic dual 
agonist.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:19008 | DOI: 10.1038/srep19008on the side chain afforded a mixture whose HPLC purification gave pure 13 in a 54% yield respect to the corre-sponding C7 epimer, compound 14.Modification on 6-ethylchenodeoxycholane scaffold in the preparation of subset B derivatives (Fig. 4). As previously demonstrated, modification at C-3 impacts on BAs selectivity and activity towards FXR and GPBAR1. Isomerization of the 3R-hydroxyl group on LCA robustly attenuates the agonistic activity on GPBAR1 with iso-LCA less potent respect to the cognate LCA. On the other hand, isochenodeoxycholic acid (iso-CDCA) is more potent than CDCA in transactivating FXR and notably has only very weak activity towards GPBAR117.With this background in mind, our speculation on 6-ethylchenodeoxycholane scaffold was expanded to the preparation of 3β -hydroxyl derivatives.As depicted in Fig. 4, in a convergent protocol, inversion at C-3 on 27 with potassium acetate in DMF/H2O followed by treatment with MeONa/MeOH gave 29 (74% over two steps) that was used as starting material in the synthesis of derivatives 15–19. In detail NaOH hydrolysis followed by LiBH4 treatment gave 17 and small amounts (about 10%) of the corresponding 7β -hydroxyl derivative 18, efficiently separated by HPLC. Tauro-conjugation on a small aliquot of 17 proceeded smoothly with the formation of 19 in good chemical yield. In a parallel pro-tocol, intermediated 29 was subjected to LiBH4 treatment affording alcohol 15 in presence of a small amount of 6α -ethyl-3β ,7β -dihydroxy-5β -cholan-24-ol (16).Compound 27 was also used as starting material for the preparation of compounds 20–21 (Fig. 4). Inversion at C-3 followed by reduction at C-7 and C-24 with NaBH4/LiBH4 treatment as described for the corresponding 3-deoxy derivatives (Fig. 3) furnished 20 and 21 as a mixture, then separated by HPLC.Preparation of the reference compound, 6-ECDCA (6) (Fig. 5). Methyl ester 24 was also converted in 6-ECDCA (6), used as reference compound in the pharmacological evaluation of our library of 6-ethylcholane derivatives. Basic treatment (NaOH, MeOH/H2O) on 24 proceeded in a straightforward manner affording the concomitant hydrolysis on side chain methyl ester, de-acetylation at C-3 and inversion at C-6 ethyl group. LiBH4 reduction of the C7-carbonyl group on intermediate 30 furnished 6-ECDCA (6) in 69% over two steps.In vitro pharmacological evaluation. Derivatives 7–21 were tested for FXR and GPBAR1 activity, in a luciferase reporter assay with HepG2 and HEK-293T cells transfected with FXR and GPBAR1, respectively (Figs 6, 8 and 9). As reported in Fig. 6A, all 6α /7α derivatives (compounds 7, 9, 10 in subset A and 15, 17 in sub-set B) are potent agonists of FXR. Within 6α /7α stereochemical arrangement, the presence of a negative charge 
Figure 2. 6-Ethylcholane scaffold derivatives generated in this study. Subset A: 3-deoxy-6-
ethylchenodeoxycholane derivatives; subset B: 3β -hydroxy-6-ethylchenodeoxycholane derivatives.
www.nature.com/scientificreports/
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Figure 3. Preparation of 3-deoxy-6-ethylchenocholane derivatives (subset A). Reagents and conditions: 
(a) p-TsOH, MeOH dry; (b) acetic anhydride, pyridine, 84% yield over two steps; (c) DIPA, n-BuLi, TMSCl, 
TEA dry, THF dry − 78 °C; (d) acetaldehyde, BF3(OEt)2, CH2Cl2, − 60 °C, 80% over two steps; (e) H2, Pd(OH)2, 
THF/MeOH 1:1, quantitative yield; (f) MeONa, MeOH; g) p-TsCl, pyridine, quantitative yield over two steps; 
(h) LiBr, Li2CO3, DMF, reflux, (i) H2, Pd(OH)2, THF/MeOH 1:1, room temperature, 88% over two steps; (j) 
LiBH4, MeOH dry, THF, 0 °C, 77%; (k) Et3N.SO3, DMF, 95 °C; (l) NaOH, MeOH:H2O 1:1 v/v, 98%; (m) LiBH4, 
MeOH dry, THF, 0 °C, 83%; (n) DMT-MM, Et3N, taurine, DMF dry; (o) MeONa, MeOH; (p) p-TsCl, pyridine, 
quantitative yield over two steps; (q) LiBr, Li2CO3, DMF, reflux; (r) H2, Pd(OH)2, THF/MeOH 1:1, room 
temperature, 94% over two steps; (s) NaBH4, MeOH; (t) LiBH4, MeOH dry, THF, 0 °C, 78% over two steps.
Figure 4. Preparation of 3β-hydroxy-6-ethylchenocholane derivatives (subset B). Reagents and conditions: 
(a) CH3COOK, DMF:H2O 5:1 v/v; (b) NaOMe, MeOH, 74% over two steps; (c) LiBH4, MeOH dry, THF, 0 °C, 
58%; (d) NaOH, MeOH:H2O 1:1 v/v; (e) LiBH4, MeOH dry, THF, 0 °C, 74% over two steps; (f) DMT-MM, Et3N, 
taurine, DMF dry; (g) NaBH4, MeOH; (h) LiBH4, MeOH dry, THF, 0 °C, 74% over three steps.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:19008 | DOI: 10.1038/srep19008on the side chain favors the 3-deoxy derivatives with the carboxylic acid 10 and the sulfate derivative 9 potent FXR activators whereas the alcoholic function at C-24 improves FXR activity of the corresponding 3β -hydroxyl derivatives (compare 10 vs 17 and 15 vs 7). Of interest are also the cellular assay results on compounds with one of the two substituents on ring B in a β -configuration (C6α /C7β or C6β /C7α ) revealing a remarkable decrease in FXR activity when compared to the corresponding 6α /7α substituted derivatives. In detail, one again, the activity is related to the functional group on the side chain and to the presence/absence of the hydroxyl group at C-3. First derivative 8, a C3-deoxy/C24-alcohol with the C6α /C7β stereochemical arrangement is completely inactive towards FXR whereas the corresponding carboxylic acid 11, even if less potent than CDCA (1), retains a certain activity. Opposite is the behavior of the corresponding 3β -hydroxyl derivatives where the presence of the alcoholic function at C-24 on the side chain improve FXR activity (compare 16 vs 18).Finally, the complete loss of activity for compounds 13 and 20 points the attention on the pharmacophoric role of the C6/C7 stereochemical arrangement with the 6β /7β relationship detrimental in FXR binding.The relative potency of selected members of this novel family was then investigated by a detailed measurement of concentration-response curve of the 3-deoxy sulfate derivative 9, the corresponding carboxylic acid 10, and the 3β -hydroxyl alcohol 15 and carboxylic acid derivative 17, all sharing the 6α /7α configuration, on FXR transacti-vation. As illustrated in Fig. 6B, compounds 9, 10, 15 and 17 transactivate FXR with an EC50 of 1.1 µ M, 950 nM, 2.2 µ M and 1.3 µ M, respectively, with compound 10 showing a comparable potency with the reference com-pound, 6-ECDCA, EC50 = 500 nM in the same assay (Supporting Information, Figure S1). Of interest, the ability in transactivating FXR is also maintained by the corresponding tauro-conjugated 12 (Fig. 6A, compare 10 vs 12), 
Figure 5. Preparation of the reference compound, 6-ECDCA (6). Reagents and conditions: (a) NaOH, 
MeOH:H2O 1:1 v/v; (b) LiBH4, MeOH dry, THF, 0 °C, 69% over two steps.
Figure 6. Transactivation assays on FXR. (A) HepG2 cells were transfected with pSG5-FXR, pSG5-RXR, 
pCMV-β gal, and p(hsp27)TKLUC vectors. Cells were stimulated with compounds 7–21 (10 µ M). CDCA (1, 
10 µ M) and 6-ECDCA (6, 1 µ M) were used as a positive control. Results are expressed as mean ± standard 
error; *p < 0.05 versus not treated cells (NT); (B) Concentration-response curve of 9, 10, 15 and 17 on FXR in a 
luciferase reporter assay using HepG2 cells transfected with FXR. Twenty-four hour post transfection cells were 
stimulated with increasing concentrations of each agent: range from 100 nM to 10 µ M.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:19008 | DOI: 10.1038/srep19008thus highlighting the therapeutical potential of 6α -ethyl-7α -hydroxy-5β -cholan-24-oic acid (10) in human FXR mediated diseases. On the contrary, tauro-conjugation on carboxylic acid 17 produces a considerable decrease in FXR transactivation activity (compare 19 vs 17 in Fig. 6A), thus first demonstrating that a longer negative Figure 8. Agonism on GPBAR1 by transactivation assay. (A) HEK-293T cells were co-transfected with GPBAR1 and a reporter gene containing a cAMP responsive element in front of the luciferase gene. Twenty-four hour post transfection cells were stimulated with 7–21 (10 µ M). Luciferase activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. TLCA (2, 10 µ M) was used as a positive control. Results are expressed as mean ± standard error. *p < 0.05 versus not treated cells (NT); (B) Concentration-response curve of 9 and 21 on GPBAR1 in HEK-293T cells co-transfected with GPBAR1 and a reporter gene containing a cAMP responsive element in front of the luciferase gene (CRE). Twenty-four hour post transfection cells were stimulated with increasing concentrations of each agent: range from 100 nM to 50 µ M. Results are expressed as mean ± standard error.
Figure 7. Coactivator recruitment assay measuring a direct interaction of FXR with SRC-1. Anti-GST-
coated acceptor beads captured GST-fusion FXR-LBD and the biotinylated-SRC-1 peptide was captured by the 
streptavidin donor beads. FXR-LBD recruited SRC-1 in the presence of ligand at 2 µ M and, upon illumination 
at 680 nm, chemical energy is transferred from donor to acceptor beads across the complex streptavidin-donor/
Src-1-biotin/ligand/GSTFXR-LBD/anti-GST-acceptor and a signal is produced. Results are expressed as 
percentage of the effect of 6 arbitrarily settled as 100%. NT is referred to the experiment carried out in absence 
of ligand. Results are expressed as mean ± standard error.
www.nature.com/scientificreports/
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charged side chain is detrimental in FXR binding when a 3β -hydroxyl group is present on the steroidal scaffold 
and second, reducing the pharmacological impact of compound 17. Finally the ability of the more active com-
pounds in transactivating FXR was measured as recruitment assay of the coactivator SRC-1, using Alphascreen 
technology. In this assay, the ligand induces the recruitment of the coactivator to the LBD of hFXR. 6-ECDCA 
(6) was used as positive control and reference molecule setting its effect as 100% (Fig. 7). All tested derivatives, 
6α -ethyl-7α -hydroxy-5β -cholan-24-oic acid (10), 6α -ethyl-3β ,7α -dihydroxy-5β -cholan-24-ol (15) and the cor-
responding carboxylic acid, 6α -ethyl-3β ,7α -dihydroxy-5β -cholan-24-oic acid (17) showed a very potent activity 
in the recruitment of SRC-1 co-activator and high affinity to FXR, almost comparable to that measured for 6, thus 
confirming the transactivation results.
Results of transactivations of CREB-responsive elements in HEK-293T, transiently transfected with the mem-
brane bile acid receptor GPBAR1 (Fig. 8A), revealed that the strategy of elimination or inversion at C-3 hydroxyl 
group could be instrumental in shifting the selectivity of 6-ethylcholane derivatives toward FXR.
Indeed, independently by the functional group on the side chain, the stereochemical arrangement of C6/
C7 substituents and the presence/absence of the hydroxyl group at C-3, all derivatives generated in this study 
are weak agonists, substantially less potent than TLCA (2) in modulating GPBAR1. By way of example, the 
concentration-response curve on compounds 9 and 21 (Fig. 8B) resulted in EC50 values of 4.3 and 2.2 µ M, sub-
stantially lesser than the corresponding value for TLCA (EC50 = 0.29 µ M)
19. As a consequent, compound 9 should 
be considered a preferential FXR modulator with a residual activity on GPBAR1 whereas compound 21, less 
potent then CDCA in transactivating FXR (Fig. 6A), is a weak but preferential GPBAR1 activator.
Moreover, 6α -ethyl-7α -hydroxy-5β -cholan-24-oic acid (10), one of the most potent derivative in transac-
tivating FXR is inactive towards GPBAR1 in agonistic mode (Fig. 8A). Of interest, when administered in pres-
ence of 10 µ M TLCA (2), compound 10 showed inhibitory activity against GPBAR1 transactivation induced by 
TLCA (Fig. 9A). The above result was also confirmed by a concentration-response curve in HEK-293T transiently 
transfected with GPBAR1, revealing for 10 an IC50 value of 11 µ M in antagonizing the effect of TLCA (Fig. 9B). 
To the best of our knowledge, this result represents the first report of a 6-ethylcholanoic derivative endowed by 
potent FXR agonism and able to antagonize GPBAR1. This discovery opens the way to a new and promising 
field of research. First, the speculation of the in vivo effects of this compound could result in the identification of 
new therapeutical approach to FXR mediated liver disorders in which the concomitant activation of GPBAR1 is 
associated to severe side effects. Second, compound 10 represents a novel tool compound, useful component of 
today’s research arsenal of BA derivatives, in dissecting and in shedding light on the complex biological pathways 
under GPBAR1 control.In vivo pharmacological characterization (Figs. 10,11). C57BL6 mice were administered with com-
pound 10 (15 mg/kg, ip). At 6 h post-treatment, livers and blood were collected. As shown in Fig. 10, compound 
10 significantly up-regulated the relative mRNA expression of canonical FXR molecular targets such as OSTα , 
SHP and BSEP in the liver exposed 6 h to 10 (*p < 0.05 versus control mice).
Analysis of plasmatic concentrations of unconjugated and tauro-conjugated bile acids demonstrated that 
in vivo administration of 10 significantly reduced total unconjugated bile acids while the quote of tauro-conjugated 
tMu, tCA, tHCA, tCDCA, tDCA and tLCA was unaffected (Fig. 11, *p < 0.05 versus control mice). Compound 
10 was only found in the conjugated form with taurine (data not shown).Discussion and Conclusion
In addition to their role in lipid absorption, and similarly to other cholesterol metabolites, bile acids are signaling 
molecules.
Each bile acid interacts with more than one receptor, however, FXR and GPBAR1 are differentially activated 
by CDCA> DCA > LCA> CA and LCA> DCA> CDCA> CA, respectively. In addition to endogenous ligands, 
Figure 9. Antagonism on GPBAR1 by transactivation assay. (A) HEK-293T cells were transfected as 
described in Fig. 8. Twenty-four hour post transfection cells were stimulated with 10 µ M TLCA (2) alone or in 
combination with 25 µ M compounds 7–21. #p < 0.05 versus TLCA stimulated cells; (B) Concentration-response 
curve of 10 on GPBAR1 in combination with TLCA (2, 10 µ M) and with increasing concentrations of 10: range 
from 5 to 25 µ M. Results are expressed as mean ± standard error.
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8Scientific RepoRts | 6:19008 | DOI: 10.1038/srep19008several semisynthetic bile acids and non-steroidal FXR ligands are currently under evaluation in the treatment of metabolic (NASH) and cholestatic liver diseases (PBC).Obeticholic acid (OCA, or 6-ECDCA (6), or INT-747), a semi-synthetic dual FXR and GPBAR1 ligand and a derivative of CDCA, has been recently evaluated in the multicenter, double-blind, randomized NASH (FLINT) trial23. Although 6-ECDCA/OCA significantly improved the primary histological outcome (NAFLD activity score) and fibrosis score compared with placebo, NASH resolution occurred in only 22% of patients after 72 weeks (p = 0.08 vs. placebo). In addition, a 5% decrease in HDL-C levels coupled with a 16% increase in LDL-C was observed with OCA as compared to placebo and the impact of these changes on long-term cardiovascular risk in NASH is unknown. One major limitation of the use of OCA is the high incidence of pruritus, occurring in up to 80% patients with primary biliary cirrhosis receiving OCA and primarily responsible for high rate of drug discontinuation in 40% of patients23,24. Indeed, OCA is a dual FXR/GPBAR1 agonist20,21, and GPBAR1 has recently been demonstrated a physiological mediator of itching15, indicating that highly selective FXR agonists might have utility in the treatment of PBC. In this context, we have modified BA scaffold generating a library of 6-ethylcholane derivatives having variable and peculiar activity toward FXR and GPBAR1.From a chemical perspective of structure-activity relationship, our investigation has been focused primar-ily on three areas: (1) the modification at C-3 hydroxyl group (elimination/inversion) on the 6-ethylcholane scaffold; (2) changes to the end group on side chain; and (3) the stereochemical orientation of C6/C7 substitu-ents on ring B. The first consideration to be drawn is that all 6-ethylcholane derivatives prepared in this study 
Figure 10. In vivo effect of 10 on FXR target genes. C57BL6 mice were administered with 10 (15 mg/Kg) for 
6 h. After treatment liver were removed and the relative mRNA expression of OSTα , SHP and BSEP was assayed 
by quantitative Real-Time PCR. *p < 0.05 versus control mice.
Figure 11. Blood concentrations of (A) total tauro-conjugated and total unconjugated bile acids; (B) 
individual conjugated and (C) unconjugated bile acids; (D) 7α -hydroxy-4-cholesten-3-one before and after  
in vivo administration of 10 at 15 mg/Kg.
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are at least weak GPBAR1 agonists (Fig. 8), thus affirming the key pharmacophoric role of the 3α -hydroxyl 
group for GPBAR1 activation by BA scaffold. Second, as expected, the presence of both substituents on ring B 
in α -configuration favors FXR binding generating potent agonists25. Among the two subsets of semisynthetic 
bile acid derivatives, 3-deoxy-chenodeoxycholane derivatives (subset A) 9 and 10, differing in the nature of the 
negative charged side chain end group (sulfate in 9 and carboxylic acid in 10) transactivate FXR with EC50 val-
ues of 1.1 µ M and 950 nM, respectively. Both values are comparable to that of 6-ECDCA (6) (Figure S1) and the 
above potency was also shared by the corresponding 3β -hydroxyl carboxylic acid 17 (EC50 values of 1.3 µ M). 
Of interest are also the results of tauro-conjugation on the potent FXR agonists, carboxylic acids 10 and 17. As 
shown in Fig. 6A, tauro-conjugation on the 3-deoxy derivative 10 produces 12, still a potent FXR agonist whereas 
tauro-conjugation on the 3β -hydroxyl carboxylic acid 17 is detrimental in term of FXR activation (compound 19 
in Fig. 6A). Because endogenous bile acids and semisynthetic bile acid derivatives undergo to extensive liver con-
jugation at the carboxyl acid end group (tauro-conjugation in mice and glyco-conjugation in human), this result 
highlights the therapeutical potential of compound 10 in human FXR mediated diseases. Indeed compound 10 is 
devoid of any activity toward GPBAR1 in agonistic mode (Fig. 8A) but when administered in combination with 
TLCA, it inhibited TLCA mediated GPBAR1 activation with an IC50 value of 11 µ M (Fig. 9B). Thus, to the best 
of our knowledge, compound 10 represents the first example of a 6-ethyl bile acid derivative endowed with FXR 
agonism/GPBAR1 antagonism.
Further investigating its pharmacological properties, compound 10 at the dose of 15 mg/kg was administered 
to intact mice. As illustrated in Fig. 10, this agent significantly increased the expression of three canonical FXR 
target genes in the liver. Indeed, compound 10 increased the expression of OSTα , SHP and BSEP in the liver as 
early as 6 h after administration. Because these three genes are endowed with canonical FXR-responsive elements 
in their promoter, their induction is fully consistent with the nature of compound 10 as potent FXR ligand. 
This view was further confirmed by analysis of bile acids in the blood of mice administered with compound 10. 
Indeed, as shown in Fig. 11, exposure to this agent results in a marked reduction of total and single unconjugated 
bile acids, a feature that is consistent with its FXR agonistic profile. Indeed, activation of FXR in the liver inhibits 
the activity of CYP7A1, thus causing a reduction of the synthesis of primary bile acids. Further supporting this 
view, 10 reduced the blood concentrations of 7α -hydroxy-4-cholesten-3-one (Fig. 11D), an intermediate in the 
synthesis of primary bile acids, that is widely used to indirectly measure CYP7A1 activity in vivo. The fact that 
7α -hydroxy-4-cholesten-3-one levels were reduced in mice administered with compound 10 further supports 
this compound as a potent FXR agonist.
In summary, in the present study we describe the synthesis and the in vitro and in vivo pharmacological char-
acterization of a novel family of compounds including several potent and selective FXR agonists. These novel 
agents might add utility in the treatment of cholestatic disorders avoiding side effects linked to unwanted activa-
tion of GPBAR1.MethodsChemistry. High-resolution ESI-MS spectra were performed with a Micromass Q-TOF mass spectrometer. 
NMR spectra were obtained on Varian Inova 400, 500 and 700 NMR spectrometers (1H at 400, 500 and 700 MHz, 
13C at 100, 125 and 175 MHz, respectively) equipped with a SUN microsystem ultra 5 hardware and recorded in 
CD3OD (δ H = 3.31 and δ C = 49.0 ppm) and CDCl3 (δ H = 7.26 and δ C = 77.0 ppm). All of the detected signals were 
in accordance with the proposed structures. Coupling constants (J values) are given in Hertz (Hz), and chemical 
shifts (δ ) are reported in ppm and referred to CHD2OD and CHCl3 as internal standards. Spin multiplicities are 
given as s (singlet), br s (broad singlet), d (doublet), or m (multiplet). Through-space 1H connectivities were evi-
denced using a NOESY experiment with mixing times of 400 ms, respectively.
HPLC was performed with a Waters Model 510 pump equipped with Waters Rheodine injector and a dif-
ferential refractometer, model 401. Reaction progress was monitored via thin-layer chromatography (TLC) on 
Alugram silica gel G/UV254 plates. Silica gel MN Kieselgel 60 (70–230 mesh) from Macherey-Nagel Company 
was used for column chromatography.
All chemicals were obtained from Sigma-Aldrich, Inc. Solvents and reagents were used as supplied from 
commercial sources with the following exceptions. Dichloromethane, tetrahydrofuran and triethylamine were 
distilled from calcium hydride immediately prior to use. Methanol was dried from magnesium methoxide as 
follow. Magnesium turnings (5 g) and iodine (0.5 g) were refluxed in a small (50–100 mL) quantity of methanol 
until all of the magnesium has reacted. The mixture was diluted (up to 1 L) with reagent grade methanol, refluxed 
for 2–3 h then distilled under nitrogen. All reactions were carried out under argon atmosphere using flame-dried 
glassware.
The purities of compounds were determined to be greater than 95% by HPLC.synthetic procedures. See the Supporting Information.
Transactivation assay. To evaluate the transcriptional activity of FXR, HepG2 cells were transiently trans-
fected with Fugene HD reagent (Promega) using the followings plasmids: pCMVSPORT-humanFXR, pSG5RXR, 
p(hsp27)TKLUC and pGL4.70, a plasmid containing the Renilla gene used for luciferase normalization. At 24 
h post transfection, cells were stimulated with compounds 7–21 (10 μ M). CDCA (1, 10 μ M) and 6-ECDCA 
(6, 1 μ M) were used as a positive controls. Dose-response curves were performed in HepG2 cells transfected as 
described above and treated with increasing concentrations of 9, 10, 15 and 17 (from 100 nM to 10 µ M).
To investigate GPBAR1 activation, HEK-293T cells were transiently transfected with Fugene HD reagent 
(Promega) using the following vectors: pCMVSPORT6-human GPBAR1, pGL4.29 (Promega), a reporter vector 
containing a cAMP response element (CRE) cloned upstream to the luciferase reporter gene luc2P and pGL4.70. 
At 24 h post transfection, cells were stimulated with compounds 7–21 (10 µ M) and TLCA (2, 10 µ M) were used as 
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a positive controls. Dose-response curves were performed in HEK-293T cells transfected as described above and 
treated with increasing concentrations of 9 and 21 (from 100 nM to 50 µ M). To evaluate the IC50 of compound 10, 
a dose response curve was performed in HEK-293T cells stimulated with 10 µ M TLCA and with increasing con-
centrations of 10: range from 5 to 25 µ M. At 18 h post stimulations, cellular lysate was assayed for luciferase and 
renilla activities using the Dual-Luciferase Reporter assay system (E1980, Promega). Luminescence was measured 
using Glomax 20/20 luminometer (Promega). Luciferase activities were normalized with Renilla activities.
Direct Interaction on FXR by Alphascreen Technology in a Coactivator Recruitment Assay. Anti-GST-coated acceptor beads were used to capture the GST-fusion FXR-LBD, whereas the 
biotinylated-SRC-1 peptide was captured by the streptavidin donor beads. Upon illumination at 680 nm, chem-
ical energy is transferred from donor to acceptor beads across the complex streptavidin-donor/Src-1-biotin/
GSTFXR-LBD/anti-GST-acceptor and a signal is produced. The assay was performed in white, low-volume, 
384-well Optiplates (PerkinElmer) using a final volume of 25 µ L containing final concentrations of 10 nM of 
purified GST-tagged FXR-LBD protein, 30 nM biotinylated Src-1 peptide, 20 µ g/mL anti-GST acceptor beads 
acceptor beads, and 10 µ g/mL of streptavidin donor bead (PerkinElmer). The assay buffer contained 50 mM Tris 
(pH 7.4), 50 mM KCl, 0.1% BSA, and 1 mM DTT. The stimulation times with 1 µ L of tested compound (dissolved 
in 50% DMSO/H2O) were fixed to 30 min at room temperature. The concentration of DMSO in each well was 
maintained at a final concentration of 4%. After the addition of the detection mix (acceptor and donor beads), 
the plates were incubated in the dark for 4 h at room temperature and then were read in an Envision microplate 
analyzer (PerkinElmer).Animal studies. All animal experimental procedures were approved by the Ethics Committee of the 
University of Perugia and by the Italian Health Ministry, according to the Italian guideline for care and use of 
laboratory animals. C57BL6 mice were treated 6 h with compound 10 (15 mg/kg, ip). At the end of the treatment, 
mice were sacrificed and liver and blood samples were collected respectively to perform real-time PCR and bile 
acids quantization.
RT-PCR. Total RNA was extracted using the TRIzol reagent (Life Technologies). First, 1 µ g of RNA was 
purified of the genomic DNA by DNase I treatment (Life Technologies) and random reverse-transcribed with 
Superscript II (Life Technologies) in a 20 µ L reaction volume. Then 10 ng of cDNA was amplified in a final volume 
of 20 µ L in a mix containing 200 nM of each sense/antisense primers and 10 µ L of 2× SYBR Select Master mix 
(Life Technologies). RT-PCR reactions were performed in duplicate and the thermal cycling conditions were: 
2 min at 95 °C, followed by 40 cycles of 95 °C for 20 s, 60 °C for 30 s on Step One Plus Instrument (ABI). The rela-
tive mRNA expression was calculated and expressed as 2−(∆∆Ct). Sense and antisense primer sequences were the 
following: mouse GAPDH, ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mOSTα , cagtggacatagccctcacc and 
gaccaaagcagcagaacaca; mBSEP, aaatcggatggtttgactgc and tgacagcgagaatcaccaag; mSHP, tctcttcttccgccctatca and 
aagggcttgctggacagtta.
Bile acid and 7α-hydroxy-4-cholesten-3-one determinations. See the Supporting Information.References
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www.nature.com/scientificreportsNavigation in bile acid chemical space: discovery of novel FXR and 
GPBARͷ ligandsClaudia Finamoreͷ, Carmen Festaͷ, Barbara Renga͸, Valentina Sepeͷ, Adriana Carino͸, Dario Masulloͷ, Michele Biagioli͸, Silvia Marchianò͸, Angela Capolupo͹, Maria Chiara Monti͹, Stefano Fiorucci͸ & Angela ZampellaͷBile acids are signaling molecules interacting with nuclear receptors and membrane G-protein-coupled receptors. Among these receptors, the farnesoid X receptor (FXR) and the membrane G-coupled 
receptor ȋGPBARͷȌ have gained increasing consideration as druggable receptors and their exogenous dual regulation represents an attractive strategy in the treatment of enterohepatic and metabolic 
disorders. However, the therapeutic use of dual modulators could be associated to severe side effects 
and therefore the discovery of selective GPBARͷ and FXR agonists is an essential step in the medicinal 
chemistry optimization of bile acid scaffold. In this study, a new series of ͼ-ethylcholane derivatives 
modified on the tetracyclic core and on the side chain has been designed and synthesized and their in vitro activities on FXR and GPBARͷ were assayed. This speculation resulted in the identification of 
compound ͽ as a potent and selective GPBARͷ agonist and of several derivatives showing potent dual agonistic activity.
Next to their ancestral roles in lipid digestion and solubilization, bile acids (BAs), the principal constituent of bile, 
are today recognized signaling molecules involved in many physiological functions and these signaling pathways 
involve the activation of several metabolic nuclear receptors, mainly the BAs sensor FXR1,2, and the dedicated 
membrane G-protein-coupled receptor, GPBAR1 (TGR5)3.
Principally, FXR functions as a sensor of bile acid level playing an important role in the regulation of their 
intracellular levels in hepatocytes4. FXR is activated by CDCA (1)1,2,5 and upon CDCA binding, FXR forms a het-
erodimer with the retinoid X receptor (RXR) that binds specific DNA sequences within the promoter regions of 
target genes. The canonical gene expression program activated by FXR leads to the reduction in the intracellular 
bile acid levels by increasing the export of bile acids out of cells, decreasing bile acid uptake and decreasing bile 
acid synthesis6–8. As a consequence, FXR has been identified as an appealing target in the treatment of cholestasis 
disorders such as primary biliary cirrhosis (PBC) and liver steatosis9–11, two severe human conditions in which 
bile acids homeostasis is impaired.
PBC is an immunologically mediated progressive liver disease characterized by the destruction of small 
intrahepatic bile ducts, with accumulation of bile acids in the liver and consequently inflammation, fibrosis, and 
potential cirrhosis. Fatigue and pruritus are the most common symptoms of primary biliary cirrhosis, and both 
can be debilitating in some patients. Cholestasis causes intense, sometimes intolerable, itch leading to scratching, 
excoriation, sleep deprivation, and depression12.
In addition, FXR plays a crucial beneficial role in hepatic triglyceride homeostasis, as well as in glucose 
metabolism and therefore, FXR agonists are also promising for the treatment of non-alcoholic fatty liver disease 
(NASH), dyslipidemia and type 2 diabetes (T2DM)13–16.
In addition to FXR and other nuclear hormone receptors, BAs can also signal through a membrane- recep-
tor (GPBAR1/TGR5/M-BAR)3. The most potent endogenous GPBAR1 activator is TLCA (2) followed by DCA, 
while other BAs are less potent. GPBAR1−/− mice display prolonged cholestasis, exacerbated inflammatory 
response and more severe liver injury after partial hepatectomy17. In addition, in a mouse model of xenobiotic 
(DDC)-induced sclerosing cholangitis, mice overexpressing GPBAR1 showed less liver injury while mice lacking 
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GPBAR1 showed aggravation of inflammation and fibrosis18. Collectively, these findings suggest a critical role of 
GPBAR1 for liver protection against BA overload but activation of GPBAR1 should be also associated with severe 
side effects, especially in the context of impaired bile acid level in the liver.
In fact, GPBAR1 has been recently identified as the physiological mediator of pruritus19, a common symptom 
observed in cholestasis and the severity of this side effect limits the pharmacological utility of dual agonists in the 
treatment of primary biliary cirrhosis (PBC) and related cholestatic disorders.
On the other hand, responses to GPBAR1 activation include increased energy expenditure, improved intes-
tinal motility, glucose metabolism and insulin sensitivity20,21. The latter two occur through the release of the 
glucagon-like peptide 1 (GLP-1) by intestinal L cells upon GPBAR1 activation22. Therefore, the exogenous regu-
lation of this receptor represents an attractive strategy to treat metabolic disorders such as NASH, hypercholes-
terolemia, hypertriglyceridemia, and T2DM23,24. Thus, in the window of metabolic disorders, the development of 
ligands endowed with dual activity toward GPBAR1 and FXR appears to be a promising strategy23–26. In contrast, 
the discovery of highly selective FXR agonists could represent a new frontier in the treatment of primary biliary 
cirrhosis (PBC) and related cholestatic disorders where the concomitant activation of GPBAR1 could increase 
patient risk for adverse side effects. Indeed, results from PBC phase II clinical trial with 6-ECDCA/OCA (3), a 
potent semi-synthetic steroidal FXR agonist27, have shown that while the compound exerts benefit, its use has 
associated with pruritus. In fact, up to 40% of PBC patients halted the treatment due to the severity of itching in 
one trial and approx. 80% of patients experienced the symptoms. The reason why OCA causes itching is unclear. 
However, this agent is almost equally potent on FXR and GPBAR1 28,29 and it is predictable that the severity of this 
side effect could prevent its use in stage III and IV PBC patients30.
Medicinal chemistry on 6-ECDCA scaffold and on bile acid scaffold has produced several derivatives modified 
on the side chain in the length and in the nature of the end-group and on the tetracyclic core11,31–33. Indeed these 
derivatives cover the same chemical space of BAs that are intrinsically promiscuous toward FXR and GPBAR1 
and therefore, with few exceptions, this kind of speculation mainly afforded dual modulators33. The most inter-
esting results have been obtained with compounds 4–6 (Fig. 1).
The replacement of the negative charged end group with a neutral polar group produced derivative 4, 
again a potent dual agonist and the above activity was also maintained by the corresponding nor-derivative 5, 
with one carbon less on the side chain. Of interest compound 5 attenuates liver damage in animal models of 
non-obstructive cholestasis without inducing itching34. Finally, speculation on stereochemical modification on 
ring B produced 6, a C-24 alcohol that represents the first example of ursodeoxycholane derivative substituted 
at C-6 with a β -oriented ethyl group. Pharmacological assays demonstrated that this derivative is a rather potent 
ligand for GPBAR1 (EC50 1.03 µ M) failing in transactivating FXR at any concentration tested
26.
Recently we have also demonstrated that compound 6 exerts portal pressure-lowering effects in rodent models 
of portal hypertension by directly regulating the expression/activity of cystathionine γ -lyase (CSE) and endothe-
lial nitric oxide synthases (eNOS) in liver sinusoidal endothelial cells (LSEC), thus affirming this compound as a 
novel approach to attenuate the hemodynamic changes in patients with liver cirrhosis35.
In addition, in an our recent contribution, we have extended the structure-activity relationship on C24 
6-ethylcholane scaffold modifying the hydroxyl group at C-3 and demonstrating that the elimination or the inver-
sion of the above functionality on ring A could shift the activity toward FXR36.
Prompted by these promising results, we decided to expand our investigation proceeding in the modification 
of the side chain length on the 6-ethylcholane scaffold. As shown in the Fig. 2, a small library of C23 6-substituted 
cholane derivatives, compounds 7–15, have been prepared.
Figure 1. CDCA and TLCA, the most potent endogenous activators of FXR and GPBAR1, respectively. 
6-ECDCA and 6α -ethylchenodeoxycholanol derivatives 4 and 5 as dual ligands and EUDCOH (6), a selective 
GPBAR1 agonist.
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3Scientific RepoRts | 6:͸Ϳ͹͸Ͷ | DOI: ͷͶ.ͷͶ͹;/srep͸Ϳ͹͸ͶIn this framework, the effects of the stereochemical arrangement of the cholane C-6/C-7 positions and the substituents adorning the C-3 position and the C-23 side chain end group (OH or COOH) have been explored in term of potency/selectivity toward FXR and GPBAR1.In addition, the chemical diversity of available bile acid receptor modulators have been increased preparing bis-homo 6-ethylcholane derivatives 16–19. Pharmacological investigations resulted in the identification of com-pounds 7 and 19 as a potent and selective GPBAR1 agonist and a potent dual agonist respectively.ResultsIn the synthesis of 6-ethyl norcholane derivatives 7–15, the first step was the preparation of the key intermediate 7-keto-norLCA methyl ester 22 from 7-KLCA (Fig. 3). A reaction sequence comprising Fisher’s esterification with formic acid and perchloric acid generated the formiate derivative 20 that was subjected to a Beckmann rear-rangement by treatment with sodium nitrite in a trifluoroacetic anhydride/trifluoroacetic acid mixture obtaining the 23-nitrile derivative 2137. Prolonged alkaline hydrolysis afforded the corresponding carboxylic acid that was in turn transformed in the methyl ester derivative 22 by methanol/p-toluensulfonic acid treatment (66% yield from 7-KLCA).Preparation of ͹α-hydroxy-ͼ-ethylnorcholane derivatives. Acetylation at C-3 on 22 and aldolic addition to a silyl enol ether intermediate generated the intermediate 23 (60% over three steps) that was hydro-genated at the exocyclic double bond (H2 on Pd(OH)2) affording exclusively the 6β -ethyl group in the compound 24 (quantitative yield). Treatment of 24 with an excess of NaBH4 in methanol followed by LiBH4 reduction on the crude reaction product to secure the reduction at the methyl ester on the side chain, gave the concomitant deacetylation at C-3 and reduction at C-7 keto and at C-23 methyl ester groups (Fig. 4).HPLC purification gave the main product 7 and small amount of its epimer at C-7, compound 9. When inter-mediate 24 was treated with a stoichiometric amount of NaBH4, the reduction occurred exclusively at C-7 keto group giving the methyl ester 25, that was subjected to basic hydrolysis furnishing the carboxylic acid 8 in 82% over two steps.Intermediate 23 was also used as starting material in the preparation of 10 and 11. Sodium borohydride/LiBH4 treatment on 23 proceeded in a stereoselective manner, affording the exclusive formation of 7β -hydroxyl derivative as judged by the shape of H-7 as a doublet (J = 9.8 Hz) which is consistent with an axial disposition for this proton, and therefore with the β -orientation of the hydroxyl group on ring B. Dipolar couplings H-7/H-24 
Figure 2. 6-Ethylcholane derivatives generated in this study. 
Figure 3. Preparation of 7-keto-norLCA methyl ester (22). Reagents and conditions: (a) HCOOH, HClO4; (b) 
TFA, trifluoroacetic anhydride, NaNO2; (c) KOH 30% in MeOH/H2O 1:1 v/v, 66% over three steps; (d) p-TsOH, 
MeOH dry, quantitative yield.
www.nature.com/scientificreports/
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and Me-25/H-5 in the NOESY spectrum allowed definition the E configuration for the exocyclic double bond as 
depicted in 10. Hydrogenation on Pd(OH)2 catalyst afforded derivative 11 with the ethyl group at C-6 α -oriented.
Preparation of ͹-deoxy- and ͹β-hydroxy-ͼα-ethylnorcholane derivatives. In the preparation of 
3-deoxy- and 3β -hydroxy-6-ethylnorcholane derivatives 12–15, a convergent protocol was applied starting from 
the methyl ester 24, that was first treated with MeONa in methanol to effect de-acetylation at C-3 and inversion 
at C-6 and then with tosyl chloride to afford 26 in 73% yield over two steps (Fig. 5).
Elimination by LiBr/Li2CO3 treatment and hydrogenation of the unsaturated-ring A transient intermediate 
furnished 27 that was used as starting material for the preparation of compounds 12 and 13.
LiBH4 treatment produced the concomitant reduction at C-24 methyl ester and at C-7 carbonyl group furnish-
ing 12 whereas alkaline hydrolysis of the methyl ester followed by LiBH4 treatment gave 10 in high chemical yield.
Finally, treatment of the tosyl derivative 26 with potassium acetate in DMF/H2O afforded inversion at C-3 on 
28. Reduction at C-7 and C-24 with LiBH4 and hydrolysis at methyl ester group on the side chain gave 14 and 15, 
respectively.Preparation of bis-homo ͼ-ethylcholane derivatives. In the preparation of bis-homo-6-ethylcholane 
derivatives 16, a four-steps reaction sequence on 29, previously prepared in our laboratory25,26, including pro-
tection of the alcoholic functions at C3 and C7, reduction of the side chain methyl ester, and subsequent one pot 
Swern oxidation/Wittig C2 homologation, gave the protected methyl ester of ∆ 24,25 bis-homoECDCA 31 (Fig. 6).
Side chain double bond hydrogenation and alcoholic function deprotection gave the methyl ester 16 that was 
used as starting material in the preparation of the carboxylic acid 17 and the corresponding alcohol 18 through 
treatment with LiOH and LiBH4, respectively. Chemoselective sulfation at C-26 hydroxyl group on a small aliquot 
of 18 gave the corresponding sulfate derivative 19 38.Discussion and Conclusion
Derivatives 7–19 were tested in the luciferase reporter assays on HepG2 and HEK-293T cells transfected with 
FXR and GPBAR1, respectively. Data shown in Fig. 7, panel A, reporting the results of the transactivation assay 
on FXR, reaffirm the 6α /7α stereochemical arrangement around ring B as the most important feature in FXR 
activity with derivatives 7–11, with one or two substituents on ring B in β configuration, devoid of any activity at 
10 µ M dose. Of interest is the behavior of derivatives 12–15, with both substituents on ring B in α -configuration 
and a shortened (C23) side chain. In a cross comparison between the above compounds, it is quite evident that 
the presence of a negative charge on the side chain favors the 3-deoxy derivatives (compare 13 with COOH vs 12 
with CH2OH), whereas the alcoholic function at C-24 improves FXR activity of the corresponding 3β -hydroxyl 
Figure 4. Synthesis of 3α-hydroxy-6-ethylnorcholane derivatives. Reagents and conditions: (a) acetic 
anhydride, pyridine; (b) DIPA, n-BuLi, TMSCl, TEA dry, THF dry − 78 °C; (c) acetaldehyde, BF3(OEt)2, CH2Cl2, 
− 60 °C, 60% over three steps; (d) H2, Pd(OH)2, THF/MeOH 1:1, quantitative yield; (e) NaBH4, MeOH dry, 0 °C; 
(f) LiBH4, MeOH, THF dry, 0 °C, 77% over two steps; (g) NaBH4, MeOH; (h) LiBH4, MeOH dry, THF, 0 °C, 85% 
over two steps; (i) H2, Pd(OH)2, THF:MeOH 1:1 v/v, quantitative yiel; (j) NaBH4, MeOH dry, 0 °C; (k) NaOH, 
MeOH:H2O 1:1 v/v, 82% over two steps.
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5Scientific RepoRts | 6:͸Ϳ͹͸Ͷ | DOI: ͷͶ.ͷͶ͹;/srep͸Ϳ͹͸Ͷderivative (compare 14 with CH2OH vs 15 with COOH). In addition, results on derivatives 16–19 demonstrate that side chain elongation on the 6-ethyl scaffold could be instrumental in generation potent FXR agonists. In this subset, the nature of the side chain end group produces a remarkable effect in FXR transactivation with the sulfate derivative 19, the most potent FXR agonist generated in this study.Results of transactivations of CREB-responsive elements in HEK-293T transiently transfected with the mem-brane bile acid receptor GPBAR1 are showed in Fig. 7, panel B. Compounds 7 and 8, with both the ethyl and the hydroxyl groups on ring B β -oriented, were demonstrated inducers of cAMP-luciferase reporter gene, with 7 showing a potency similar to that of TLCA (2), the most potent endogenous GPBAR1 agonist. As expected, all derivatives with both substituents on ring B in α -configuration are endowed with GPBAR1 agonistic activity, and 
Figure 5. Synthesis of 3-deoxy- and 3β-hydroxy-6α-ethylnorcholane derivatives. Reagents and conditions: 
(a) MeONa, MeOH; (b) p-TsCl, pyridine, 73% over two steps; (c) LiBr, Li2CO3, DMF, reflux, (d) H2, Pd(OH)2, 
THF/MeOH 1:1, room temperature, quantitative yield over two steps; (e) LiBH4, MeOH dry, THF, 0 °C, 70%;  
(f) NaOH, MeOH:H2O 1:1 v/v; (g) LiBH4, MeOH dry, THF, 0 °C, 92% over two steps; (h) CH3COOK, 
DMF:H2O 5:1 v/v; (i) NaOH, MeOH:H2O 1:1 v/v; (j) LiBH4, MeOH dry, THF, 0 °C, 58% over two steps;  
(k) LiBH4, MeOH dry, THF, 0 °C, 57%.
Figure 6. Preparation of bis-homo 6-ethylcholane derivatives. Reagents and conditions: (a) 2,6-lutidine, 
t-butyldimethylsilyl trifluoromethanesulfonate, CH2Cl2, 0 °C; (b) LiBH4, MeOH dry, THF, 0 °C, 68% over two 
steps; (c) DMSO, oxalyl chloride, TEA dry, CH2Cl2, − 78 °C then methyl(triphenylphosphoranylidene)acetate, 
79%; (d) H2, Pd(OH)2/C Degussa type, THF/MeOH 1:1, quantitative yield; (e) HCl 37%, MeOH, 88%; (f) 
NaOH 5% in MeOH/H2O 1:1 v/v, 89%; (g) LiBH4, MeOH dry, THF, 0 °C, 78%; (h) Et3N.SO3, DMF, 95 °C, 25%.
www.nature.com/scientificreports/
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the above activity is quite independent of the length and the functionalization of the side chain and by the substi-
tution at C-3 with 3α -, 3β -hydroxy and 3-deoxy derivatives sharing a similar behavior. Even if, by comparing FXR 
and GPBAR1 transactivation results, derivatives 12–19 are to be considered dual agonists, there is a considerable 
difference in GPBAR1 activity of C26 derivatives 16–19. It is quite evident that the presence of a neutral (COOMe 
in 16) or a non-charged polar group (CH2OH in 18) on the elongated side chain is preferable respect to a negative 
charged end group such as the COOH in 17 and the sulfate in 19.
The relative potency of selected members of this novel family was then investigated by a detailed measure-
ment of the concentration-response curve of the 3-deoxy C-23 carboxylic acid derivative 13, the 3β -hydroxyl 
C-23 alcohol 14 and the C-26 sulfate derivative 19, all sharing the 6α /7α configuration, on FXR and GPBAR1 
transactivation.
As illustrated in Figs 8 and 9, compounds 13, 14, and 19 transactivate FXR with an EC50 of 2.3 µ M, 5.3 µ M and 
1.7 µ M, respectively. In addition, 13, 14, and 19 transactivate GPBAR1 with EC50 of 4.3 µ M, 1.0 µ M and 0.95 µ M, 
respectively. Combining these data, compound 19 represents the most potent FXR/GPBAR1 dual agonist identi-
fied in this study. Finally, compound 7 exerted a concentration-dependent effect on activation of cAMP respon-
sive element in HEK-293T cells transfected with GPBAR1 with an EC50 of 0.91 µ M.
The ability of compound 19, the most potent FXR agonist in these series, in the recruitment of the coactivator 
SRC-1 was also measured through Alpha screen technology. CDCA (1) and 6-ECDCA (3) were used as positive 
controls at 2 µ M concentration and the effect of 6-ECDCA (3) was settled as 100%. As shown in Fig. 10, panel A, 
compound 19 showed an activity in the recruitment of SRC-1 co-activator at least comparable, if not better, to 
that measured for 3, thus confirming the transactivation results. Interestingly, the presence of the non-conjugable 
functional group such as the sulfate group on the side chain instead of the carboxyl end group as in 6-ECDCA (3) 
points the attention on the positive pharmacokinetic properties of compound 19 and therefore on its therapeuti-
cal potential in liver FXR mediated diseases. On the other hand, panel A in Fig. 10 shows compounds 7, 9 and 10 
completely unable to recruit SRC-1 in cell free Alpha screen assay, thus excluding any pharmacokinetic elements 
in their FXR inactivity on cellular luciferase assays (Fig. 7, panel A) and indirectly reaffirming compound 7 as a 
selective GPBAR1 agonist (Fig. 7, panel B).
RT-PCR further confirmed 19 as a dual FXR/GPBAR1 agonist and the GPBAR1 mediated pharmacological 
effect of compound 7. As shown in Fig. 10 panels B–D, 19 was able to induce the expression of BSEP and OSTα , 
two canonical FXR targeted genes, whereas both compounds increased pro-glucagon gene expression in GLUTAg 
cells. The observed 2 fold of BSEP upregulation as well as the robust induction of OSTα mRNA is consistent with 
the activation of the FXR-mediated effect by compound 19 39.
In summary, a series of 6-ethylcholane derivatives were designed and synthesized and all the newly synthe-
sized compounds were evaluated in vitro for their activity towards FXR and GPBAR1. Concerning the structural 
features, α -substituents introduced at C-6 and C-7 positions play a significant role in FXR and GPBAR1 activity, 
with all derivatives showing this configurational disposition able to transactivate both receptors. Even if the sul-
fate derivative 19 is the most potent FXR agonist discovered in this study, the dual modulation is a general trend 
within compounds 12–19, independently by the length and the functional group of the side chain as well as by the 
substitution at C-3. On the contrary, modification at the configurational disposition of one or both substituents 
Figure 7. Agonism on bile acid receptors by transactivation assay. (A) HepG2 cells were transfected with 
pSG5-FXR, pSG5-RXR, pCMV-β gal, and p(hsp27)TKLUC vectors. Cells were stimulated with compounds 
7–19 (10 µ M). CDCA (1, 10 µ M) and 6-ECDCA (3, 1 µ M) were used as a positive control. (B) HEK-293T cells 
were co-transfected with GPBAR1 and a reporter gene containing a cAMP responsive element in front of the 
luciferase gene. Cells were stimulated with 7–19 (10 µ M). TLCA (2, 10 µ M) was used as a positive control. 
Luciferase activity served as a measure of the rise in intracellular cAMP following activation of GPBAR1. In 
both panels, results are expressed as mean ± standard error. * p < 0.05 versus not treated cells (NT).
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Figure 8. Concentration-response curve of 13, 14, and 19 on FXR. HepG2 cells were transfected with 
FXR as described above and used in a luciferase reporter assay. Twenty-four hour post transfection cells were 
stimulated with increasing concentrations of each agent: range from 100 nM to 25 µ M. Results are expressed as 
mean  ± standard error.
Figure 9. Concentration-response curve of compounds 13, 14 and 19 on FXR. HepG2 cells were transfected 
with FXR as described above and used in a luciferase reporter assay. Twenty-four hour post transfection 
cells were stimulated with increasing concentrations of each agent: range from 100 nM to 25 µ M. Results are 
expressed as mean ± standard error.
Figure 10. (A) Coactivator recruitment assay measuring a direct interaction of FXR with SRC-1; ligands at 
2 µM. Results are expressed as percentage of the effect of 3 arbitrarily settled as 100%. NT is referred to the 
experiment in absence of ligand. Results are expressed as mean ± standard error. (B,C) Real-time PCR analysis 
of mRNA expression on FXR target genes BSEP (B), and OSTα (C) in HepG2 cells primed with 10 µ M  
of compound 19. CDCA (1) was used as a positive control at 10 µ M. (D) Real-time PCR analysis of mRNA 
expression of GPBAR1 target gene Pro-glucagon in GLUTAg cells stimulated with 10 µ M of compounds 7 and 
19, and TLCA (2) used as a positive control at 10 µ M. Values are normalized to GAPDH and are expressed 
relative to those of not treated cells (NT) which are arbitrarily settled to 1. The relative mRNA expression is 
expressed as 2(− ∆ ∆ Ct).
www.nature.com/scientificreports/
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on ring B is clearly deleterious in term of FXR activation but represents a promising strategy in the identification 
and development of selective GPBAR1 agonists with compound 7, the most potent GPBAR1 activator identified 
in this study.MethodsChemistry. Specific rotations were measured on a Jasco P-2000 polarimeter. High-resolution ESI-MS spectra 
were performed with a Micromass Q-TOF mass spectrometer. NMR spectra were obtained on Varian Inova 400, 
500 and 700 NMR spectrometers (1H at 400 and 700 MHz, 13C at 100 and 175 MHz, respectively) equipped with a 
SUN microsystem ultra5 hardware and recorded in CD3OD (δ H = 3.30 and δ C = 49.0 ppm) and CDCl3 (δ H = 7.26 
and δ C = 77.0 ppm). All of the detected signals were in accordance with the proposed structures. Coupling con-
stants (J values) are given in Hertz (Hz), and chemical shifts (δ ) are reported in ppm and referred to CHD2OD 
and CHCl3 as internal standards. Spin multiplicities are given as s (singlet), br s (broad singlet), d (doublet), or 
m (multiplet). Through-space 1H connectivities were evidenced using NOESY experiment with mixing time of 
400 ms. HPLC was performed with a Waters Model 510 pump equipped with Waters Rheodine injector and a 
differential refractometer, model 401. Reaction progress was monitored via thin-layer chromatography (TLC) on 
Alugram silica gel G/UV254 plates. Silica gel MN Kieselgel 60 (70–230 mesh) from Macherey-Nagel Company 
was used for column chromatography. All chemicals were obtained from Sigma-Aldrich, Inc. Solvents and rea-
gents were used as supplied from commercial sources with the following exceptions. Tetrahydrofuran and tri-
ethylamine were distilled from calcium hydride immediately prior to use. Methanol was dried from magnesium 
methoxide as follow. Magnesium turnings (5 g) and iodine (0.5 g) are refluxed in a small (50–100 mL) quantity of 
methanol until all of the magnesium has reacted. The mixture is diluted (up to 1 L) with reagent grade methanol, 
refluxed for 2–3 h then distilled under nitrogen. All reactions were carried out under argon atmosphere using 
flame-dried glassware. The purities of compounds were determined to be greater than 95% by HPLC.Synthetic procedures. See the Supporting Information.
Transactivation assay. For FXR and GP BAR1 mediated transactivations, HepG2 cells and HEK293T cells 
were transfected as described previously25. At 24 h post-transfection, cells were stimulated 18 h with 10 µ M CDCA 
(1), TLCA (2), 6-ECDCA (3) and compounds 7–19. After treatments, 20 µ L of cellular lysates were read using 
Dual Luciferase Reporter Assay System (Promega Italia s.r.l., Milan, Italy) according manufacturer specifica-
tions using the Glomax 20/20 luminometer (Promega Italia s.r.l., Milan, Italy). To evaluate GPBAR1 mediated 
transactivation, HEK-293T cells were transfected with 200 ng of human pGL4.29 (Promega), a reporter vector 
containing a cAMP response element (CRE) that drives the transcription of the luciferase reporter gene luc2P, 
with 100 ng of pCMVSPORT6-human GPBAR1, and with 100 ng of pGL4.70. Dose-response curves were per-
formed in HepG2 and HEK-293T cells transfected as described above and then treated with increasing concentra-
tions of compounds 7 (1–10 µ M), 13, 14 and 19 (100 nM–25 µ M). At 18 h post stimulations, cellular lysates were 
assayed for luciferase and Renilla activities using the Dual-Luciferase Reporter assay system (E1980, Promega). 
Luminescence was measured using Glomax 20/20 luminometer (Promega). Luciferase activities were normalized 
with Renilla activities.
RNA isolation and RT-PCR. Total RNA was isolated from HepG2 or GLUTAg cells using the TRIzol rea-
gent according to the manufacturer’s specifications (Invitrogen). One microgram of purified RNA was treated 
with DNase-I and reverse transcribed with Superscript II (Invitrogen). For Real Time PCR, 10 ng template was 
dissolved in 25 µ L containing 200 nmol/L of each primer and 12.5 µ L of 2 × SYBR FAST Universal ready mix 
(Invitrogen). All reactions were performed in triplicate, and the thermal cycling conditions were as follows: 2 min 
at 95 °C, followed by 40 cycles of 95 °C for 20 s and 60 °C for 30 s in iCycler iQ instrument (Biorad). The relative 
mRNA expression was calculated and expressed as 2-(∆ ∆ Ct). Forward and reverse primer sequences were the 
following: human GAPDH, gaaggtgaaggtcggagt and catgggtggaatcatattggaa; human OSTα , tgttgggccctttccaatac 
and ggctcccatgttctgctcac; human BSEP, gggccattgtacgagatcctaa and tgcaccgtcttttcactttctg; mouse GAPDH, ctgag-
tatgtcgtggagtctac and gttggtggtgcaggatgcattg; mouse Pro-glucagon, tgaagacaaacgccactcac and caatgttgttccggttcctc.Direct interaction on FXR by Alpha screen technology in a coactivator recruitment assay. 
Anti-GST-coated acceptor beads were used to capture the GST-fusion FXR-LBD whereas the biotinylated-SRC-1 
peptide was captured by the streptavidin donor beads. Upon illumination at 680 nm, chemical energy is trans-
ferred from donor to acceptor beads across the complex streptavidin-Donor/Src-1-Biotin/GSTFXR-LBD/
Anti-GST-Acceptor and a signal is produced. The assay was performed in white, low-volume, 384-well Optiplates 
(PerkinElmer) using a final volume of 25 µ L containing final concentrations of 10 nM of purified GST-tagged 
FXR-LBD protein, 30 nM biotinylated Src-1 peptide, 20 µ g/mL anti-GST acceptor beads acceptor beads and 10 µ 
g/mL of streptavidin donor bead (PerkinElmer). The assay buffer contained 50 mM Tris (pH 7.4), 50 mM KCl, 
0.1% BSA, and 1 mM DTT. The stimulation times with 1 µ L of tested compound (dissolved in 50% DMSO/H2O) 
were fixed to 30 min at room temperature. The concentration of DMSO in each well was maintained at a final 
concentration of 4%. After the addition of the detection mix (acceptor and donor beads) the plates were incubated 
in the dark for 4 h at room temperature and then were read in Envision microplate analyzer (PerkinElmer).References
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Abstract The presence of a halogen atom in the proximity
of a homoallylic amine, obtained by asymmetric addition
of allylzinc bromide to the corresponding tert-butyl
sulfinimine, makes them versatile building blocks suit-
able to participate in several palladium-catalyzed pro-
cesses, such as the intramolecular Heck reaction or the
Sonogashira cross-coupling. The thus obtained ortho-
alkynyl derivatives display two unsaturated functional
groups which may be further modified by means of the
intramolecular Pauson–Khand reaction or the ring-closing
enyne metathesis. In this way, a variety of benzo-fused
amines can be obtained in 2–3 steps from readily available
starting materials.
Keywords Homoallylic amine ! Pauson–Khand reaction !
Sonogashira cross-coupling ! Intramolecular Heck
reaction ! Diversity-oriented synthesis ! Asymmetric
synthesis
Introduction
Diversity-oriented synthesis (DOS) aims to provide maxi-
mum coverage of the chemical space, from a common
precursor, by using the minimum number of steps (usually
4–5) [1–6]. Usually, the key for the success of such a
strategy is the identification of a suitable substrate carrying
specific functional groups at appropriate positions. In this
way, the product of a given transformation becomes the
substrate of the subsequent. These functional groups must
be able to participate in as many different reactions as
possible, thus increasing the achievable molecular com-
plexity. In this context, during the last few years, our group
has studied the use of 2-halobenzaldehyde derivatives as
common building blocks for the asymmetric synthesis of
benzo-fused carbo—[7–11] and heterocycles [12–15]
(Scheme 1) [16].
The use of this strategy has allowed us to synthesize
interesting building blocks such as fluorinated [13, 14] and
non-fluorinated isoindolines [14], indanones [11] and, more
recently, fluorinated isoindolinones [12] and amino steroid
derivatives [8]. In the course of the latter study, we found
that significant amounts of an undesired intramolecular
Heck reaction by-product 4a was obtained upon Sono-
gashira cross-coupling of homoallylic o-bromobenzylsul-
finamide 3a (Scheme 2). The formation of 4a was
unambiguously determined by the presence of two char-
acteristic methylene protons at 5.1 and 5.5 ppm in the 1H-
NMR spectrum, as well as the corresponding signal at
104.4 ppm at the 13C-NMR spectrum.
In our previous communication [7], the formation of this
undesired by-product could be suppressed by increasing the
amount of alkyne (from 3 to 5 equivalents) and the reaction
concentration (from 0.1 to 0.5 M), thus favoring the
intermolecular Sonogashira cross-coupling over the
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intramolecular Heck reaction. In this report, we describe
the optimization of the intramolecular Heck reaction along
with the implementation of a one-pot condensation/asym-
metric allylation/intramolecular PKR protocol for the
synthesis of tricyclic amines. In addition, the RCEYM
reaction of intermediates 3 will also be discussed.
Results and discussion
Intramolecular Heck reaction
Obtaining the undesired intramolecular Heck reaction
product as a by-product of the Sonogashira reaction of
substrate 1a was the starting point for trying to optimize
this process, as mentioned in the introduction (Scheme 2).
Of course, we started by removing the no-longer necessary
alkyne and the CuI from the reaction medium (Table 1,
Entry 1). By doing so, we obtained an overall moderate
yield; however, a significant amount of it in the form of the
isomerized product 6. Replacing Et3N with an inorganic
base (Ag2CO3) suppressed the formation of the undesired
isomerized product, giving exclusively the desired product
in moderate yield (Table 1, Entry 2). The use of microwave
irradiation both in toluene and THF did not bring any
beneficial effect, nor did the addition of external ligands
(Table 1, Entries 3–6). Finally, the use of an equimolar
ratio of Et3N and Ag2CO3 as base gave rise to an optimized
70 % yield (Table 1, Entry 7). It should be noted that
recently, Yus et al. [17] have described similar reaction
conditions for this transformation.
Once an optimized set of reaction conditions had been
established, a small library of 3-methylene-1-aminoindane
derivatives were synthesized in moderate to good yields
(Scheme 3). For substrate 1b, the isomerized product 4b0
was obtained in 68 % yield.1
Aiming toward a more sustainable and practical
methodology, and in view of our own experience in the use
of one-pot reactions in the context of DOS, we then studied
the one-pot condensation/asymmetric allylation/Heck
reaction sequence on 2-iodobenzaldehyde 8a achieving the
desired product in 70 % yield over the three steps and as a
single diastereoisomer (Scheme 4).
In order to increase the range of molecular structures
available through our methodology, two simple transfor-
mations were carried out on the exocyclic double bond of
the unsubstituted substrate 4a, namely the hydrogenation
and the oxidative cleavage (Scheme 5). As expected, the
Pd/C-catalyzed heterogeneous hydrogenation of the double
bond proceeded with high anti selectivity affording the cis
product 9 in excellent yield (Scheme 5). On the other hand,
the oxidative cleavage of the exo-methylene afforded the
3-aminoindanone derivative 10 in good yield (Scheme 5).
Note that the –SOtBu group was concomitantly oxidized to
the –SO2tBu group under the reaction conditions. Com-
pound 10 was further transformed into cis 1,3-aminoalco-
hol 11 by BH3!THF-mediated diastereoselective reduction
of the ketone (Scheme 5).
The relative configuration of the chiral centers in
products 9 and 11 was determined by means of 2D-NMR
NOESY experiments, which showed cross peaks between
the NH and the CH3 protons, and also between the two
benzylic methyne protons Ha and Hb (Fig. 1). In both
cases, these observations are in agreement with a cis
arrangement. For compound 9, this result could be foreseen
since catalytic heterogeneous hydrogenations usually pro-
ceed on the less hindered face of the olefin, in this case anti
to the bulky NHSOtBu group, resulting in the observed cis
product.
Ring-closing enyne metathesis (RCEYM)
Taking advantage of the densely functionalized interme-
diates 3 synthesized in our recent report [8], we envisioned
to expand their reactivity to other well-established trans-
formations of enynes. Among these, RCEYM has become a
powerful tool for the creation of carbo- and heterocycles of
several ring sizes with the added value of presenting an
exocyclic conjugated vinyl moiety amenable for subse-
quent transformations [18].
Using 3a as a model substrate, an optimization of the
reaction conditions was carried out using our recently
reported parent transformation on the corresponding
Scheme 1 2-Halobenzaldehyde in DOS
1 Under the reaction conditions described by Yus the isomerized
product is also obtained, see Sirvent et al. [17].
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alcohols as starting point (second generation Grubbs’ cat-
alyst [Ru-II], DCM, 45 "C, 1,7-octadiene) (Table 2)
[19, 20].
Under the original reaction conditions, a moderate 55 %
yield was obtained (Table 2, entry 1). We envisioned that
this modest result might be the result of an inefficient
in situ ethylene formation along with some catalyst
deactivation. In an attempt to tackle these issues, we car-
ried out the reaction in a sealed tube and added two por-
tions of both the catalyst and 1,7-octadiene, obtaining an
excellent yield (Table 2, entry 2). The reaction time could
be shortened by rising the temperature, however, at
expense of chemical yield (Table 2, entry 3). Finally, while
the addition of a Lewis acid improved the catalytic activity
Table 1 Optimization of the intramolecular Heck reaction conditions
Entry Catalyst Ligand Base Solvent T ("C) 1 (%) 4 (%) 5 (%) 6 (%)
1 Pd(OAc)2 PPh3 Et3N Tol. 120 – 25 – 31
2 Pd(OAc)2 PPh3 Ag2CO3 Tol. 120 – 66 – –
3 Pd(dba)2 PPh3 Ag2CO3 Tol. 120 MW – 50 – –
4 Pd(dba)2 PPh3 Ag2CO3 THF 100 MW – 25 25 –
5 Pd(dba)2 XANP Ag2CO3 THF 100 MW – 37.5 12.5 –
6 Pd(dba)2 JOHNP Ag2CO3 THF 100 MW 80 – – –
7 Pd(OAc)2 PPh3 Et3N/Ag2CO3 Tol. 90 – 70 – –
Scheme 3 Scope and
limitations
Scheme 2 Preliminary results
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(Table 2, entry 4), the results were not as satisfactory as the
ones obtained in entry 2. Hence, the reaction conditions
shown in entry 2 were used for the study of the reaction
scope.
With a small library of enynes 12 from our previous
study in hand [8], the scope of this transformation was
studied using the optimized conditions shown in Table 2,
entry 2 (Scheme 6).
Substitution at both aromatic rings is well tolerated
without significantly modifying the high chemical yield
(Scheme 6, 12a-e). On the other hand, replacing the aryl
substituent at the triple bond by an alkyl one results in a
significant drop, although still obtaining a synthetically
useful 50 % yield (Scheme 6, 12f). The better performance
of aryl- over alkyl-substituted triple bonds might be
rationalized by the higher stabilization of the resulting
diene by conjugation with the aromatic ring, since RCEYM
is an enthalpy driven transformation.
With the aim of further increasing the structural com-
plexity and diversity affordable with our strategy, a Diels–
Alder reaction of diene 12a with dimethyl acetylene
dicarboxylate (DMAD) was envisioned. However, no
reaction was observed even after prolonged heating in DCE
(Scheme 7).
We believe the reason behind this unexpectedly low
reactivity of diene 12a in Diels–Alder reactions could be its
preference for the s-trans over the required s-cis confor-
mation, due to the steric hinderance between the ortho
protons at the aromatic substituents of the dienic moiety,
which would clash by adopting such conformation (Fig. 2).
Study of the one-pot condensation/asymmetric
allylation/intramolecular Pauson–Khand reaction
(PKR) sequence
Finally, building on our own experience in the area of one-
pot transformations with Ellman’s sulfinimides [9], we
envisioned setting up a one-pot protocol for our recently
reported asymmetric synthesis of tricyclic enones by means
of intramolecular PKR [8]. We started our study using the
simplest starting material and tackling the most ambitious
four-step one-pot transformation (condensation/allylation/
Scheme 4 One-pot condensation/asymmetric allylation/Heck reac-
tion sequence
Scheme 5 Transformations on
the 1-amino-3-methyleneindane
skeleton
Fig. 1 Assignment of the relative stereochemistry of products 9 and
11
Table 2 Optimization of the RCEYM reaction conditions
Entry T ("C) 12a (%)
1 45 55
2a,b,c 45 [99
3a,b,c 90 73
4a,d 45 84
a Sealed tube, b 2 9 5 mol % catalyst loading, c 2 9 4 equiv 1,7-
octadiene, d 1 equiv Ti(OEt)4
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Sonogashira/PKR). However, although the desired product
13a was detected in the crude reaction mixture, most of the
recovered material was identified as 1a, suggesting that the
Sonogashira reaction was not fully compatible with the
reaction medium from the previous condensation/allylation
steps (Scheme 8).
Since the Sonogashira coupling seemed to be the bot-
tleneck for this one-pot procedure, we decided to carry out
this step independently and then run the one-pot procedure
on the corresponding o-alkynylbenzadehyde derivatives
14a, b (Scheme 9). In both examples, the chemical yield of
the one-pot procedure is significantly lower than the cor-
responding stepwise protocol (Scheme 9). The one-pot
methodology, though, benefits from operational simplicity.
Regarding the diastereoselectivity, for 14a, a diminished dr
was obtained, as expected (Scheme 9). This is due to the
dependence of the diastereoselectivity with the substitution
at the triple bond that we described in our previous report
[8]. The isolation of a single diastereoisomer for 14b might
be due to the loss of small quantities of minor
diastereoisomers during purification, which would also
account for the low chemical yield (Scheme 9).
Conclusions
In recent years, 2-iodobenzaldehyde has shown its superior
performance as a substrate for diversity-oriented synthesis.
In this report, we have further increased the molecular
variability accessible from this readily available starting
material. More specifically, the asymmetric allylation of
the corresponding Ellman’s imines followed by
intramolecular Heck reaction affords 3-methylene-1-
aminoindane derivatives. On the other hand, the introduc-
tion of al alkynyl group at the ortho-position affords sub-
strates suitable for a RCEYM reaction achieving
conjugated dienes. One-pot procedures have been devel-
oped for both the asymmetric allylation/intramolecular
Heck reaction and the condensation/asymmetric allylation/
Pauson–Kahnd reaction sequence.
Experimental section
General procedure for the intramolecular Heck
reaction
Scheme 6 Scope and limitations
Scheme 7 Failed Diels–Alder reaction between 12a and DMAD
Fig. 2 S-cis/S-trans conformational equilibrium of 12a
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A solution of the corresponding substituted 2-iodoben-
zyl sulfinyl amide 1 (1.0 equiv), Pd(OAc)2 (0.1 equiv),
PPh3 (0.2 equiv), Et3N (2.0 equiv) and Ag2CO3 (2.0 equiv)
in toluene (0.1 M) was heated to 70 "C for 12 h. The
solvent was removed under reduced pressure, and the crude
product was purified by flash chromatography to give
compounds 4.
Compounds 4a–d have previously been described, and
their spectroscopic data are in fully agreement with the
literature [17].
General procedure for the ring-closing enyne
metathesis
A solution of 3 (1.0 equiv), 1,7-octadiene (8.0 equiv)
and Grubbs II catalyst (0.05 equiv) in CH2Cl2 (0.1 M) was
heated to 90 "C for 24 h. The solvent was removed under
reduced pressure, and the crude product was purified by
flash chromatography to give compounds 12.
(RS)-2-Methyl-N-[(S)-4-(1-phenilvinyl)-1,2-dihydronaph-
thalen-1-yl]propane-2-sulfinamide (12a)
The title compound was obtained following the general
procedure described above. Flash chromatography [n-
hexane/EtOAc (1:1)] afforded compound 12a as a brown
solid ([99 %). [a]D
25
= ? 24.3 (c 1.0; CHCl3).
1H RMN
(300 MHz, CDCl3) d 1.23 (s, 9H),2.68 (ddd, J = 17.2, 7.1,
4.9 Hz, 1H), 2.89 (ddd, J = 17.2, 5.7, 4.3 Hz, 1H), 3.51 (d,
J = 8.1 Hz, 1H), 4.59 (dd, J = 13.7, 7.2 Hz, 1H), 5.35 (d,
J = 1.6 Hz, 1H), 5.67 (d, J = 1.6 Hz, 1H), 6.10 (t,
J = 4.5 Hz, 1H), 7.00 (dd, J = 7.6, 1.2 Hz, 1H), 7.10
(td, J = 7.5, 1.5 Hz, 1H), 7.17 (td, J = 7.4, 1.5 Hz, 1H),
7.23 (d, J = 1.9 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 7.26 (s,
1H), 7.36–7.43 (m, 3H). 13C RMN (75 MHz, CDCl3)
Scheme 8 One-pot
condensation/asymmetric
allylation/Sonogashira
coupling//PKR
Scheme 9 One-pot
condensation/asymmetric
allylation/PKR sequence
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d22.7 (3xCH3), 32.6 (CH2), 54.3 (CH), 56.1 (C), 115.4
(CH2), 125.1 (CH), 126.3 (CH), 126.6 (2xCH), 126.8 (CH),
127.3 (CH), 127.7 (CH), 128.0 (CH), 128.3 (2xCH), 133.5
(C), 135.6 (C), 139.6 (C), 139.7 (C), 147.9 (C). HRMS (EI)
calcd for C22H25NOS [M ? H]
?: 352.1730, found:
352.1737.
(RS)-N-[(S)-7-Methoxy-4-(1-phenylvinyl)-1,2-dihydron-
aphthalen-1-yl]-2-methylpropane-2-sulfinamide (12b)
The title compound was obtained following the general
procedure described above. Flash chromatography [n-
hexane/EtOAc (1:1)] afforded compound 12b as a brown
solid (82 %). [a]D
25
= ? 21.0 (c 1.0; CHCl3).
1H RMN
(300 MHz, CDCl3) d 1.25 (s, 9H), 2.62 (ddd, J = 16.9, 8.0,
4.6 Hz, 1H), 2.87 (ddd, J = 16.9, 5.7, 4.5 Hz, 1H), 3.49 (d,
J = 7.5 Hz, 1H), 3.76 (s, 3H), 4.49–4.60 (m, 1H), 5.34 (d,
J = 1.7 Hz, 1H), 5.64 (d, J = 1.7 Hz, 1H), 5.97 (t,
J = 4.5 Hz, 1H), 6.61 (dd, J = 8.5, 2.7 Hz, 1H), 6.91 (d,
J = 8.5 Hz, 1H), 6.97 (d, J = 2.7 Hz, 1H), 7.21–7.26 (m,
3H), 7.37–7.42 (m, 2H).13C RMN (75 MHz, CDCl3) d
22.7, 32.7, 54.9, 55.2, 56.2, 112.3, 112.8, 115.2, 122.7,
126.6, 127.7, 128.3, 137.7, 139.3, 139.8, 148.1, 158.8.
HRMS (EI) calcd for C23H27NO2S[M ? H]
?: 382.1762,
found: 382.1760.
(RS)-N-[(S)-4-(1-(3-Methoxyphenyl)vinyl)-1,2-dihydron-
aphthalen-1-yl]-2-methylpropane-2-sulfinamide (12c)
The title compound was obtained following the general
procedure described above. Flash chromatography [n-
hexane/EtOAc (1:1)] afforded compound 12c as a brown
solid (95 %). [a]D
25
= ? 5.0 (c 1.0; CHCl3).
1H RMN
(300 MHz, CDCl3) d 1.23 (s, 9H), 2.67 (ddd, J = 17.2,
7.3, 4.8 Hz, 1H), 2.88 (ddd, J = 17.2, 5.8, 4.3 Hz, 1H),
3.51 (d, J = 8.5 Hz, 1H), 3.76 (s, 3H), 4.57 (dd, J = 13.9,
7.6 Hz, 1H), 5.34 (d, J = 1.6 Hz, 1H), 5.66 (d,
J = 1.6 Hz, 1H), 6.08 (t, J = 4.5 Hz, 1H), 6.78 (ddd,
J = 8.2, 2.5, 0.9 Hz, 1H), 6.95–6.99 (m, 2H), 7.01 (dd,
J = 7.5, 1.4 Hz, 1H), 7.08–7.20 (m, 3H), 7.35–7.41 (m,
1H). 13C RMN (75 MHz, CDCl3) d 22.7 (3xCH3),32.7
(CH2), 54.5 (CH), 55.2 (CH3), 56.1 (C), 112.7 (CH), 112.7
(CH), 115.7 (CH2), 119.3 (CH), 125.2 (CH), 126.3 (CH),
126.6 (2xCH), 127.4 (CH), 127.9 (2xCH), 129.3 (CH),
133.5 (C), 135.7 (C), 139.6 (C), 141.3 (C), 147.8 (C), 159.6
(C). HRMS (EI) calcd for C23H27NO2S [M ? H]
?:
382.1835, found: 382.1819.
(RS)-N-[(S)-4-(1-(3,5-Bis(trifluoromethyl)phenyl)vinyl)-
1,2-dihydronaphthalen-1-yl]-2-methylpropane-2-sulfi-
namide (12d)
The title compound was obtained following the general
procedure described above. Flash chromatography [n-
hexane/EtOAc (1:1)] afforded compound 12d as a brown
solid (73 %). [a]D
25
= ? 15.0 (c 1.0; CHCl3).
1H RMN
(300 MHz, CDCl3) d 1.22 (s, 9H), 2.74 (ddd, J = 17.4, 7.1,
4.8 Hz, 1H), 2.92 (ddd, J = 17.3, 6.0, 4.3 Hz, 1H),3.48 (d,
J = 8.8 Hz, 1H), 4.58 (dd, J = 15.2, 6.7 Hz, 1H), 5.56 (d,
J = 0.7 Hz, 1H), 5.78 (d, J = 0.9 Hz, 1H), 6.15 (t,
J = 4.5 Hz, 1H), 6.90 (dd, J = 7.6, 1.1 Hz, 1H), 7.13
(td, J = 7.5, 1.4 Hz, 1H), 7.22 (td, J = 7.5, 1.4 Hz, 1H),
7.41 (d, J = 7.4 Hz, 1H), 7.75 (s, 1H), 7.80 (s, 2H). 19F
RMN (282 MHz, CDCl3) d -62.84 (2xCF3).
13C RMN
(75 MHz, CDCl3) d 22.6 (3xCH3), 32.7 (CH2), 54.4 (CH),
56.2 (C), 119.1 (CH2), 121.5 (d,
3
JCF = 5.5 Hz, 2xCH),
125.9 (CH), 126.6(CH), 126.8 (q, 1JCF = 272.9 Hz,
2xCF3), 126.9 (CH), 127.1 (CH), 127.9 (CH), 128.1
(CH), 131.8 (d, 2JCF = 33.2 Hz, 2xC), 132.4 (C), 135.9
(C), 138.2 (C), 142.2 (C), 145.7 (C). HRMS (EI) calcd for
C24H23NOF6S [M ? H]
?: 488.1477, found: 488.1464.
(RS)-N-[(S)-4-(1-(4-Methoxyphenyl)vinyl)-1,2-dihydron-
aphthalen-1-yl]-2-methylpropane-2-sulfinamide (12e)
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The title compound was obtained following the general
procedure described above. Flash chromatography [n-
hexane/EtOAc (1:1)] afforded compound 12e as a brown
solid (98 %). [a]D
25
= ? 6.0 (c 1.0; CHCl3).
1H RMN
(300 MHz, CDCl3) d 1.23 (s, 9H), 2.66 (ddd, J = 17.2,
7.2, 4.8 Hz, 1H), 2.88 (ddd, J = 17.1, 5.7, 4.3 Hz, 1H),
3.52 (d, J = 8.1 Hz, 1H), 3.76 (s, 3H), 4.58 (dd, J = 13.7,
7.4 Hz, 1H), 5.24 (d, J = 1.6 Hz, 1H), 5.57 (d,
J = 1.7 Hz, 1H), 6.08 (t, J = 4.5 Hz, 1H), 6.74–6.80 (m,
2H), 7.00 (dd, J = 7.5, 1.3 Hz, 1H), 7.10 (td, J = 7.5,
1.5 Hz, 1H), 7.17 (td, J = 7.4, 1.5 Hz, 1H), 7.30–7.36 (m,
2H), 7.39 (d, J = 6.9 Hz, 1H). 13C RMN (75 MHz,
CDCl3) d 22.7 (3xCH3), 32.6 (CH2), 54.4 (CH), 55.2
(CH3), 56.1 (C), 113.6 (CH2), 113.7 (CH), 124.9 (CH),
126.4 (2xCH), 126.7 (CH), 127.3 (CH), 127.8 (2xCH),
128.0 (CH), 132.3 (C), 133.6 (C), 135.6 (C), 139.8 (C),
147.3 (C), 159.3 (C). HRMS (EI) calcd for C23H27NO2S
[M ? H]?: 382.1835, found: 382.1833.
(RS)-N-[(S)-4-(Hex-1-en-2-yl)-1,2-dihydronaphthalen-1-
yl]-2-methylpropane-2-sulfinamide (12f)
The title compound was obtained following the general
procedure described above. Flash chromatography [n-
hexane/EtOAc (1:1)] afforded compound 12f as a brown
solid (50 %). [a]D
25
= ? 7.9 (c 1.0; CHCl3).
1H RMN
(300 MHz, CDCl3) d 0.86 (t, J = 7.1 Hz, 3H), 1.18 (s,
9H), 1.28–1.35 (m, 2H), 1.47 (d, J = 4.8 Hz, 2H), 2.24 (t,
J = 7.0 Hz, 2H), 2.58 (ddd, J = 17.0, 6.9, 5.0 Hz, 1H),
2.73 (ddd, J = 17.0, 5.6, 4.3 Hz, 1H), 3.47 (d, J = 8.7 Hz,
1H), 4.45 (dd, J = 14.8, 6.5 Hz, 1H), 5.00 (d, J = 2.3 Hz,
1H), 5.08 (ddd, J = 2.3, 1.2 Hz, 1.2 Hz, 1H), 5.86 (t,
J = 4.5 Hz, 1H), 7.19–7.28 (m, 3H),7.35–7.40 (m, 1H).13-
C RMN (75 MHz, CDCl3) d 13.9 (CH3),22.2 (CH2), 22.6
(3xCH3), 30.5 (CH2), 32.4 (CH2), 35.5 (CH2), 54.7 (CH),
56.1 (C), 114.2 (CH2), 122.0 (CH), 125.7 (CH), 126.7
(CH), 127.3 (CH), 127.9 (CH), 133.3 (C), 136.3 (C), 140.8
(C), 148.7 (C).HRMS (EI) calcd for C20H29NOS
[M ? H]?: 332.2043, found: 332.2040.
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www.nature.com/scientificreportsHyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonistsSimona De Marinoͷ, Adriana Carino͸, Dario Masulloͷ, Claudia Finamoreͷ, Silvia Marchianò͸, Sabrina Cipriani͸, Francesco Saverio Di Levaͷ, Bruno Catalanottiͷ, Ettore Novellinoͷ, Vittorio Limongelliͷ,͹, Stefano Fiorucci͸,* & Angela Zampellaͷ,*Bile acids are extensively investigated for their potential in the treatment of human disorders. The liver X receptors (LXRs), activated by oxysterols and by a secondary bile acid named hyodeoxycholic acid (HDCA), have been found essential in the regulation of lipid homeostasis in mammals. Unfortunately, LXRα activates lipogenic enzymes causing accumulation of lipid in the liver. In addition to LXRs, HDCA 
has been also shown to function as ligand for GPBARͷ, a G protein coupled receptor for secondary bile acids whose activation represents a promising approach to liver steatosis. In the present study, we report a library of HDCA derivatives endowed with modulatory activity on the two receptors. The lead optimization of HDCA moiety was rationally driven by the structural information on the binding 
site of the two targets and results from pharmacological characterization allowed the identification of hyodeoxycholane derivatives with selective agonistic activity toward LXRα and GPBARͷ and notably to 
the identification of the first example of potent dual LXRα/GPBARͷ agonists. The new chemical entities might hold utility in the treatment of dyslipidemic disorders.
Liver X receptor α and β (LXRs) are ligand activated transcription factors. LXRs function as heterodimers with the 
retinoid X receptor (RXR) and are activated by naturally occurring cholesterol metabolites known as oxysterols1,2. 
LXRα and LXRβ share a high structural homology3, but are differentially expressed in mammalian tissues. Thus, 
while LXRα is primarily expressed in liver, intestine, adipose tissue, and macrophages, LXRβ is ubiquitously 
expressed.
Upon ligand-induced activation, both LXR isoforms regulate gene expression through binding to LXR 
response elements (LXREs) in the promoter regions of the target genes. In the liver, LXRα directly induces 
cytochrome 7A1 (CYP7A1), promoting the conversion of cholesterol into bile acids. In macrophages and adipo-
cytes, LXRs induce the expression of ATP-binding cassettes ABCA1, ABCG1 and apolipoprotein (apoE), increas-
ing the efflux of cholesterol from cells4,5, and exerts anti-inflammatory activities6,7 with beneficial effects in rodent 
models of diabetes and insulin resistance8,9.
These genetic and pharmacological approaches have shown that LXRs are potentially druggable receptors that 
might hold utility in the treatment of highly prevalent human diseases including obesity, diabetes, neurodegen-
erative diseases and chronic inflammatory states10,11. Unfortunately, the available synthetic agonists for LXRα 
cause the activation of hepatic lipogenic enzymes, thereby increasing triglyceride synthesis and accumulation, 
hampering their clinical utility in cardiovascular disease12. In mammalians, hyodeoxycholic acid (HDCA, 1 in 
Fig. 1), a naturally occurring secondary bile acid generated in human small intestine by bacterial C-6 hydroxyla-
tion of lithocholic acid (LCA, 2)13, is a weak LXRα agonist14. Indeed, HDCA has been shown effective in the treat-
ment of rodent models of metabolic disorders15,16 and a diet enriched with HDCA was found to protect against 
atherosclerotic plaques formation in LDL receptor-knockout mice by reducing intestinal cholesterol absorption 
and increasing HDL-mediated cholesterol efflux from foam cells and macrophages17. In addition, HDCA exerts 
hypolipidemic effect in mice, reducing in liver the gene expression of sterol regulatory element binding protein 
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1c (SREPB1c), acetyl-CoA carboxylase (ACoA synthase), fatty acid synthase (FAS), and stearoyl-CoA desaturase 
(S-CoA Des)18.
In vitro studies have also demonstrated that HDCA is a weak agonist for the G-protein-coupled bile acid 
receptor GPBAR1 (also known as TGR5), with an EC50 of 31.6 µ M19. GPBAR1 is a membrane bile acid receptor20, 
highly expressed in non-parenchymal liver cells, gallbladder, intestine, heart, spleen, kidney, placenta, leukocytes, 
skeletal muscle and brown adipose tissue (BAT)21. GPBAR1 is preferentially activated by LCA (2) and taurolitho-
cholic acid (TLCA, 3 in Fig. 1), with EC50 of 0.53 µ M and 0.29 µ M, respectively22.
GPBAR1 activation leads to genomic and non-genomic effects. While non-genomic effects are mediated by 
the modulation of intracellular concentrations of cAMP, the genomic effects are mediated by the PKA-dependent 
phosphorylation of CREB (cAMP response element-binding protein), a cellular transcription factor that binds 
to specific DNA sequences called cAMP response elements (CRE), in the promoter of target genes. In mus-
cles and brown adipose tissue, GPBAR1 increases energy expenditure and oxygen consumption23, while in the 
entero-endocrine L cells, stimulates the secretion of glucagon-like peptide (GLP)-1, an incretin that increases 
insulin release, thus regulating glucose blood levels, gastrointestinal motility and appetite24.
Similarly to LXRs, GPBAR1 is a potentially druggable receptor and might have application in the treatment 
of metabolic disorders including obesity, diabetes, dyslipidemias, atherosclerosis, liver steatohepatitis, and neu-
rologic disorders25,26.
In this framework, we have set to explore the chemical space of HDCA with the aim to develop ligands 
endowed with dual agonist activity towards LXRα and GPBAR1. The newly identified compounds by simul-
taneously activating LXRα and GPBAR1 could allow targeting metabolic/inflammatory disorders with a novel 
mechanism of action.
With this background in mind, a large family of hyodeoxycholane derivatives was prepared through various 
chemical modifications. As shown in Fig. 2, we first introduced on the HDCA scaffold numerous apolar side 
chains, differing in length, ramification and presence/absence of unsaturation (Subset A). The rationale of this 
choice relies on the structural features of the ligand-binding site of both LXRα and GPBAR1. In particular, the 
binding pocket of LXRα is rather amphipathic and thus able to host ligands endowed with both polar and hydro-
phobic branches27. On the other hand, the GPBAR1 ligand-binding pocket presents a small lipophilic cleft that 
might be targeted by relatively short hydrophobic chains (Fig. 3). Therefore, the introduction on the HDCA ste-
roidal scaffold of hydrophobic side chains with different length can help in deciphering the structural requisites to 
achieve a dual activity on the two receptors. The obtained set of derivatives was then subjected to a second round 
of chemical modifications focused on the steroidal scaffold. This step allowed investigating the effect of the A/B 
ring junction, the stereochemistry at C-3 and the hydroxyl group at C-6 on the ligand affinity towards the recep-
tors (Subset B, Fig. 4). Pharmacological experiments resulted in the identification of several compounds endowed 
with selective agonistic activity toward LXRα and GPBAR1 and notably to the identification of compound 14, the 
first example of potent dual LXRα /GPBAR1 modulator. In vivo administration of this modulator, allowed us to 
investigate the effects of dual LXRα /GPBAR1 activation on mice metabolism.ResultsPreparation of Subset A derivatives. Aldehyde 34 was used as a cornerstone intermediate in the prepa-
ration of compounds 4–12. A four-step reaction sequence on HDCA, including preparation of methyl ester 31, 
protection of alcoholic functions at C-3 and C-6, reduction of the side chain methyl ester and subsequent Swern 
oxidation furnished aldehyde 34 in quantitative yield (Fig. 5).
As depicted in Fig. 6, Wittig olefination with isopropyl triphenylphosphonium iodide followed by the removal 
of 3α , 6α -dihydroxy protective groups gave 4 that was also used as starting material in double bound hydrogena-
tion affording the saturated derivative 5 in quantitative yield.
Compounds 6–1228 (Figs 6 and 7) were prepared following the same synthetic protocol and using isobutyl 
triphenylphosponium iodide, methyl triphenylphosphonium iodide and benzyl triphenylphosphonium iodide, 
respectively in Wittig olefination.
Figures 8 and 9 illustrate the synthetic protocols for the preparation of HDCA derivatives with nor and bisnor 
alkenyl and alkyl side chains. As previously reported29, HDCA was subjected to one-carbon degradation at C-24 
through the so-called second order “Beckmann rearrangement” affording the 24-normethyl ester 37 (Fig. 8). 
Protection at C-3 and C-6 hydroxyl groups, followed by reduction of side chain methyl ester and subsequent 
Swern oxidation furnished key intermediate aldehyde 38 in 94% yield.
Figure 1. Naturally occurring bile acids. HDCA, a weak LXRα /GPBAR1 dual agonist and LCA and its tauro-
conjugated derivative, TLCA, the most potent endogenous activators of GPBAR1.
www.nature.com/scientificreports/
3Scientific RepoRts | ͽ:ͺ͹͸ͿͶ | DOI: ͷͶ.ͷͶ͹;/srepͺ͹͸ͿͶWittig olefination and double bond hydrogenation, in the same operative conditions described for the prepa-ration of derivatives 4/5 and 8/9, gave the corresponding nor derivatives 13/14 and 15/16.The preparation of C23-analogues 17 and 18 began with the acetylation of HDCA (Fig. 9). Radical oxidative decarboxylation of protected carboxylic acid 39 by treatment with Cu(OAc)2 and Pb(OAc)4 furnished the ∆22 derivative 40. Sodium methoxide treatment gave the alkene 17 in 90% yield that in turn was also used as starting material to obtain the corresponding saturated derivative 18.Preparation of subset B derivatives. At this point, our chemical speculation was extended to the tetra-cyclic nucleus exploring the influence of the hydroxyl group at C-6 as well as the configuration of the hydroxyl group at C-3 and the A/B ring junction. Thus, to obtain the corresponding 6-deoxy derivatives 19–24, LCA was subjected to the four-step sequence depicted in Fig. 10 including TBS-protection at C-3, methyl ester formation at C-24, reduction to the corresponding primary alcohol and finally Swern oxidation to obtain aldehyde 41. Witting olefination with methyl triphenylphosponium iodide and with isopropyl triphenylphosphonium iodide furnished the installation of a terminal alkene and a dimethyl branched alkene as side chain end group in 19 and 21, respec-tively. Hydrogenation with Pd(OH)2 as catalyst on a small portion of each compound gave the corresponding saturated derivatives 20 and 22. Finally, oxidative decarboxylation on 3-O-acethyl LCA 42 followed by removal of the protecting group at C-3 position gave the alkene 23 that in turn was hydrogenated to the corresponding C23-alkyl derivative 24 (Fig. 10).In the preparation of 3β -hydroxy-5α -cholane derivatives 25–30, HDCA was transformed in the methyl 3β -hydroxy-5α -cholan-24-oate 43 following our previously published procedure (Fig. 11)30.Then, conversion to aldehyde 44 and Wittig olefination/reduction gave compounds 25–28, following the same synthetic protocol described in Fig. 6.Intermediate 43 was also used as starting material in the oxidative decarboxylation affording alkene 29 in 62% yield. Hydrogenation at the side chain double bond furnished compound 30.
Figure 2. Subset A: installation of a hydrophobic side chain on hyodeoxycholane scaffold. 
Figure 3. Ligand binding sites of GPBAR1 and LXRα. In (A) the amino acids defining the small lipophilic 
cleft in GPBAR1 are highlighted as yellow transparent surface. (B) Shows the amphipathic nature of LXRα -LBD 
characterized by the presence of both polar and hydrophobic residues. GPBAR1 and LXRα are shown as gray 
and orange cartoons, respectively. In both receptors, representative residues are depicted as sticks. Non-polar 
hydrogens are omitted for clarity.
www.nature.com/scientificreports/
4Scientific RepoRts | ͽ:ͺ͹͸ͿͶ | DOI: ͷͶ.ͷͶ͹;/srepͺ͹͸ͿͶIn vitro pharmacological evaluation. Derivatives 4–30 were tested for their activity in a luciferase reporter assay with HepG2 and HEK-293T cells transfected with LXRα ,β and GPBAR1, respectively. Table 1 reports the efficacy of tested compounds compared to those of reference compounds, GW3965 for LXRα /β and TLCA for GPBAR1.Each compound was tested at the concentration of 10 µ M and transactivation activity of GW3965 on LXRs and TLCA on CRE (i.e. TGR5/GPBAR1) was considered equal to 100%.As shown in Table 1, the introduction of a hydrophobic side chain on the hyodeoxycholane scaffold (Subset A, compounds 4–18) produced beneficial effects on LXRα . Inspection of biological activity clearly indicates that 
Figure 4. Subset B: installation of a hydrophobic side chain on modified A-B ring hyodeoxycholane 
scaffold. 
Figure 5. Synthesis of key aldehyde 34. Reagents and conditions: (a) p-TsOH, MeOH dry, quantitative yield; 
(b) 2,6-lutidine, t-butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C, quantitative yield; (c) LiBH4, 
MeOH dry, THF, 0 °C, 56%; (d) DMSO, oxalyl chloride, TEA dry, CH2Cl2, − 78 °C, quantitative yield.
Figure 6. Preparation of Subset A derivatives: introduction of C25 linear and C26/C27 branched aliphatic 
side chains on hyodeoxycholane scaffold. Reagents and conditions: (a) n-BuLi, isopropyl triphenylphosponium 
iodide, THF dry, r.t., 84%; (b) HCl 37%, MeOH, quantitative yield; (c) H2, Pd(OH)2 degussa type, THF:MeOH 
dry 1:1, quantitative yield; (d) n-BuLi, isobutyl triphenylphosponium iodide, THF dry, r.t.; (e) HCl 37%, MeOH; 
(f) H2, Pd(OH)2 degussa type, THF:MeOH dry 1:1; (g) n-BuLi, methyl triphenylphosponium iodide, THF dry, 
r.t, 60%; (h) HCl 37%, MeOH, quantitative yield; (i) H2, Pd(OH)2 degussa type, THF:MeOH dry 1:1, 70%.
www.nature.com/scientificreports/
5Scientific RepoRts | ͽ:ͺ͹͸ͿͶ | DOI: ͷͶ.ͷͶ͹;/srepͺ͹͸ͿͶin the above subset, the efficacy in transactivating LXRα is in correlation with the size of the installed side chain and with the presence of a double bond. The correlation activity/side chain length is not linear with a reduction in LXRα activity for derivatives with too long (compounds 6 and 7) or too short side chain (compounds 15–18) whereas, as general trend, the presence of a double bond leads to a reduction of the efficacy. Therefore, the best match has been found for compounds 5, 12 and 14 with an efficacy of 73%, 63% and 109%, respectively.On the other hand, the length of side chain produces opposite effects on GPBAR1 with improved efficacy of hyodeoxycholane derivatives with shortened side chains (derivatives 13–17).Analysis of biological data for subset B compounds reveals that the elimination of the hydroxyl group at C-6 is detrimental in term of LXRα transactivation whereas produce positive effects on GPBAR1. Derivatives 19–30 shows GPBAR1 efficacy in a 51–96% range.While the above activity is slightly affected by the configuration of the hydroxyl group at C-3 and of the A/B ring junction, the GPBAR1 efficacy is favored with the shortening of the side chain with compounds 24 and 29, the most efficacious GPBAR1 selective agonists identified in this study. Of interest the presence of a double bond 
Figure 7. Preparation of Subset A derivatives: introduction of an aromatic end-group side chain on 
hyodeoxycholane scaffold. Reagents and conditions: (a) n-BuLi, benzyl triphenylphosponiumiodide, THF dry; 
(b) HCl 37%, MeOH, 67% over two steps; (c) H2, Pd(OH)2 degussa type, THF:MeOH dry 1:1, quantitative yield.
Figure 8. Preparation of Subset A derivatives: introduction of C24 linear and C25 branched 
aliphatic side chains on hyodeoxycholane scaffold. Reagents and conditions: (a) 2,6-lutidine, 
t-butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C; (b) LiBH4, MeOH dry in THF dry; (c) DMSO, 
oxalyl chloride, TEA dry, CH2Cl2, − 78 °C, 94% over three steps; (d) n-BuLi, isopropyl triphenylphosphonium 
iodide, THF dry, r.t.; (e) HCl 37%, MeOH, 80% over two steps; (f) H2, Pd(OH)2 degussa type, THF/MeOH 1:1, 
90%; (g) n-BuLi, methyl triphenylphosphonium iodide, THF dry; (h) HCl 37%, MeOH, 95% over two steps; (i) 
H2, Pd(OH)2 degussa type, THF/MeOH dry 1:1, 88%.
Figure 9. Preparation of Subset A derivatives: introduction of a C23 linear aliphatic side chain on 
hyodeoxycholane scaffold. Reagents and conditions: (a) Ac2O, pyridine, quantitative yield; (b) Cu(OAc)2 H2O, 
Pb(OAc)4 in toluene dry/pyridine dry, 17%; (c) CH3ONa, CHCl3 dry/MeOH dry 5:3 v/v, 90%; (d) H2, Pd(OH)2 
degussa type, THF dry/MeOH dry 1:1 v/v, quantitative yield.
www.nature.com/scientificreports/
6Scientific RepoRts | ͽ:ͺ͹͸ͿͶ | DOI: ͷͶ.ͷͶ͹;/srepͺ͹͸ͿͶon the side chain increases the efficacy of the derivatives with trans A/B ring junction (compare efficacy of 25 vs 26, 27 vs 28 and 29 vs 30).The behavior of compounds with 5β -configuration is quite the contrary, thus indicating that the introduction of a saturated side chain produces beneficial effects on bent shaped nuclei (compare efficacy of 24 vs 23). None of tested compounds was able to transactivate LXRβ (Table 1) and FXR (Figure S1).
Figure 10. Preparation of Subset B derivatives. Linear C23/C25 and branched C26 aliphatic side chains 
on 6-deoxyhyodeoxycholane scaffold. Reagents and conditions: (a) p-TsOH, MeOH dry; (b) 2,6-lutidine, 
t-butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C; (c) LiBH4, MeOH dry, THF, 0 °C; (d) DMSO, 
oxalyl chloride, TEA dry, CH2Cl2, − 78 °C, 72% over four steps; (e) n-BuLi, methyl triphenylphosponium iodide, 
THF dry, r.t.; (f) HCl 37%, MeOH, quantitative yield over two steps; (g) H2, Pd(OH)2 degussa type, THF:MeOH 
dry 1:1, 86%; (h) n-BuLi, isopropyl triphenylphosponium iodide, THF dry, r.t.; (i) HCl 37%, MeOH, 40% over 
two steps; (j) H2, Pd(OH)2 degussa type, THF:MeOH dry 1:1, quantitative yield; (k) Ac2O, Pyr; (l) Cu(OAc)2 
H2O, Pb(OAc)4 in toluene dry/pyridine dry, quantitative yield over two steps; (m) CH3ONa, CHCl3 dry/MeOH 
dry 5:3 v/v, 27%; (n) H2, Pd(OH)2 degussa type, THF dry/MeOH dry 1:1 v/v, 22%.
Figure 11. Preparation of Subset B derivatives. Linear C23/C25 and branched C26 aliphatic side 
chains on 3β -hydroxy-6-deoxy-5α -hyodeoxycholane scaffold. Reagents and conditions: (a) 2,6-lutidine, 
t-butyldimethylsilyltrifluoromethanesulfonate, CH2Cl2, 0 °C; (b) LiBH4, MeOH dry, THF, 0 °C; (c) DMSO, 
oxalyl chloride, TEA dry, CH2Cl2, − 78 °C, 34% over three steps; (d) n-BuLi, isopropyl triphenylphosponium 
iodide, THF dry, r.t.; (e) HCl 37%, MeOH, 34% over two steps; (f) H2, Pd(OH)2 degussa type, THF:MeOH dry 
1:1, quantitative yield; (g) n-BuLi, methyl triphenylphosponium iodide, THF dry, r.t.; (h) HCl 37%, MeOH, 38% 
over two steps; (i) H2, Pd(OH)2 degussa type, THF:MeOH dry 1:1, quantitative yield; (j) NaOH, MeOH/H2O 
1:1 v/v, reflux; (k) Ac2O, pyridine; (l) Cu(OAc)2 H2O, Pb(OAc)4 in toluene dry/pyridine dry, 78%; (m) CH3ONa, 
CHCl3 dry/MeOH dry 5:3 v/v, 62%; (n) H2, Pd(OH)2 degussa type, THF dry/MeOH dry 1:1 v/v, quantitative 
yield.
www.nature.com/scientificreports/
7Scientific RepoRts | ͽ:ͺ͹͸ͿͶ | DOI: ͷͶ.ͷͶ͹;/srepͺ͹͸ͿͶTable 2 shows EC50 values of the most efficacious compounds identified in this study.Compounds 14 was further investigated in vitro to evaluate its effects on LXRα and GPBAR1 target genes by RT-PCR. The HepG2 and Glutag cells (1 × 106) were plated and, after 24 hours of starvation, were stimulated with receptor agonists GW3965, TLCA and HDCA (10 µ M) and with increasing concentration of compound 14 (1, 5, 10, 25, 50 µ M). As shown in Fig. 12, compound 14 was able to induce the expression of ABCA1 and SREBP1c genes in HepG2 cells in dose-dependent manner with an EC50 of 8.3 µ M and 5.8 µ M respectively.The compound was also able to activate the expression of pro-glucagon mRNA in Glutag cells; however, the induction is dose-dependent only until the 10 µ M concentration with an EC50 of 6.5 µ M. These results demon-strate that this compound is a potent, effective and selective LXRα and GPBAR1 dual agonist.Compound 14 was also investigated in vivo to verify whether the LXRα activation causes lipid accumulation in the liver. C57BL6 mice were administered with 14 (30 mg/Kg daily by oral gavage) for two weeks. As showed in Fig. 13, no effects were observed in mice treated with compound 14 on the plasmatic levels of AST, cholesterol and triglycerides (Fig. 13A). Liver histology (H&E staining), in which no differences were observed between control group and mice treated with 14 (Fig. 13B), confirmed this result. Real-Time PCR assayed on liver tissue demonstrated that the compound does not induce the expression of steatosis markers genes, FAS, SREBP1c, CD36 and PPARs (Fig. 13C). Of interest, compound 14 increases the expression of GPBAR1 target genes GLP1 and Fgf21 in terminal ileum (Fig. 13D). These results demonstrate that, despite its activity on LXRα , compound 14 does not induce lipid accumulation and liver steatosis and this positive effect is closely related to the simulta-neous activation of GPBAR1, as evidenced by the in vivo induction of GPBAR1 target genes in the gut.
Compound
GPBAR1* LXRα∗∗ LXRβ
Efficacy Efficacy Efficacy
(% vs TLCA) (% vs HDCA) (% vs GW3965) (% vs HDCA) (% vs GW3965)
HDCA 26 15, 5 NA***
4 26, 3 101, 0 49, 3 317, 1 NA
5 14, 9 57, 5 72, 8 468, 1 NA
6 65, 0 249, 8 32, 6 209, 7 NA
7 26, 3 101, 2 28, 0 180, 1 NA
8 25, 5 98, 0 42, 9 276, 3 NA
9 27, 0 103, 9 54, 1 348, 3 NA
10 26, 0 100, 0 12, 2 78, 5 NA
11 33, 2 127, 7 26, 2 168, 3 NA
12 18, 6 71, 7 63, 1 406, 1 NA
13 52, 6 202, 4 36, 1 232, 0 NA
14 55, 1 211, 9 109, 3 703, 3 NA
15 68, 7 264, 0 NA — NA
16 53, 7 206, 6 23, 8 153, 0 NA
17 53, 1 204, 3 17, 3 111, 7 NA
18 22, 8 87, 6 NA — NA
19 75, 1 288, 7 NA — NA
20 74, 0 284, 6 20, 0 128, 6 NA
21 73, 0 280, 7 NA — NA
22 77, 1 296, 5 NA — NA
23 59, 6 229, 1 NA — NA
24 92, 9 357, 1 NA — NA
25 58, 1 223, 2 NA — NA
26 50, 9 195, 8 NA — NA
27 64, 4 247, 7 NA — NA
28 54, 9 211, 1 NA — NA
29 96, 0 368, 8 15, 0 96, 7 NA
30 58, 1 223, 5 NA — NA
Table 1.  GPBAR1 and LXRs efficacy of compounds 4–30. *Activity toward GPBAR1 in a reporter assay 
was assessed in HEK-293T cells transfected with a cAMP responsive element (CRE) cloned upstream to the 
luciferase gene. For calculation of efficacy data, maximal transactivation of CRE caused by each compound 
(10 µ M) was compared to maximal transactivation caused by TLCA (10 µ M) and by HDCA (10 µ M). **Activity 
toward LXRα in a reporter assay was assessed in HepG2 cells transfected with an LXRα responsive element 
(LRE) cloned upstream to the luciferase gene. For calculation of efficacy data, maximal transactivation of LRE 
caused by each compound (10 µ M) was compared to maximal transactivation caused by GW3965 (10 µ M) and 
by HDCA (10 µ M). ***NA: no activity at 10 µ M.
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8Scientific RepoRts | ͽ:ͺ͹͸ͿͶ | DOI: ͷͶ.ͷͶ͹;/srepͺ͹͸ͿͶMolecular Modeling. In order to investigate the molecular bases of the dual LXRα /GPBAR1 activity of 14, a thorough computational study has been carried out. First, we performed docking calculations of 14 in the homol-ogy model of GPBAR1 that we have previously developed and successfully used for drug design31. The best scored docking pose (Fig. 14A) shows that 14 binds to GPBAR1 similarly to other bile acids recently reported by us as agonists of this receptor31–33. Nevertheless, some differences can be found. In detail, while the ligand 3α -hydroxyl group engages the typical H-bond interaction with the Glu169 side chain, the hydrophobic side chain of 14 occu-pies the small lipophilic pocket formed by Ala66, Leu68 and Leu71 on TM2. This orientation of the side chain in the binding site is different respect to that of the derivatives with polar functional groups on the side chain, which occupy the site interacting with the serine residues of transmembrane helices TM7 and TM1. The ligand binding mode is further stabilized by a set of hydrophobic interactions established by the steroidal scaffold with the side chains of Leu71, Phe96, Leu174 and Trp237.In order to elucidate the binding mode of 14 to LXRα , docking simulations were performed using the crystal structure of the ligand binding domain (LBD) of the receptor (PDB code: 3IPU)34. In this case, docking calcu-lations suggest two possible binding modes, A and B, where the ligand assumes two opposite orientations in the LBD (Figure S2). Specifically, in A the hydrophobic chain of 14 is oriented towards the helices 11 and 12 of LXRα , while the 3α - and 6α -hydroxyl groups interact with the residues of the β -sheet close to H1. In B, the steroidal scaffold is oriented in the opposite direction relative to A in the LBD. In particular, the 3α - and 6α -hydroxyl groups are close to His421 of helix 11, while the hydrophobic side chain extends towards the β -sheet in the ligand binding pocket. We decided to further investigate the two binding modes assessing their stability through over 100 ns molecular dynamics (MD) calculations. In particular, we evaluated, during the simulation, the conser-vation of the interactions engaged by the ligand with the protein and the geometrical stability of the ligand by computing the root mean square displacement (rmsd) of its heavy atoms relative to their starting position (see 
GPBAR1 LXRα
Compound Affinity (µM)* Affinity (µM)
Selective LXRα agonists
4 6.99 ± 0.31
5 8.2 ± 0.16
8 2.7 ± 0.65
9 5.1 ± 0.43
12 12.4 ± 0.41
GPBAR1/LXRα dual agonists
13 4.2 ± 0.79 22.3 ± 3.05
14 4.9 ± 0.2 3.2 ± 0.03
Selective GPBAR1 agonists
15 3.7 ± 0.38
17 2.54 ± 0.015
20 6.8 ± 0.08
21 5.9 ± 0.055
24 0.91 ± 0.092
25 7.6 ± 0.71
27 1 ± 0.062
29 4.9 ± 0.06
30 1.98 ± 0.145
Table 2.  EC50 values for selected compounds. *Data are mean ± SE of 3 experiments in duplicate.
Figure 12. Quantitative Real-Time PCR analysis of mRNA expression on LXRα and GPBAR1 target genes. 
ABCA1 (A) and SREBP1c (B) expression in HepG2 cells primed with increasing concentration of compound 
14 (1, 5, 10 and 25 µ M). GW3965 and HDCA were used as positive controls. Pro-glucagon (C) expression in 
Glutag cells stimulated with increasing dose of compound 14 (1, 10, 25 and 50 µ M). TLCA and HDCA were 
used as a positive control. Values are normalized to GAPDH and are expressed relative to those of not treated 
cells (NT) which are arbitrarily settled to 1. The relative mRNA expression is expressed as 2(−∆∆Ct).
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9Scientific RepoRts | ͽ:ͺ͹͸ͿͶ | DOI: ͷͶ.ͷͶ͹;/srepͺ͹͸ͿͶFigure S3 for details). In B, the original ligand/protein interactions, such as the H-bond between 14 and His421, are lost and the ligand rmsd value increases during the simulation showing instability of this binding mode. At variance with B, in A the ligand rmsd values are low (Figure S3) and all the starting ligand/protein interactions are conserved throughout the simulation. The MD results prompted us to consider only binding mode A for further analysis. In this pose (Fig. 14B and S4), the steroidal scaffold of 14 establishes favorable contacts with lipophilic residues such as Phe257, Phe315 and Phe326, while the 3α -group of 14 H-bonds with the Ser264 side chain. Additional water-mediated interactions are engaged by both the ligand hydroxyl groups with the side chains of Arg232, Glu267 and Glu301. On the other hand, the ligand hydrophobic side chain inserts into a deep lipophilic pocket shaped by helices (H) 3, 4, 6, 11, and 12, where it can establish favorable contacts with several residues such as Phe254, Phe335, Leu435, Leu439 and Trp443. This hydrophobic network stabilizes the position of Trp443 
Figure 13. Effects of compound 14 on hepatic lipid metabolism and on terminal ileum after administration 
on intact mice. C57BL6 mice were treated with 14 (30 mg/Kg daily per os) for two weeks. Results are the 
mean ± SE of 3–5 mice per group; *p < 0.05 versus control mice. (A) Serum levels of AST, total cholesterol and 
triglycerides; (B) Histopathology analysis (Hematoxilin and Eosin) of liver sections. Magnification 4x. Insets 
magnification 40x. The images show that no fat deposition occurs in the liver of mice treated up to 2 weeks with 
14 at the dose of 30 mg/Kg; (C) Relative hepatic mRNA expression of genes involved in fatty acids metabolism 
(FASN, SREBP1C, CD36) and genes for nuclear receptors (PPARα , PPARγ , LXR α ); (D) Relative hepatic 
mRNA expression of GLP-1, FGF21, FXR and LXRα genes in terminal ileum.
Figure 14. Binding mode of 14 in GPBAR1 and in LXRα. (A) Docking pose in the homology model 
of GPBAR1. (B) Conformation obtained from MD simulations within the LXRα LBD (PDB code: 3IPU). 
Compound 14 is represented as cyan sticks. GPBAR1 and LXRα are shown as gray and orange cartoons, 
respectively. Amino acids important for ligand binding are depicted as sticks. Non-polar hydrogens are omitted 
for clarity.
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in the binding site favoring its interaction through a cation-pi interaction with His421. Such interaction is consid-
ered fundamental for the activation of nuclear receptors like LXRα , since it allows the C-terminal H12 to adopt 
a conformation competent for the binding of co-activator peptides. This event triggers in turn the LXRα /RXR 
dimerization and the transcription of target genes27. Although 14 is devoid of a polar side chain, its binding mode 
to LXRα is overall similar to that reported for some oxysterols27 and to the crystallographic binding pose of 24(S), 
25-epoxycholesterol in LXRβ (Figure S4)35. Furthermore, the binding mode of 14 is in line with the mutagenesis 
data that suggest a functional role of Glu267 in the binding of oxysterols to LXRs27.Discussion and Conclusion
Understanding the structural requisites for selective affinity of a ligand towards its molecular target is of para-
mount relevance in drug design. This task can be particularly difficult when proteins involved in different cellular 
pathways discriminate among ligands with small chemical changes as in the case of bile acid receptors. On the 
other hand, one might exploit the possibility to simultaneously activate more than one molecular target develop-
ing multi-target compounds that could be beneficial from the therapeutic point of view. In the present work, we 
have explored the chemical space of hyodeoxycholic acid (HDCA) introducing a hydrophobic side chain on hyo-
deoxycholane scaffold and on A/B ring modified hyodeoxycholane scaffold. Several selective LXRα and GPBAR1 
agonists as well the first example of LXRα /GPBAR1 dual modulators have been identified. The lead optimization 
of HDCA was rationally driven by the structural informations on the binding site of the two targets. Moreover, 
the information coming from binding calculations of 14 in GPBAR1 and LXRα and the pharmacological activ-
ity of structurally related compounds, allowed us to delineate the structural requirements for ligand binding to 
either receptor. In particular, the binding mode of 14 to LXRα suggests that the 3α - and 6α -hydroxyl groups as 
well as C25/C26 hydrophobic chains are crucial for ligand activity. In fact, compounds without the 6α -OH group 
(19–30) or endowed with too short side chains (linear C24/C23, compounds 15–18) and too long (branched C27, 
compounds 6 and 7) are inactive towards LXRα . At variance with LXRα , the 6α -hydroxyl group is not a prerequi-
site for ligand binding to GPBAR1, with compounds 19–30 invariably able in transactivating GPBAR1 (Table 1), 
while in this receptor, compounds with a hydrophobic side chain longer than C25 are inactive since their lipo-
philic branch can difficulty insert into the small hydrophobic cleft of the receptor binding site. Overall, our results 
lead to conclude that subset A derivatives (Fig. 2) with linear C25 (compounds 8 and 9), phenyl-substituted C25 
(compound 12) and methyl-branched C26 (compounds 4 and 5) side chains are LXRα selective. On the other 
hand, subset A derivatives with linear C24/C23 side chains (compounds 15–17) and compounds without the 
6α -hydroxyl group (Subset B in Fig. 4) turn out to be active only on GPBAR1. Finally, the concurrent presence 
of the 6α -OH group and of a C-25 methyl-branched side chain as in compounds 13 and 14 allow achieving dual 
LXRα /GPBAR1 activity.
Compound 14 was effective in modulating the expression of canonical LXRα and GPBAR1 target genes. 
We have shown that 14 increases the expression of SREPB1c, ABCG1 and GLP1 in vitro. Noteworthy, in vivo 
administration of compound 14 on intact mice demonstrated beneficial effects. Compound 14 does not induced 
the typical effects of LXRα agonists, which usually activate lipogenic enzymes causing accumulation of lipid 
in the liver. Conversely, the expression of steatosis marker genes FAS, SREBP1c and CD36 was not modulated 
compared to the control group. This positive effect is closely related to the simultaneous activation of GPBAR1, as 
demonstrated by the in vivo induction of GLP1 expression in the gut. Collectively, these data strongly support a 
further pharmacological characterization of the newly discovered agent in rodent models of metabolic disorders. 
In summary, we have generated a novel series of HDCA derivatives that allowed targeting metabolic disorders 
including diabetes, chronic inflammatory states and neurodegenerative diseases, by exploiting a completely novel 
mechanism of action, i.e. the simultaneous activation of LXRα and GPBAR1.MethodsChemistry. High-resolution ESI-MS spectra were performed with a Micromass Q-TOF mass spectrome-
ter. NMR spectra were obtained on Varian Inova 400 NMR spectrometer (1H at 400, MHz, 13C at 100 MHz, 
respectively) equipped with a SUN microsystem ultra 5 hardware and recorded in CD3OD (δ H = 3.31 and 
δ C = 49.0 ppm) and CDCl3 (δ H = 7.26 and δ C = 77.0 ppm). All of the detected signals were in accordance with the 
proposed structures. Coupling constants (J values) are given in Hertz (Hz), and chemical shifts (δ ) are reported 
in ppm and referred to CHD2OD and CHCl3 as internal standards. Spin multiplicities are given as s (singlet), br s 
(broad singlet), d (doublet), or m (multiplet).
HPLC was performed with a Waters Model 510 pump equipped with Waters Rheodine injector and a dif-
ferential refractometer, model 401. Reaction progress was monitored via thin-layer chromatography (TLC) on 
Alugram silica gel G/UV254 plates. Silica gel MN Kieselgel 60 (70–230 mesh) from Macherey-Nagel Company 
was used for column chromatography. All chemicals were obtained from Sigma-Aldrich, Inc. Solvents and rea-
gents were used as supplied from commercial sources with the following exceptions. Dichloromethane, tetrahy-
drofuran and trimethylamine were distilled from calcium hydride immediately prior to use. Methanol was dried 
from magnesium methoxide as follow. Magnesium turnings (5 g) and iodine (0.5 g) were refluxed in a small 
(50–100 mL) quantity of methanol until all of the magnesium has reacted. The mixture was diluted (up to 1 L) 
with reagent grade methanol, refluxed for 2–3 h then distilled under nitrogen. All reactions were carried out 
under argon atmosphere using flame-dried glassware.
The purities of compounds were determined to be greater than 95% by HPLC.Synthetic procedures. See the Supporting Information.
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Cell culture. HepG2, an immortalized human epatocarcinoma cell line, was cultured and maintained at 37 °C 
and 5% CO2 in E-MEM additioned with 10% FBS, 1% glutamine and 1% penicillin/streptomycin. HEK-293T 
and Glutag cells were cultured and maintained at 37 °C and 5% CO2 in D-MEM additioned with 10% FBS, 1% 
glutamine and 1% penicillin/streptomycin.Luciferase reporter gene assay and dose-response curves. To evaluate LXRα mediated trans-
activation, HepG2 cells were transfected with 20 ng of the reporter vector p(UAS)5XTKLuc, 100 ng of a vec-
tor containing the ligand binding domain of LXRα cloned upstream of the GAL4-DNA binding domain (i.e. 
pSG5-LXRα LBD-GAL4DBD) and 100 of pGL4.70 (Promega), a vector encoding the human Renilla gene. To 
evaluate GPBAR1 mediated transactivation, HEK-293T cells were transfected with 200 ng of human pGL4.29 
(Promega), a reporter vector containing a cAMP response element (CRE) that drives the transcription of the lucif-
erase reporter gene luc2P, with 100 ng of pCMVSPORT6-human GPBAR1, and with 100 ng of pGL4.70 Renilla. 
To evaluate FXR mediated transactivation, HepG2 cells were transfected with 100 ng of human pSG5-FXR, 
100 ng of human pSG5-RXR, 200 ng of the reporter vector p(hsp27)-TK-LUC containing the FXR response ele-
ment IR1 cloned from the promoter of heat shock protein 27 (hsp27) and with 100 ng of pGL4.70 Renilla. At 
24 h post-transfection, cells were stimulated 18 h with 10 µ M GW3965, TLCA, or CDCA and compounds 4–30 
(10 µM). Luciferase activities were assayed and normalized with Renilla activities. Dose-response curves were 
performed in HepG2 and HEK-293T cells transfected as described above and then treated with increasing con-
centrations of compounds 4, 5, 8, 9, 12–15, 17, 20, 21, 24, 25, 27, 29, 30 (1, 5, 10, 25 and 50 µ M). At 18 h post 
stimulations, cellular lysates were assayed for luciferase and Renilla activities using the Dual-Luciferase Reporter 
assay system (E1980, Promega). Luminescence was measured using Glomax 20/20 luminometer (Promega). 
Luciferase activities (RLU) were normalized with Renilla activities (RRU).Animal model. C57BL6 mice were originally donated by Dr. Galya Vassileva (Schering-Plough Research 
Institute, Kenilworth). The colonies were maintained in the animal facility of University of Perugia. Mice were 
treated with compound 14 (30 mg/Kg daily by oral gavage) or vehicle (distilled water) for two weeks. Mice were 
housed under controlled temperatures (22 °C) and photoperiods (12:12-h light/dark cycle), allowed unrestricted 
access to standard mouse chow and tap water and allowed to acclimate to these conditions for at least 5 days 
before inclusion in an experiment. The study was conducted in agreement with the Italian law and the protocol 
was approved by ethical committee of University of Perugia and by National committee of Ministry of Health 
(permission n. 42/2014-B). The Veterinarian monitored the health and body conditions of the animals daily 
in the animal facility. The study protocol caused minor suffering; however, animals that lost more than 25% of 
the initial body weight were euthanized. At the day of sacrifice mice were deeply anesthetized with a mixture of 
tiletamine hypochlorite and zolazepam hypochlorite/xylazine at a dose of 50/5 mg/Kg. Blood, liver and terminal 
ileum were collected for further analysis. Aspartate aminotransferase (AST), total cholesterol and triglycerides 
were measured by routine biochemical clinical chemistry. For histological examination, portions of liver lobes 
were fixed in 10% formalin, embedded in paraffin, sectioned (5 µ m thin) and stained with Hematoxylin/Eosin 
(H&E) for morphometric analysis.RNA isolation and RT-PCR. HepG2 and Glutag cells were plated at 1 × 106 cells/well in a 6 well plate. After 
an overnight incubation, cells were starved and then stimulated for 18 h with GW3965 or TLCA (10 µ M), HDCA 
(10 µ M), and with increasing concentrations of compound 14 (1, 5, 10, 25, 50 µ M).
Total RNA was isolated from HepG2 or Glutag cells and from animal tissues (liver and terminal ileum) using 
the TRIzol reagent according to the manufacturer’s specifications (Invitrogen). One microgram of purified RNA 
was treated with DNase-I and reverse transcribed with Superscript II (Invitrogen). For Real Time PCR, 25 ng tem-
plate was dissolved in 25 µ L containing 200 nmol/L of each primer and 12.5 µ L of 2 × SYBR FAST Universal ready 
mix (Invitrogen). All reactions were performed in triplicate, and the thermal cycling conditions were as follows: 
2 min at 95 °C, followed by 40 cycles of 95 °C for 20 s and 60 °C for 30 s in StepOnePlus (Applied Biosystems). The 
relative mRNA expression was calculated and expressed as 2(−∆∆Ct). Forward and reverse primer sequences were 
the following: human GAPDH, gaaggtgaaggtcggagt and catgggtggaatcatattggaa; human ABCA1, gcttgggaagat-
ttatgacagg and aggggatgattgaaagcagtaa; human SREBP1c, gcaaggccatcgactacatt and ggtcagtgtgtcctccacct; mouse 
GAPDH, ctgagtatgtcgtggagtctac and gttggtggtgcaggatgcattg; mouse Pro-glucagon, tgaagacaaacgccactcac and 
caatgttgttccggttcctc; mouse FAS, tcaagatgaaggtggcagaggtgct and ttgagcagtgccgggattcgg; mouse SREBP1c, gatcaaa-
gaggagccagtgc and tagatggtggctgctgagtg; mouse CD36, cggagacatgcttattgagaa and actctgtatgtgtaaggacct; mouse 
PPARα , cagaggtccgattcttccac and gatcagcatcccgtgtttgt; mouse PPARγ , gccagtttcgatccgtagaa and aatccttggccctct-
gagat; mouse LXRα , ggctcaccagcttcattagc and gcaggaccagctccaagtag; mouse FXR, tgtgagggctgcaaaggttt and 
acatccccatctctctgcac; mouse Fgf21, acacagatgacgaccaagacac and aagtgaggcgatccatagagag.Molecular docking. The Glide (version 7.1) software package36 was used to perform molecular docking 
calculations in the three-dimensional model of hGPBAR131 and in the crystal structure of LXRα -LBD bound to 
a synthetic benzisoxazole urea agonist (PDB code: 3IPU)34.
This structure was selected among the several available using the following criteria: i) the higher resolution of 
the electron density map; ii) the presence of all amino acids in helix 1, which is not fully resolved in all the LXRα 
crystal structures; iii) the presence of an agonist with bulkiness comparable to bile acid derivatives. Missing resi-
dues in the loop connecting H1 with H3 were added and refined using Prime37. Ligand and receptors structures 
were prepared as described in a previous paper32.
For both GPBAR1 and LXRα , a box of 30 × 30 × 30 Å centered on the ligand binding cavities was created. 
The standard precision (SP) mode of the GlideScore function38,39 was used to score the predicted binding poses.
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Molecular dynamics. All the simulations were performed with NAMD 2.1040 using the ff14SB41 and gaff42 
Amber force field parameters for the protein and the ligand, respectively. Each complex was solvated in a 12.0 Å 
layer cubic water box using the TIP3P water model parameters43. The addition of 2 Na+ ions ensured neutrality. 
Amber charges were applied to the proteins and water molecules, whereas the ligand charges were computed 
using the restrained electrostatic potential (RESP) fitting procedure44. The ESP was first calculated by means of 
the Gaussian09 package45 using a 6–31 G* basis set at Hartree-Fock level of theory, and then the RESP charges 
were obtained by a two-stages fitting procedure using Antechamber46. A 10 Å cutoff (switched at 8.0 Å) was used 
for atom-pair interactions47,48. The long-range electrostatic interactions were computed by means of the particle 
mesh Ewald (PME) method49, using a 1.0 Å grid spacing in periodic boundary conditions. The SHAKE algorithm 
was applied to constraint bonds involving hydrogen atoms, and thus an integration time step of 2 fs could be used. 
Each complex was heated up to 300 K while putting harmonic constraints on the protein and the ligand, which 
were gradually released along the thermalization process. Production runs were then performed under NPT 
conditions at 1 atm and 300 K.
All figures were rendered using PyMOL (http://www.pymol.org).References
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